BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Julien Willard//Catalyst Calendar//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:Biotech catalysts: clinical readouts X-WR-CALDESC:Industry-sponsored Phase 2 and Phase 3 trials whose sponsors h ave told ClinicalTrials.gov to expect primary completion in the next six m onths. URL:https://julienwillard.com/calendar/clinical X-PUBLISHED-TTL:PT24H REFRESH-INTERVAL;VALUE=DURATION:PT24H BEGIN:VEVENT UID:924cc2d6bca32efeb978f2d7830fe000 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260812 DTEND;VALUE=DATE:20260813 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:USWM CT\, LLC Autologous genetically modified ADP-A2M4CD8 cells: Tr ial primary completion DESCRIPTION:As of 25 February 2026\, USWM CT estimated primary completion o f a Phase 2 trial in Ovarian Cancer\, on 12 August 2026.\n\nSource: clinic altrials NCT05601752\nhttps://clinicaltrials.gov/study/NCT05601752 URL:https://julienwillard.com/calendar/clinical#e-f5a34422-5d48-4c3f-b43d-7 8eed15182e6 END:VEVENT BEGIN:VEVENT UID:0d8a21993512db805d83b6e6e457d134 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260812 DTEND;VALUE=DATE:20260813 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Enlicitide: Trial primary completion DESCRIPTION:As of 5 August 2026\, Merck Sharp & Dohme estimated primary com pletion of a Phase 3 trial in hyperlipidemia\, on 12 August 2026.\n\nSourc e: clinicaltrials NCT07216482\nhttps://clinicaltrials.gov/study/NCT0721648 2 URL:https://julienwillard.com/calendar/clinical#e-1f2ff79d-6dc9-4d07-8c11-a a21e2a6061b END:VEVENT BEGIN:VEVENT UID:59f52844bc7f13a067179851446ec080 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260813 DTEND;VALUE=DATE:20260814 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Crovalimab: Trial primary completion DESCRIPTION:As of 5 August 2026\, Hoffmann-La Roche estimated primary compl etion of a Phase 2 trial in Paroxysmal Hemoglobinuria\, Nocturnal\, on 13 August 2026.\n\nSource: clinicaltrials NCT03157635\nhttps://clinicaltrials .gov/study/NCT03157635 URL:https://julienwillard.com/calendar/clinical#e-87bbcfdf-2050-43da-8769-a 09f7b31db9a END:VEVENT BEGIN:VEVENT UID:60fdf5f534717ea92569423a708e7876 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260813 DTEND;VALUE=DATE:20260814 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Zealand Pharma Petrelintide: Trial primary completion DESCRIPTION:As of 15 January 2026\, Zealand Pharma estimated primary comple tion of a Phase 2 trial in overweight\, on 13 August 2026.\n\nSource: clin icaltrials NCT06926842\nhttps://clinicaltrials.gov/study/NCT06926842 URL:https://julienwillard.com/calendar/clinical#e-5095bad2-bd7f-4dcb-ba92-2 85ec5af0ca8 END:VEVENT BEGIN:VEVENT UID:53521d272755941dbcf1a6f2abbb4055 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260813 DTEND;VALUE=DATE:20260814 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hinova Pharmaceuticals Inc. HP515 10 mg Tablet: Trial primary compl etion DESCRIPTION:As of 29 December 2025\, Hinova Pharmaceuticals estimated prima ry completion of a Phase 2 trial in NAFLD (Non-alcoholic Fatty Liver Disea se)\, on 13 August 2026.\n\nSource: clinicaltrials NCT07308548\nhttps://cl inicaltrials.gov/study/NCT07308548 URL:https://julienwillard.com/calendar/clinical#e-dd73ce9d-509f-4c00-adc8-0 73a2ff6643d END:VEVENT BEGIN:VEVENT UID:0254aebaebaa584369bd0119d2ad234a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260813 DTEND;VALUE=DATE:20260814 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:pH-D Feminine Health LLC Boric acid: Trial primary completion DESCRIPTION:As of 3 August 2026\, pH-D Feminine Health estimated primary co mpletion of a Phase 3 trial in Vulvovaginal Candidiases\, on 13 August 202 6.\n\nSource: clinicaltrials NCT07109869\nhttps://clinicaltrials.gov/study /NCT07109869 URL:https://julienwillard.com/calendar/clinical#e-3af7afd9-0c65-4edd-85ef-2 09170d94002 END:VEVENT BEGIN:VEVENT UID:8f1127b5fbe4a1d7365231de0e29616e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260814 DTEND;VALUE=DATE:20260815 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Nexium 20mg: Trial primary completion DESCRIPTION:As of 27 July 2026\, AstraZeneca estimated primary completion o f a Phase 3 trial in Erosive Esophagitis\, on 14 August 2026.\n\nSource: c linicaltrials NCT05267613\nhttps://clinicaltrials.gov/study/NCT05267613 URL:https://julienwillard.com/calendar/clinical#e-76656d53-61e7-4d7b-9b8d-1 91dfc38e1da END:VEVENT BEGIN:VEVENT UID:b26628d60012dfc7f8eb88a27d4cafe7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260815 DTEND;VALUE=DATE:20260816 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Genzyme\, a Sanofi Company Fitusiran: Trial primary completion DESCRIPTION:As of 22 June 2026\, Genzyme\, a Sanofi estimated primary compl etion of a Phase 3 trial in hemophilia\, on 15 August 2026.\n\nSource: cli nicaltrials NCT03974113\nhttps://clinicaltrials.gov/study/NCT03974113 URL:https://julienwillard.com/calendar/clinical#e-91c9e75f-44a9-4b68-a167-9 e0c09854699 END:VEVENT BEGIN:VEVENT UID:3d38522ded598ff5dc131e03d53caa1f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260815 DTEND;VALUE=DATE:20260816 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:PMV Pharmaceuticals\, Inc rezatapopt: Trial primary completion DESCRIPTION:As of 10 August 2026\, PMV Pharmaceuticals estimated primary co mpletion of a Phase 2 trial in Advanced Solid Tumor\, on 15 August 2026.\n \nSource: clinicaltrials NCT04585750\nhttps://clinicaltrials.gov/study/NCT 04585750 URL:https://julienwillard.com/calendar/clinical#e-de17bf13-ea18-4bf2-87f0-1 f05662bafa8 END:VEVENT BEGIN:VEVENT UID:cf3392974baca14db7bf72bbcc88c017 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260816 DTEND;VALUE=DATE:20260817 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:JenKem Technology Co.\, Ltd. JK-1201I: Trial primary completion DESCRIPTION:As of 19 September 2024\, JenKem Technology Co. estimated prima ry completion of a Phase 2 trial in Glioblastoma Multiforme (GBM)\, on 16 August 2026.\n\nSource: clinicaltrials NCT06595186\nhttps://clinicaltrials .gov/study/NCT06595186 URL:https://julienwillard.com/calendar/clinical#e-363340aa-7abc-4657-9444-5 1711aee3071 END:VEVENT BEGIN:VEVENT UID:841bdfd4bbe53e231425b00ec5592b1e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260817 DTEND;VALUE=DATE:20260818 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Verona Pharma\, Inc.\, a subsidiary of Merck & Co.\, Inc. (Rahway\, New Jersey USA Ensifentrine 3 mg: Trial primary completion DESCRIPTION:As of 23 July 2026\, Verona Pharma estimated primary completion of a Phase 2 trial in Chronic Obstructive Pulmonary Disease\, on 17 Augus t 2026.\n\nSource: clinicaltrials NCT07016412\nhttps://clinicaltrials.gov/ study/NCT07016412 URL:https://julienwillard.com/calendar/clinical#e-fcb54160-2095-46e8-8cd1-e 9aa5f95ad98 END:VEVENT BEGIN:VEVENT UID:de7376249fbc4323434238f73ed81d4a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260817 DTEND;VALUE=DATE:20260818 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BioArctic AB exidavnemab: Trial primary completion DESCRIPTION:As of 10 March 2026\, BioArctic estimated primary completion of a Phase 2 trial in Parkinson Disease\, on 17 August 2026.\n\nSource: clin icaltrials NCT06671938\nhttps://clinicaltrials.gov/study/NCT06671938 URL:https://julienwillard.com/calendar/clinical#e-e6909dfc-4e21-4670-8286-7 853547d02c8 END:VEVENT BEGIN:VEVENT UID:3c4b2259ad17a266dadf48fa67b22cba DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260818 DTEND;VALUE=DATE:20260819 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.\, Ltd. FDA018-ADC: Trial primary completion DESCRIPTION:As of 22 January 2026\, Shanghai Fudan-Zhangjiang Bio-Pharmaceu tical Co. estimated primary completion of a Phase 3 trial in Triple Negati ve Breast Cancer\, on 18 August 2026.\n\nSource: clinicaltrials NCT0651937 0\nhttps://clinicaltrials.gov/study/NCT06519370 URL:https://julienwillard.com/calendar/clinical#e-7177f994-fd49-43fc-ad3e-2 c3e6df04333 END:VEVENT BEGIN:VEVENT UID:ee0243f48ee194229b445baca86d2771 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260818 DTEND;VALUE=DATE:20260819 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Janssen Sciences Ireland UC Rilpivirine: Trial primary completion DESCRIPTION:As of 6 July 2026\, Janssen Sciences Ireland UC estimated prima ry completion of a Phase 2 trial in Human Immunodeficiency Virus Type 1\, on 18 August 2026.\n\nSource: clinicaltrials NCT02494986\nhttps://clinical trials.gov/study/NCT02494986 URL:https://julienwillard.com/calendar/clinical#e-a2402c2c-2913-426f-a2dc-2 46eb02ba4f2 END:VEVENT BEGIN:VEVENT UID:0776b8320a5e5e465f8cd72be2a59959 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260818 DTEND;VALUE=DATE:20260819 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Raludotatug Deruxtecan (R-DXd): Trial prima ry completion DESCRIPTION:As of 23 April 2026\, Merck Sharp & Dohme estimated primary com pletion of a Phase 2 trial in Gastrointestinal Cancer\, on 18 August 2026. \n\nSource: clinicaltrials NCT06864169\nhttps://clinicaltrials.gov/study/N CT06864169 URL:https://julienwillard.com/calendar/clinical#e-85e14e21-740f-4ae5-9873-b c36b0ac2b8b END:VEVENT BEGIN:VEVENT UID:be48df52f9fe83abc3e953ad130a969a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260819 DTEND;VALUE=DATE:20260820 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ViiV Healthcare CAB LA + RPV LA: Trial primary completion DESCRIPTION:As of 29 July 2026\, ViiV Healthcare estimated primary completi on of a Phase 3 trial in HIV Infections\, on 19 August 2026.\n\nSource: cl inicaltrials NCT06694805\nhttps://clinicaltrials.gov/study/NCT06694805 URL:https://julienwillard.com/calendar/clinical#e-5c2353e5-aece-4d05-a220-0 161de7d05b8 END:VEVENT BEGIN:VEVENT UID:7ee03348f12e9249407d4afb0b42e4b2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260819 DTEND;VALUE=DATE:20260820 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amgen Dazodalibep: Trial primary completion DESCRIPTION:As of 16 January 2026\, Amgen estimated primary completion of a Phase 3 trial in Sjogren's Syndrome\, on 19 August 2026.\n\nSource: clini caltrials NCT06104124\nhttps://clinicaltrials.gov/study/NCT06104124 URL:https://julienwillard.com/calendar/clinical#e-bfde3181-61b3-4064-a2dc-2 593030a29c2 END:VEVENT BEGIN:VEVENT UID:c7a220dba82835009c27598a6e0f8e93 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260820 DTEND;VALUE=DATE:20260821 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Boehringer Ingelheim Vicadrostat: Trial primary completion DESCRIPTION:As of 7 August 2026\, Boehringer Ingelheim estimated primary co mpletion of a Phase 2 trial in Chronic Kidney Disease\, on 20 August 2026. \n\nSource: clinicaltrials NCT06926660\nhttps://clinicaltrials.gov/study/N CT06926660 URL:https://julienwillard.com/calendar/clinical#e-914fab7e-2574-4549-b257-0 c3eebde7e86 END:VEVENT BEGIN:VEVENT UID:5055aed04bff9a9a224feb76d1e937a7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260820 DTEND;VALUE=DATE:20260821 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD7798: Trial primary completion DESCRIPTION:As of 1 June 2026\, AstraZeneca estimated primary completion of a Phase 2 trial in Crohn's Disease\, on 20 August 2026.\n\nSource: clinic altrials NCT06681324\nhttps://clinicaltrials.gov/study/NCT06681324 URL:https://julienwillard.com/calendar/clinical#e-ba865008-7340-4ee6-aefe-9 f5c3433bbf8 END:VEVENT BEGIN:VEVENT UID:6f75057f504737e39951e825d70773e0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260821 DTEND;VALUE=DATE:20260822 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NodThera Limited NT-0796: Trial primary completion DESCRIPTION:As of 8 April 2026\, NodThera estimated primary completion of a Phase 2 trial in obesity\, on 21 August 2026.\n\nSource: clinicaltrials N CT07220629\nhttps://clinicaltrials.gov/study/NCT07220629 URL:https://julienwillard.com/calendar/clinical#e-52147299-60e2-4f60-947e-f db4796d5b77 END:VEVENT BEGIN:VEVENT UID:2478be234976acdba5daf7a49699b691 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260821 DTEND;VALUE=DATE:20260822 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Pembrolizumab: Trial primary completion DESCRIPTION:As of 30 July 2026\, Merck Sharp & Dohme estimated primary comp letion of a Phase 2 trial in Carcinoma\, Renal Cell\, on 21 August 2026.\n \nSource: clinicaltrials NCT04626518\nhttps://clinicaltrials.gov/study/NCT 04626518 URL:https://julienwillard.com/calendar/clinical#e-e8a3a294-361f-445d-85e2-8 35ce8a658e2 END:VEVENT BEGIN:VEVENT UID:ea164800423d7141c7290a18fa8118bc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260821 DTEND;VALUE=DATE:20260822 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Pembrolizumab: Trial primary completion DESCRIPTION:As of 30 July 2026\, Merck Sharp & Dohme estimated primary comp letion of a Phase 2 trial in Carcinoma\, Renal Cell\, on 21 August 2026.\n \nSource: clinicaltrials NCT04626479\nhttps://clinicaltrials.gov/study/NCT 04626479 URL:https://julienwillard.com/calendar/clinical#e-1e068d0e-5490-4b8e-a888-c c82114f1ac7 END:VEVENT BEGIN:VEVENT UID:5e3acfd57c0568947242861c53c94574 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260821 DTEND;VALUE=DATE:20260822 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novo Nordisk A/S CagriSema (Cagrilintide B and Semaglutide I): Tria l primary completion DESCRIPTION:As of 5 December 2025\, Novo Nordisk estimated primary completi on of a Phase 2 trial in Diabetes Mellitus\, Type 2\, on 21 August 2026.\n \nSource: clinicaltrials NCT06797869\nhttps://clinicaltrials.gov/study/NCT 06797869 URL:https://julienwillard.com/calendar/clinical#e-7fb6260c-1dd9-4f2c-a9e3-2 10ca97171cc END:VEVENT BEGIN:VEVENT UID:7ed850c1b286419cc0e731e70e3d3427 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260821 DTEND;VALUE=DATE:20260822 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:EMD Serono Research & Development Institute\, Inc. Avelumab: Trial primary completion DESCRIPTION:As of 29 June 2026\, EMD Serono Research & Development Institut e estimated primary completion of a Phase 3 trial in Solid Tumors\, on 21 August 2026.\n\nSource: clinicaltrials NCT03815643\nhttps://clinicaltrials .gov/study/NCT03815643 URL:https://julienwillard.com/calendar/clinical#e-4ed8317b-e7d0-4293-ab08-4 ee2ca8e465d END:VEVENT BEGIN:VEVENT UID:126352537aa6a03b2185cb87d206fff1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260821 DTEND;VALUE=DATE:20260822 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Longboard Pharmaceuticals LP352: Trial primary completion DESCRIPTION:As of 10 August 2026\, Longboard Pharmaceuticals estimated prim ary completion of a Phase 3 trial in Dravet Syndrome\, on 21 August 2026.\ n\nSource: clinicaltrials NCT06660394\nhttps://clinicaltrials.gov/study/NC T06660394 URL:https://julienwillard.com/calendar/clinical#e-24638210-ce49-47f4-9674-9 fa6a6dbf0e2 END:VEVENT BEGIN:VEVENT UID:e0393d26693a2f0bdde3c15bbee48047 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260822 DTEND;VALUE=DATE:20260823 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bazelet Nehushtan LtD. Oral CBD oil enriched with terpenes: Trial p rimary completion DESCRIPTION:As of 23 August 2024\, Bazelet Nehushtan estimated primary comp letion of a Phase 2 trial in Attention Deficit Hyperactivity Disorder (ADH D)\, on 22 August 2026.\n\nSource: clinicaltrials NCT06542445\nhttps://cli nicaltrials.gov/study/NCT06542445 URL:https://julienwillard.com/calendar/clinical#e-2e49ab15-afc7-4946-b977-4 fb3adcb5c32 END:VEVENT BEGIN:VEVENT UID:13a694b23601592728b1c164f3681d0e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260822 DTEND;VALUE=DATE:20260823 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche RO7204239: Trial primary completion DESCRIPTION:As of 11 August 2026\, Hoffmann-La Roche estimated primary comp letion of a Phase 2 trial in obesity\, on 22 August 2026.\n\nSource: clini caltrials NCT06965413\nhttps://clinicaltrials.gov/study/NCT06965413 URL:https://julienwillard.com/calendar/clinical#e-6bc3f38f-34a7-4676-8263-d c9cd3725943 END:VEVENT BEGIN:VEVENT UID:c747c8b722f1485fffbff95b8a4f8db7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260823 DTEND;VALUE=DATE:20260824 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer PF-07220060 + PF-07104091 combination dose escalation: Trial primary completion DESCRIPTION:As of 18 November 2024\, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer\, on 23 August 2026.\n\nSource: clinical trials NCT05262400\nhttps://clinicaltrials.gov/study/NCT05262400 URL:https://julienwillard.com/calendar/clinical#e-65ed8037-b0af-42c5-9219-9 6f8286766fd END:VEVENT BEGIN:VEVENT UID:3dc0c6587f75e3f5ff7cbf644accd966 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260824 DTEND;VALUE=DATE:20260825 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD9833: Trial primary completion DESCRIPTION:As of 14 October 2025\, AstraZeneca estimated primary completio n of a Phase 3 trial in ER-Positive HER2-Negative Breast Cancer\, on 24 Au gust 2026.\n\nSource: clinicaltrials NCT04711252\nhttps://clinicaltrials.g ov/study/NCT04711252 URL:https://julienwillard.com/calendar/clinical#e-9db0a6f8-a17b-4ec2-a78a-0 0e3b2dfb35a END:VEVENT BEGIN:VEVENT UID:b22c586a6717f558944d57a189b77b37 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260824 DTEND;VALUE=DATE:20260825 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou HepaThera Biotech Co.\, Ltd. HT-101: Trial primary completio n DESCRIPTION:As of 19 September 2025\, Suzhou HepaThera Biotech Co. estimate d primary completion of a Phase 2 trial in Chronic Hepatitis B\, on 24 Aug ust 2026.\n\nSource: clinicaltrials NCT07183306\nhttps://clinicaltrials.go v/study/NCT07183306 URL:https://julienwillard.com/calendar/clinical#e-ef624489-1fcb-4dd9-8146-8 b2e35d3d508 END:VEVENT BEGIN:VEVENT UID:3922a0bbe1d734f98856128da337029b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260824 DTEND;VALUE=DATE:20260825 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Alexion Pharmaceuticals\, Inc. Danicopan: Trial primary completion DESCRIPTION:As of 18 June 2026\, Alexion Pharmaceuticals estimated primary completion of a Phase 3 trial in Paroxysmal Nocturnal Hemoglobinuria\, on 24 August 2026.\n\nSource: clinicaltrials NCT05389449\nhttps://clinicaltri als.gov/study/NCT05389449 URL:https://julienwillard.com/calendar/clinical#e-9b7b1aa6-7add-4b76-b4a3-a 5c6cd053621 END:VEVENT BEGIN:VEVENT UID:6c205a211fad41bd0d97144280f81a71 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260824 DTEND;VALUE=DATE:20260825 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Regeneron Pharmaceuticals Fianlimab: Trial primary completion DESCRIPTION:As of 10 August 2026\, Regeneron Pharmaceuticals estimated prim ary completion of a Phase 2 trial in Resectable Non-small Cell Lung Cancer \, on 24 August 2026.\n\nSource: clinicaltrials NCT06161441\nhttps://clini caltrials.gov/study/NCT06161441 URL:https://julienwillard.com/calendar/clinical#e-fa63b15c-3e09-4497-9831-5 ba7ea3675ef END:VEVENT BEGIN:VEVENT UID:f2355a890fefa2141faffc3c1151ae69 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260825 DTEND;VALUE=DATE:20260826 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BPGbio BPM31510: Trial primary completion DESCRIPTION:As of 26 January 2026\, BPGbio estimated primary completion of a Phase 2 trial in glioblastoma\, on 25 August 2026.\n\nSource: clinicaltr ials NCT04752813\nhttps://clinicaltrials.gov/study/NCT04752813 URL:https://julienwillard.com/calendar/clinical#e-2cdd138e-9feb-4cbc-9a4b-8 f4e0cfe740f END:VEVENT BEGIN:VEVENT UID:5b8dfdb86604a5332854aa2197c44bf1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260825 DTEND;VALUE=DATE:20260826 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals JDQ443: Trial primary completion DESCRIPTION:As of 25 June 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer\, on 25 Augus t 2026.\n\nSource: clinicaltrials NCT05132075\nhttps://clinicaltrials.gov/ study/NCT05132075 URL:https://julienwillard.com/calendar/clinical#e-0ee33319-9bce-4257-b5d6-3 82740518a80 END:VEVENT BEGIN:VEVENT UID:0142a30a1178e422f56226abe70b63ac DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260825 DTEND;VALUE=DATE:20260826 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi Rilzabrutinib dose 1: Trial primary completion DESCRIPTION:As of 7 July 2026\, Sanofi estimated primary completion of a Ph ase 2 trial in Graves' Disease\, on 25 August 2026.\n\nSource: clinicaltri als NCT06984627\nhttps://clinicaltrials.gov/study/NCT06984627 URL:https://julienwillard.com/calendar/clinical#e-cc3ac380-95ab-4f79-826f-b 3764e18f845 END:VEVENT BEGIN:VEVENT UID:2fb46ee01adf511bd40e507e9213b6da DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260826 DTEND;VALUE=DATE:20260827 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ParagonClinicals Inc. Paragon Novel Metabolic Regulator (PNMR): Tri al primary completion DESCRIPTION:As of 4 June 2026\, ParagonClinicals estimated primary completi on of a Phase 2 trial in Long COVID\, on 26 August 2026.\n\nSource: clinic altrials NCT07627815\nhttps://clinicaltrials.gov/study/NCT07627815 URL:https://julienwillard.com/calendar/clinical#e-03d8d111-5814-4bb1-983a-0 cf234f259bf END:VEVENT BEGIN:VEVENT UID:bd727b48fa6072ee6270e6fe0b196d1a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260826 DTEND;VALUE=DATE:20260827 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Satralizumab: Trial primary completion DESCRIPTION:As of 15 May 2026\, Hoffmann-La Roche estimated primary complet ion of a Phase 2 trial in Duchenne Muscular Dystrophy\, on 26 August 2026. \n\nSource: clinicaltrials NCT06450639\nhttps://clinicaltrials.gov/study/N CT06450639 URL:https://julienwillard.com/calendar/clinical#e-ceb8b8d9-55c1-4bb3-8583-5 d4e1b561e7a END:VEVENT BEGIN:VEVENT UID:18f186613921f0b9e3e2911c2ebfa421 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260827 DTEND;VALUE=DATE:20260828 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Blue Earth Therapeutics Ltd Lutetium (177Lu) rhPSMA-10.1 Injection: Trial primary completion DESCRIPTION:As of 14 May 2026\, Blue Earth Therapeutics estimated primary c ompletion of a Phase 2 trial in Prostate Cancer\, on 27 August 2026.\n\nSo urce: clinicaltrials NCT05413850\nhttps://clinicaltrials.gov/study/NCT0541 3850 URL:https://julienwillard.com/calendar/clinical#e-d4689a13-4811-427b-b5b2-d 1f88eb27001 END:VEVENT BEGIN:VEVENT UID:70d013c445939e8c4692555b49b3a234 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260828 DTEND;VALUE=DATE:20260829 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:4Moving Biotech 4P004: Trial primary completion DESCRIPTION:As of 27 July 2026\, 4Moving Biotech estimated primary completi on of a Phase 2 trial in Knee Osteoarthritis\, on 28 August 2026.\n\nSourc e: clinicaltrials NCT07225829\nhttps://clinicaltrials.gov/study/NCT0722582 9 URL:https://julienwillard.com/calendar/clinical#e-0f2b41f7-d0f1-4c66-8fcb-1 97e4aee99e9 END:VEVENT BEGIN:VEVENT UID:601f55dbd3343a804384c105c17a7be1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260828 DTEND;VALUE=DATE:20260829 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Alectinib: Trial primary completion DESCRIPTION:As of 2 July 2026\, Hoffmann-La Roche estimated primary complet ion of a Phase 2 trial in Non-Small Cell Lung Cancer\, on 28 August 2026.\ n\nSource: clinicaltrials NCT06624059\nhttps://clinicaltrials.gov/study/NC T06624059 URL:https://julienwillard.com/calendar/clinical#e-39c42e1d-1894-4c2c-bad7-e 7aa1e687350 END:VEVENT BEGIN:VEVENT UID:b77c2647e05397184bbc6b89f8483b64 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260828 DTEND;VALUE=DATE:20260829 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD2936: Trial primary completion DESCRIPTION:As of 14 July 2026\, AstraZeneca estimated primary completion o f a Phase 2 trial in Non-Small-Cell Lung Carcinoma\, on 28 August 2026.\n\ nSource: clinicaltrials NCT04995523\nhttps://clinicaltrials.gov/study/NCT0 4995523 URL:https://julienwillard.com/calendar/clinical#e-636761d3-0923-4a10-9230-9 a41d512fa54 END:VEVENT BEGIN:VEVENT UID:617d5dc76d584eb892cce5a830622251 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260828 DTEND;VALUE=DATE:20260829 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Giredestrant: Trial primary completion DESCRIPTION:As of 10 July 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 2 trial in Endometrial Cancer\, on 28 August 2026.\n\nSour ce: clinicaltrials NCT05634499\nhttps://clinicaltrials.gov/study/NCT056344 99 URL:https://julienwillard.com/calendar/clinical#e-4761b7ee-cd65-4a56-9c4b-8 ff87b10ca13 END:VEVENT BEGIN:VEVENT UID:3a3a6c1bd73402f29d861cb5dd5aeea6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260829 DTEND;VALUE=DATE:20260830 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Panbela Therapeutics\, Inc. SBP-101: Trial primary completion DESCRIPTION:As of 6 November 2024\, Panbela Therapeutics estimated primary completion of a Phase 3 trial in Pancreatic Cancer Metastatic\, on 29 Augu st 2026.\n\nSource: clinicaltrials NCT05254171\nhttps://clinicaltrials.gov /study/NCT05254171 URL:https://julienwillard.com/calendar/clinical#e-4741d462-ab8c-4e8c-b67b-2 cc5bba0fa0f END:VEVENT BEGIN:VEVENT UID:fce809f9fad712f64ae23731a1eb7463 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NeuroPro Therapeutics\, Inc. NPT 2042: Trial primary completion DESCRIPTION:As of 29 May 2026\, NeuroPro Therapeutics estimated primary com pletion of a Phase 2 trial in Epilepsy\, Generalized\, on 30 August 2026.\ n\nSource: clinicaltrials NCT06769659\nhttps://clinicaltrials.gov/study/NC T06769659 URL:https://julienwillard.com/calendar/clinical#e-f05fe319-3a88-4ee5-831f-a 577e1d03149 END:VEVENT BEGIN:VEVENT UID:e63b55b2604156c8888b374e9871739e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TCM Biotech International Corp. PTX-9908 Injection: Trial primary c ompletion DESCRIPTION:As of 21 November 2024\, TCM Biotech International estimated pr imary completion of a Phase 2 trial in Carcinoma\, Hepatocellular\, on 30 August 2026.\n\nSource: clinicaltrials NCT03812874\nhttps://clinicaltrials .gov/study/NCT03812874 URL:https://julienwillard.com/calendar/clinical#e-821ace8e-729e-456f-abe1-9 056293b86f2 END:VEVENT BEGIN:VEVENT UID:539597ebdd18dd6e09e3b721947bd22d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Fujian Shengdi Pharmaceutical Co.\, Ltd. HRS-5635 Injection: Trial primary completion DESCRIPTION:As of 17 November 2025\, Fujian Shengdi Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Chronic Hepatitis B\, on 30 August 2026.\n\nSource: clinicaltrials NCT06425341\nhttps://clinicaltrial s.gov/study/NCT06425341 URL:https://julienwillard.com/calendar/clinical#e-405295c2-5c8a-462d-9ddb-b 183f2938f51 END:VEVENT BEGIN:VEVENT UID:5f3b96b4493ac363e66e576be0cc5e32 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Keymed Biosciences Co.Ltd CM310: Trial primary completion DESCRIPTION:As of 2 October 2025\, Keymed Biosciences Co. estimated primary completion of a Phase 3 trial in Atopic Dermatitis\, on 30 August 2026.\n \nSource: clinicaltrials NCT06495229\nhttps://clinicaltrials.gov/study/NCT 06495229 URL:https://julienwillard.com/calendar/clinical#e-0e477219-6995-4d4a-b8df-9 c888afd3565 END:VEVENT BEGIN:VEVENT UID:644fffad5581d214edf6871e731fcd4a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Satellos Bioscience\, Inc. SAT-3247: Trial primary completion DESCRIPTION:As of 23 April 2026\, Satellos Bioscience estimated primary com pletion of a Phase 2 trial in Duchenne Muscular Dystrophy (DMD)\, on 30 Au gust 2026.\n\nSource: clinicaltrials NCT06867107\nhttps://clinicaltrials.g ov/study/NCT06867107 URL:https://julienwillard.com/calendar/clinical#e-363d628d-7cee-4bf4-b2a9-9 5c9a4c3a8b1 END:VEVENT BEGIN:VEVENT UID:4a403811e53e1296861410a5aa59245a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ReCode Therapeutics RCT2100: Trial primary completion DESCRIPTION:As of 16 January 2026\, ReCode Therapeutics estimated primary c ompletion of a Phase 2 trial in Cystic Fibrosis\, on 30 August 2026.\n\nSo urce: clinicaltrials NCT06237335\nhttps://clinicaltrials.gov/study/NCT0623 7335 URL:https://julienwillard.com/calendar/clinical#e-e8ca3897-a034-4161-8a7f-7 fad0880338c END:VEVENT BEGIN:VEVENT UID:a66d3bb21794d268e44a27d7145afb53 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TJ Biopharma Co.\, Ltd. Uliledlimab: Trial primary completion DESCRIPTION:As of 30 January 2026\, TJ Biopharma Co. estimated primary comp letion of a Phase 2 trial in Non Small Cell Lung Cancer\, on 30 August 202 6.\n\nSource: clinicaltrials NCT07005336\nhttps://clinicaltrials.gov/study /NCT07005336 URL:https://julienwillard.com/calendar/clinical#e-8634e3e8-12a4-4750-8e31-6 bb4c1a297ee END:VEVENT BEGIN:VEVENT UID:cde6e900e7114856758048e2ab8fb55b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Fujian Haixi Pharmaceuticals Co.\, Ltd. C019199: Trial primary comp letion DESCRIPTION:As of 28 November 2025\, Fujian Haixi Pharmaceuticals Co. estim ated primary completion of a Phase 2 trial in Solid Tumor\, on 30 August 2 026.\n\nSource: clinicaltrials NCT06220318\nhttps://clinicaltrials.gov/stu dy/NCT06220318 URL:https://julienwillard.com/calendar/clinical#e-0579c1aa-4899-4194-b903-e bf0d9d07795 END:VEVENT BEGIN:VEVENT UID:d6f07b74936f295d4de4e2cb7d10f4db DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beletalent (Zhuhai) Pharmaceutical Co.\, Ltd TNTL: Trial primary co mpletion DESCRIPTION:As of 24 August 2025\, Beletalent (Zhuhai) Pharmaceutical Co. e stimated primary completion of a Phase 3 trial in Non-Proliferative Diabet ic Retinopathy\, on 30 August 2026.\n\nSource: clinicaltrials NCT06817265\ nhttps://clinicaltrials.gov/study/NCT06817265 URL:https://julienwillard.com/calendar/clinical#e-c4c4d47b-b738-4046-8dee-a ab6e400c3eb END:VEVENT BEGIN:VEVENT UID:b927c06655a84e8e31a0d959761cbd33 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Il-Yang Pharm. Co.\, Ltd. Ilaprazole: Trial primary completion DESCRIPTION:As of 30 May 2025\, Il-Yang Pharm. Co. estimated primary comple tion of a Phase 3 trial in Peptic Ulcer\, on 30 August 2026.\n\nSource: cl inicaltrials NCT06284876\nhttps://clinicaltrials.gov/study/NCT06284876 URL:https://julienwillard.com/calendar/clinical#e-343c8da1-3595-439d-8c74-c ce5c083eee9 END:VEVENT BEGIN:VEVENT UID:ab24407a030da2b3d0f2cca9f1475455 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:OncoC4\, Inc. ONC-392: Trial primary completion DESCRIPTION:As of 13 April 2026\, OncoC4 estimated primary completion of a Phase 2 trial in Ovarian Cancer\, on 30 August 2026.\n\nSource: clinicaltr ials NCT05446298\nhttps://clinicaltrials.gov/study/NCT05446298 URL:https://julienwillard.com/calendar/clinical#e-6451744c-5ed0-46f6-aff2-0 0aeb58d1ee8 END:VEVENT BEGIN:VEVENT UID:59ba1ca9d93e8035272a784f0d647fc5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Innovent Biologics Technology Limited (Shanghai R&D Center) IBI302 8mg dose: Trial primary completion DESCRIPTION:As of 8 January 2026\, Innovent Biologics Technology estimated primary completion of a Phase 2 trial in Neovascular Age-related Macular D egeneration\, on 30 August 2026.\n\nSource: clinicaltrials NCT07275840\nht tps://clinicaltrials.gov/study/NCT07275840 URL:https://julienwillard.com/calendar/clinical#e-96cef251-edb1-40a3-99c9-4 77996ad4506 END:VEVENT BEGIN:VEVENT UID:7a2ad77b40b95ec514166fcea0ab5091 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer Elranatamab: Trial primary completion DESCRIPTION:As of 31 July 2026\, Pfizer estimated primary completion of a P hase 3 trial in Multiple Myeloma\, on 30 August 2026.\n\nSource: clinicalt rials NCT06152575\nhttps://clinicaltrials.gov/study/NCT06152575 URL:https://julienwillard.com/calendar/clinical#e-914463ff-6ec8-4da2-981a-c d4469404729 END:VEVENT BEGIN:VEVENT UID:bf174d0d4aced54fccbecead0ddfb094 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260830 DTEND;VALUE=DATE:20260831 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Haisco Pharmaceutical Group Co.\, Ltd. HSK39004 Dry Powder Inhaler- 0.75mg: Trial primary completion DESCRIPTION:As of 8 April 2026\, Haisco Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Chronic Obstructive Pulmonary Dis ease (COPD)\, on 30 August 2026.\n\nSource: clinicaltrials NCT07108699\nht tps://clinicaltrials.gov/study/NCT07108699 URL:https://julienwillard.com/calendar/clinical#e-fa58f912-8e88-43da-9591-0 5ee17e19329 END:VEVENT BEGIN:VEVENT UID:7f4831d433f7e2fda88a6ab2bf72954e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MediLink Therapeutics (Suzhou) Co.\, Ltd. YL202: Trial primary comp letion DESCRIPTION:As of 9 March 2026\, MediLink Therapeutics (Suzhou) Co. estimat ed primary completion of a Phase 2 trial in Non Small Cell Lung Cancer\, o n 31 August 2026.\n\nSource: clinicaltrials NCT07202364\nhttps://clinicalt rials.gov/study/NCT07202364 URL:https://julienwillard.com/calendar/clinical#e-b0d7fbd0-319d-420f-af2e-1 128a4de2c59 END:VEVENT BEGIN:VEVENT UID:13eedb48d1e87fab9a440f77ca4177e1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Lumen Bioscience\, Inc. LMN-201: Trial primary completion DESCRIPTION:As of 30 July 2026\, Lumen Bioscience estimated primary complet ion of a Phase 3 trial in Clostridioides Difficile Infection\, on 31 Augus t 2026.\n\nSource: clinicaltrials NCT05330182\nhttps://clinicaltrials.gov/ study/NCT05330182 URL:https://julienwillard.com/calendar/clinical#e-94a427d9-8c85-4e54-a69f-d 64134766d80 END:VEVENT BEGIN:VEVENT UID:d647d2caf966071822ea1ba6b13bd8f3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bayer BAY3723113: Trial primary completion DESCRIPTION:As of 26 June 2026\, Bayer estimated primary completion of a Ph ase 3 trial in Obstructive Hypertrophic Cardiomyopathy\, on 31 August 2026 .\n\nSource: clinicaltrials NCT07023341\nhttps://clinicaltrials.gov/study/ NCT07023341 URL:https://julienwillard.com/calendar/clinical#e-5bff0428-a651-4d9a-ade9-6 6769b2d1fd9 END:VEVENT BEGIN:VEVENT UID:bc1ec7a6e2fefa6252fe7871614ff09c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:UCB Biopharma SRL Staccato alprazolam: Trial primary completion DESCRIPTION:As of 31 July 2026\, UCB Biopharma SRL estimated primary comple tion of a Phase 3 trial in Stereotypical Prolonged Seizures\, on 31 August 2026.\n\nSource: clinicaltrials NCT05077904\nhttps://clinicaltrials.gov/s tudy/NCT05077904 URL:https://julienwillard.com/calendar/clinical#e-63bf0d6a-6835-4776-8606-8 10d4ad5ff3b END:VEVENT BEGIN:VEVENT UID:a80a5c1d55ff8e4103bf65b1bcda133f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ipsen Corabotase: Trial primary completion DESCRIPTION:As of 28 July 2026\, Ipsen estimated primary completion of a Ph ase 2 trial in Moderate to Severe Upper Facial Lines\, on 31 August 2026.\ n\nSource: clinicaltrials NCT04821089\nhttps://clinicaltrials.gov/study/NC T04821089 URL:https://julienwillard.com/calendar/clinical#e-8160a161-f855-4420-b2b2-9 f381d4d75d4 END:VEVENT BEGIN:VEVENT UID:db4299c1656fcd81dc2826cbbfec1dd4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kyowa Kirin Co.\, Ltd. KHK4951: Trial primary completion DESCRIPTION:As of 30 October 2025\, Kyowa Kirin Co. estimated primary compl etion of a Phase 2 trial in Diabetic Macular Edema (DME)\, on 31 August 20 26.\n\nSource: clinicaltrials NCT06116916\nhttps://clinicaltrials.gov/stud y/NCT06116916 URL:https://julienwillard.com/calendar/clinical#e-3b3277d2-f761-4eba-8259-d 14c1d879805 END:VEVENT BEGIN:VEVENT UID:b302705afee7273ae3eae5c902461e00 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Santen Pharmaceutical Co.\, Ltd. DE-117B Eye Drops: Trial primary c ompletion DESCRIPTION:As of 15 May 2026\, Santen Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Open Angle Glaucoma\, on 31 August 2026. \n\nSource: clinicaltrials NCT06666855\nhttps://clinicaltrials.gov/study/N CT06666855 URL:https://julienwillard.com/calendar/clinical#e-476a761b-bf9e-4f66-be67-9 3558640f802 END:VEVENT BEGIN:VEVENT UID:6d81a052805764fcf75256abd7cc4e4c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AMAG Pharmaceuticals\, Inc. Ferumoxytol: Trial primary completion DESCRIPTION:As of 17 April 2026\, AMAG Pharmaceuticals estimated primary co mpletion of a Phase 3 trial in Chronic Kidney Disease\; Iron Deficiency An emia\, on 31 August 2026.\n\nSource: clinicaltrials NCT03619850\nhttps://c linicaltrials.gov/study/NCT03619850 URL:https://julienwillard.com/calendar/clinical#e-89c3e12d-7793-40a7-a67f-5 a6f94c18e2d END:VEVENT BEGIN:VEVENT UID:f386e3339f1dcca23db691d6e99a2678 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Daewon Pharmaceutical Co.\, Ltd. Experimental: Trial primary comple tion DESCRIPTION:As of 11 September 2025\, Daewon Pharmaceutical Co. estimated p rimary completion of a Phase 3 trial in Perennial Allergic Rhinitis Accomp anied by Asthma\, on 31 August 2026.\n\nSource: clinicaltrials NCT07168473 \nhttps://clinicaltrials.gov/study/NCT07168473 URL:https://julienwillard.com/calendar/clinical#e-27807f03-976a-4760-9dbb-e 85c989d17e5 END:VEVENT BEGIN:VEVENT UID:03ffefba4cac14619730b7e0811a5c33 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Sefaxersen (RO7434656): Trial primary completion DESCRIPTION:As of 15 June 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 3 trial in Primary IgA Nephropathy\, on 31 August 2026.\n\ nSource: clinicaltrials NCT05797610\nhttps://clinicaltrials.gov/study/NCT0 5797610 URL:https://julienwillard.com/calendar/clinical#e-2214b51a-468d-4e20-bd12-a 020585c1345 END:VEVENT BEGIN:VEVENT UID:79c38da47d7881b23afdf1e99e70850e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Daiichi Sankyo Trastuzumab deruxtecan: Trial primary completion DESCRIPTION:As of 27 May 2026\, Daiichi Sankyo estimated primary completion of a Phase 3 trial in Gastric Cancer\, Adenocarcinoma\, on 31 August 2026 .\n\nSource: clinicaltrials NCT04704934\nhttps://clinicaltrials.gov/study/ NCT04704934 URL:https://julienwillard.com/calendar/clinical#e-97ad74dc-a79f-4877-a160-a fdd286d14b7 END:VEVENT BEGIN:VEVENT UID:c22db9f8a90ec9eac34708dec103a8ef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Translational Sciences\, Inc. TS23: Trial primary completion DESCRIPTION:As of 1 July 2026\, Translational Sciences estimated primary co mpletion of a Phase 2 trial in Pulmonary Embolism\, on 31 August 2026.\n\n Source: clinicaltrials NCT05408546\nhttps://clinicaltrials.gov/study/NCT05 408546 URL:https://julienwillard.com/calendar/clinical#e-9974bf1c-5bda-4eea-bc9d-8 de939cd0473 END:VEVENT BEGIN:VEVENT UID:3c2605fb5beefbf97f59d5fe8efd0822 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Galderma R&D Nemolizumab: Trial primary completion DESCRIPTION:As of 30 October 2024\, Galderma R&D estimated primary completi on of a Phase 3 trial in Moderate-to-Severe Atopic Dermatitis\, on 31 Augu st 2026.\n\nSource: clinicaltrials NCT03989206\nhttps://clinicaltrials.gov /study/NCT03989206 URL:https://julienwillard.com/calendar/clinical#e-b53b20d2-0976-4106-b6aa-4 95a505b9977 END:VEVENT BEGIN:VEVENT UID:b8a5dfc27a7b4235c16892e2bbef1fd9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hansoh BioMedical R&D Company HS-20093: Trial primary completion DESCRIPTION:As of 9 April 2026\, Hansoh BioMedical R&D estimated primary co mpletion of a Phase 3 trial in osteosarcoma\, on 31 August 2026.\n\nSource : clinicaltrials NCT06935409\nhttps://clinicaltrials.gov/study/NCT06935409 URL:https://julienwillard.com/calendar/clinical#e-48b463d7-2cf3-493d-aae9-c e89472af81f END:VEVENT BEGIN:VEVENT UID:c08132c901982fa5d6e8dafdbedeafd0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Nantong Bencao Quadriga Medical Technology Co. Ltd. NBQ72S: Trial p rimary completion DESCRIPTION:As of 13 April 2026\, Nantong Bencao Quadriga Medical Technolog y Co. estimated primary completion of a Phase 2 trial in Breast Cancer\, o n 31 August 2026.\n\nSource: clinicaltrials NCT06810804\nhttps://clinicalt rials.gov/study/NCT06810804 URL:https://julienwillard.com/calendar/clinical#e-7acc24de-bce5-404d-9bee-c 92f23468ae7 END:VEVENT BEGIN:VEVENT UID:d9abd55023911b2ce6d3dd1213b1e634 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Verastem\, Inc. avutometinib (VS-6766) and defactinib in combinatio n with gemcitabine and nab-paclitaxel: Trial primary completion DESCRIPTION:As of 2 September 2025\, Verastem estimated primary completion of a Phase 2 trial in KRAS Activating Mutation\, on 31 August 2026.\n\nSou rce: clinicaltrials NCT05669482\nhttps://clinicaltrials.gov/study/NCT05669 482 URL:https://julienwillard.com/calendar/clinical#e-31c21610-fa8c-4397-a302-8 54ea9bc5b97 END:VEVENT BEGIN:VEVENT UID:6a841ed745790debd8209367ad11a917 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Jishengtang Pharmaceutical Co.\, Ltd. Wujia Yizhi granules: Trial primary completion DESCRIPTION:As of 29 December 2025\, Sichuan Jishengtang Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Alzheimer's Dementia\, on 31 August 2026.\n\nSource: clinicaltrials NCT06534723\nhttps://clinica ltrials.gov/study/NCT06534723 URL:https://julienwillard.com/calendar/clinical#e-b51529e4-274e-472e-95f7-9 71bf729651e END:VEVENT BEGIN:VEVENT UID:0db8a1384f0ba6aa03362cd35ea1ca66 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kyowa Kirin Co.\, Ltd. KHK4951: Trial primary completion DESCRIPTION:As of 30 October 2025\, Kyowa Kirin Co. estimated primary compl etion of a Phase 2 trial in Neovascular Age-Related Macular Degeneration ( nAMD)\, on 31 August 2026.\n\nSource: clinicaltrials NCT06116890\nhttps:// clinicaltrials.gov/study/NCT06116890 URL:https://julienwillard.com/calendar/clinical#e-74ede089-ce15-49f7-8635-8 43fafc80f1a END:VEVENT BEGIN:VEVENT UID:55de865a83d85acbe450bbbba3208c48 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Astellas Pharma Global Development\, Inc. zolbetuximab: Trial prima ry completion DESCRIPTION:As of 14 July 2026\, Astellas Pharma Global Development estimat ed primary completion of a Phase 2 trial in Pancreatic Cancer\, on 31 Augu st 2026.\n\nSource: clinicaltrials NCT03816163\nhttps://clinicaltrials.gov /study/NCT03816163 URL:https://julienwillard.com/calendar/clinical#e-80b489f2-e5fd-46a4-9b07-1 bf928d9b842 END:VEVENT BEGIN:VEVENT UID:2be1c8224b23bb3800ecad7076e8b2ef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer RSVpreF: Trial primary completion DESCRIPTION:As of 2 June 2026\, Pfizer estimated primary completion of a Ph ase 3 trial in Respiratory Syncytial Virus (RSV)\, on 31 August 2026.\n\nS ource: clinicaltrials NCT07543380\nhttps://clinicaltrials.gov/study/NCT075 43380 URL:https://julienwillard.com/calendar/clinical#e-aad77804-cf5d-4268-8060-6 743d36d5e01 END:VEVENT BEGIN:VEVENT UID:177789a4814c8b1eda64dc33ca5b1fae DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shenyang Sunshine Pharmaceutical Co.\, LTD. SSGJ-706: Trial primary completion DESCRIPTION:As of 18 December 2025\, Shenyang Sunshine Pharmaceutical Co. e stimated primary completion of a Phase 2 trial in First-line Advanced NSCL C Patients\, on 31 August 2026.\n\nSource: clinicaltrials NCT07171606\nhtt ps://clinicaltrials.gov/study/NCT07171606 URL:https://julienwillard.com/calendar/clinical#e-b602b066-bf86-4016-a045-1 0b39a373314 END:VEVENT BEGIN:VEVENT UID:1a782d034b30333b0de19f50cb971ee2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Myrtelle Inc. rAAV-Olig001-ASPA: Trial primary completion DESCRIPTION:As of 14 November 2025\, Myrtelle estimated primary completion of a Phase 2 trial in Canavan Disease\, on 31 August 2026.\n\nSource: clin icaltrials NCT04833907\nhttps://clinicaltrials.gov/study/NCT04833907 URL:https://julienwillard.com/calendar/clinical#e-3c131065-1964-4545-8e70-9 c6d427bcf83 END:VEVENT BEGIN:VEVENT UID:af3f91844be6548c515cfcde4dbd2f29 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260831 DTEND;VALUE=DATE:20260901 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. SHR-1826；Adebrelima b；SHR-8068；Bevacizumab: Trial primary completion DESCRIPTION:As of 19 March 2025\, Suzhou Suncadia Biopharmaceuticals Co. es timated primary completion of a Phase 2 trial in nSCLC\, on 31 August 2026 .\n\nSource: clinicaltrials NCT06844474\nhttps://clinicaltrials.gov/study/ NCT06844474 URL:https://julienwillard.com/calendar/clinical#e-5589c40e-7e8f-4e28-a243-c 5342f7c040c END:VEVENT BEGIN:VEVENT UID:398c7168ebcc2807dd33d5cd4505acef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ORIC Pharmaceuticals ORIC-114: Trial primary completion DESCRIPTION:As of 5 August 2025\, ORIC Pharmaceuticals estimated primary co mpletion of a Phase 2 trial in Solid Tumors\, in September 2026.\n\nSource : clinicaltrials NCT05315700\nhttps://clinicaltrials.gov/study/NCT05315700 URL:https://julienwillard.com/calendar/clinical#e-357d338b-e9a6-4656-a97e-c 176b91248ed END:VEVENT BEGIN:VEVENT UID:415b0d35a1c4271768a6ae12de979faf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Georgiamune Inc GIM122: Trial primary completion DESCRIPTION:As of 11 July 2025\, Georgiamune estimated primary completion o f a Phase 2 trial in Advanced Solid Malignancies\, in September 2026.\n\nS ource: clinicaltrials NCT06028074\nhttps://clinicaltrials.gov/study/NCT060 28074 URL:https://julienwillard.com/calendar/clinical#e-04116947-3304-4346-bdd9-f 32999871366 END:VEVENT BEGIN:VEVENT UID:d59efb4bc80da59d3b001d1b925e71b0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Clarity Pharmaceuticals Ltd 64Cu-SAR-bisPSMA: Trial primary complet ion DESCRIPTION:As of 14 May 2026\, Clarity Pharmaceuticals estimated primary c ompletion of a Phase 3 trial in Prostate Cancer\, in September 2026.\n\nSo urce: clinicaltrials NCT06056830\nhttps://clinicaltrials.gov/study/NCT0605 6830 URL:https://julienwillard.com/calendar/clinical#e-47886e04-a60b-49d1-ae39-9 0a1151ae1e0 END:VEVENT BEGIN:VEVENT UID:dbe9426117b048e6b41c94b1439fb96b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Dostarlimab: Trial primary completion DESCRIPTION:As of 24 June 2026\, GlaxoSmithKline estimated primary completi on of a Phase 2 trial in Neoplasms\, Head and Neck\, on 1 September 2026.\ n\nSource: clinicaltrials NCT06062420\nhttps://clinicaltrials.gov/study/NC T06062420 URL:https://julienwillard.com/calendar/clinical#e-e48c0421-939b-4eb7-b671-1 06d30e710f6 END:VEVENT BEGIN:VEVENT UID:31757ea04896edaf23eeb673e6af3a29 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pharmazz\, Inc. Drug: Normal Saline: Trial primary completion DESCRIPTION:As of 24 June 2026\, Pharmazz estimated primary completion of a Phase 3 trial in Acute Ischemic Stroke\, in September 2026.\n\nSource: cl inicaltrials NCT05691244\nhttps://clinicaltrials.gov/study/NCT05691244 URL:https://julienwillard.com/calendar/clinical#e-f949be40-de4b-45f4-8216-a 4363837ae26 END:VEVENT BEGIN:VEVENT UID:a2b7dec0f00687ca69e0e109d3dbef13 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Zelgen Biopharmaceuticals Co.\,Ltd ZG006: Trial primary comp letion DESCRIPTION:As of 5 January 2026\, Suzhou Zelgen Biopharmaceuticals Co. est imated primary completion of a Phase 2 trial in Small Cell Lung Cancer\, i n September 2026.\n\nSource: clinicaltrials NCT05978284\nhttps://clinicalt rials.gov/study/NCT05978284 URL:https://julienwillard.com/calendar/clinical#e-994f1236-cd7a-421b-8cce-b cc4c7642f46 END:VEVENT BEGIN:VEVENT UID:2e9c0dfd396a0101b77ecaee122600e4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ribocure Pharmaceuticals AB RBD1016: Trial primary completion DESCRIPTION:As of 3 February 2026\, Ribocure Pharmaceuticals estimated prim ary completion of a Phase 2 trial in Chronic Hepatitis D\, in September 20 26.\n\nSource: clinicaltrials NCT06649266\nhttps://clinicaltrials.gov/stud y/NCT06649266 URL:https://julienwillard.com/calendar/clinical#e-28f45400-f51f-493d-b17c-e ba931f35dd2 END:VEVENT BEGIN:VEVENT UID:9ea51a19f4c63c22cc9f222fd4dfa8b2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Supernus Pharmaceuticals\, Inc. SPN-812: Trial primary completion DESCRIPTION:As of 15 July 2026\, Supernus Pharmaceuticals estimated primary completion of a Phase 3 trial in Attention-Deficit/Hyperactivity Disorder \, in September 2026.\n\nSource: clinicaltrials NCT02736656\nhttps://clini caltrials.gov/study/NCT02736656 URL:https://julienwillard.com/calendar/clinical#e-e020ca85-b22f-4c0b-b6a0-0 8a2fdae7817 END:VEVENT BEGIN:VEVENT UID:a9a94a800908f8a27f8bb0fd992d2cc0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ScandiBio Therapeutics AB Combined metabolic activators: Trial prim ary completion DESCRIPTION:As of 6 February 2026\, ScandiBio Therapeutics estimated primar y completion of a Phase 3 trial in Alzheimer Disease\, in September 2026.\ n\nSource: clinicaltrials NCT07062198\nhttps://clinicaltrials.gov/study/NC T07062198 URL:https://julienwillard.com/calendar/clinical#e-51505ee8-9ee1-45ad-9d79-5 a9f0fec4ed4 END:VEVENT BEGIN:VEVENT UID:e994a7e914bcc3719e8de8715eda6f9c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Corcept Therapeutics Nenocorilant 200 mg: Trial primary completion DESCRIPTION:As of 30 June 2026\, Corcept Therapeutics estimated primary com pletion of a Phase 2 trial in neoplasms\, in September 2026.\n\nSource: cl inicaltrials NCT07276373\nhttps://clinicaltrials.gov/study/NCT07276373 URL:https://julienwillard.com/calendar/clinical#e-2d05d6d5-bbb1-49dc-b446-a 18f88efa0e6 END:VEVENT BEGIN:VEVENT UID:a72dc5e987361fa3feeaee8b0faa2cfb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu BioJeTay Biotechnology Co.\, Ltd. STSP-0601 for Injection: Trial primary completion DESCRIPTION:As of 23 April 2026\, Jiangsu BioJeTay Biotechnology Co. estima ted primary completion of a Phase 3 trial in hemophilia\, in September 202 6.\n\nSource: clinicaltrials NCT06922045\nhttps://clinicaltrials.gov/study /NCT06922045 URL:https://julienwillard.com/calendar/clinical#e-902ce75c-c07e-40d0-8e10-4 314368ac847 END:VEVENT BEGIN:VEVENT UID:4cd06246cc11cf86703540c268f065f5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TYK Medicines\, Inc TYK-00540: Trial primary completion DESCRIPTION:As of 29 April 2025\, TYK Medicines estimated primary completio n of a Phase 2 trial in HR-positive\, HER2-negative Advanced Breast Cancer \, in September 2026.\n\nSource: clinicaltrials NCT06950086\nhttps://clini caltrials.gov/study/NCT06950086 URL:https://julienwillard.com/calendar/clinical#e-965679d2-4260-4f88-8346-e 46ef690b35e END:VEVENT BEGIN:VEVENT UID:1329bdcc628abc667e36f81b31cf8336 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Qilu Pharmaceutical Co.\, Ltd. GM1: Trial primary completion DESCRIPTION:As of 6 August 2025\, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Chemotherapy-induced Peripheral Neuropat hy (CIPN)\, in September 2026.\n\nSource: clinicaltrials NCT06994507\nhttp s://clinicaltrials.gov/study/NCT06994507 URL:https://julienwillard.com/calendar/clinical#e-37f14cb3-4910-4bad-bc65-0 c347e9c6c14 END:VEVENT BEGIN:VEVENT UID:08cb18bba720ee4c2458396d28c52bff DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Coordination Pharmaceuticals\, Inc. RiMO-301: Trial primary complet ion DESCRIPTION:As of 17 September 2025\, Coordination Pharmaceuticals estimate d primary completion of a Phase 2 trial in Head Neck Cancer\, in September 2026.\n\nSource: clinicaltrials NCT05838729\nhttps://clinicaltrials.gov/s tudy/NCT05838729 URL:https://julienwillard.com/calendar/clinical#e-848592a1-000a-41af-b349-e bff5e0951e1 END:VEVENT BEGIN:VEVENT UID:72541a3b0a1c638242682b3cb3574a3c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Octapharma Newnorm: Trial primary completion DESCRIPTION:As of 6 August 2026\, Octapharma estimated primary completion o f a Phase 3 trial in Primary Immune Deficiency\, in September 2026.\n\nSou rce: clinicaltrials NCT04640142\nhttps://clinicaltrials.gov/study/NCT04640 142 URL:https://julienwillard.com/calendar/clinical#e-ea0bd0e6-c702-4b6c-a51c-2 37bb32ad5cd END:VEVENT BEGIN:VEVENT UID:ebfff907875a4c617df0f74dd859788e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MediLink Therapeutics (Suzhou) Co.\, Ltd. YL202 for injection\; Tor ipalimab injection: Trial primary completion DESCRIPTION:As of 12 September 2025\, MediLink Therapeutics (Suzhou) Co. es timated primary completion of a Phase 2 trial in Advanced Solid Tumors\, o n 1 September 2026.\n\nSource: clinicaltrials NCT07169994\nhttps://clinica ltrials.gov/study/NCT07169994 URL:https://julienwillard.com/calendar/clinical#e-e2a5b335-8c36-4132-8b1e-3 377b0832194 END:VEVENT BEGIN:VEVENT UID:0076b5e33c3addfc82f3da6a67e8b0fc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hexaell Biotech Co.\, Ltd. HepaCure: Trial primary completion DESCRIPTION:As of 25 February 2025\, Hexaell Biotech Co. estimated primary completion of a Phase 2 trial in Acute on Chronic Hepatic Failure\, in Sep tember 2026.\n\nSource: clinicaltrials NCT05989958\nhttps://clinicaltrials .gov/study/NCT05989958 URL:https://julienwillard.com/calendar/clinical#e-f1fc0763-3ff0-4ef3-9bd4-f 496fdb99b91 END:VEVENT BEGIN:VEVENT UID:97b453415b3c9fbe9d03e98909b0f895 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Maze Therapeutics MZE829: Trial primary completion DESCRIPTION:As of 27 July 2026\, Maze Therapeutics estimated primary comple tion of a Phase 2 trial in Proteinuric Kidney Disease\, in September 2026. \n\nSource: clinicaltrials NCT06830629\nhttps://clinicaltrials.gov/study/N CT06830629 URL:https://julienwillard.com/calendar/clinical#e-42913b59-7905-484d-939e-c 244ff287762 END:VEVENT BEGIN:VEVENT UID:347b181a9b697e8d53b4c9959cd078fa DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gilead Sciences Sacituzumab Govitecan-hziy (SG): Trial primary comp letion DESCRIPTION:As of 11 February 2026\, Gilead Sciences estimated primary comp letion of a Phase 2 trial in Non-small Cell Lung Cancer\, in September 202 6.\n\nSource: clinicaltrials NCT05186974\nhttps://clinicaltrials.gov/study /NCT05186974 URL:https://julienwillard.com/calendar/clinical#e-9ffe7e98-e640-46e4-a752-1 b7f6a5e4f6d END:VEVENT BEGIN:VEVENT UID:0e5cd156dac8f51df31df0eaca27a85c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vanda Pharmaceuticals Tasimelteon: Trial primary completion DESCRIPTION:As of 27 July 2026\, Vanda Pharmaceuticals estimated primary co mpletion of a Phase 3 trial in Sleep Wake Disorders\, in September 2026.\n \nSource: clinicaltrials NCT04652882\nhttps://clinicaltrials.gov/study/NCT 04652882 URL:https://julienwillard.com/calendar/clinical#e-93866912-df05-47a9-bc5d-d 070bb8b46b6 END:VEVENT BEGIN:VEVENT UID:eb83adc3bd4e2ea9d80cd3aeb5c649f3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Disc Medicine\, Inc DISC-1459: Trial primary completion DESCRIPTION:As of 3 August 2026\, Disc Medicine estimated primary completio n of a Phase 3 trial in Erythropoietic Protoporphyria (EPP)\, in September 2026.\n\nSource: clinicaltrials NCT06910358\nhttps://clinicaltrials.gov/s tudy/NCT06910358 URL:https://julienwillard.com/calendar/clinical#e-549b1376-1e47-4af2-86c3-b 22f2ad4bcce END:VEVENT BEGIN:VEVENT UID:04d9d732a20d817c6756e213d4e900e1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Zelgen Biopharmaceuticals Co.\,Ltd ZG005 for Injection: Tria l primary completion DESCRIPTION:As of 16 December 2024\, Suzhou Zelgen Biopharmaceuticals Co. e stimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma \, in September 2026.\n\nSource: clinicaltrials NCT06558227\nhttps://clini caltrials.gov/study/NCT06558227 URL:https://julienwillard.com/calendar/clinical#e-ba7097d1-a32a-4296-93c5-f 6ca11eb6b7a END:VEVENT BEGIN:VEVENT UID:5e16f7813818d638e47253e6bc8ac109 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Abscint NV/SA 68Ga-NOTA-ABSCINT-HER2 PET/CT: Trial primary completi on DESCRIPTION:As of 2 June 2026\, Abscint NV/SA estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer\, in September 2026.\n\nSou rce: clinicaltrials NCT06369831\nhttps://clinicaltrials.gov/study/NCT06369 831 URL:https://julienwillard.com/calendar/clinical#e-990bdf15-73ee-4d1e-8415-3 abec52044a3 END:VEVENT BEGIN:VEVENT UID:7912098b5eab0ee0a0147615050ba21e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer ARV-471: Trial primary completion DESCRIPTION:As of 10 February 2026\, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer\, on 1 September 2026.\n\nSource: clinic altrials NCT05548127\nhttps://clinicaltrials.gov/study/NCT05548127 URL:https://julienwillard.com/calendar/clinical#e-d6a8d5e8-8dba-4950-973b-0 4416d12ddc2 END:VEVENT BEGIN:VEVENT UID:701eff533ed612527ec78c0c74bfb7d6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Qlaris Bio\, Inc. QLS-111 Ophthalmic Solution (0.015%): Trial prima ry completion DESCRIPTION:As of 6 July 2026\, Qlaris Bio estimated primary completion of a Phase 2 trial in Non-proliferative Diabetic Retinopathy (NPDR)\, in Sept ember 2026.\n\nSource: clinicaltrials NCT07354477\nhttps://clinicaltrials. gov/study/NCT07354477 URL:https://julienwillard.com/calendar/clinical#e-1f33554d-c342-49a2-897a-9 2405a8c7d7d END:VEVENT BEGIN:VEVENT UID:80f8b025bec62addd62ac40ff844ed65 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Guangdong Hengrui Pharmaceutical Co.\, Ltd SHR-1905 Injection: Tria l primary completion DESCRIPTION:As of 8 April 2026\, Guangdong Hengrui Pharmaceutical Co. estim ated primary completion of a Phase 2 trial in Moderate-to-severe Atopic De rmatitis\, in September 2026.\n\nSource: clinicaltrials NCT07211542\nhttps ://clinicaltrials.gov/study/NCT07211542 URL:https://julienwillard.com/calendar/clinical#e-53133ee0-7753-4514-aca1-4 d9bf2112561 END:VEVENT BEGIN:VEVENT UID:98774140abdc626d603b04f0eda35bb0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai HyaMab Biotech Co.\,Ltd. PE0116&PE0105: Trial primary comp letion DESCRIPTION:As of 15 December 2023\, Shanghai HyaMab Biotech Co. estimated primary completion of a Phase 2 trial in Locally Advanced/Metastatic Solid Tumors\, in September 2026.\n\nSource: clinicaltrials NCT05801237\nhttps: //clinicaltrials.gov/study/NCT05801237 URL:https://julienwillard.com/calendar/clinical#e-9b77a3ad-59d6-49b3-b133-b 2c581929ca7 END:VEVENT BEGIN:VEVENT UID:4f8df328f904f3766db3d1e1a1ce25eb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:R-Pharm International\, LLC OKZ q4w: Trial primary completion DESCRIPTION:As of 8 April 2026\, R-Pharm International estimated primary co mpletion of a Phase 2 trial in Juvenile Idiopathic Arthritis\, in Septembe r 2026.\n\nSource: clinicaltrials NCT07517575\nhttps://clinicaltrials.gov/ study/NCT07517575 URL:https://julienwillard.com/calendar/clinical#e-6b4a3a06-fd13-4423-b173-9 dfe93e744c0 END:VEVENT BEGIN:VEVENT UID:b6aea8c25699f2c15027ee45f5e33d84 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biohaven Therapeutics Ltd. Taldefgrobep Alfa: Trial primary complet ion DESCRIPTION:As of 20 March 2026\, Biohaven Therapeutics estimated primary c ompletion of a Phase 2 trial in obesity\, in September 2026.\n\nSource: cl inicaltrials NCT07281495\nhttps://clinicaltrials.gov/study/NCT07281495 URL:https://julienwillard.com/calendar/clinical#e-c3bc70ad-ac96-42a4-a5ce-4 36693c75ab0 END:VEVENT BEGIN:VEVENT UID:211bb638fa8a877d52923b691b9754a1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Agitated Solutions\, Inc. Agitated Saline SoC: Trial primary comple tion DESCRIPTION:As of 6 July 2026\, Agitated Solutions estimated primary comple tion of a Phase 3 trial in Right-To-Left Shunt\, in September 2026.\n\nSou rce: clinicaltrials NCT06938347\nhttps://clinicaltrials.gov/study/NCT06938 347 URL:https://julienwillard.com/calendar/clinical#e-47f3de3b-10d2-4d9b-af98-2 6580a04e2bf END:VEVENT BEGIN:VEVENT UID:f1eaab61114c3b84eaf405a19beb3674 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novo Nordisk A/S NNC0519-0130: Trial primary completion DESCRIPTION:As of 11 March 2026\, Novo Nordisk estimated primary completion of a Phase 2 trial in Chronic Kidney Disease\, on 1 September 2026.\n\nSo urce: clinicaltrials NCT06717698\nhttps://clinicaltrials.gov/study/NCT0671 7698 URL:https://julienwillard.com/calendar/clinical#e-0f7addd0-dd46-4049-9e08-2 03a31463b5c END:VEVENT BEGIN:VEVENT UID:e1da2bc592d1df6aa9764cdb31094796 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sinovac Life Sciences Co.\, Ltd. Sinovac PCV24: Trial primary compl etion DESCRIPTION:As of 24 December 2025\, Sinovac Life Sciences Co. estimated pr imary completion of a Phase 2 trial in Pneumococcal Infectious Disease\, i n September 2026.\n\nSource: clinicaltrials NCT07300644\nhttps://clinicalt rials.gov/study/NCT07300644 URL:https://julienwillard.com/calendar/clinical#e-5c2391c3-c77c-4b97-b260-3 d69c1b9ecf6 END:VEVENT BEGIN:VEVENT UID:0be96a271f0bbc55f85b2c07578a2d39 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company LY3650150: Trial primary completion DESCRIPTION:As of 22 July 2026\, Eli Lilly and estimated primary completion of a Phase 3 trial in Perennial Allergic Rhinitis (PAR)\, in September 20 26.\n\nSource: clinicaltrials NCT06339008\nhttps://clinicaltrials.gov/stud y/NCT06339008 URL:https://julienwillard.com/calendar/clinical#e-ed3c3a47-e48f-48ff-9a3a-f 1becf3b8a08 END:VEVENT BEGIN:VEVENT UID:545d0849061f82d6e85b968ee862de12 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Nacuity Pharmaceuticals\, Inc. NPI-002 Intravitreal Implant: Trial primary completion DESCRIPTION:As of 13 April 2026\, Nacuity Pharmaceuticals estimated primary completion of a Phase 2 trial in cataract\, in September 2026.\n\nSource: clinicaltrials NCT05026632\nhttps://clinicaltrials.gov/study/NCT05026632 URL:https://julienwillard.com/calendar/clinical#e-d09f9c8d-6255-4c0c-bf87-7 718a2e3f791 END:VEVENT BEGIN:VEVENT UID:e2415fe8ac1a1c274d327c8c3cffc744 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tourmaline Bio\, Inc.\, a Novartis Company TOUR006 - 20 MG: Trial p rimary completion DESCRIPTION:As of 23 April 2026\, Tourmaline Bio\, Inc.\, a Novartis estima ted primary completion of a Phase 2 trial in Thyroid Eye Disease\, in Sept ember 2026.\n\nSource: clinicaltrials NCT06088979\nhttps://clinicaltrials. gov/study/NCT06088979 URL:https://julienwillard.com/calendar/clinical#e-0038f6e1-85cd-4648-a33a-7 d1d13b9cd40 END:VEVENT BEGIN:VEVENT UID:c3080435215c93e00d79c345e048939a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Processa Pharmaceuticals PCS6422 and capecitabine: Trial primary co mpletion DESCRIPTION:As of 19 June 2025\, Processa Pharmaceuticals estimated primary completion of a Phase 2 trial in Breast Cancer\, in September 2026.\n\nSo urce: clinicaltrials NCT06568692\nhttps://clinicaltrials.gov/study/NCT0656 8692 URL:https://julienwillard.com/calendar/clinical#e-517baf7a-11b2-4279-af64-b 302cba54597 END:VEVENT BEGIN:VEVENT UID:6ef8792ca47c2f3e0a7db033593b9a3a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shandong Suncadia Medicine Co.\, Ltd. HRS-1893 Tablets: Trial prima ry completion DESCRIPTION:As of 20 August 2025\, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 3 trial in Obstructive Hypertrophic Cardiom yopathy\, in September 2026.\n\nSource: clinicaltrials NCT07021976\nhttps: //clinicaltrials.gov/study/NCT07021976 URL:https://julienwillard.com/calendar/clinical#e-a40301b5-8d8c-4b0b-965a-1 b0803a1de79 END:VEVENT BEGIN:VEVENT UID:b6a2bb42b6db0d6710390bef8ff0e619 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NewAmsterdam Pharma Obicetrapib 10mg: Trial primary completion DESCRIPTION:As of 20 October 2025\, NewAmsterdam Pharma estimated primary c ompletion of a Phase 2 trial in Antioxidant Absorption\, in September 2026 .\n\nSource: clinicaltrials NCT06982508\nhttps://clinicaltrials.gov/study/ NCT06982508 URL:https://julienwillard.com/calendar/clinical#e-90510ce2-db6a-4583-953e-8 dc37e7ec9b2 END:VEVENT BEGIN:VEVENT UID:248cde6124e46fc103f58847739df2c0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CuraSen Therapeutics\, Inc. CST-3056: Trial primary completion DESCRIPTION:As of 30 July 2026\, CuraSen Therapeutics estimated primary com pletion of a Phase 2 trial in Neurogenic Orthostatic Hypotension\, in Sept ember 2026.\n\nSource: clinicaltrials NCT07089043\nhttps://clinicaltrials. gov/study/NCT07089043 URL:https://julienwillard.com/calendar/clinical#e-afc60bf1-493a-49dc-a806-5 3d5cdf8d8c9 END:VEVENT BEGIN:VEVENT UID:352cb228df2b337a11aaa7ef266a6776 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tango Therapeutics\, Inc. TNG260: Trial primary completion DESCRIPTION:As of 6 July 2026\, Tango Therapeutics estimated primary comple tion of a Phase 2 trial in Non Small Cell Lung Cancer\, in September 2026. \n\nSource: clinicaltrials NCT05887492\nhttps://clinicaltrials.gov/study/N CT05887492 URL:https://julienwillard.com/calendar/clinical#e-b2f2874d-0156-490f-9aa6-6 fe4a7f9c6ac END:VEVENT BEGIN:VEVENT UID:8158c062950ae1b4ca4f64c8259453fe DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Incyte Corporation Tafasitamab: Trial primary completion DESCRIPTION:As of 1 April 2026\, Incyte estimated primary completion of a P hase 3 trial in Diffuse Large B-cell Lymphoma\, on 1 September 2026.\n\nSo urce: clinicaltrials NCT04824092\nhttps://clinicaltrials.gov/study/NCT0482 4092 URL:https://julienwillard.com/calendar/clinical#e-9189900f-0c04-4ae1-92d3-d d464a01bd59 END:VEVENT BEGIN:VEVENT UID:4fc924cdfe0c8b1e3f51439b434cc505 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gilead Sciences TAF: Trial primary completion DESCRIPTION:As of 18 June 2026\, Gilead Sciences estimated primary completi on of a Phase 2 trial in Chronic Hepatitis B\, in September 2026.\n\nSourc e: clinicaltrials NCT02932150\nhttps://clinicaltrials.gov/study/NCT0293215 0 URL:https://julienwillard.com/calendar/clinical#e-8e7e5cfe-658f-4f30-9000-1 f9dd4cc9ce9 END:VEVENT BEGIN:VEVENT UID:4456d0e02a5ce47148d0c9eca7383530 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gasherbrum Bio\, Inc.\, a wholly owned subsidiary of Structure Ther apeutics Aleniglipron: Trial primary completion DESCRIPTION:As of 27 April 2026\, Gasherbrum Bio estimated primary completi on of a Phase 2 trial in obese\, in September 2026.\n\nSource: clinicaltri als NCT07400588\nhttps://clinicaltrials.gov/study/NCT07400588 URL:https://julienwillard.com/calendar/clinical#e-99d6d25e-d85a-4d3a-ac90-b 640fdf53d00 END:VEVENT BEGIN:VEVENT UID:136b63e2f1228037a60290cf35f37322 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Corcept Therapeutics Miricorilant (Cohort A): Trial primary complet ion DESCRIPTION:As of 8 May 2026\, Corcept Therapeutics estimated primary compl etion of a Phase 2 trial in Nonalcoholic Steatohepatitis (NASH)\, in Septe mber 2026.\n\nSource: clinicaltrials NCT06108219\nhttps://clinicaltrials.g ov/study/NCT06108219 URL:https://julienwillard.com/calendar/clinical#e-8333350f-04a8-4c88-bcf6-e a93b2a73a15 END:VEVENT BEGIN:VEVENT UID:88da413dbc16571e440425e2bc888752 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amydis Inc. AMDX-2011P: Trial primary completion DESCRIPTION:As of 13 February 2026\, Amydis estimated primary completion of a Phase 2 trial in Alzheimer Disease\, in September 2026.\n\nSource: clin icaltrials NCT06514001\nhttps://clinicaltrials.gov/study/NCT06514001 URL:https://julienwillard.com/calendar/clinical#e-40e91285-f886-4eb3-81fc-d bd98a077020 END:VEVENT BEGIN:VEVENT UID:e5980d06b719bf68a9da65d61c6c6205 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Edgewise Therapeutics\, Inc. Sevasemten 10 mg: Trial primary comple tion DESCRIPTION:As of 31 July 2026\, Edgewise Therapeutics estimated primary co mpletion of a Phase 2 trial in Becker Muscular Dystrophy\, in September 20 26.\n\nSource: clinicaltrials NCT05291091\nhttps://clinicaltrials.gov/stud y/NCT05291091 URL:https://julienwillard.com/calendar/clinical#e-90585667-8ef4-4dca-a37a-4 e75cc3be12b END:VEVENT BEGIN:VEVENT UID:591d883d6086c61577ef26e902979310 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Arthrosi Therapeutics AR882 50 mg: Trial primary completion DESCRIPTION:As of 12 May 2026\, Arthrosi Therapeutics estimated primary com pletion of a Phase 3 trial in gout\, in September 2026.\n\nSource: clinica ltrials NCT06846515\nhttps://clinicaltrials.gov/study/NCT06846515 URL:https://julienwillard.com/calendar/clinical#e-870ad692-9282-4d6b-96fc-5 48c8df1aaf0 END:VEVENT BEGIN:VEVENT UID:e563ca0ae445e09629054d842ce4263d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Glaukos Corporation GLK-321 low dose BID: Trial primary completion DESCRIPTION:As of 27 February 2026\, Glaukos estimated primary completion o f a Phase 2 trial in Demodex Blepharitis\, in September 2026.\n\nSource: c linicaltrials NCT07400965\nhttps://clinicaltrials.gov/study/NCT07400965 URL:https://julienwillard.com/calendar/clinical#e-f8d55dcf-f9d3-49ee-bf02-c 5a7356cb0b5 END:VEVENT BEGIN:VEVENT UID:dc42171c8d57f0ee6c3f0d81202dedb1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:EIP Pharma Inc Neflamapimod: Trial primary completion DESCRIPTION:As of 6 July 2026\, EIP Pharma estimated primary completion of a Phase 2 trial in Nonfluent Variant Primary Progressive Aphasia (nfvPPA)\ , in September 2026.\n\nSource: clinicaltrials NCT07033481\nhttps://clinic altrials.gov/study/NCT07033481 URL:https://julienwillard.com/calendar/clinical#e-b4a6e8ff-a757-4c65-b254-f b3320411a38 END:VEVENT BEGIN:VEVENT UID:a6338059e28f872368df3d3de2ec30d9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cytokinetics CK-4021586 (150 mg\, 300 mg\, 450 mg\, and 600 mg): Tr ial primary completion DESCRIPTION:As of 29 May 2026\, Cytokinetics estimated primary completion o f a Phase 2 trial in Symptomatic Heart Failure With Preserved Ejection Fra ction (HFpEF)\, in September 2026.\n\nSource: clinicaltrials NCT06793371\n https://clinicaltrials.gov/study/NCT06793371 URL:https://julienwillard.com/calendar/clinical#e-4c62df99-548b-49cc-b59e-e a4dbff8df77 END:VEVENT BEGIN:VEVENT UID:14b1b9851ef3237c646d9081d56221ff DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Karyopharm Therapeutics Inc Selinexor: Trial primary completion DESCRIPTION:As of 2 July 2026\, Karyopharm Therapeutics estimated primary c ompletion of a Phase 2 trial in myelofibrosis\, in September 2026.\n\nSour ce: clinicaltrials NCT04562870\nhttps://clinicaltrials.gov/study/NCT045628 70 URL:https://julienwillard.com/calendar/clinical#e-32f8ea52-dae7-48ed-973e-4 108efc60600 END:VEVENT BEGIN:VEVENT UID:0295dcf81179130f9c44332719ba1d9c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Initiator Pharma Pudafensine: Trial primary completion DESCRIPTION:As of 5 February 2026\, Initiator Pharma estimated primary comp letion of a Phase 2 trial in vulvodynia\, on 1 September 2026.\n\nSource: clinicaltrials NCT07391241\nhttps://clinicaltrials.gov/study/NCT07391241 URL:https://julienwillard.com/calendar/clinical#e-9536023d-43b9-42c1-9ed3-4 574d9e53845 END:VEVENT BEGIN:VEVENT UID:db498da20d7d49c1b8096f1e1358c8c9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Design Therapeutics\, Inc. DT-168: Trial primary completion DESCRIPTION:As of 29 December 2025\, Design Therapeutics estimated primary completion of a Phase 2 trial in Fuchs Endothelial Corneal Dystrophy\, in September 2026.\n\nSource: clinicaltrials NCT07024693\nhttps://clinicaltri als.gov/study/NCT07024693 URL:https://julienwillard.com/calendar/clinical#e-9df7332e-33e6-47d2-a06d-c 1566dbee32a END:VEVENT BEGIN:VEVENT UID:547b21e17195022473a832211294bd09 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vigonvita Life Sciences LV232 40mg: Trial primary completion DESCRIPTION:As of 20 May 2026\, Vigonvita Life Sciences estimated primary c ompletion of a Phase 2 trial in mDD\, on 1 September 2026.\n\nSource: clin icaltrials NCT06828887\nhttps://clinicaltrials.gov/study/NCT06828887 URL:https://julienwillard.com/calendar/clinical#e-a696ace5-6ed2-423e-be78-f eac3fde47b9 END:VEVENT BEGIN:VEVENT UID:42bed133037c217a2663158c1fbd3095 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vanda Pharmaceuticals VSJ-110: Trial primary completion DESCRIPTION:As of 17 September 2025\, Vanda Pharmaceuticals estimated prima ry completion of a Phase 2 trial in Dry Eye\, in September 2026.\n\nSource : clinicaltrials NCT07179055\nhttps://clinicaltrials.gov/study/NCT07179055 URL:https://julienwillard.com/calendar/clinical#e-46666be3-0932-4090-9f14-c 381d9113bad END:VEVENT BEGIN:VEVENT UID:0b2e64d56a03aa566fb24580426a6b6f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Fujian Shengdi Pharmaceutical Co.\, Ltd. HRS-7249 Injection: Trial primary completion DESCRIPTION:As of 3 June 2026\, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in hyperlipidemia\, in September 20 26.\n\nSource: clinicaltrials NCT07100418\nhttps://clinicaltrials.gov/stud y/NCT07100418 URL:https://julienwillard.com/calendar/clinical#e-6359774f-d3fe-4f02-9530-0 6314947a44f END:VEVENT BEGIN:VEVENT UID:56ef14cc7a77ab118bfb7339dca9f33a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Alkermes\, Inc. OLZ/SAM: Trial primary completion DESCRIPTION:As of 3 June 2026\, Alkermes estimated primary completion of a Phase 3 trial in schizophrenia\, in September 2026.\n\nSource: clinicaltri als NCT05303064\nhttps://clinicaltrials.gov/study/NCT05303064 URL:https://julienwillard.com/calendar/clinical#e-e7a1b847-ba7e-4baf-9ab6-c ac599207cd2 END:VEVENT BEGIN:VEVENT UID:ceff9f31a085f2f8f9e5d4c09825a27e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tiziana Life Sciences LTD Foralumab: Trial primary completion DESCRIPTION:As of 2 July 2026\, Tiziana Life Sciences estimated primary com pletion of a Phase 2 trial in Secondary Progressive Multiple Sclerosis\, i n September 2026.\n\nSource: clinicaltrials NCT06292923\nhttps://clinicalt rials.gov/study/NCT06292923 URL:https://julienwillard.com/calendar/clinical#e-95abf599-931b-451f-b00a-9 0eb733da072 END:VEVENT BEGIN:VEVENT UID:b0e162155c2b84758ea5dcb52276f7bd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Silence Therapeutics plc SLN124: Trial primary completion DESCRIPTION:As of 19 December 2025\, Silence Therapeutics estimated primary completion of a Phase 2 trial in Polycythemia Vera\, in September 2026.\n \nSource: clinicaltrials NCT05499013\nhttps://clinicaltrials.gov/study/NCT 05499013 URL:https://julienwillard.com/calendar/clinical#e-93aaf15a-3a6c-4d6b-99eb-d c3105a93e69 END:VEVENT BEGIN:VEVENT UID:89d7794c79f935c9ba4952b4778b2285 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Clarity Pharmaceuticals Ltd 64Cu-SAR-bisPSMA: Trial primary complet ion DESCRIPTION:As of 6 May 2026\, Clarity Pharmaceuticals estimated primary co mpletion of a Phase 2 trial in Prostatic Neoplasms\, Castration-Resistant\ , in September 2026.\n\nSource: clinicaltrials NCT04868604\nhttps://clinic altrials.gov/study/NCT04868604 URL:https://julienwillard.com/calendar/clinical#e-0bb16fba-5c95-47c1-bb7d-3 edbd0c06e7d END:VEVENT BEGIN:VEVENT UID:119f55d0dd4cd3c8a442053135111220 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Mabwell (Shanghai) Bioscience Co.\, Ltd. 9MW2821: Trial primary com pletion DESCRIPTION:As of 13 April 2025\, Mabwell (Shanghai) Bioscience Co. estimat ed primary completion of a Phase 3 trial in Advanced Urothelial Carcinoma\ , in September 2026.\n\nSource: clinicaltrials NCT06196736\nhttps://clinic altrials.gov/study/NCT06196736 URL:https://julienwillard.com/calendar/clinical#e-940bba22-dd2b-4795-854c-6 9dfbeb2006d END:VEVENT BEGIN:VEVENT UID:9698db65369d5e1713dbca412c755541 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. TQB6411 Injection : Trial primary completion DESCRIPTION:As of 2 July 2026\, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Esophageal Cancer\, in September 2026.\n\nSource: clinicaltrials NCT07367516\nhttps://clinicaltri als.gov/study/NCT07367516 URL:https://julienwillard.com/calendar/clinical#e-a045ef92-de23-4aeb-a71b-0 cf62995ae07 END:VEVENT BEGIN:VEVENT UID:09e13a7f5d570d1e53cff4639ad3d00d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Colgate Palmolive 8% arginine + Zinc toothpaste: Trial primary comp letion DESCRIPTION:As of 7 August 2026\, Colgate Palmolive estimated primary compl etion of a Phase 3 trial in Dentinal Sensitivity\, in September 2026.\n\nS ource: clinicaltrials NCT07664592\nhttps://clinicaltrials.gov/study/NCT076 64592 URL:https://julienwillard.com/calendar/clinical#e-29403a80-f156-46ae-9d35-6 6b2687de3dc END:VEVENT BEGIN:VEVENT UID:f3e16a1a63e50c747a85e99ede7a9d5c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Syndax Pharmaceuticals Axatilimab: Trial primary completion DESCRIPTION:As of 27 March 2026\, Syndax Pharmaceuticals estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis\, in Septem ber 2026.\n\nSource: clinicaltrials NCT06132256\nhttps://clinicaltrials.go v/study/NCT06132256 URL:https://julienwillard.com/calendar/clinical#e-0beb6e20-3120-47d9-8376-0 50ee834de58 END:VEVENT BEGIN:VEVENT UID:3cd8b02439b945ab5a4b458a4dc141cb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Atea Pharmaceuticals\, Inc. Bemnifosbuvir-Ruzasvir (BEM/RZR): Trial primary completion DESCRIPTION:As of 5 December 2025\, Atea Pharmaceuticals estimated primary completion of a Phase 3 trial in HEPATITIS C VIRUS CHRONIC INFECTION\, in September 2026.\n\nSource: clinicaltrials NCT06868264\nhttps://clinicaltri als.gov/study/NCT06868264 URL:https://julienwillard.com/calendar/clinical#e-600355db-d286-440b-ac6d-7 6980402b198 END:VEVENT BEGIN:VEVENT UID:6f3b4df88e1b56126f33c4e274fa717d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:argenx Empasiprubart: Trial primary completion DESCRIPTION:As of 20 May 2026\, argenx estimated primary completion of a Ph ase 3 trial in Multifocal Motor Neuropathy (MMN)\, in September 2026.\n\nS ource: clinicaltrials NCT06742190\nhttps://clinicaltrials.gov/study/NCT067 42190 URL:https://julienwillard.com/calendar/clinical#e-5f51c131-e892-46f2-9419-4 734596e4e36 END:VEVENT BEGIN:VEVENT UID:7431178e30a49b2fbda5e0743be2ae7c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company Tirzepatide: Trial primary completion DESCRIPTION:As of 8 May 2026\, Eli Lilly and estimated primary completion o f a Phase 2 trial in overweight\, in September 2026.\n\nSource: clinicaltr ials NCT05536804\nhttps://clinicaltrials.gov/study/NCT05536804 URL:https://julienwillard.com/calendar/clinical#e-44d79db7-bb6e-428c-b8fd-f 05b2b7092ea END:VEVENT BEGIN:VEVENT UID:1450e5f553f5d44d7e2a48a54185c17e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Repurposed Therapeutics\, Inc. DPI-386 Nasal Gel: Trial primary com pletion DESCRIPTION:As of 16 May 2024\, Repurposed Therapeutics estimated primary c ompletion of a Phase 2 trial in Motion Sickness\, Space\, in September 202 6.\n\nSource: clinicaltrials NCT05852730\nhttps://clinicaltrials.gov/study /NCT05852730 URL:https://julienwillard.com/calendar/clinical#e-a2268ab3-74b3-4280-b7a4-0 0b3dfe1a853 END:VEVENT BEGIN:VEVENT UID:e7172261d12d1c9ddf5f9558c8a2211d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vanda Pharmaceuticals Trichostatin A: Trial primary completion DESCRIPTION:As of 4 February 2026\, Vanda Pharmaceuticals estimated primary completion of a Phase 2 trial in Onychomycosis of Toenail\, in September 2026.\n\nSource: clinicaltrials NCT07065773\nhttps://clinicaltrials.gov/st udy/NCT07065773 URL:https://julienwillard.com/calendar/clinical#e-fc629019-e63d-4c0f-a05c-a 93a352bd39f END:VEVENT BEGIN:VEVENT UID:9a6ca896931f38ec541c44a4fd915183 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie Adalimumab: Trial primary completion DESCRIPTION:As of 31 July 2026\, AbbVie estimated primary completion of a P hase 3 trial in Juvenile Psoriatic Arthritis\, in September 2026.\n\nSourc e: clinicaltrials NCT06100744\nhttps://clinicaltrials.gov/study/NCT0610074 4 URL:https://julienwillard.com/calendar/clinical#e-9f79a263-42d1-4b85-8ce0-4 bd3a48a58b1 END:VEVENT BEGIN:VEVENT UID:fe46c1dc48491b62ac4a9dada8904018 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cook MyoSite AMDC-USR (iltamiocel): Trial primary completion DESCRIPTION:As of 13 March 2026\, Cook MyoSite estimated primary completion of a Phase 3 trial in Stress Urinary Incontinence\, in September 2026.\n\ nSource: clinicaltrials NCT03104517\nhttps://clinicaltrials.gov/study/NCT0 3104517 URL:https://julienwillard.com/calendar/clinical#e-7c981518-d7e3-433b-baf0-d b7282c18d91 END:VEVENT BEGIN:VEVENT UID:af8348e2b6a8948daaef2bdf414be58e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tarian Pharma Brimonidine tartrate Gel: Trial primary completion DESCRIPTION:As of 10 February 2025\, Tarian Pharma estimated primary comple tion of a Phase 2 trial in EGFR Inhibitor-associated Rash\, on 1 September 2026.\n\nSource: clinicaltrials NCT06818058\nhttps://clinicaltrials.gov/s tudy/NCT06818058 URL:https://julienwillard.com/calendar/clinical#e-1f863553-b8de-4283-a6f6-f e95be3d0694 END:VEVENT BEGIN:VEVENT UID:e276e4b5809de069b76487ccbe24d0a5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Lubris Bio Pty Ltd rhPRG4 450ug/ml: Trial primary completion DESCRIPTION:As of 20 January 2026\, Lubris Bio Pty estimated primary comple tion of a Phase 2 trial in Ocular Graft Versus Host Disease\, in September 2026.\n\nSource: clinicaltrials NCT07118254\nhttps://clinicaltrials.gov/s tudy/NCT07118254 URL:https://julienwillard.com/calendar/clinical#e-40eccffb-426d-4ed0-8895-4 3d2888c66dc END:VEVENT BEGIN:VEVENT UID:d60585b36caf514db0572a13c9ad071e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ardelyx Tenapanor 50 MG: Trial primary completion DESCRIPTION:As of 4 June 2026\, Ardelyx estimated primary completion of a P hase 3 trial in Irritable Bowel Syndrome With Constipation (IBS-C)\, on 1 September 2026.\n\nSource: clinicaltrials NCT05643534\nhttps://clinicaltri als.gov/study/NCT05643534 URL:https://julienwillard.com/calendar/clinical#e-f6b7fced-1c61-41c0-a060-4 02c40c27235 END:VEVENT BEGIN:VEVENT UID:7f36449f121547b65edfa54dccd88a85 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Alfasigma S.p.A. Filgotinib: Trial primary completion DESCRIPTION:As of 22 May 2026\, Alfasigma S.p.A. estimated primary completi on of a Phase 3 trial in Ulcerative Colitis\, in September 2026.\n\nSource : clinicaltrials NCT02914535\nhttps://clinicaltrials.gov/study/NCT02914535 URL:https://julienwillard.com/calendar/clinical#e-b0c9fcd0-163b-4114-92ba-e 435ef93f959 END:VEVENT BEGIN:VEVENT UID:ef44f85028fcaa81c612d36b70334d14 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bio-Thera Solutions Recombinant humanized anti-PD-1 monoclonal anti body injection: Trial primary completion DESCRIPTION:As of 10 February 2025\, Bio-Thera Solutions estimated primary completion of a Phase 3 trial in Cervical Cancer\, in September 2026.\n\nS ource: clinicaltrials NCT06123884\nhttps://clinicaltrials.gov/study/NCT061 23884 URL:https://julienwillard.com/calendar/clinical#e-a8aaf6c5-2c09-4ab7-805a-a 05a9bc3db15 END:VEVENT BEGIN:VEVENT UID:515c368b84d7b98c3cef8462a5ecb8e2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing Continent Pharmaceutical Co\, Ltd. F573 for injection: Tria l primary completion DESCRIPTION:As of 19 November 2025\, Beijing Continent Pharmaceutical Co es timated primary completion of a Phase 2 trial in Acute Liver Failure\, on 1 September 2026.\n\nSource: clinicaltrials NCT05689645\nhttps://clinicalt rials.gov/study/NCT05689645 URL:https://julienwillard.com/calendar/clinical#e-2f20de4c-f0dd-432a-bc13-1 7970c9e31b8 END:VEVENT BEGIN:VEVENT UID:8723d0f968cd06fa2be1af8cf3e22edd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Mabwell (Shanghai) Bioscience Co.\, Ltd. 9MW2921: Trial primary com pletion DESCRIPTION:As of 21 November 2024\, Mabwell (Shanghai) Bioscience Co. esti mated primary completion of a Phase 2 trial in Advanced Solid Tumor\, on 1 September 2026.\n\nSource: clinicaltrials NCT05990452\nhttps://clinicaltr ials.gov/study/NCT05990452 URL:https://julienwillard.com/calendar/clinical#e-866d83e4-700f-4565-9cb8-a fcb07371124 END:VEVENT BEGIN:VEVENT UID:093eb735674438bc78f052ae78c5f27e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Curium US LLC Copper Cu 64 PSMA I&T: Trial primary completion DESCRIPTION:As of 4 June 2026\, Curium US estimated primary completion of a Phase 3 trial in Prostate Cancer\, in September 2026.\n\nSource: clinical trials NCT06235151\nhttps://clinicaltrials.gov/study/NCT06235151 URL:https://julienwillard.com/calendar/clinical#e-f9205a09-7463-43b9-a2f0-8 f3260f4af82 END:VEVENT BEGIN:VEVENT UID:e2695a18c636ff22e28d7fa44064adcf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Wave Life Sciences USA\, Inc. WVE-006: Trial primary completion DESCRIPTION:As of 14 April 2026\, Wave Life Sciences USA estimated primary completion of a Phase 2 trial in Alpha-1 Antitrypsin Deficiency\, in Septe mber 2026.\n\nSource: clinicaltrials NCT06405633\nhttps://clinicaltrials.g ov/study/NCT06405633 URL:https://julienwillard.com/calendar/clinical#e-ca91509b-7cab-45b6-906f-7 df29c7f24b4 END:VEVENT BEGIN:VEVENT UID:bfd51d2a69746afcad321cbd165e59be DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutic al Co.\, Ltd. TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy: Trial primary completion DESCRIPTION:As of 30 July 2025\, Chia Tai Tianqing Pharmaceutical Group Nan jing Shunxin Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Gastroesophageal Adenocarcinoma\, in September 2026.\n\nSource: c linicaltrials NCT06767800\nhttps://clinicaltrials.gov/study/NCT06767800 URL:https://julienwillard.com/calendar/clinical#e-b5162a6d-921e-4b5c-bfde-0 d5d625252e1 END:VEVENT BEGIN:VEVENT UID:c7abb96485611c940bc2135aa690079d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. SHR-8068: Trial prima ry completion DESCRIPTION:As of 4 May 2026\, Suzhou Suncadia Biopharmaceuticals Co. estim ated primary completion of a Phase 3 trial in Advanced Hepatocellular Carc inoma\, in September 2026.\n\nSource: clinicaltrials NCT06618664\nhttps:// clinicaltrials.gov/study/NCT06618664 URL:https://julienwillard.com/calendar/clinical#e-de89aeaa-0b76-4f71-ab36-f 97e63f07ca4 END:VEVENT BEGIN:VEVENT UID:e0b05ada99b37db52e89130cbcae7af4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:REGENXBIO Inc. RGX-202: Trial primary completion DESCRIPTION:As of 21 July 2026\, REGENXBIO estimated primary completion of a Phase 3 trial in Duchenne Muscular Dystrophy\, in September 2026.\n\nSou rce: clinicaltrials NCT05693142\nhttps://clinicaltrials.gov/study/NCT05693 142 URL:https://julienwillard.com/calendar/clinical#e-e2454f18-ca8f-4199-af3a-2 d8ba7c4aa66 END:VEVENT BEGIN:VEVENT UID:faa8eddc53b733da3c41d2f8ac9239b1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:UCB BIOSCIENCES\, Inc. fenfluramine: Trial primary completion DESCRIPTION:As of 7 August 2026\, UCB BIOSCIENCES estimated primary complet ion of a Phase 3 trial in Dravet Syndrome\, on 1 September 2026.\n\nSource : clinicaltrials NCT06118255\nhttps://clinicaltrials.gov/study/NCT06118255 URL:https://julienwillard.com/calendar/clinical#e-84fc94cb-29d1-443e-9f26-c 91bee96c038 END:VEVENT BEGIN:VEVENT UID:f010466adb4d96dd1f837e56db39a3d5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Purity Pharmaceutical Technology Co.\, Ltd. PRT-064040 nasa l spray: Trial primary completion DESCRIPTION:As of 29 January 2026\, Sichuan Purity Pharmaceutical Technolog y Co. estimated primary completion of a Phase 2 trial in migraine\, in Sep tember 2026.\n\nSource: clinicaltrials NCT07304518\nhttps://clinicaltrials .gov/study/NCT07304518 URL:https://julienwillard.com/calendar/clinical#e-3d0a06cf-eb34-458a-b55c-4 9148ae3ac05 END:VEVENT BEGIN:VEVENT UID:60ca3f615f8fb2ed8f4052c2a561c92c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vera Therapeutics\, Inc. Atacicept: Trial primary completion DESCRIPTION:As of 13 April 2026\, Vera Therapeutics estimated primary compl etion of a Phase 2 trial in IgA Nephropathy (IgAN)\, in September 2026.\n\ nSource: clinicaltrials NCT07020923\nhttps://clinicaltrials.gov/study/NCT0 7020923 URL:https://julienwillard.com/calendar/clinical#e-4dd3b391-a999-447a-b355-0 5f6f0ef30e9 END:VEVENT BEGIN:VEVENT UID:0c85e41f2cd103669d751c93ce6c19ef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260902 DTEND;VALUE=DATE:20260903 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Boehringer Ingelheim zongertinib: Trial primary completion DESCRIPTION:As of 23 July 2026\, Boehringer Ingelheim estimated primary com pletion of a Phase 3 trial in Lung Cancer\, Non-squamous\, Non-small Cell\ , on 2 September 2026.\n\nSource: clinicaltrials NCT06151574\nhttps://clin icaltrials.gov/study/NCT06151574 URL:https://julienwillard.com/calendar/clinical#e-9469afb5-5b24-494d-a586-9 48907655840 END:VEVENT BEGIN:VEVENT UID:3b1abccf1430eca12d7467c8321f37d4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260902 DTEND;VALUE=DATE:20260903 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer PF-07868489: Trial primary completion DESCRIPTION:As of 19 May 2026\, Pfizer estimated primary completion of a Ph ase 2 trial in Pulmonary Arterial Hypertension\, on 2 September 2026.\n\nS ource: clinicaltrials NCT06137742\nhttps://clinicaltrials.gov/study/NCT061 37742 URL:https://julienwillard.com/calendar/clinical#e-ce00beff-f312-47a8-a668-0 8a753e6ca90 END:VEVENT BEGIN:VEVENT UID:79f5e7088ff0534897b8e9fe38c91c06 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260903 DTEND;VALUE=DATE:20260904 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi SAR441344 IV: Trial primary completion DESCRIPTION:As of 6 August 2026\, Sanofi estimated primary completion of a Phase 2 trial in Systemic Lupus Erythematosus\, on 3 September 2026.\n\nSo urce: clinicaltrials NCT05039840\nhttps://clinicaltrials.gov/study/NCT0503 9840 URL:https://julienwillard.com/calendar/clinical#e-299641f1-792c-494a-a7c7-6 7bc330a4eeb END:VEVENT BEGIN:VEVENT UID:7e728e210f7d591f0635a11750495276 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260904 DTEND;VALUE=DATE:20260905 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Clear Scientific\, Inc. Methamphetamine: Trial primary completion DESCRIPTION:As of 7 July 2026\, Clear Scientific estimated primary completi on of a Phase 2 trial in Methamphetamine Intoxication\, on 4 September 202 6.\n\nSource: clinicaltrials NCT06721494\nhttps://clinicaltrials.gov/study /NCT06721494 URL:https://julienwillard.com/calendar/clinical#e-4f5ec661-e942-4843-b686-5 a905fe03fb2 END:VEVENT BEGIN:VEVENT UID:53e66d54da2ff2e07304810b63ec669b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260905 DTEND;VALUE=DATE:20260906 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:H. Lundbeck A/S Eptinezumab: Trial primary completion DESCRIPTION:As of 14 July 2026\, H. Lundbeck estimated primary completion o f a Phase 3 trial in Chronic Migraine in Children\, on 5 September 2026.\n \nSource: clinicaltrials NCT04965675\nhttps://clinicaltrials.gov/study/NCT 04965675 URL:https://julienwillard.com/calendar/clinical#e-3855f930-9047-4d2b-ad79-8 82d7cb6dfb0 END:VEVENT BEGIN:VEVENT UID:1104cd50af340dde194365249eaaa652 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260905 DTEND;VALUE=DATE:20260906 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bristol-Myers Squibb BMS-986490: Trial primary completion DESCRIPTION:As of 2 July 2026\, Bristol-Myers Squibb estimated primary comp letion of a Phase 2 trial in Advanced Solid Tumors\, on 5 September 2026.\ n\nSource: clinicaltrials NCT06730750\nhttps://clinicaltrials.gov/study/NC T06730750 URL:https://julienwillard.com/calendar/clinical#e-ba884bb6-bf17-43c7-baab-d f2a05f398dc END:VEVENT BEGIN:VEVENT UID:80520c4dc957562199e67f3eb10c5ca6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260905 DTEND;VALUE=DATE:20260906 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Tulisokibart: Trial primary completion DESCRIPTION:As of 12 June 2026\, Merck Sharp & Dohme estimated primary comp letion of a Phase 2 trial in Arthritis\, Rheumatoid\, on 5 September 2026. \n\nSource: clinicaltrials NCT07176390\nhttps://clinicaltrials.gov/study/N CT07176390 URL:https://julienwillard.com/calendar/clinical#e-8b203be6-b683-46f0-8e46-d 2f10417adbb END:VEVENT BEGIN:VEVENT UID:ba72060207ba624a58761d7487f62830 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260906 DTEND;VALUE=DATE:20260907 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CastleVax Inc. NDV-HXP-S-KP.2: Trial primary completion DESCRIPTION:As of 22 July 2026\, CastleVax estimated primary completion of a Phase 2 trial in cOVID-19\, on 6 September 2026.\n\nSource: clinicaltria ls NCT07215520\nhttps://clinicaltrials.gov/study/NCT07215520 URL:https://julienwillard.com/calendar/clinical#e-0b4e6485-e4a1-4eb3-bb7c-1 cac408ef35a END:VEVENT BEGIN:VEVENT UID:4a3b7467d7ce4a74f1908f00ec93b8cd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260906 DTEND;VALUE=DATE:20260907 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. IBI306: Trial primary completi on DESCRIPTION:As of 14 April 2026\, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 3 trial in Non-Familial Hypercholesterolemi a and Mixed Hyperlipidemia\, on 6 September 2026.\n\nSource: clinicaltrial s NCT07473960\nhttps://clinicaltrials.gov/study/NCT07473960 URL:https://julienwillard.com/calendar/clinical#e-c4b1b7b3-d344-4aa7-8afb-7 2d7643e3cd2 END:VEVENT BEGIN:VEVENT UID:5a228d16c31920724245f12642c5a42c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260906 DTEND;VALUE=DATE:20260907 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ALK-Abelló A/S HDM SLIT-tablet (12 SQ-HDM): Trial primary completi on DESCRIPTION:As of 20 July 2026\, ALK-Abelló estimated primary completion o f a Phase 3 trial in Allergic Rhinoconjunctivitis\, on 6 September 2026.\n \nSource: clinicaltrials NCT07060885\nhttps://clinicaltrials.gov/study/NCT 07060885 URL:https://julienwillard.com/calendar/clinical#e-dadef6fe-d31b-4da7-9606-c 35ecf9dead0 END:VEVENT BEGIN:VEVENT UID:f5ad2cacd3293e4c5ad2c0570257270b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260909 DTEND;VALUE=DATE:20260910 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ViiV Healthcare CAB LA: Trial primary completion DESCRIPTION:As of 18 November 2025\, ViiV Healthcare estimated primary comp letion of a Phase 2 trial in HIV Infections\, on 9 September 2026.\n\nSour ce: clinicaltrials NCT06741397\nhttps://clinicaltrials.gov/study/NCT067413 97 URL:https://julienwillard.com/calendar/clinical#e-0785b9d7-a0da-4d88-8204-c c69a4778b92 END:VEVENT BEGIN:VEVENT UID:761a56db3f98f8a9382e6ed939ffa9b2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260910 DTEND;VALUE=DATE:20260911 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Candidate varicella vaccine: Trial primary completi on DESCRIPTION:As of 29 May 2026\, GlaxoSmithKline estimated primary completio n of a Phase 3 trial in chickenpox\, on 10 September 2026.\n\nSource: clin icaltrials NCT06855160\nhttps://clinicaltrials.gov/study/NCT06855160 URL:https://julienwillard.com/calendar/clinical#e-a864708a-ff35-4a11-b17c-1 ee610a472d1 END:VEVENT BEGIN:VEVENT UID:69199ac3bfc8fe86b034aafadd524101 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260910 DTEND;VALUE=DATE:20260911 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Vitalgen BioPharma Co.\, Ltd. VGN-R09b: Trial primary comp letion DESCRIPTION:As of 31 March 2026\, Shanghai Vitalgen BioPharma Co. estimated primary completion of a Phase 2 trial in Parkinson's Disease\, on 10 Sept ember 2026.\n\nSource: clinicaltrials NCT06480461\nhttps://clinicaltrials. gov/study/NCT06480461 URL:https://julienwillard.com/calendar/clinical#e-09c931ed-0351-41ae-aec8-9 9e9ff44b49e END:VEVENT BEGIN:VEVENT UID:eb0b50797e3676057773491805867bc6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260910 DTEND;VALUE=DATE:20260911 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Galaxy Therapeutics INC The SEAL™ Saccular Endovascular Aneurysm Lattice System: Trial primary completion DESCRIPTION:As of 16 January 2026\, Galaxy Therapeutics estimated primary c ompletion of a Phase 3 trial in Intracranial Aneurysm\, on 10 September 20 26.\n\nSource: clinicaltrials NCT05831202\nhttps://clinicaltrials.gov/stud y/NCT05831202 URL:https://julienwillard.com/calendar/clinical#e-e42ec202-3fad-440d-8545-2 d89376cf44d END:VEVENT BEGIN:VEVENT UID:2bc1d39236e8a31acf21dab13da45e5a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260911 DTEND;VALUE=DATE:20260912 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NS Pharma\, Inc. NS-089/NCNP-02: Trial primary completion DESCRIPTION:As of 6 March 2026\, NS Pharma estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy\, on 11 September 2026.\n\n Source: clinicaltrials NCT05996003\nhttps://clinicaltrials.gov/study/NCT05 996003 URL:https://julienwillard.com/calendar/clinical#e-53052be4-cec8-44b5-9cc7-0 f54baad0174 END:VEVENT BEGIN:VEVENT UID:eca0290b3518748f4f57f796fd990308 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260911 DTEND;VALUE=DATE:20260912 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Priovant Therapeutics\, Inc. Brepocitinib PO QD: Trial primary comp letion DESCRIPTION:As of 12 January 2026\, Priovant Therapeutics estimated primary completion of a Phase 3 trial in Uveitis\, Posterior\, on 11 September 20 26.\n\nSource: clinicaltrials NCT06431373\nhttps://clinicaltrials.gov/stud y/NCT06431373 URL:https://julienwillard.com/calendar/clinical#e-e02199fb-e070-4a7f-9b4b-e a4ebc96d9aa END:VEVENT BEGIN:VEVENT UID:ddb3026247d9dbbd5daff5520c8d0c02 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260913 DTEND;VALUE=DATE:20260914 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Grit Biotechnology GT201: Trial primary completion DESCRIPTION:As of 27 April 2026\, Grit Biotechnology estimated primary comp letion of a Phase 2 trial in Solid Tumor\, Adult\, on 13 September 2026.\n \nSource: clinicaltrials NCT06144671\nhttps://clinicaltrials.gov/study/NCT 06144671 URL:https://julienwillard.com/calendar/clinical#e-de7986fb-2501-4573-921b-3 a23c8221933 END:VEVENT BEGIN:VEVENT UID:2bed369a295f233b2591fa94a3d1464b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260915 DTEND;VALUE=DATE:20260916 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Wuhan YZY Biopharma Co.\, Ltd. M701 pleural infusion: Trial primary completion DESCRIPTION:As of 8 July 2026\, Wuhan YZY Biopharma Co. estimated primary c ompletion of a Phase 2 trial in Malignant Pleural Effusions\, on 15 Septem ber 2026.\n\nSource: clinicaltrials NCT05543330\nhttps://clinicaltrials.go v/study/NCT05543330 URL:https://julienwillard.com/calendar/clinical#e-ac19a949-c3fd-4515-ab64-d 5ca29915051 END:VEVENT BEGIN:VEVENT UID:d5ba6fdb71583e81be0764571240ac8f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260915 DTEND;VALUE=DATE:20260916 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bayer BAY2599023 (DTX201): Trial primary completion DESCRIPTION:As of 6 July 2026\, Bayer estimated primary completion of a Pha se 2 trial in Hemophilia A\, on 15 September 2026.\n\nSource: clinicaltria ls NCT03588299\nhttps://clinicaltrials.gov/study/NCT03588299 URL:https://julienwillard.com/calendar/clinical#e-920a51ec-5306-4b17-bd49-5 49d45ec1d17 END:VEVENT BEGIN:VEVENT UID:fbcf600a682ba0969736f9354698a482 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260915 DTEND;VALUE=DATE:20260916 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:H. Lundbeck A/S Lu AG13909: Trial primary completion DESCRIPTION:As of 12 June 2026\, H. Lundbeck estimated primary completion o f a Phase 2 trial in Cushing's Disease\, on 15 September 2026.\n\nSource: clinicaltrials NCT06471829\nhttps://clinicaltrials.gov/study/NCT06471829 URL:https://julienwillard.com/calendar/clinical#e-a16d6929-f645-4f9a-ab17-b 5cc70b2431d END:VEVENT BEGIN:VEVENT UID:a4bfe2ad3eadb70a2070d3fc588f89df DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260915 DTEND;VALUE=DATE:20260916 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Thirty Respiratory Limited RESP30TB: Trial primary completion DESCRIPTION:As of 12 January 2026\, Thirty Respiratory estimated primary co mpletion of a Phase 2 trial in Pulmonary Tuberculoses\, on 15 September 20 26.\n\nSource: clinicaltrials NCT07073638\nhttps://clinicaltrials.gov/stud y/NCT07073638 URL:https://julienwillard.com/calendar/clinical#e-160602a3-e0d8-46e1-976b-9 05b6dd12633 END:VEVENT BEGIN:VEVENT UID:6b6d452292b76d312e5ea474ce1c71a1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260915 DTEND;VALUE=DATE:20260916 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Pembrolizumab: Trial primary completion DESCRIPTION:As of 24 July 2026\, Merck Sharp & Dohme estimated primary comp letion of a Phase 3 trial in Endometrial Neoplasms\, on 15 September 2026. \n\nSource: clinicaltrials NCT04634877\nhttps://clinicaltrials.gov/study/N CT04634877 URL:https://julienwillard.com/calendar/clinical#e-0b76581c-2457-450d-9be4-a 48cb6518bd6 END:VEVENT BEGIN:VEVENT UID:b3cf26160049c875263ce1807ddf8110 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260915 DTEND;VALUE=DATE:20260916 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer MET233 and MET097: Trial primary completion DESCRIPTION:As of 1 June 2026\, Pfizer estimated primary completion of a Ph ase 2 trial in Obesity and Obesity-related Medical Conditions\, on 15 Sept ember 2026.\n\nSource: clinicaltrials NCT06924320\nhttps://clinicaltrials. gov/study/NCT06924320 URL:https://julienwillard.com/calendar/clinical#e-479a7dab-a21e-468a-973e-f 0c4a23eb0f5 END:VEVENT BEGIN:VEVENT UID:b2856bc212e67aa80f27e75f59563ac7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260915 DTEND;VALUE=DATE:20260916 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Teva Branded Pharmaceutical Products R&D LLC TEV-53408: Trial prima ry completion DESCRIPTION:As of 27 July 2026\, Teva Branded Pharmaceutical Products R&D e stimated primary completion of a Phase 2 trial in Celiac Disease\, on 15 S eptember 2026.\n\nSource: clinicaltrials NCT06807463\nhttps://clinicaltria ls.gov/study/NCT06807463 URL:https://julienwillard.com/calendar/clinical#e-ba5c190e-a25e-49b6-97f4-3 f084c7847aa END:VEVENT BEGIN:VEVENT UID:284a509f4d7008b599adab7455a88a52 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260917 DTEND;VALUE=DATE:20260918 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Ocrelizumab Test Formulation: Trial primary compl etion DESCRIPTION:As of 6 August 2026\, Hoffmann-La Roche estimated primary compl etion of a Phase 2 trial in Multiple Sclerosis\, on 17 September 2026.\n\n Source: clinicaltrials NCT07074886\nhttps://clinicaltrials.gov/study/NCT07 074886 URL:https://julienwillard.com/calendar/clinical#e-edfb3628-a340-4a85-a4c0-7 750366db5e8 END:VEVENT BEGIN:VEVENT UID:c20dbcae95926db9769cae13a477ad0a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260917 DTEND;VALUE=DATE:20260918 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vertex Pharmaceuticals Incorporated Biological/Vaccine: Trial prima ry completion DESCRIPTION:As of 23 March 2026\, Vertex Pharmaceuticals Incorporated estim ated primary completion of a Phase 3 trial in Type 1 Diabetes\, on 17 Sept ember 2026.\n\nSource: clinicaltrials NCT06832410\nhttps://clinicaltrials. gov/study/NCT06832410 URL:https://julienwillard.com/calendar/clinical#e-7db638fc-2ee4-4839-a070-d b182e0bb612 END:VEVENT BEGIN:VEVENT UID:ca1a84ae916da65303a22b5730f11fd0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260918 DTEND;VALUE=DATE:20260919 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Takeda TAK-279: Trial primary completion DESCRIPTION:As of 6 July 2026\, Takeda estimated primary completion of a Ph ase 2 trial in Crohn's Disease\, on 18 September 2026.\n\nSource: clinical trials NCT06233461\nhttps://clinicaltrials.gov/study/NCT06233461 URL:https://julienwillard.com/calendar/clinical#e-079fa468-0276-4e15-9a2f-f 008ebb6b7d6 END:VEVENT BEGIN:VEVENT UID:c0a31fab1e4fe66bf63cc7f9ccb1717c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260918 DTEND;VALUE=DATE:20260919 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Han Xu\, M.D.\, Ph.D.\, FAPCR\, Sponsor-Investigator\, IRB Chair To potecan - usual: Trial primary completion DESCRIPTION:As of 8 September 2025\, Han Xu\, M.D.\, Ph.D.\, FAPCR\, Sponso r-Investigator\, IRB Chair estimated primary completion of a Phase 3 trial in sCLC\, on 18 September 2026.\n\nSource: clinicaltrials NCT07145333\nht tps://clinicaltrials.gov/study/NCT07145333 URL:https://julienwillard.com/calendar/clinical#e-2fc039e3-a724-4c6b-be60-6 71794547cf9 END:VEVENT BEGIN:VEVENT UID:8678de5a431088b53d024808e1451f20 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260919 DTEND;VALUE=DATE:20260920 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Teva Branded Pharmaceutical Products R&D LLC Fp/ABS: Trial primary completion DESCRIPTION:As of 25 June 2026\, Teva Branded Pharmaceutical Products R&D e stimated primary completion of a Phase 3 trial in asthma\, on 19 September 2026.\n\nSource: clinicaltrials NCT06664619\nhttps://clinicaltrials.gov/s tudy/NCT06664619 URL:https://julienwillard.com/calendar/clinical#e-19c1ed51-52e4-419b-8612-7 49059af3143 END:VEVENT BEGIN:VEVENT UID:5248ffb719988c30127d628643513e7f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260920 DTEND;VALUE=DATE:20260921 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bharat Biotech International Limited BBV87 Chikungunya vaccine: Tri al primary completion DESCRIPTION:As of 29 April 2026\, Bharat Biotech International estimated pr imary completion of a Phase 3 trial in Active Immunisation for Chikungunya Virus Infection\, on 20 September 2026.\n\nSource: clinicaltrials NCT0755 5392\nhttps://clinicaltrials.gov/study/NCT07555392 URL:https://julienwillard.com/calendar/clinical#e-80082423-e616-485b-97e3-8 a9a8d5de32d END:VEVENT BEGIN:VEVENT UID:9e2127720d8407fc23a3785ff9025c84 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260920 DTEND;VALUE=DATE:20260921 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hangzhou Zhongmei Huadong Pharmaceutical Co.\, Ltd. HDM1005 1: Tria l primary completion DESCRIPTION:As of 12 December 2025\, Hangzhou Zhongmei Huadong Pharmaceutic al Co. estimated primary completion of a Phase 3 trial in Obesity & Overwe ight\, on 20 September 2026.\n\nSource: clinicaltrials NCT07279194\nhttps: //clinicaltrials.gov/study/NCT07279194 URL:https://julienwillard.com/calendar/clinical#e-cb2bc70e-68a8-4d5e-9492-d 82c077bd07e END:VEVENT BEGIN:VEVENT UID:4c8230d9b54e821f1a85633fb8d18f78 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260921 DTEND;VALUE=DATE:20260922 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cardiol Therapeutics Inc. CardiolRx: Trial primary completion DESCRIPTION:As of 23 July 2026\, Cardiol Therapeutics estimated primary com pletion of a Phase 3 trial in Recurrent Pericarditis\, on 21 September 202 6.\n\nSource: clinicaltrials NCT06708299\nhttps://clinicaltrials.gov/study /NCT06708299 URL:https://julienwillard.com/calendar/clinical#e-ff0f6c13-bd7b-436d-a851-4 980cdbfd626 END:VEVENT BEGIN:VEVENT UID:a8393724e77d63bad8869e78972bbbb5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260922 DTEND;VALUE=DATE:20260923 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ModernaTX\, Inc. mRNA-1403: Trial primary completion DESCRIPTION:As of 3 April 2026\, ModernaTX estimated primary completion of a Phase 2 trial in Norovirus Acute Gastroenteritis\, on 22 September 2026. \n\nSource: clinicaltrials NCT05992935\nhttps://clinicaltrials.gov/study/N CT05992935 URL:https://julienwillard.com/calendar/clinical#e-734deea5-55aa-46dd-acf7-c aff7b1a405b END:VEVENT BEGIN:VEVENT UID:b3d1d6ab9f8efa88f3554c6a7501e797 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260922 DTEND;VALUE=DATE:20260923 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ImmVira Pharma Co. Ltd T3011: Trial primary completion DESCRIPTION:As of 8 October 2025\, ImmVira Pharma Co. estimated primary com pletion of a Phase 2 trial in Solid Tumor\, on 22 September 2026.\n\nSourc e: clinicaltrials NCT04370587\nhttps://clinicaltrials.gov/study/NCT0437058 7 URL:https://julienwillard.com/calendar/clinical#e-a3be4b30-5ef2-410d-8fb5-2 d6e0fb641e4 END:VEVENT BEGIN:VEVENT UID:a1f09932eeda5d6e7ded6cbb63fc3027 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260922 DTEND;VALUE=DATE:20260923 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Belzutifan: Trial primary completion DESCRIPTION:As of 22 July 2026\, Merck Sharp & Dohme estimated primary comp letion of a Phase 2 trial in Renal Cell Carcinoma\, on 22 September 2026.\ n\nSource: clinicaltrials NCT05468697\nhttps://clinicaltrials.gov/study/NC T05468697 URL:https://julienwillard.com/calendar/clinical#e-91ffcf0c-21fc-44c5-bc40-6 8af0b1fb55a END:VEVENT BEGIN:VEVENT UID:a7aeb65254b4606c18162be63b9412ec DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260922 DTEND;VALUE=DATE:20260923 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BeOne Medicines Sonrotoclax: Trial primary completion DESCRIPTION:As of 2 January 2026\, BeOne Medicines estimated primary comple tion of a Phase 2 trial in Waldenstrom Macroglobulinemia\, on 22 September 2026.\n\nSource: clinicaltrials NCT05952037\nhttps://clinicaltrials.gov/s tudy/NCT05952037 URL:https://julienwillard.com/calendar/clinical#e-72761681-3d5b-4184-bbf9-e bcac632e36f END:VEVENT BEGIN:VEVENT UID:723fe37c6c43502b29543bacb86ce76b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260923 DTEND;VALUE=DATE:20260924 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer PF-07220060: Trial primary completion DESCRIPTION:As of 1 October 2025\, Pfizer estimated primary completion of a Phase 2 trial in liposarcoma\, on 23 September 2026.\n\nSource: clinicalt rials NCT04557449\nhttps://clinicaltrials.gov/study/NCT04557449 URL:https://julienwillard.com/calendar/clinical#e-7219cdb1-140c-4a6e-9b36-2 ffe593c0958 END:VEVENT BEGIN:VEVENT UID:6923234d9e26ad3e04a25333cdc0a2d7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260923 DTEND;VALUE=DATE:20260924 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sinocelltech Ltd. SCT520FF: Trial primary completion DESCRIPTION:As of 4 September 2025\, Sinocelltech estimated primary complet ion of a Phase 2 trial in nAMD\, on 23 September 2026.\n\nSource: clinical trials NCT06672536\nhttps://clinicaltrials.gov/study/NCT06672536 URL:https://julienwillard.com/calendar/clinical#e-2fe2f14f-6f50-4848-a0af-f 42c21d1b2fc END:VEVENT BEGIN:VEVENT UID:1b4bcd10865d2bb808d7f6a1fe6090d9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260924 DTEND;VALUE=DATE:20260925 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. IBI362: Trial primary completi on DESCRIPTION:As of 11 July 2025\, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 2 trial in obesity\, on 24 September 2026.\n \nSource: clinicaltrials NCT06862908\nhttps://clinicaltrials.gov/study/NCT 06862908 URL:https://julienwillard.com/calendar/clinical#e-4a2a0538-f40f-41cb-9e48-a 08d275ecb7d END:VEVENT BEGIN:VEVENT UID:1ed6aa4f1cfc304d7508ff813378857a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260924 DTEND;VALUE=DATE:20260925 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals YTB323: Trial primary completion DESCRIPTION:As of 24 July 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Systemic Lupus Erythematosus\, on 24 Sep tember 2026.\n\nSource: clinicaltrials NCT05798117\nhttps://clinicaltrials .gov/study/NCT05798117 URL:https://julienwillard.com/calendar/clinical#e-4084e37b-3ea7-4ca9-b2d8-6 66d01ce6aee END:VEVENT BEGIN:VEVENT UID:2a405f5eb66e821453fbe2d8f3209753 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260927 DTEND;VALUE=DATE:20260928 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biogen Litifilimab: Trial primary completion DESCRIPTION:As of 29 January 2026\, Biogen estimated primary completion of a Phase 3 trial in Lupus Erythematosus\, Systemic\, on 27 September 2026.\ n\nSource: clinicaltrials NCT04961567\nhttps://clinicaltrials.gov/study/NC T04961567 URL:https://julienwillard.com/calendar/clinical#e-654ced0a-9fa8-4c92-8dab-c 9cfc962b31d END:VEVENT BEGIN:VEVENT UID:e26d6699df21c14e095321477b635b8e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260928 DTEND;VALUE=DATE:20260929 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MoonLake Immunotherapeutics AG Sonelokimab: Trial primary completio n DESCRIPTION:As of 6 May 2026\, MoonLake Immunotherapeutics estimated primar y completion of a Phase 3 trial in Hidradenitis Suppurativa\, on 28 Septem ber 2026.\n\nSource: clinicaltrials NCT06768671\nhttps://clinicaltrials.go v/study/NCT06768671 URL:https://julienwillard.com/calendar/clinical#e-1fd76975-4438-495d-957f-7 03621596517 END:VEVENT BEGIN:VEVENT UID:611adde55299c36fb965c3fc2a83abae DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260928 DTEND;VALUE=DATE:20260929 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD0901: Trial primary completion DESCRIPTION:As of 17 June 2026\, AstraZeneca estimated primary completion o f a Phase 2 trial in Gastric Cancer\, on 28 September 2026.\n\nSource: cli nicaltrials NCT07143604\nhttps://clinicaltrials.gov/study/NCT07143604 URL:https://julienwillard.com/calendar/clinical#e-c7e981f3-853d-4237-9ca7-3 2fcc583a8a0 END:VEVENT BEGIN:VEVENT UID:03db3031876cfbbd04830e167fc88225 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260928 DTEND;VALUE=DATE:20260929 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ocugen OCU410ST: Trial primary completion DESCRIPTION:As of 31 July 2026\, Ocugen estimated primary completion of a P hase 3 trial in Stargardt Disease\, on 28 September 2026.\n\nSource: clini caltrials NCT05956626\nhttps://clinicaltrials.gov/study/NCT05956626 URL:https://julienwillard.com/calendar/clinical#e-74c31712-dff2-4df7-894d-0 8a357a91b4a END:VEVENT BEGIN:VEVENT UID:61a476036b9ebca9e4b046a68fa92eec DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260928 DTEND;VALUE=DATE:20260929 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Incyte Corporation INCB099280: Trial primary completion DESCRIPTION:As of 24 February 2026\, Incyte estimated primary completion of a Phase 2 trial in Cutaneous Squamous Cell Carcinoma\, on 28 September 20 26.\n\nSource: clinicaltrials NCT05888844\nhttps://clinicaltrials.gov/stud y/NCT05888844 URL:https://julienwillard.com/calendar/clinical#e-6ddf070a-d10e-443c-8be3-0 9510344e73b END:VEVENT BEGIN:VEVENT UID:482d4f508f7f999ca32b74539d6d0c07 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260928 DTEND;VALUE=DATE:20260929 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Attralus\, Inc. AT02: Trial primary completion DESCRIPTION:As of 6 May 2026\, Attralus estimated primary completion of a P hase 2 trial in Amyloidosis\; Systemic\, on 28 September 2026.\n\nSource: clinicaltrials NCT05951049\nhttps://clinicaltrials.gov/study/NCT05951049 URL:https://julienwillard.com/calendar/clinical#e-de9bc696-4f4d-4d89-9142-8 3f2a9f18c73 END:VEVENT BEGIN:VEVENT UID:34a13e1e814d74af316b7046c3fdeaea DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260929 DTEND;VALUE=DATE:20260930 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi Amlitelimab: Trial primary completion DESCRIPTION:As of 20 May 2026\, Sanofi estimated primary completion of a Ph ase 2 trial in asthma\, on 29 September 2026.\n\nSource: clinicaltrials NC T06033833\nhttps://clinicaltrials.gov/study/NCT06033833 URL:https://julienwillard.com/calendar/clinical#e-f87eb617-8338-4ffb-b4c7-c 7fed771fec9 END:VEVENT BEGIN:VEVENT UID:dd02fb22a53b555e30762259fa7cfe31 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260929 DTEND;VALUE=DATE:20260930 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Depemokimab: Trial primary completion DESCRIPTION:As of 8 July 2026\, GlaxoSmithKline estimated primary completio n of a Phase 3 trial in Eosinophilic Granulomatosis With Polyangiitis\, on 29 September 2026.\n\nSource: clinicaltrials NCT05263934\nhttps://clinica ltrials.gov/study/NCT05263934 URL:https://julienwillard.com/calendar/clinical#e-5197167a-b665-40f6-9ec9-b a497b432320 END:VEVENT BEGIN:VEVENT UID:5ef9ceb9b1f0ad6cc3c38bb267aabab0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Stamford Pharmaceuticals\, Inc. SP-002: Trial primary completion DESCRIPTION:As of 20 September 2024\, Stamford Pharmaceuticals estimated pr imary completion of a Phase 2 trial in Basal Cell Carcinoma\, on 30 Septem ber 2026.\n\nSource: clinicaltrials NCT06344052\nhttps://clinicaltrials.go v/study/NCT06344052 URL:https://julienwillard.com/calendar/clinical#e-929871b1-79cd-40f3-b229-b 2c47db050cf END:VEVENT BEGIN:VEVENT UID:3e2a6d084c3825b959a8b0b5b89ff2dd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Durvalumab: Trial primary completion DESCRIPTION:As of 26 June 2026\, AstraZeneca estimated primary completion o f a Phase 3 trial in Hepatocellular Carcinoma\, on 30 September 2026.\n\nS ource: clinicaltrials NCT05557838\nhttps://clinicaltrials.gov/study/NCT055 57838 URL:https://julienwillard.com/calendar/clinical#e-d4aa02bb-3629-422a-8f6b-9 6ea57468444 END:VEVENT BEGIN:VEVENT UID:314b847563dbeb50d84bf35e1529a61c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline iNTS-GMMA Dose C: Trial primary completion DESCRIPTION:As of 19 May 2026\, GlaxoSmithKline estimated primary completio n of a Phase 2 trial in Salmonella Infections\, on 30 September 2026.\n\nS ource: clinicaltrials NCT06213506\nhttps://clinicaltrials.gov/study/NCT062 13506 URL:https://julienwillard.com/calendar/clinical#e-b333e321-fdd7-4ba1-9e0d-a a3dee6b9e54 END:VEVENT BEGIN:VEVENT UID:03da76be3334a73a162321ad8957c1bb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CSPC Ouyi Pharmaceutical Co.\, Ltd. Dextromethorphan and Bupropion Sustained-Release Tablets: Trial primary completion DESCRIPTION:As of 6 May 2025\, CSPC Ouyi Pharmaceutical Co. estimated prima ry completion of a Phase 3 trial in Major Depressive Disorder (MDD)\, on 3 0 September 2026.\n\nSource: clinicaltrials NCT06958692\nhttps://clinicalt rials.gov/study/NCT06958692 URL:https://julienwillard.com/calendar/clinical#e-a54741ac-94b3-47db-811e-4 a59a58e7ed2 END:VEVENT BEGIN:VEVENT UID:c7d0ad4df2713ed2feed9c4e0b0fdf51 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Graegis Pharmaceuticals Ltd GR1014-CG 2.4%: Trial primary completio n DESCRIPTION:As of 25 September 2025\, Graegis Pharmaceuticals estimated pri mary completion of a Phase 2 trial in Radiodermatitis\; Acute\, on 30 Sept ember 2026.\n\nSource: clinicaltrials NCT07192588\nhttps://clinicaltrials. gov/study/NCT07192588 URL:https://julienwillard.com/calendar/clinical#e-9982b39b-4461-440c-b43d-2 32ce180a153 END:VEVENT BEGIN:VEVENT UID:c0194ce127323a5c9f08f9ec228d049d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline GSK4527226: Trial primary completion DESCRIPTION:As of 14 November 2025\, GlaxoSmithKline estimated primary comp letion of a Phase 2 trial in Alzheimer's Disease\, on 30 September 2026.\n \nSource: clinicaltrials NCT06079190\nhttps://clinicaltrials.gov/study/NCT 06079190 URL:https://julienwillard.com/calendar/clinical#e-48ab605e-69f7-4279-b4a1-9 b0863ae7b27 END:VEVENT BEGIN:VEVENT UID:99f8e92dcbfa82c0796496701f6a50cd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing Pearl Biotechnology Limited Liability Company PLB1001: Tria l primary completion DESCRIPTION:As of 29 June 2025\, Beijing Pearl Biotechnology Limited Liabil ity estimated primary completion of a Phase 3 trial in Non-small Cell Lung Cancer\, on 30 September 2026.\n\nSource: clinicaltrials NCT05989542\nhtt ps://clinicaltrials.gov/study/NCT05989542 URL:https://julienwillard.com/calendar/clinical#e-1279046f-7527-4a00-9b3c-8 c1ae4a85782 END:VEVENT BEGIN:VEVENT UID:3cac1d124c0a190ab5ad52706878e3cf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Mirati Therapeutics Inc. Adagrasib oral dose of 400 mg twice daily tablets: Trial primary completion DESCRIPTION:As of 23 June 2026\, Mirati Therapeutics estimated primary comp letion of a Phase 2 trial in Advanced NSCLC\, on 30 September 2026.\n\nSou rce: clinicaltrials NCT05609578\nhttps://clinicaltrials.gov/study/NCT05609 578 URL:https://julienwillard.com/calendar/clinical#e-4a2afe4d-144f-4f42-b59b-f e6481b1f66d END:VEVENT BEGIN:VEVENT UID:8a889c6cc760e40895d71a36c123c527 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kahr Bio Australia Pty Ltd DSP107 + Atezolizumab: Trial primary com pletion DESCRIPTION:As of 8 June 2026\, Kahr Bio Australia Pty estimated primary co mpletion of a Phase 2 trial in Colorectal Cancer\, on 30 September 2026.\n \nSource: clinicaltrials NCT07235293\nhttps://clinicaltrials.gov/study/NCT 07235293 URL:https://julienwillard.com/calendar/clinical#e-b0494a03-2242-48bf-8097-5 25cbb83a14f END:VEVENT BEGIN:VEVENT UID:a3e09a8c0cb33d2975d4903c9ec63df2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Glofitamab: Trial primary completion DESCRIPTION:As of 17 February 2026\, Hoffmann-La Roche estimated primary co mpletion of a Phase 2 trial in lymphoma\, on 30 September 2026.\n\nSource: clinicaltrials NCT04980222\nhttps://clinicaltrials.gov/study/NCT04980222 URL:https://julienwillard.com/calendar/clinical#e-77e89eed-7e9a-421d-9017-c 67cbe129af6 END:VEVENT BEGIN:VEVENT UID:ef7915ca886b6c71c43bbc18499689be DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:UniQure Biopharma B.V. AMT-162: Trial primary completion DESCRIPTION:As of 22 October 2025\, UniQure Biopharma B.V. estimated primar y completion of a Phase 2 trial in Amyotrophic Lateral Sclerosis\, on 30 S eptember 2026.\n\nSource: clinicaltrials NCT06100276\nhttps://clinicaltria ls.gov/study/NCT06100276 URL:https://julienwillard.com/calendar/clinical#e-0b255b16-09ed-4579-aafb-e 35b801dd5a0 END:VEVENT BEGIN:VEVENT UID:0687cbfbfb4a027f114c02e4c22a2f9a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals JDQ443: Trial primary completion DESCRIPTION:As of 15 June 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in KRAS G12C Mutant Solid Tumors\, on 30 Se ptember 2026.\n\nSource: clinicaltrials NCT05358249\nhttps://clinicaltrial s.gov/study/NCT05358249 URL:https://julienwillard.com/calendar/clinical#e-a00d00fb-c3cb-4cff-8fc6-6 d1bc33fc830 END:VEVENT BEGIN:VEVENT UID:57a4e715aaf3168609599f3ab237c8fe DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing Continent Pharmaceutical Co\, Ltd. Pirfenidone Capsules: Tr ial primary completion DESCRIPTION:As of 24 November 2025\, Beijing Continent Pharmaceutical Co es timated primary completion of a Phase 3 trial in pneumoconiosis\, on 30 Se ptember 2026.\n\nSource: clinicaltrials NCT05288179\nhttps://clinicaltrial s.gov/study/NCT05288179 URL:https://julienwillard.com/calendar/clinical#e-bd2bd318-4b87-448a-aba8-e a5ae9e1807d END:VEVENT BEGIN:VEVENT UID:ab4f349f285efae35ab976bd7707d689 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Durvalumab: Trial primary completion DESCRIPTION:As of 18 June 2026\, AstraZeneca estimated primary completion o f a Phase 3 trial in Non-Small Cell Lung Cancer\, on 30 September 2026.\n\ nSource: clinicaltrials NCT05221840\nhttps://clinicaltrials.gov/study/NCT0 5221840 URL:https://julienwillard.com/calendar/clinical#e-f630bbd7-8f31-4b1e-9cf2-b de8a3d75890 END:VEVENT BEGIN:VEVENT UID:e20031ef087de255ef531a477447a98d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Glycomine\, Inc. GLM101 (Part A\, Double-blind): Trial primary comp letion DESCRIPTION:As of 27 February 2026\, Glycomine estimated primary completion of a Phase 3 trial in Phosphomannomutase 2 Deficiency\, on 30 September 2 026.\n\nSource: clinicaltrials NCT06892288\nhttps://clinicaltrials.gov/stu dy/NCT06892288 URL:https://julienwillard.com/calendar/clinical#e-c6a16d68-d430-4aa1-8d3b-3 48376a5fe07 END:VEVENT BEGIN:VEVENT UID:c22cd2f27de9419b0a880d224f979036 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:argenx Efgartigimod PH20 SC: Trial primary completion DESCRIPTION:As of 4 June 2026\, argenx estimated primary completion of a Ph ase 3 trial in Generalized Myasthenia Gravis\, on 30 September 2026.\n\nSo urce: clinicaltrials NCT06392386\nhttps://clinicaltrials.gov/study/NCT0639 2386 URL:https://julienwillard.com/calendar/clinical#e-907477be-afe3-4e45-ae1a-e 824760975f3 END:VEVENT BEGIN:VEVENT UID:d5e5c055a3bfd4f216d5f4c1b5877a97 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:EIP Pharma Inc Neflamapimod: Trial primary completion DESCRIPTION:As of 8 July 2026\, EIP Pharma estimated primary completion of a Phase 2 trial in Moderate to Severe Acute Ischaemic Stroke\, on 30 Septe mber 2026.\n\nSource: clinicaltrials NCT06987643\nhttps://clinicaltrials.g ov/study/NCT06987643 URL:https://julienwillard.com/calendar/clinical#e-02479a36-72c1-4ccb-9db9-f 33a32182005 END:VEVENT BEGIN:VEVENT UID:2c4827b9cb98b72e8b42ea25ddd48483 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Linerixibat: Trial primary completion DESCRIPTION:As of 22 June 2026\, GlaxoSmithKline estimated primary completi on of a Phase 3 trial in cholestasis\, on 30 September 2026.\n\nSource: cl inicaltrials NCT04167358\nhttps://clinicaltrials.gov/study/NCT04167358 URL:https://julienwillard.com/calendar/clinical#e-dd23850e-e08f-4354-96de-1 c8a23ffd3d9 END:VEVENT BEGIN:VEVENT UID:6fed7e9326768b3199d72c487641f5d9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. Pemetrexed: Trial primary comp letion DESCRIPTION:As of 26 June 2025\, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer\, on 3 0 September 2026.\n\nSource: clinicaltrials NCT05116462\nhttps://clinicalt rials.gov/study/NCT05116462 URL:https://julienwillard.com/calendar/clinical#e-f76cdc31-315e-4b6a-9378-c ca280bb6649 END:VEVENT BEGIN:VEVENT UID:837f5391ef2e32312393a5bd24979e9b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bristol-Myers Squibb BMS-986449: Trial primary completion DESCRIPTION:As of 11 June 2025\, Bristol-Myers Squibb estimated primary com pletion of a Phase 2 trial in Advanced Solid Tumors\, on 30 September 2026 .\n\nSource: clinicaltrials NCT05888831\nhttps://clinicaltrials.gov/study/ NCT05888831 URL:https://julienwillard.com/calendar/clinical#e-ce0f33dd-2a59-41e9-9a58-8 5870deed00c END:VEVENT BEGIN:VEVENT UID:97997818515f943aca73163068fa5c3e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:EveryONE Medicines Inc. Individualized ASO: Trial primary completio n DESCRIPTION:As of 17 March 2026\, EveryONE Medicines estimated primary comp letion of a Phase 2 trial in Pediatric SDLT CNS Disorders\, on 30 Septembe r 2026.\n\nSource: clinicaltrials NCT07410143\nhttps://clinicaltrials.gov/ study/NCT07410143 URL:https://julienwillard.com/calendar/clinical#e-a98ec382-50e5-4b9f-a0ec-9 51f4e43ba18 END:VEVENT BEGIN:VEVENT UID:78832c3bb4d04fcb42f51e88f3b90299 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hansoh BioMedical R&D Company HS-20093: Trial primary completion DESCRIPTION:As of 16 October 2024\, Hansoh BioMedical R&D estimated primary completion of a Phase 3 trial in Small Cell Lung Cancer\, on 30 September 2026.\n\nSource: clinicaltrials NCT06498479\nhttps://clinicaltrials.gov/s tudy/NCT06498479 URL:https://julienwillard.com/calendar/clinical#e-1422d13c-53d1-4982-a689-4 c92e8e9b798 END:VEVENT BEGIN:VEVENT UID:f94bb5fe54e9671bcbd26e9d4289bb84 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Uniquity One (UNI) Biological: Solrikitug low dose: Trial primary c ompletion DESCRIPTION:As of 11 August 2026\, Uniquity One estimated primary completio n of a Phase 2 trial in cOPD\, on 30 September 2026.\n\nSource: clinicaltr ials NCT06496620\nhttps://clinicaltrials.gov/study/NCT06496620 URL:https://julienwillard.com/calendar/clinical#e-fdce55a4-1e64-4381-a6fc-c bb3d7946116 END:VEVENT BEGIN:VEVENT UID:76b749182f99c62b183be7cc9524d791 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline RSVPreF3 OA vaccine: Trial primary completion DESCRIPTION:As of 29 July 2026\, GlaxoSmithKline estimated primary completi on of a Phase 3 trial in Respiratory Syncytial Virus Infections\, on 30 Se ptember 2026.\n\nSource: clinicaltrials NCT06534892\nhttps://clinicaltrial s.gov/study/NCT06534892 URL:https://julienwillard.com/calendar/clinical#e-960b06ba-873a-4698-a263-5 4172eee94e7 END:VEVENT BEGIN:VEVENT UID:5e1732e771a20d5618a870fa64857bd0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ImmunityBio\, Inc. BCG (50mg/instillation) + N-803 (400 μg/instill ation): Trial primary completion DESCRIPTION:As of 31 March 2026\, ImmunityBio estimated primary completion of a Phase 2 trial in Non-muscle Invasive Bladder Cancer\, on 30 September 2026.\n\nSource: clinicaltrials NCT02138734\nhttps://clinicaltrials.gov/s tudy/NCT02138734 URL:https://julienwillard.com/calendar/clinical#e-dd4a79ed-8bd5-414b-966e-6 6a3816174a9 END:VEVENT BEGIN:VEVENT UID:6c6efb99757bf0e6050d80664a9a2f3a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD0780: Trial primary completion DESCRIPTION:As of 4 June 2026\, AstraZeneca estimated primary completion of a Phase 2 trial in dyslipidaemia\, on 30 September 2026.\n\nSource: clini caltrials NCT07218900\nhttps://clinicaltrials.gov/study/NCT07218900 URL:https://julienwillard.com/calendar/clinical#e-ec83ff2f-695b-4655-85e0-d beefb66a049 END:VEVENT BEGIN:VEVENT UID:366bc4bd3c191e4be313bce2ee0e72a5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:J Ints Bio JIN-A02: Trial primary completion DESCRIPTION:As of 16 May 2025\, J Ints Bio estimated primary completion of a Phase 2 trial in EGFR Mutant Advanced Non-small Cell Lung Cancer\, on 30 September 2026.\n\nSource: clinicaltrials NCT05394831\nhttps://clinicaltr ials.gov/study/NCT05394831 URL:https://julienwillard.com/calendar/clinical#e-232c2e21-ccce-430d-a381-3 63faa5ef8bf END:VEVENT BEGIN:VEVENT UID:15f5fbb602e7f9f429e94ac1924020b3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Allist Pharmaceuticals\, Inc. JAB-21822: Trial primary completion DESCRIPTION:As of 4 April 2025\, Allist Pharmaceuticals estimated primary c ompletion of a Phase 3 trial in Advanced Non-squamous Non-small-cell Lung Cancer\, on 30 September 2026.\n\nSource: clinicaltrials NCT06416410\nhttp s://clinicaltrials.gov/study/NCT06416410 URL:https://julienwillard.com/calendar/clinical#e-819497d4-79ac-4e8e-8a63-0 910c3bcf73b END:VEVENT BEGIN:VEVENT UID:71338d12cf2e903b74a84f1122091e28 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:H. Lundbeck A/S Lu AG13909: Trial primary completion DESCRIPTION:As of 9 March 2026\, H. Lundbeck estimated primary completion o f a Phase 2 trial in Congenital Adrenal Hyperplasia\, on 30 September 2026 .\n\nSource: clinicaltrials NCT05669950\nhttps://clinicaltrials.gov/study/ NCT05669950 URL:https://julienwillard.com/calendar/clinical#e-eaafaaae-753f-4e85-ab6d-2 79addb708b8 END:VEVENT BEGIN:VEVENT UID:0459925c1a0afdaf077b877a63afb54c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biogen Litifilimab: Trial primary completion DESCRIPTION:As of 10 February 2026\, Biogen estimated primary completion of a Phase 3 trial in Lupus Erythematosus\, Systemic\, on 30 September 2026. \n\nSource: clinicaltrials NCT04895241\nhttps://clinicaltrials.gov/study/N CT04895241 URL:https://julienwillard.com/calendar/clinical#e-767d46ad-90a6-4968-9394-6 7082fab6695 END:VEVENT BEGIN:VEVENT UID:61ede82f1a55bb41c294af7906ad1565 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Pharmaceuticals Holding Co.\, Ltd T3011: Trial primary com pletion DESCRIPTION:As of 6 August 2026\, Shanghai Pharmaceuticals Holding Co. esti mated primary completion of a Phase 2 trial in Advanced Melanoma\, on 30 S eptember 2026.\n\nSource: clinicaltrials NCT06214156\nhttps://clinicaltria ls.gov/study/NCT06214156 URL:https://julienwillard.com/calendar/clinical#e-6df63655-0bdc-4282-a8d8-4 0159160d0df END:VEVENT BEGIN:VEVENT UID:bb73d02bbdd0b32e6cdfa630ec2898eb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:OM Pharma SA OM-85: Trial primary completion DESCRIPTION:As of 23 February 2026\, OM Pharma SA estimated primary complet ion of a Phase 2 trial in Recurrent Wheezing\, on 30 September 2026.\n\nSo urce: clinicaltrials NCT05857930\nhttps://clinicaltrials.gov/study/NCT0585 7930 URL:https://julienwillard.com/calendar/clinical#e-ed7a0628-5114-4511-adbf-c bb5ec697394 END:VEVENT BEGIN:VEVENT UID:04453ac22ec9c5a48d4f6f76ab4def87 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai JMT-Bio Inc. JMT101: Trial primary completion DESCRIPTION:As of 16 December 2024\, Shanghai JMT-Bio estimated primary com pletion of a Phase 3 trial in Locally Advanced or Metastatic Non-squamous NSCLC\, on 30 September 2026.\n\nSource: clinicaltrials NCT06735391\nhttps ://clinicaltrials.gov/study/NCT06735391 URL:https://julienwillard.com/calendar/clinical#e-623f3cdd-8fad-475e-a614-d 71755ab9d30 END:VEVENT BEGIN:VEVENT UID:35000ca4cfe8c01e23e89ec455ce7865 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Turning Point Therapeutics\, Inc. Oral repotrectinib (TPX-0005): Tr ial primary completion DESCRIPTION:As of 19 November 2025\, Turning Point Therapeutics estimated p rimary completion of a Phase 2 trial in Locally Advanced Solid Tumors\, on 30 September 2026.\n\nSource: clinicaltrials NCT04094610\nhttps://clinica ltrials.gov/study/NCT04094610 URL:https://julienwillard.com/calendar/clinical#e-d19c51d8-df2d-42ee-8b20-8 89ea39c103f END:VEVENT BEGIN:VEVENT UID:f853a4ca16de2c60c0b88982cf15135a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Dato-DXd: Trial primary completion DESCRIPTION:As of 14 May 2026\, AstraZeneca estimated primary completion of a Phase 3 trial in Metastatic Non-small Cell Lung Cancer\, on 30 Septembe r 2026.\n\nSource: clinicaltrials NCT06417814\nhttps://clinicaltrials.gov/ study/NCT06417814 URL:https://julienwillard.com/calendar/clinical#e-de2674c0-7fe9-4084-837b-c 199cb4b798e END:VEVENT BEGIN:VEVENT UID:b62d6e020505e32a97ecfa76132c28e6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Joincare Pharmaceutical Group Industry Co.\, Ltd JKN2403 Tablets: T rial primary completion DESCRIPTION:As of 20 January 2026\, Joincare Pharmaceutical Group Industry Co. estimated primary completion of a Phase 2 trial in COPD (Chronic Obstr uctive Pulmonary Disease)\, on 30 September 2026.\n\nSource: clinicaltrial s NCT07351734\nhttps://clinicaltrials.gov/study/NCT07351734 URL:https://julienwillard.com/calendar/clinical#e-cbe99c7b-5115-4a2d-b120-9 5380040cbf3 END:VEVENT BEGIN:VEVENT UID:1c2039fe591f11a5c178b2261666e6d5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Innovent Biopharmaceutical Technology (Hangzhou) Co.\, LTD. IBI112: Trial primary completion DESCRIPTION:As of 22 December 2025\, Innovent Biopharmaceutical Technology (Hangzhou) Co. estimated primary completion of a Phase 3 trial in psoriasi s\, on 30 September 2026.\n\nSource: clinicaltrials NCT07265284\nhttps://c linicaltrials.gov/study/NCT07265284 URL:https://julienwillard.com/calendar/clinical#e-1d027b74-950f-4f9f-a322-5 c6ce63931d9 END:VEVENT BEGIN:VEVENT UID:4b4ef09a5692ef14e5cfb6d26326249c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BioInvent International AB BI-1206: Trial primary completion DESCRIPTION:As of 24 April 2025\, BioInvent International estimated primary completion of a Phase 2 trial in Indolent B-Cell Non-Hodgkin Lymphoma\, o n 30 September 2026.\n\nSource: clinicaltrials NCT03571568\nhttps://clinic altrials.gov/study/NCT03571568 URL:https://julienwillard.com/calendar/clinical#e-8f8dd207-e7ba-437c-8ddb-d cb19048b52d END:VEVENT BEGIN:VEVENT UID:4c86da19d93905fa4f10004996361f52 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chongqing Claruvis Pharmaceutical Co.\, Ltd. Recombinant Botulinum Toxin Type A for injection (YY001): Trial primary completion DESCRIPTION:As of 22 January 2026\, Chongqing Claruvis Pharmaceutical Co. e stimated primary completion of a Phase 3 trial in Upper Limb Spasticity\, on 30 September 2026.\n\nSource: clinicaltrials NCT06783114\nhttps://clini caltrials.gov/study/NCT06783114 URL:https://julienwillard.com/calendar/clinical#e-ab86ed83-1c03-4610-b027-8 0489b14d888 END:VEVENT BEGIN:VEVENT UID:e510adbf0d66585ebaf511b504074879 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. Tirzepatide: Trial primary com pletion DESCRIPTION:As of 15 December 2025\, Innovent Biologics (Suzhou) Co. estima ted primary completion of a Phase 2 trial in obesity\, on 30 September 202 6.\n\nSource: clinicaltrials NCT07000955\nhttps://clinicaltrials.gov/study /NCT07000955 URL:https://julienwillard.com/calendar/clinical#e-dac0016f-b338-434a-8c6d-9 a404c4694d5 END:VEVENT BEGIN:VEVENT UID:8ceffc6505cf00d6093d04af4491e341 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:EyeBiotech Ltd. Ranibizumab: Trial primary completion DESCRIPTION:As of 26 June 2026\, EyeBiotech estimated primary completion of a Phase 3 trial in Diabetic Macular Edema (DME)\, on 30 September 2026.\n \nSource: clinicaltrials NCT06571045\nhttps://clinicaltrials.gov/study/NCT 06571045 URL:https://julienwillard.com/calendar/clinical#e-953b666b-3a86-48cc-b391-e fd37fc69056 END:VEVENT BEGIN:VEVENT UID:16bc1db518a63bd744b1cd77c0657162 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Takeda TAK-279: Trial primary completion DESCRIPTION:As of 6 May 2026\, Takeda estimated primary completion of a Pha se 2 trial in Ulcerative Colitis\, on 30 September 2026.\n\nSource: clinic altrials NCT06254950\nhttps://clinicaltrials.gov/study/NCT06254950 URL:https://julienwillard.com/calendar/clinical#e-20aa88a1-d672-4dff-a809-4 5bbb37d76ae END:VEVENT BEGIN:VEVENT UID:7a1e4360a62a43e3ffba9d8849c75ca3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Umecrine Cognition AB golexanolone: Trial primary completion DESCRIPTION:As of 26 June 2026\, Umecrine Cognition estimated primary compl etion of a Phase 2 trial in Primary Biliary Cholangitis (PBC)\, on 30 Sept ember 2026.\n\nSource: clinicaltrials NCT07304843\nhttps://clinicaltrials. gov/study/NCT07304843 URL:https://julienwillard.com/calendar/clinical#e-1eb1dc89-24a3-40d4-b1c5-e e9784ed046d END:VEVENT BEGIN:VEVENT UID:ed8559d9509afb37de8f9fd7f2f36dfd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:SyneuRx International (Taiwan) Corp NaBen®: Trial primary completi on DESCRIPTION:As of 13 September 2021\, SyneuRx International (Taiwan) estima ted primary completion of a Phase 3 trial in Refractory Schizophrenia\, on 30 September 2026.\n\nSource: clinicaltrials NCT03094429\nhttps://clinica ltrials.gov/study/NCT03094429 URL:https://julienwillard.com/calendar/clinical#e-c8093021-cb8f-40e2-b541-1 a663e9cd6ea END:VEVENT BEGIN:VEVENT UID:2f0447f4b3c394c2d7bdc18f6eb19b74 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cantex Pharmaceuticals Azeliragon: Trial primary completion DESCRIPTION:As of 31 March 2026\, Cantex Pharmaceuticals estimated primary completion of a Phase 2 trial in glioblastoma\, on 30 September 2026.\n\nS ource: clinicaltrials NCT05986851\nhttps://clinicaltrials.gov/study/NCT059 86851 URL:https://julienwillard.com/calendar/clinical#e-5a781452-c2f1-453f-b109-1 7476f8bcb11 END:VEVENT BEGIN:VEVENT UID:d6589d5f4227dbe652c7fba29a4b103f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Daiichi Sankyo Ifinatamab deruxtecan: Trial primary completion DESCRIPTION:As of 6 February 2026\, Daiichi Sankyo estimated primary comple tion of a Phase 2 trial in Extensive Stage-small Cell Lung Cancer\, on 30 September 2026.\n\nSource: clinicaltrials NCT06362252\nhttps://clinicaltri als.gov/study/NCT06362252 URL:https://julienwillard.com/calendar/clinical#e-24b2c55e-1753-4b1f-8b99-9 c4806f1bb4b END:VEVENT BEGIN:VEVENT UID:2e2a4dbb8e237f84b70c4e8f4330d9dc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Arrowhead Pharmaceuticals ARO-DIMERPA: Trial primary completion DESCRIPTION:As of 13 July 2026\, Arrowhead Pharmaceuticals estimated primar y completion of a Phase 2 trial in Hyperlipidemia\; Mixed\, on 30 Septembe r 2026.\n\nSource: clinicaltrials NCT07223658\nhttps://clinicaltrials.gov/ study/NCT07223658 URL:https://julienwillard.com/calendar/clinical#e-4b543849-368b-4422-88ca-0 9b8e5eeeb8c END:VEVENT BEGIN:VEVENT UID:5d33a02b61745b7ded8c6bfd266fb167 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Accro Bioscience (Suzhou) Limited AC-101: Trial primary completion DESCRIPTION:As of 24 July 2025\, Accro Bioscience (Suzhou) estimated primar y completion of a Phase 2 trial in Ulcerative Colitis\, on 30 September 20 26.\n\nSource: clinicaltrials NCT07083193\nhttps://clinicaltrials.gov/stud y/NCT07083193 URL:https://julienwillard.com/calendar/clinical#e-8c45cef4-a375-4e12-94e5-b 1aab801413c END:VEVENT BEGIN:VEVENT UID:3c39dfbd684f0b6d7d070a87702edfa1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20260930 DTEND;VALUE=DATE:20261001 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:EMD Serono Research & Development Institute\, Inc. M1774: Trial pri mary completion DESCRIPTION:As of 28 May 2026\, EMD Serono Research & Development Institute estimated primary completion of a Phase 2 trial in Non-Small Cell Lung Ca ncer\, on 30 September 2026.\n\nSource: clinicaltrials NCT05882734\nhttps: //clinicaltrials.gov/study/NCT05882734 URL:https://julienwillard.com/calendar/clinical#e-977b870d-a925-42ac-a941-4 7ff071e9cc4 END:VEVENT BEGIN:VEVENT UID:c3736127aac1a62d2a632235da23c3cc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing Dongfang Biotech Co.\, Ltd. Exendin-4 Fc fusion protein inj ection(1.2mg）: Trial primary completion DESCRIPTION:As of 17 September 2025\, Beijing Dongfang Biotech Co. estimate d primary completion of a Phase 3 trial in Type2 Diabetes Mellitus\, on 1 October 2026.\n\nSource: clinicaltrials NCT06257966\nhttps://clinicaltrial s.gov/study/NCT06257966 URL:https://julienwillard.com/calendar/clinical#e-e74431e9-61fb-4d00-bbe4-a a844cd9e6ed END:VEVENT BEGIN:VEVENT UID:c6b98b2e45cfa36e313aee3fdbc5a7b7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sol-Gel Technologies\, Ltd. Patidegib Topical Gel: Trial primary co mpletion DESCRIPTION:As of 11 August 2026\, Sol-Gel Technologies estimated primary c ompletion of a Phase 3 trial in Gorlin Syndrome\, in October 2026.\n\nSour ce: clinicaltrials NCT06050122\nhttps://clinicaltrials.gov/study/NCT060501 22 URL:https://julienwillard.com/calendar/clinical#e-cf3b0b32-bb83-4169-9f71-f 5202bb10df9 END:VEVENT BEGIN:VEVENT UID:b859f9b26c559c697a29cee838d36aef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. SHR-A1811: Trial prim ary completion DESCRIPTION:As of 6 June 2025\, Suzhou Suncadia Biopharmaceuticals Co. esti mated primary completion of a Phase 2 trial in Recurrent or Metastatic Cer vical Cancer\, in October 2026.\n\nSource: clinicaltrials NCT06859775\nhtt ps://clinicaltrials.gov/study/NCT06859775 URL:https://julienwillard.com/calendar/clinical#e-2df9e832-dc53-4d82-87f0-0 943f329cea9 END:VEVENT BEGIN:VEVENT UID:debf67c58c3f883158998ac730096204 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Huilun Pharmaceutical Co.\, Ltd. HL-1186: Trial primary co mpletion DESCRIPTION:As of 13 July 2026\, Shanghai Huilun Pharmaceutical Co. estimat ed primary completion of a Phase 3 trial in Postoperative Pain\, in Octobe r 2026.\n\nSource: clinicaltrials NCT07699601\nhttps://clinicaltrials.gov/ study/NCT07699601 URL:https://julienwillard.com/calendar/clinical#e-983383e8-0a53-43a3-9686-e d5ad40fb125 END:VEVENT BEGIN:VEVENT UID:38b2aad9fc1e6e09a4ee3f9afd07c90b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MedTrace Pharma A/S [O-15]-Water PET Myocardial Perfusion Imaging ( MPI): Trial primary completion DESCRIPTION:As of 10 August 2026\, MedTrace Pharma estimated primary comple tion of a Phase 3 trial in Coronary Artery Disease\, in October 2026.\n\nS ource: clinicaltrials NCT05134012\nhttps://clinicaltrials.gov/study/NCT051 34012 URL:https://julienwillard.com/calendar/clinical#e-f2b8698e-7bd0-4def-9be6-8 25b242b28dc END:VEVENT BEGIN:VEVENT UID:4650292a2aaccd53709c036b66a9982b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Retension Pharmaceuticals. Inc. RTN-001: Trial primary completion DESCRIPTION:As of 29 June 2026\, Retension Pharmaceuticals. estimated prima ry completion of a Phase 2 trial in Uncontrolled Hypertension\, in October 2026.\n\nSource: clinicaltrials NCT07142356\nhttps://clinicaltrials.gov/s tudy/NCT07142356 URL:https://julienwillard.com/calendar/clinical#e-84e3067d-32b1-41da-8949-a cba3fcefa52 END:VEVENT BEGIN:VEVENT UID:65cfe0e1862bebb9e6ecf4db7f1c7a28 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novaliq GmbH Tacrolimus ophthalmic solution: Trial primary completi on DESCRIPTION:As of 28 July 2026\, Novaliq estimated primary completion of a Phase 2 trial in Non-infectious Anterior Uveitis\, in October 2026.\n\nSou rce: clinicaltrials NCT07285070\nhttps://clinicaltrials.gov/study/NCT07285 070 URL:https://julienwillard.com/calendar/clinical#e-6352e766-665e-4ffc-8f7d-c a008acffd55 END:VEVENT BEGIN:VEVENT UID:d0dde0ee94f918f73d12c1c9a597bd99 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:PersonGen BioTherapeutics (Suzhou) Co.\, Ltd. T cell injection targ eting CD7 chimeric antigen receptor: Trial primary completion DESCRIPTION:As of 6 July 2026\, PersonGen BioTherapeutics (Suzhou) Co. esti mated primary completion of a Phase 2 trial in CD7-positive Relapsed/Refra ctory T Lymphoblastic Leukemia/Lymphoma\, on 1 October 2026.\n\nSource: cl inicaltrials NCT07188610\nhttps://clinicaltrials.gov/study/NCT07188610 URL:https://julienwillard.com/calendar/clinical#e-10b7d25a-96c4-4b3f-b8d6-1 311b1fbf745 END:VEVENT BEGIN:VEVENT UID:520a6b165916489ba5a6c6178cb54577 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gilead Sciences Sacituzumab Govitecan-hziy: Trial primary completio n DESCRIPTION:As of 17 November 2025\, Gilead Sciences estimated primary comp letion of a Phase 2 trial in Solid Tumor\, in October 2026.\n\nSource: cli nicaltrials NCT05119907\nhttps://clinicaltrials.gov/study/NCT05119907 URL:https://julienwillard.com/calendar/clinical#e-4553864c-94df-4fd1-82e0-c f5670a898a8 END:VEVENT BEGIN:VEVENT UID:eb3ccfb2475e5c551e86e51338d9c861 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Privo Technologies PRV211 (Intraoperative Cisplatin System): Trial primary completion DESCRIPTION:As of 23 April 2026\, Privo Technologies estimated primary comp letion of a Phase 3 trial in Oral Squamous Cell Carcinoma\, in October 202 6.\n\nSource: clinicaltrials NCT05893888\nhttps://clinicaltrials.gov/study /NCT05893888 URL:https://julienwillard.com/calendar/clinical#e-d8c36ec2-15ba-4658-9f8a-0 cdca280c881 END:VEVENT BEGIN:VEVENT UID:337ff3958ff98c0cc1ae71231cc8e16b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Mirum Pharmaceuticals\, Inc. Maralixibat: Trial primary completion DESCRIPTION:As of 11 August 2026\, Mirum Pharmaceuticals estimated primary completion of a Phase 3 trial in October 2026.\n\nSource: clinicaltrials N CT06553768\nhttps://clinicaltrials.gov/study/NCT06553768 URL:https://julienwillard.com/calendar/clinical#e-46b650b7-6520-4862-b56a-7 b2bb9b97039 END:VEVENT BEGIN:VEVENT UID:aca9c736254c66aee3e8f1c9821f7bea DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing InnoCare Pharma Tech Co.\, Ltd. ICP-332 Tablets: Trial prim ary completion DESCRIPTION:As of 31 December 2025\, Beijing InnoCare Pharma Tech Co. estim ated primary completion of a Phase 2 trial in Plaque Psoriasis\, in Octobe r 2026.\n\nSource: clinicaltrials NCT07251998\nhttps://clinicaltrials.gov/ study/NCT07251998 URL:https://julienwillard.com/calendar/clinical#e-391fa434-058c-4611-80b2-2 f6ad6b8a3f5 END:VEVENT BEGIN:VEVENT UID:83bfa0e86f2156f77204273fb065cc61 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kynexis B.V. KYN-5356 low dose: Trial primary completion DESCRIPTION:As of 23 June 2026\, Kynexis B.V. estimated primary completion of a Phase 2 trial in Cognitive Impairment Associated With Schizophrenia ( CIAS)\, in October 2026.\n\nSource: clinicaltrials NCT07191483\nhttps://cl inicaltrials.gov/study/NCT07191483 URL:https://julienwillard.com/calendar/clinical#e-9066dbe2-c0be-4d48-8bca-2 14b48e75966 END:VEVENT BEGIN:VEVENT UID:403d312c08dc0162905a47b1fc924aa6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company Retatrutide: Trial primary completion DESCRIPTION:As of 20 July 2026\, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 2 Diabetes\, in October 2026.\n\nSource: clini caltrials NCT06297603\nhttps://clinicaltrials.gov/study/NCT06297603 URL:https://julienwillard.com/calendar/clinical#e-73132fa8-bb40-453c-afca-6 36323357274 END:VEVENT BEGIN:VEVENT UID:509cdb7ee7af2063f3b0a5029e924f99 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pharming Technologies B.V. Leniolisib: Trial primary completion DESCRIPTION:As of 12 February 2026\, Pharming Technologies B.V. estimated p rimary completion of a Phase 2 trial in Common Variable Immunodeficiency ( CVID)\, in October 2026.\n\nSource: clinicaltrials NCT06897358\nhttps://cl inicaltrials.gov/study/NCT06897358 URL:https://julienwillard.com/calendar/clinical#e-70cc416d-f94e-4e65-b113-4 c50730bed09 END:VEVENT BEGIN:VEVENT UID:a409f225c1db9dd35602decbac461525 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Actinogen Medical Xanamem: Trial primary completion DESCRIPTION:As of 21 July 2026\, Actinogen Medical estimated primary comple tion of a Phase 3 trial in Dementia Moderate\, in October 2026.\n\nSource: clinicaltrials NCT06125951\nhttps://clinicaltrials.gov/study/NCT06125951 URL:https://julienwillard.com/calendar/clinical#e-d34353fa-2d6c-41a9-a5d8-8 cf14b44a0d0 END:VEVENT BEGIN:VEVENT UID:84459139e14432cd5493069fb0c3c415 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Phathom Pharmaceuticals\, Inc. Vonoprazan: Trial primary completion DESCRIPTION:As of 29 June 2026\, Phathom Pharmaceuticals estimated primary completion of a Phase 2 trial in Eosinophilic Esophagitis\, in October 202 6.\n\nSource: clinicaltrials NCT06851559\nhttps://clinicaltrials.gov/study /NCT06851559 URL:https://julienwillard.com/calendar/clinical#e-6ed3f88d-a8da-4497-8f27-5 690655caad5 END:VEVENT BEGIN:VEVENT UID:dd25d174ff68d0a62e467e1898693232 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novadip Biosciences NVD003: Trial primary completion DESCRIPTION:As of 1 April 2026\, Novadip Biosciences estimated primary comp letion of a Phase 3 trial in Congenital Pseudarthrosis of Tibia\, in Octob er 2026.\n\nSource: clinicaltrials NCT07112443\nhttps://clinicaltrials.gov /study/NCT07112443 URL:https://julienwillard.com/calendar/clinical#e-42064e6d-e7bb-4bb1-85dd-6 cd9cc5e34cc END:VEVENT BEGIN:VEVENT UID:64ed05347cf943464a365d41327cdf77 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Disc Medicine\, Inc DISC-0974: Trial primary completion DESCRIPTION:As of 3 August 2026\, Disc Medicine estimated primary completio n of a Phase 2 trial in Inflammatory Bowel Disease (IBD)\, in October 2026 .\n\nSource: clinicaltrials NCT07368972\nhttps://clinicaltrials.gov/study/ NCT07368972 URL:https://julienwillard.com/calendar/clinical#e-0cd4ee89-62c8-4293-9ee3-7 9661e46b005 END:VEVENT BEGIN:VEVENT UID:43999ef8b03333c10517701214d82fa2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company Baricitinib: Trial primary completion DESCRIPTION:As of 11 August 2026\, Eli Lilly and estimated primary completi on of a Phase 3 trial in Systemic Juvenile Idiopathic Arthritis\, in Octob er 2026.\n\nSource: clinicaltrials NCT04088396\nhttps://clinicaltrials.gov /study/NCT04088396 URL:https://julienwillard.com/calendar/clinical#e-e2c1f9a7-d882-4e61-81a2-6 ffe0bbc4333 END:VEVENT BEGIN:VEVENT UID:92f55298e6bf31aa6e894eb440f8b068 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Citryll BV [89Zr]Zr-CIT: Trial primary completion DESCRIPTION:As of 30 January 2026\, Citryll BV estimated primary completion of a Phase 2 trial in rA\, on 1 October 2026.\n\nSource: clinicaltrials N CT07147959\nhttps://clinicaltrials.gov/study/NCT07147959 URL:https://julienwillard.com/calendar/clinical#e-bebf15e7-02fc-47bd-9c3b-2 3bab383c45b END:VEVENT BEGIN:VEVENT UID:78b22c278628c679e30bcb38773c741b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Xenon Pharmaceuticals Inc. XEN1101: Trial primary completion DESCRIPTION:As of 14 May 2026\, Xenon Pharmaceuticals estimated primary com pletion of a Phase 3 trial in Focal Onset Seizures\, in October 2026.\n\nS ource: clinicaltrials NCT05716100\nhttps://clinicaltrials.gov/study/NCT057 16100 URL:https://julienwillard.com/calendar/clinical#e-7b8d912c-4c16-4bab-aa9b-6 4f314e055c8 END:VEVENT BEGIN:VEVENT UID:d95f13cc14e790ae484af0cf9767b84e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie ABBV-RGX-314 Dose 1: Trial primary completion DESCRIPTION:As of 3 August 2026\, AbbVie estimated primary completion of a Phase 3 trial in aMD\, in October 2026.\n\nSource: clinicaltrials NCT05407 636\nhttps://clinicaltrials.gov/study/NCT05407636 URL:https://julienwillard.com/calendar/clinical#e-9248bf53-6bf4-49de-873d-c f8717cf8d1f END:VEVENT BEGIN:VEVENT UID:c82bfe3c577a1ad8c600c30b79ffa5b6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Celldex Therapeutics barzolvolimab: Trial primary completion DESCRIPTION:As of 25 March 2026\, Celldex Therapeutics estimated primary co mpletion of a Phase 3 trial in Chronic Spontaneous Urticaria\, in October 2026.\n\nSource: clinicaltrials NCT06455202\nhttps://clinicaltrials.gov/st udy/NCT06455202 URL:https://julienwillard.com/calendar/clinical#e-75e1bb2d-8f6c-4ae8-93e9-0 2cb7ab7bb39 END:VEVENT BEGIN:VEVENT UID:5123ec459400f53ea85fbffd09dedec7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Lallemand Health Solutions Probiotic Formula 1: Trial primary compl etion DESCRIPTION:As of 18 June 2026\, Lallemand Health Solutions estimated prima ry completion of a Phase 2 trial in Focus is on Healthy Subjects\, in Octo ber 2026.\n\nSource: clinicaltrials NCT07246161\nhttps://clinicaltrials.go v/study/NCT07246161 URL:https://julienwillard.com/calendar/clinical#e-c999de34-3006-4a41-9180-f 7e42fdd3ba3 END:VEVENT BEGIN:VEVENT UID:0e2b1674224ae28f93ab5ddf950d2b51 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Prana Therapies Inc PRA-216: Trial primary completion DESCRIPTION:As of 6 August 2026\, Prana Therapies estimated primary complet ion of a Phase 2 trial in Mild to Moderate Asthma\, on 1 October 2026.\n\n Source: clinicaltrials NCT07245368\nhttps://clinicaltrials.gov/study/NCT07 245368 URL:https://julienwillard.com/calendar/clinical#e-bfcd60e7-2c02-41bc-a49d-3 ac64a53bf7f END:VEVENT BEGIN:VEVENT UID:f65b0f19210a141114a27888d8ff2a2a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Teligene Ltd. TL938 Capsules: Trial primary completion DESCRIPTION:As of 28 April 2026\, Suzhou Teligene estimated primary complet ion of a Phase 2 trial in Colorectal Cancer Metastatic\, in October 2026.\ n\nSource: clinicaltrials NCT06589830\nhttps://clinicaltrials.gov/study/NC T06589830 URL:https://julienwillard.com/calendar/clinical#e-cb8b0a6d-348f-45a8-bdc5-f e64da542c70 END:VEVENT BEGIN:VEVENT UID:e10c95bb66deed6138869376cf92e511 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Zhejiang Sunshine Mandi Pharmaceutical Co.\,Ltd. Clascoterone: Tria l primary completion DESCRIPTION:As of 9 July 2025\, Zhejiang Sunshine Mandi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Acne Vulgaris\, in Octo ber 2026.\n\nSource: clinicaltrials NCT06403501\nhttps://clinicaltrials.go v/study/NCT06403501 URL:https://julienwillard.com/calendar/clinical#e-58144f8a-7c3c-4bc3-bffc-f 86d6b9115d2 END:VEVENT BEGIN:VEVENT UID:800959af146cea5cddf46609f3b53371 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biohaven Therapeutics Ltd. BHV-7000: Trial primary completion DESCRIPTION:As of 1 July 2026\, Biohaven Therapeutics estimated primary com pletion of a Phase 3 trial in Focal Epilepsy\, in October 2026.\n\nSource: clinicaltrials NCT06309966\nhttps://clinicaltrials.gov/study/NCT06309966 URL:https://julienwillard.com/calendar/clinical#e-7094eb30-951d-4f15-8ac9-c 5e29dccd329 END:VEVENT BEGIN:VEVENT UID:6370a1aba81e578ac753746511adc846 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Corcept Therapeutics Dazucorilant 300 mg: Trial primary completion DESCRIPTION:As of 16 June 2026\, Corcept Therapeutics estimated primary com pletion of a Phase 2 trial in Amyotrophic Lateral Sclerosis\, in October 2 026.\n\nSource: clinicaltrials NCT05407324\nhttps://clinicaltrials.gov/stu dy/NCT05407324 URL:https://julienwillard.com/calendar/clinical#e-4a09b3d8-2426-4d60-9112-d ef4ad6b0c38 END:VEVENT BEGIN:VEVENT UID:3af175ad17345eaea4c9b1b1ca5e4eda DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:RemeGen Co.\, Ltd. Disitamab Vedotin: Trial primary completion DESCRIPTION:As of 17 February 2025\, RemeGen Co. estimated primary completi on of a Phase 2 trial in Breast Cancer\, on 1 October 2026.\n\nSource: cli nicaltrials NCT06642545\nhttps://clinicaltrials.gov/study/NCT06642545 URL:https://julienwillard.com/calendar/clinical#e-3f2ef42c-33f7-45af-8fed-3 49b7601c6d3 END:VEVENT BEGIN:VEVENT UID:20cf936b741b9d0b8c4dedcddf061736 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:EyePoint Pharmaceuticals\, Inc. EYP-1901: Trial primary completion DESCRIPTION:As of 4 August 2026\, EyePoint Pharmaceuticals estimated primar y completion of a Phase 3 trial in Wet Age Related Macular Degeneration\, in October 2026.\n\nSource: clinicaltrials NCT06683742\nhttps://clinicaltr ials.gov/study/NCT06683742 URL:https://julienwillard.com/calendar/clinical#e-94c6937d-1ba6-4015-a269-6 20b18f05fbe END:VEVENT BEGIN:VEVENT UID:c2e9e3b55bc5d4b1d57b6f37a7e69ea7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Immunovant Sciences GmbH IMVT-1402: Trial primary completion DESCRIPTION:As of 10 July 2026\, Immunovant Sciences estimated primary comp letion of a Phase 2 trial in Subacute Cutaneous Lupus Erythematosus\, in O ctober 2026.\n\nSource: clinicaltrials NCT06980805\nhttps://clinicaltrials .gov/study/NCT06980805 URL:https://julienwillard.com/calendar/clinical#e-b000b4f7-8196-4a33-a605-1 acfcd27ed0a END:VEVENT BEGIN:VEVENT UID:a83f0ed0a0265ced166f19927a290774 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals Iptacopan (LNP023): Trial primary completi on DESCRIPTION:As of 3 July 2025\, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Age-Related Macular Degeneration\, on 1 O ctober 2026.\n\nSource: clinicaltrials NCT05230537\nhttps://clinicaltrials .gov/study/NCT05230537 URL:https://julienwillard.com/calendar/clinical#e-a06e0bd6-1a64-4d04-9a17-4 a0dca1e5d7c END:VEVENT BEGIN:VEVENT UID:333af459ca1e1456cfe21e0757032c4f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Organon and Co tapinarof cream\, 1%: Trial primary completion DESCRIPTION:As of 17 April 2026\, Organon and estimated primary completion of a Phase 3 trial in Plaque Psoriasis\, in October 2026.\n\nSource: clini caltrials NCT05172726\nhttps://clinicaltrials.gov/study/NCT05172726 URL:https://julienwillard.com/calendar/clinical#e-2e033cbc-e197-41cc-b42b-8 ad4b2d061ea END:VEVENT BEGIN:VEVENT UID:2ffd67e0f05183b1fb2b70c72a98d2a1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gilgamesh Pharmaceuticals GM-2505: Trial primary completion DESCRIPTION:As of 9 February 2026\, Gilgamesh Pharmaceuticals estimated pri mary completion of a Phase 2 trial in Major Depressive Disorder\, in Octob er 2026.\n\nSource: clinicaltrials NCT06236880\nhttps://clinicaltrials.gov /study/NCT06236880 URL:https://julienwillard.com/calendar/clinical#e-279fe174-e326-40a5-89ad-8 ca62b25bf59 END:VEVENT BEGIN:VEVENT UID:2343000e6a3d0e01b1d5eea53deedf64 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Fujian Akeylink Biotechnology Co.\, Ltd. GST-HG141: Trial primary c ompletion DESCRIPTION:As of 17 July 2026\, Fujian Akeylink Biotechnology Co. estimate d primary completion of a Phase 2 trial in Chronic Hepatitis B\, on 1 Octo ber 2026.\n\nSource: clinicaltrials NCT07709520\nhttps://clinicaltrials.go v/study/NCT07709520 URL:https://julienwillard.com/calendar/clinical#e-1dab9e44-d0bd-4dbe-99b7-9 a231d2b931c END:VEVENT BEGIN:VEVENT UID:9873eb9c3fa7d9e5a44695856a8a4f99 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ImmunityBio\, Inc. N-803 (IL-15 Superagonist): Trial primary comple tion DESCRIPTION:As of 11 May 2026\, ImmunityBio estimated primary completion of a Phase 2 trial in Long COVID\, in October 2026.\n\nSource: clinicaltrial s NCT07108036\nhttps://clinicaltrials.gov/study/NCT07108036 URL:https://julienwillard.com/calendar/clinical#e-01e27a68-b37b-481c-8b05-7 2a8f4227bbe END:VEVENT BEGIN:VEVENT UID:9961d4d5aa093552b18b048a07e718d0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Senseye\, Inc. Senseye Diagnostic Tool (DT): Trial primary completi on DESCRIPTION:As of 29 April 2026\, Senseye estimated primary completion of a Phase 3 trial in PTSD - Post Traumatic Stress Disorder\, in October 2026. \n\nSource: clinicaltrials NCT07280065\nhttps://clinicaltrials.gov/study/N CT07280065 URL:https://julienwillard.com/calendar/clinical#e-1fb05ab2-56f9-4901-ac16-f 69dc8755f6a END:VEVENT BEGIN:VEVENT UID:9db873261d23f3b33e676eb1d74c5b3e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Debiopharm International SA Debio 4326: Trial primary completion DESCRIPTION:As of 27 July 2026\, Debiopharm International SA estimated prim ary completion of a Phase 3 trial in Central Precocious Puberty\, in Octob er 2026.\n\nSource: clinicaltrials NCT06129539\nhttps://clinicaltrials.gov /study/NCT06129539 URL:https://julienwillard.com/calendar/clinical#e-97c71c98-a440-4409-b995-f 349774a60f6 END:VEVENT BEGIN:VEVENT UID:271f5e83708bf23de7003cda358e92f3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vyriad\, Inc. VV1: Trial primary completion DESCRIPTION:As of 8 July 2026\, Vyriad estimated primary completion of a Ph ase 2 trial in melanoma\, in October 2026.\n\nSource: clinicaltrials NCT04 291105\nhttps://clinicaltrials.gov/study/NCT04291105 URL:https://julienwillard.com/calendar/clinical#e-40634e9f-c046-4d0c-bdc9-e 4d0c5f30eae END:VEVENT BEGIN:VEVENT UID:efa201274fc70ae778d5e0111026a913 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Industrial Farmacéutica Cantabria\, S.A. Minoxidil Tablets: Trial primary completion DESCRIPTION:As of 12 May 2026\, Industrial Farmacéutica Cantabria estimate d primary completion of a Phase 3 trial in Androgenetic Alopecia\, in Octo ber 2026.\n\nSource: clinicaltrials NCT05888922\nhttps://clinicaltrials.go v/study/NCT05888922 URL:https://julienwillard.com/calendar/clinical#e-69a406d2-eaa6-4a50-b972-b 8c9f8a2280f END:VEVENT BEGIN:VEVENT UID:80a148e30e0e493f556dd26e7e1ea407 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Inhatarget Therapeutics CIS-DPI: Trial primary completion DESCRIPTION:As of 26 March 2025\, Inhatarget Therapeutics estimated primary completion of a Phase 2 trial in NSCLC (advanced Non-small Cell Lung Canc er)\, on 1 October 2026.\n\nSource: clinicaltrials NCT06896890\nhttps://cl inicaltrials.gov/study/NCT06896890 URL:https://julienwillard.com/calendar/clinical#e-3109f92e-9919-4fea-91a7-e 5af1e840e3e END:VEVENT BEGIN:VEVENT UID:80ab567b9f970d2d446cb877515c8d49 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Hengrui Pharmaceutical Co.\, Ltd. SHR-A2102 for Injection: Trial primary completion DESCRIPTION:As of 23 December 2025\, Shanghai Hengrui Pharmaceutical Co. es timated primary completion of a Phase 2 trial in Advanced or Metastatic No n-small Cell Lung Cancer\, in October 2026.\n\nSource: clinicaltrials NCT0 6512051\nhttps://clinicaltrials.gov/study/NCT06512051 URL:https://julienwillard.com/calendar/clinical#e-9e3032e1-77f5-4188-ab6d-1 7b23eb09868 END:VEVENT BEGIN:VEVENT UID:709f61b72e3f04c147307dc1802bf92b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:argenx efgartigimod PH20 SC: Trial primary completion DESCRIPTION:As of 12 January 2026\, argenx estimated primary completion of a Phase 3 trial in Primary Immune Thrombocytopenia\, on 1 October 2026.\n\ nSource: clinicaltrials NCT04812925\nhttps://clinicaltrials.gov/study/NCT0 4812925 URL:https://julienwillard.com/calendar/clinical#e-677a81da-b7ab-4d65-b217-0 ff6979a701e END:VEVENT BEGIN:VEVENT UID:bcaceda3fa1339a3bb2d02da9c8e4d77 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MediLink Therapeutics (Suzhou) Co.\, Ltd. YL201 for Injection: Tria l primary completion DESCRIPTION:As of 12 March 2026\, MediLink Therapeutics (Suzhou) Co. estima ted primary completion of a Phase 2 trial in Advanced Solid Tumor\, in Oct ober 2026.\n\nSource: clinicaltrials NCT06057922\nhttps://clinicaltrials.g ov/study/NCT06057922 URL:https://julienwillard.com/calendar/clinical#e-99e9a7f9-6b15-473f-a2b7-8 ead0362fc57 END:VEVENT BEGIN:VEVENT UID:2f7262bf2cf158567e14d55d19c9f4f3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vanda Pharmaceuticals iloperidone: Trial primary completion DESCRIPTION:As of 27 February 2026\, Vanda Pharmaceuticals estimated primar y completion of a Phase 2 trial in hypertension\, in October 2026.\n\nSour ce: clinicaltrials NCT07090161\nhttps://clinicaltrials.gov/study/NCT070901 61 URL:https://julienwillard.com/calendar/clinical#e-94543c03-fe99-4934-aa02-f 483bf7c4f25 END:VEVENT BEGIN:VEVENT UID:1c6309941bf2915648fb1f7cc7b15381 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Research Institute of Geroprotective Technologies Aroxxen: Trial pr imary completion DESCRIPTION:As of 6 May 2026\, Research Institute of Geroprotective Technol ogies estimated primary completion of a Phase 2 trial in Coronary Artery D isease\, on 1 October 2026.\n\nSource: clinicaltrials NCT07397351\nhttps:/ /clinicaltrials.gov/study/NCT07397351 URL:https://julienwillard.com/calendar/clinical#e-f9500368-095e-4a5b-bdaf-1 18654bedf3c END:VEVENT BEGIN:VEVENT UID:721ab8ce2681addbe2b8d204a62f9508 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Endeavor Biomedicines\, Inc. ENV-101: Trial primary completion DESCRIPTION:As of 24 February 2026\, Endeavor Biomedicines estimated primar y completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis\, in Octo ber 2026.\n\nSource: clinicaltrials NCT06422884\nhttps://clinicaltrials.go v/study/NCT06422884 URL:https://julienwillard.com/calendar/clinical#e-4a90e7ac-3c77-4b1f-8e2c-f 9fac6edd721 END:VEVENT BEGIN:VEVENT UID:9b063499dec06a4306f51892d789cf8f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Aldena Therapeutics ALD-102 Solution: Trial primary completion DESCRIPTION:As of 4 March 2026\, Aldena Therapeutics estimated primary comp letion of a Phase 2 trial in Alopecia Areata (AA)\, in October 2026.\n\nSo urce: clinicaltrials NCT06826196\nhttps://clinicaltrials.gov/study/NCT0682 6196 URL:https://julienwillard.com/calendar/clinical#e-2201fefa-add1-4c4f-9553-3 5c482af0910 END:VEVENT BEGIN:VEVENT UID:2141578498742853b3e94ab912149a72 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Acumen Pharmaceuticals sabirnetug: Trial primary completion DESCRIPTION:As of 27 October 2025\, Acumen Pharmaceuticals estimated primar y completion of a Phase 2 trial in Alzheimer Disease\, in October 2026.\n\ nSource: clinicaltrials NCT06335173\nhttps://clinicaltrials.gov/study/NCT0 6335173 URL:https://julienwillard.com/calendar/clinical#e-5716d844-0177-4d25-ac79-d d8900f0894b END:VEVENT BEGIN:VEVENT UID:3e30383d04a18f75d0271fc2d928decc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sernova Biotherapeutics Inc. Sernova Cell Pouch: Trial primary comp letion DESCRIPTION:As of 25 February 2026\, Sernova Biotherapeutics estimated prim ary completion of a Phase 2 trial in Type 1 Diabetes Mellitus\, in October 2026.\n\nSource: clinicaltrials NCT03513939\nhttps://clinicaltrials.gov/s tudy/NCT03513939 URL:https://julienwillard.com/calendar/clinical#e-8affc756-1ee4-4b4d-8d94-6 b06baec326f END:VEVENT BEGIN:VEVENT UID:fbd7ebb1b259e894b9fccfcf93ab587c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Akeso AK112\, Gemcitabine\, Cisplatin: Trial primary completion DESCRIPTION:As of 21 January 2026\, Akeso estimated primary completion of a Phase 3 trial in Biliary Tract Cancer\, in October 2026.\n\nSource: clini caltrials NCT06591520\nhttps://clinicaltrials.gov/study/NCT06591520 URL:https://julienwillard.com/calendar/clinical#e-41864eca-a2b9-4ff1-8f07-6 a2fac0ac265 END:VEVENT BEGIN:VEVENT UID:92d24db48001e51e7e9c7474667fc5e8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Philogen S.p.A. Onfekafusp alfa: Trial primary completion DESCRIPTION:As of 10 October 2023\, Philogen S.p.A. estimated primary compl etion of a Phase 2 trial in glioblastoma\, in October 2026.\n\nSource: cli nicaltrials NCT04443010\nhttps://clinicaltrials.gov/study/NCT04443010 URL:https://julienwillard.com/calendar/clinical#e-444ac3fd-b5c7-4db7-8647-0 182e55e10d5 END:VEVENT BEGIN:VEVENT UID:24445254fe44b14e14efc06797d5e38f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Hengrui Pharmaceutical Co.\, Ltd. SHR-A2102；Adebrelimab ；Cisplatin: Trial primary completion DESCRIPTION:As of 3 January 2025\, Shanghai Hengrui Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Advanced or Metastatic Esop hageal Cancer\, in October 2026.\n\nSource: clinicaltrials NCT06474468\nht tps://clinicaltrials.gov/study/NCT06474468 URL:https://julienwillard.com/calendar/clinical#e-6ebaccc7-7734-4cac-a310-d 20a416c1d53 END:VEVENT BEGIN:VEVENT UID:1208812d7bbc8f025ae37bae1160af2f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Shengdi Pharmaceutical Co.\, Ltd SHR-4610 Injection: Trial primary completion DESCRIPTION:As of 24 July 2026\, Shanghai Shengdi Pharmaceutical Co. estima ted primary completion of a Phase 2 trial in Solid Tumors\, in October 202 6.\n\nSource: clinicaltrials NCT07231211\nhttps://clinicaltrials.gov/study /NCT07231211 URL:https://julienwillard.com/calendar/clinical#e-cbcb10e9-c290-4602-87a7-1 a7501fb967a END:VEVENT BEGIN:VEVENT UID:490ab76d988e75e3dabd009ca5a14810 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Loxo Oncology\, Inc. Pirtobrutinib: Trial primary completion DESCRIPTION:As of 29 January 2026\, Loxo Oncology estimated primary complet ion of a Phase 3 trial in Chronic Lymphocytic Leukemia\, in October 2026.\ n\nSource: clinicaltrials NCT04965493\nhttps://clinicaltrials.gov/study/NC T04965493 URL:https://julienwillard.com/calendar/clinical#e-22cc60a3-1a35-4e17-9a4c-4 7880d7f5bbe END:VEVENT BEGIN:VEVENT UID:9e1a1b59a4c3b8c8abde3526090623dd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Laminar Pharmaceuticals LAM561: Trial primary completion DESCRIPTION:As of 20 November 2025\, Laminar Pharmaceuticals estimated prim ary completion of a Phase 2 trial in High-grade Glioma\, in October 2026.\ n\nSource: clinicaltrials NCT04299191\nhttps://clinicaltrials.gov/study/NC T04299191 URL:https://julienwillard.com/calendar/clinical#e-c033133d-0ace-497d-b014-8 b1edeaa1d56 END:VEVENT BEGIN:VEVENT UID:da836f5e8c19f5cce4f9160bc4443d02 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Inmunotek S.L. 10\,000 MG01 +10\,000 T521: Trial primary completion DESCRIPTION:As of 13 May 2025\, Inmunotek S.L. estimated primary completion of a Phase 3 trial in Rhinitis\, Allergic\, in October 2026.\n\nSource: c linicaltrials NCT04898283\nhttps://clinicaltrials.gov/study/NCT04898283 URL:https://julienwillard.com/calendar/clinical#e-f279807f-7e38-43a1-b22e-7 bd2506b4ef5 END:VEVENT BEGIN:VEVENT UID:0e45a41696cc04f346c6efa2b49f50ef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1 for Injection: Tri al primary completion DESCRIPTION:As of 7 May 2025\, Sichuan Baili Pharmaceutical Co. estimated p rimary completion of a Phase 2 trial in Recurrent Glioblastoma\, in Octobe r 2026.\n\nSource: clinicaltrials NCT06598787\nhttps://clinicaltrials.gov/ study/NCT06598787 URL:https://julienwillard.com/calendar/clinical#e-de4ecc60-0054-4bb6-9335-1 fee49efadaf END:VEVENT BEGIN:VEVENT UID:418a635c5655c7f58cc0bb81fb5e1b0f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cocrystal Pharma\, Inc. CDI-988: Trial primary completion DESCRIPTION:As of 17 February 2026\, Cocrystal Pharma estimated primary com pletion of a Phase 2 trial in norovirus\, on 1 October 2026.\n\nSource: cl inicaltrials NCT07198139\nhttps://clinicaltrials.gov/study/NCT07198139 URL:https://julienwillard.com/calendar/clinical#e-a6db2b8a-d4e4-4828-9ffc-6 1a5dcc06fc3 END:VEVENT BEGIN:VEVENT UID:e285209744f073f7e6981624bf0ac4e4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GIE Medical GIE Medical ProTractX3 TTS DCB: Trial primary completio n DESCRIPTION:As of 25 June 2025\, GIE Medical estimated primary completion o f a Phase 3 trial in Esophageal Stricture\, in October 2026.\n\nSource: cl inicaltrials NCT05561114\nhttps://clinicaltrials.gov/study/NCT05561114 URL:https://julienwillard.com/calendar/clinical#e-c6e0afc9-e522-4712-9949-8 f5802a183fe END:VEVENT BEGIN:VEVENT UID:1bf35005c77ad4073ca68715184a9d4b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Aramis Biotechnologies Inc. Recombinant Influenza vaccine candidate : Trial primary completion DESCRIPTION:As of 4 August 2026\, Aramis Biotechnologies estimated primary completion of a Phase 2 trial in influenza\, in October 2026.\n\nSource: c linicaltrials NCT07291635\nhttps://clinicaltrials.gov/study/NCT07291635 URL:https://julienwillard.com/calendar/clinical#e-4763ca26-ffc2-4f60-917f-8 0186c8d48a3 END:VEVENT BEGIN:VEVENT UID:951b2d117c06a90f34b74fa99da326ef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BioAegis Therapeutics Inc. Rhu-pGSN: Trial primary completion DESCRIPTION:As of 15 June 2026\, BioAegis Therapeutics estimated primary co mpletion of a Phase 2 trial in Acute Respiratory Distress Syndrome\, on 1 October 2026.\n\nSource: clinicaltrials NCT05947955\nhttps://clinicaltrial s.gov/study/NCT05947955 URL:https://julienwillard.com/calendar/clinical#e-c968a932-0493-450a-92ec-8 c148c738559 END:VEVENT BEGIN:VEVENT UID:b9360a2943c5bc3226f5694dab831089 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merz North America\, Inc. NT 201: Trial primary completion DESCRIPTION:As of 22 May 2026\, Merz North America estimated primary comple tion of a Phase 3 trial in Neuromuscular Agents\, in October 2026.\n\nSour ce: clinicaltrials NCT07122193\nhttps://clinicaltrials.gov/study/NCT071221 93 URL:https://julienwillard.com/calendar/clinical#e-5fe650a6-1075-42d1-bb6d-9 827f35a4cc9 END:VEVENT BEGIN:VEVENT UID:29aed7a4aa9ece325bf40a8f2e1b9f1e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Huilun Pharmaceutical Co.\, Ltd. HL-1186: Trial primary co mpletion DESCRIPTION:As of 16 July 2026\, Shanghai Huilun Pharmaceutical Co. estimat ed primary completion of a Phase 3 trial in Postoperative Pain\, in Octobe r 2026.\n\nSource: clinicaltrials NCT07709598\nhttps://clinicaltrials.gov/ study/NCT07709598 URL:https://julienwillard.com/calendar/clinical#e-0fe483a0-798a-4a6c-b7dd-6 7bdd1e5a51d END:VEVENT BEGIN:VEVENT UID:a9c44909c6e1ddc8c93e45d168764434 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CanSino Biologics Inc. Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose: Trial primary completion DESCRIPTION:As of 6 August 2026\, CanSino Biologics estimated primary compl etion of a Phase 2 trial in poliomyelitis\, in October 2026.\n\nSource: cl inicaltrials NCT06577298\nhttps://clinicaltrials.gov/study/NCT06577298 URL:https://julienwillard.com/calendar/clinical#e-235b53c3-a64c-4e23-8185-4 f7c37654d07 END:VEVENT BEGIN:VEVENT UID:f90cec752b65e6e84aa3a9c8441ed4b1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novo Nordisk A/S Ziltivekimab: Trial primary completion DESCRIPTION:As of 31 July 2026\, Novo Nordisk estimated primary completion of a Phase 3 trial in Heart Failure\, on 1 October 2026.\n\nSource: clinic altrials NCT06200207\nhttps://clinicaltrials.gov/study/NCT06200207 URL:https://julienwillard.com/calendar/clinical#e-405cb4a4-e23b-4df3-8241-3 d5964330361 END:VEVENT BEGIN:VEVENT UID:2c3062d4a9e40118a8f8f289989e81e1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-M07D1: Trial primary com pletion DESCRIPTION:As of 6 August 2025\, Sichuan Baili Pharmaceutical Co. estimate d primary completion of a Phase 2 trial in HER2-positive Gastric or Gastro esophageal Junction Adenocarcinoma\, in October 2026.\n\nSource: clinicalt rials NCT06423885\nhttps://clinicaltrials.gov/study/NCT06423885 URL:https://julienwillard.com/calendar/clinical#e-73437507-08b8-48e5-9086-a 8b41d935e7a END:VEVENT BEGIN:VEVENT UID:8752454690ae734ecad43dfd68e9b0da DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Qilu Pharmaceutical Co.\, Ltd. QLC5508: Trial primary completion DESCRIPTION:As of 1 December 2025\, Qilu Pharmaceutical Co. estimated prima ry completion of a Phase 2 trial in Advanced Solid Tumor\, in October 2026 .\n\nSource: clinicaltrials NCT07256782\nhttps://clinicaltrials.gov/study/ NCT07256782 URL:https://julienwillard.com/calendar/clinical#e-4db54792-de78-49a4-851d-2 302eee83bd0 END:VEVENT BEGIN:VEVENT UID:4bb5cc13fdd98a36b8d95e2c8e69417c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Housey Healthcare ULC HP-211: Trial primary completion DESCRIPTION:As of 23 April 2026\, Housey Healthcare ULC estimated primary c ompletion of a Phase 2 trial in Type 2 Diabetes\, in October 2026.\n\nSour ce: clinicaltrials NCT07546929\nhttps://clinicaltrials.gov/study/NCT075469 29 URL:https://julienwillard.com/calendar/clinical#e-2fac5eed-e2a0-46fc-aa2d-c 2bc8ce2c993 END:VEVENT BEGIN:VEVENT UID:bc7a7277748b658bb3bdbf9149a09362 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261002 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:USWM CT\, LLC Afamitresgene autoleucel: Trial primary completion DESCRIPTION:As of 11 August 2026\, USWM CT estimated primary completion of a Phase 2 trial in Synovial Sarcoma\, on 1 October 2026.\n\nSource: clinic altrials NCT05642455\nhttps://clinicaltrials.gov/study/NCT05642455 URL:https://julienwillard.com/calendar/clinical#e-d15d24aa-753a-48ef-bedc-9 391b4f716df END:VEVENT BEGIN:VEVENT UID:3a4dbcbf8381527f1b1d6f18f0464835 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Triveni Bio TRIV-509: Trial primary completion DESCRIPTION:As of 27 April 2026\, Triveni Bio estimated primary completion of a Phase 2 trial in Atopic Dermatitis\, in October 2026.\n\nSource: clin icaltrials NCT07167758\nhttps://clinicaltrials.gov/study/NCT07167758 URL:https://julienwillard.com/calendar/clinical#e-e21945d5-eae0-4296-ab28-1 89375655715 END:VEVENT BEGIN:VEVENT UID:03b2595a4beadfda05f56f4e35776523 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Celldex Therapeutics barzolvolimab: Trial primary completion DESCRIPTION:As of 25 March 2026\, Celldex Therapeutics estimated primary co mpletion of a Phase 3 trial in Chronic Spontaneous Urticaria\, in October 2026.\n\nSource: clinicaltrials NCT06445023\nhttps://clinicaltrials.gov/st udy/NCT06445023 URL:https://julienwillard.com/calendar/clinical#e-6e4d3989-5880-4eb4-a0e1-d a6c1b0d3d12 END:VEVENT BEGIN:VEVENT UID:e86191ab728f03bc3032b1b2b5cca349 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. D-1553 Tablet: Tr ial primary completion DESCRIPTION:As of 26 April 2024\, Chia Tai Tianqing Pharmaceutical Group Co . estimated primary completion of a Phase 3 trial in Non Small Cell Lung C ancer\, in October 2026.\n\nSource: clinicaltrials NCT06300177\nhttps://cl inicaltrials.gov/study/NCT06300177 URL:https://julienwillard.com/calendar/clinical#e-3adff6cf-6d93-4009-92f8-8 e1b87a9f292 END:VEVENT BEGIN:VEVENT UID:c75ff64785e43425b083a8e90b7bfec7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ingenia Therapeutics INC IGT-303: Trial primary completion DESCRIPTION:As of 18 May 2026\, Ingenia Therapeutics estimated primary comp letion of a Phase 2 trial in Healthy Volunteers\, in October 2026.\n\nSour ce: clinicaltrials NCT07231679\nhttps://clinicaltrials.gov/study/NCT072316 79 URL:https://julienwillard.com/calendar/clinical#e-a35b7e4d-5e2f-443e-9f7e-9 ee6616856ca END:VEVENT BEGIN:VEVENT UID:2e1da9c0f649f5a6fc870db3c4773dc7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Crinetics Pharmaceuticals Inc. atumelnant: Trial primary completion DESCRIPTION:As of 4 June 2026\, Crinetics Pharmaceuticals estimated primary completion of a Phase 2 trial in Cushing Syndrome\, in October 2026.\n\nS ource: clinicaltrials NCT05804669\nhttps://clinicaltrials.gov/study/NCT058 04669 URL:https://julienwillard.com/calendar/clinical#e-628acd57-2f43-4ed3-a0c6-2 54233829a77 END:VEVENT BEGIN:VEVENT UID:806feee7689dcfab2555ff7767d30521 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-M07D1: Trial primary com pletion DESCRIPTION:As of 23 July 2026\, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in HER2-positive Breast Cancer\, in October 2026.\n\nSource: clinicaltrials NCT06316531\nhttps://clinicaltria ls.gov/study/NCT06316531 URL:https://julienwillard.com/calendar/clinical#e-255a4627-f70a-4a5f-bfdd-f c55660038a8 END:VEVENT BEGIN:VEVENT UID:52fba39aa4c7082f0dc159961d91d07c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Fujian Shengdi Pharmaceutical Co.\, Ltd. HRS-7450 Injection: Trial primary completion DESCRIPTION:As of 29 June 2026\, Fujian Shengdi Pharmaceutical Co. estimate d primary completion of a Phase 2 trial in Acute Ischemic Stroke\, in Octo ber 2026.\n\nSource: clinicaltrials NCT07233070\nhttps://clinicaltrials.go v/study/NCT07233070 URL:https://julienwillard.com/calendar/clinical#e-d591b859-ecef-4a3f-9523-d 1fadfa18887 END:VEVENT BEGIN:VEVENT UID:0ddacfebf820c6133871f6fd6f11e712 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Hengrui Pharmaceutical Co.\, Ltd. SHR-A2102: Trial primary completion DESCRIPTION:As of 1 December 2025\, Shanghai Hengrui Pharmaceutical Co. est imated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer \, in October 2026.\n\nSource: clinicaltrials NCT07229729\nhttps://clinica ltrials.gov/study/NCT07229729 URL:https://julienwillard.com/calendar/clinical#e-870bbae1-f1d8-4bda-92e5-3 7fab71fd901 END:VEVENT BEGIN:VEVENT UID:56cc434648639ce1e4ca649f24248537 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Immunocore Ltd Brenetafusp: Trial primary completion DESCRIPTION:As of 6 March 2026\, Immunocore estimated primary completion of a Phase 2 trial in Select Advanced Solid Tumors\, in October 2026.\n\nSou rce: clinicaltrials NCT04262466\nhttps://clinicaltrials.gov/study/NCT04262 466 URL:https://julienwillard.com/calendar/clinical#e-d9713d47-67c1-4381-886c-c c13768965b5 END:VEVENT BEGIN:VEVENT UID:dc51950573f445d7b63cc2e5b90cae1e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261001 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GEn1E Lifesciences GEn-1124: Trial primary completion DESCRIPTION:As of 23 June 2026\, GEn1E Lifesciences estimated primary compl etion of a Phase 2 trial in Respiratory Distress Syndrome\, Acute\, in Oct ober 2026.\n\nSource: clinicaltrials NCT05795465\nhttps://clinicaltrials.g ov/study/NCT05795465 URL:https://julienwillard.com/calendar/clinical#e-c8db5a41-3a8c-4592-9e97-c 4a3ca456d55 END:VEVENT BEGIN:VEVENT UID:fe42564d169041333a698e2bd175e3ef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261002 DTEND;VALUE=DATE:20261003 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:PEACHES BIOTECH PRS CK STORM: Trial primary completion DESCRIPTION:As of 10 June 2026\, PEACHES BIOTECH estimated primary completi on of a Phase 2 trial in sARS-CoV-2\, on 2 October 2026.\n\nSource: clinic altrials NCT06684379\nhttps://clinicaltrials.gov/study/NCT06684379 URL:https://julienwillard.com/calendar/clinical#e-6eb3f14c-b320-4672-86ae-6 81f4c95d642 END:VEVENT BEGIN:VEVENT UID:fad2e1b3cc010de4655c4bc5241b68cf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261002 DTEND;VALUE=DATE:20261003 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Takeda TAK-861: Trial primary completion DESCRIPTION:As of 8 July 2026\, Takeda estimated primary completion of a Ph ase 3 trial in Narcolepsy Type 1 (NT1)\, on 2 October 2026.\n\nSource: cli nicaltrials NCT07363720\nhttps://clinicaltrials.gov/study/NCT07363720 URL:https://julienwillard.com/calendar/clinical#e-2dad0c77-8c4d-416f-9520-3 081297b25e0 END:VEVENT BEGIN:VEVENT UID:b7eb3c2b25fa11c5664e4fbed9f36623 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261004 DTEND;VALUE=DATE:20261005 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eddingpharm (Zhuhai) Co.\, Ltd. EDP167: Trial primary completion DESCRIPTION:As of 20 May 2026\, Eddingpharm (Zhuhai) Co. estimated primary completion of a Phase 2 trial in Homozygous Familial Hypercholesterolemia (HoFH)\, on 4 October 2026.\n\nSource: clinicaltrials NCT07489209\nhttps:/ /clinicaltrials.gov/study/NCT07489209 URL:https://julienwillard.com/calendar/clinical#e-967112c7-3a72-4f8f-b498-0 a47373cd178 END:VEVENT BEGIN:VEVENT UID:8b4faad180586e10c3cad6cec23c0e45 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261005 DTEND;VALUE=DATE:20261006 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ModernaTX\, Inc. mRNA-1189: Trial primary completion DESCRIPTION:As of 6 May 2026\, ModernaTX estimated primary completion of a Phase 2 trial in Epstein-Barr Virus Infection\, on 5 October 2026.\n\nSour ce: clinicaltrials NCT05164094\nhttps://clinicaltrials.gov/study/NCT051640 94 URL:https://julienwillard.com/calendar/clinical#e-1edad944-9a1a-4d70-806e-e 8a575313cc6 END:VEVENT BEGIN:VEVENT UID:8c98102d669e5b6f91f5c758c9cc533e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261005 DTEND;VALUE=DATE:20261006 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Swedish Orphan Biovitrum Pacritinib: Trial primary completion DESCRIPTION:As of 30 April 2026\, Swedish Orphan Biovitrum estimated primar y completion of a Phase 3 trial in Primary Myelofibrosis\, on 5 October 20 26.\n\nSource: clinicaltrials NCT03165734\nhttps://clinicaltrials.gov/stud y/NCT03165734 URL:https://julienwillard.com/calendar/clinical#e-93d03545-22e2-4265-8d96-0 8c86afabb1a END:VEVENT BEGIN:VEVENT UID:2584bc85289f59ac3433a14f103f8e7c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261006 DTEND;VALUE=DATE:20261007 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bristol-Myers Squibb BMS-986278: Trial primary completion DESCRIPTION:As of 24 March 2026\, Bristol-Myers Squibb estimated primary co mpletion of a Phase 3 trial in Idiopathic Pulmonary Fibrosis\, on 6 Octobe r 2026.\n\nSource: clinicaltrials NCT06003426\nhttps://clinicaltrials.gov/ study/NCT06003426 URL:https://julienwillard.com/calendar/clinical#e-3e4911e9-eb9c-4f3c-bac3-f 22b0f4e34ae END:VEVENT BEGIN:VEVENT UID:8669235dac308c7c8aac115f1260efaf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261007 DTEND;VALUE=DATE:20261008 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Regeneron Pharmaceuticals Dupilumab: Trial primary completion DESCRIPTION:As of 29 May 2026\, Regeneron Pharmaceuticals estimated primary completion of a Phase 3 trial in Atopic Dermatitis\, on 7 October 2026.\n \nSource: clinicaltrials NCT02612454\nhttps://clinicaltrials.gov/study/NCT 02612454 URL:https://julienwillard.com/calendar/clinical#e-a6fd0a42-bc0a-4482-82f5-3 9f3629cc44d END:VEVENT BEGIN:VEVENT UID:47296c311201cd945286b99d62cd7573 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261008 DTEND;VALUE=DATE:20261009 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Tobemstomig: Trial primary completion DESCRIPTION:As of 10 August 2026\, Hoffmann-La Roche estimated primary comp letion of a Phase 2 trial in Renal Cell Carcinoma\, on 8 October 2026.\n\n Source: clinicaltrials NCT05805501\nhttps://clinicaltrials.gov/study/NCT05 805501 URL:https://julienwillard.com/calendar/clinical#e-c9ab3114-6a1e-44a6-ac19-4 8b48df61bfd END:VEVENT BEGIN:VEVENT UID:65253ca5e4f46b3621e2438213889aad DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261009 DTEND;VALUE=DATE:20261010 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Incyte Corporation Ruxolitinib Cream: Trial primary completion DESCRIPTION:As of 8 July 2026\, Incyte estimated primary completion of a Ph ase 3 trial in Hidradenitis Suppurativa\, on 9 October 2026.\n\nSource: cl inicaltrials NCT06958211\nhttps://clinicaltrials.gov/study/NCT06958211 URL:https://julienwillard.com/calendar/clinical#e-696757ab-0ba8-4594-a85b-3 a977869cf9c END:VEVENT BEGIN:VEVENT UID:fa88726c4856d9c0390f0f5951267c44 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261009 DTEND;VALUE=DATE:20261010 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Incyte Corporation Ruxolitinib Cream: Trial primary completion DESCRIPTION:As of 28 July 2026\, Incyte estimated primary completion of a P hase 3 trial in Hidradenitis Suppurativa\, on 9 October 2026.\n\nSource: c linicaltrials NCT06959225\nhttps://clinicaltrials.gov/study/NCT06959225 URL:https://julienwillard.com/calendar/clinical#e-0848fcbc-bf25-4ea5-a3b8-0 7b7804f76a3 END:VEVENT BEGIN:VEVENT UID:7cc38408178ddd040510493ed44adeef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261010 DTEND;VALUE=DATE:20261011 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hangzhou Zhongmei Huadong Pharmaceutical Co.\, Ltd. MC2-01 cream: T rial primary completion DESCRIPTION:As of 23 June 2026\, Hangzhou Zhongmei Huadong Pharmaceutical C o. estimated primary completion of a Phase 3 trial in Plaque Psoriasis\, o n 10 October 2026.\n\nSource: clinicaltrials NCT07357831\nhttps://clinical trials.gov/study/NCT07357831 URL:https://julienwillard.com/calendar/clinical#e-3ac9bd6b-276f-420f-81d9-f 58251c77372 END:VEVENT BEGIN:VEVENT UID:9e785aa14ee37bf4bc6c82b6d680c685 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261010 DTEND;VALUE=DATE:20261011 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hangzhou Zhongmei Huadong Pharmaceutical Co.\, Ltd. HDM1002 200 mg: Trial primary completion DESCRIPTION:As of 25 September 2025\, Hangzhou Zhongmei Huadong Pharmaceuti cal Co. estimated primary completion of a Phase 3 trial in Type 2 Diabetes \, on 10 October 2026.\n\nSource: clinicaltrials NCT07193459\nhttps://clin icaltrials.gov/study/NCT07193459 URL:https://julienwillard.com/calendar/clinical#e-9438196a-6a93-4c98-bf20-0 f0d53896cf7 END:VEVENT BEGIN:VEVENT UID:aaefdf44009752175891f73bdc3a205c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261011 DTEND;VALUE=DATE:20261012 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biocodex Saccharomyces Boulardii 250 MG: Trial primary completion DESCRIPTION:As of 18 November 2025\, Biocodex estimated primary completion of a Phase 3 trial in IBS (Irritable Bowel Syndrome)\, on 11 October 2026. \n\nSource: clinicaltrials NCT07168434\nhttps://clinicaltrials.gov/study/N CT07168434 URL:https://julienwillard.com/calendar/clinical#e-f20aa1c3-49c4-405e-8422-6 d0e3f19afe8 END:VEVENT BEGIN:VEVENT UID:fa60a8e6a370638cc5f15e05a82d567d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261012 DTEND;VALUE=DATE:20261013 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bristol-Myers Squibb CC-92480: Trial primary completion DESCRIPTION:As of 5 September 2025\, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Multiple Myeloma\, on 12 October 2026.\n \nSource: clinicaltrials NCT05372354\nhttps://clinicaltrials.gov/study/NCT 05372354 URL:https://julienwillard.com/calendar/clinical#e-b4bdd40c-d5b0-4e4d-8903-c f0c132d8705 END:VEVENT BEGIN:VEVENT UID:c32617082144fca433bf32b1ae3063a3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261012 DTEND;VALUE=DATE:20261013 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Janssen Research & Development\, LLC Apalutamide: Trial primary com pletion DESCRIPTION:As of 31 July 2026\, Janssen Research & Development estimated p rimary completion of a Phase 3 trial in Metastatic Castrate-sensitive Pros tate Cancer\, on 12 October 2026.\n\nSource: clinicaltrials NCT05884398\nh ttps://clinicaltrials.gov/study/NCT05884398 URL:https://julienwillard.com/calendar/clinical#e-f5763113-6400-4d82-b8c1-3 dded6c3c054 END:VEVENT BEGIN:VEVENT UID:3c9fa4a9e73d1504d80f5dd5854c3ac3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261012 DTEND;VALUE=DATE:20261013 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Regeneron Pharmaceuticals Ravulizumab: Trial primary completion DESCRIPTION:As of 30 April 2026\, Regeneron Pharmaceuticals estimated prima ry completion of a Phase 3 trial in Paroxysmal Nocturnal Hemoglobinuria\, on 12 October 2026.\n\nSource: clinicaltrials NCT05133531\nhttps://clinica ltrials.gov/study/NCT05133531 URL:https://julienwillard.com/calendar/clinical#e-4ad0607b-73e7-422a-95ba-d 68d1fb6b544 END:VEVENT BEGIN:VEVENT UID:523f830f2e6e71041b9a4668edd2e580 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261013 DTEND;VALUE=DATE:20261014 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai JMT-Bio Inc. JSKN003: Trial primary completion DESCRIPTION:As of 24 March 2025\, Shanghai JMT-Bio estimated primary comple tion of a Phase 3 trial on 13 October 2026.\n\nSource: clinicaltrials NCT0 6846437\nhttps://clinicaltrials.gov/study/NCT06846437 URL:https://julienwillard.com/calendar/clinical#e-82c2aa36-9d23-4191-aabb-4 1d64f293f9d END:VEVENT BEGIN:VEVENT UID:6fc64627d4c17946a1ee941dde96d9bf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261013 DTEND;VALUE=DATE:20261014 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Aspa Therapeutics AAV9 BBP-812: Trial primary completion DESCRIPTION:As of 17 April 2026\, Aspa Therapeutics estimated primary compl etion of a Phase 2 trial in Canavan Disease\, on 13 October 2026.\n\nSourc e: clinicaltrials NCT04998396\nhttps://clinicaltrials.gov/study/NCT0499839 6 URL:https://julienwillard.com/calendar/clinical#e-ec82c6c3-ae18-433c-aeda-6 c7f715a6d8a END:VEVENT BEGIN:VEVENT UID:c5fa508c5939d91bc96df6ff94b2311b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261013 DTEND;VALUE=DATE:20261014 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Cobolimab: Trial primary completion DESCRIPTION:As of 12 November 2025\, GlaxoSmithKline estimated primary comp letion of a Phase 2 trial in melanoma\, on 13 October 2026.\n\nSource: cli nicaltrials NCT06521567\nhttps://clinicaltrials.gov/study/NCT06521567 URL:https://julienwillard.com/calendar/clinical#e-3d0aa4ca-9c81-4f8e-875f-a a4f3d65c0c9 END:VEVENT BEGIN:VEVENT UID:dea456e8b80bc9593fbb8569006a43b4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261013 DTEND;VALUE=DATE:20261014 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Daewoong Pharmaceutical Co. LTD. DWN12088: Trial primary completion DESCRIPTION:As of 16 July 2026\, Daewoong Pharmaceutical Co. estimated prim ary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis\, on 13 October 2026.\n\nSource: clinicaltrials NCT05389215\nhttps://clinicaltria ls.gov/study/NCT05389215 URL:https://julienwillard.com/calendar/clinical#e-cb4ac794-eee0-4360-bc6e-2 7d731879491 END:VEVENT BEGIN:VEVENT UID:e2e1a9cacb50bebf30b99745422bfe3d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261014 DTEND;VALUE=DATE:20261015 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Inozyme Pharma INZ-701: Trial primary completion DESCRIPTION:As of 10 August 2026\, Inozyme Pharma estimated primary complet ion of a Phase 3 trial in Ectonucleotide Pyrophosphatase/phosphodiesterase 1 Deficiency\, on 14 October 2026.\n\nSource: clinicaltrials NCT07473973\n https://clinicaltrials.gov/study/NCT07473973 URL:https://julienwillard.com/calendar/clinical#e-ef5c6eec-4e3f-4c9d-a5ce-f c597bfaa42b END:VEVENT BEGIN:VEVENT UID:2051187c2c317321fbbe68c5411ab60a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261014 DTEND;VALUE=DATE:20261015 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi Itepekimab (SAR440340): Trial primary completion DESCRIPTION:As of 20 May 2026\, Sanofi estimated primary completion of a Ph ase 3 trial in Chronic Rhinosinusitis With Nasal Polyps\, on 14 October 20 26.\n\nSource: clinicaltrials NCT06834347\nhttps://clinicaltrials.gov/stud y/NCT06834347 URL:https://julienwillard.com/calendar/clinical#e-87057dbc-e791-46f0-815a-0 9ec76d3e2ba END:VEVENT BEGIN:VEVENT UID:3a35b20fa767ff8aea77af2ca62aa88e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261014 DTEND;VALUE=DATE:20261015 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline dTpa vaccine: Trial primary completion DESCRIPTION:As of 28 July 2026\, GlaxoSmithKline estimated primary completi on of a Phase 3 trial in Diphtheria-Tetanus-acellular Pertussis Vaccines\, on 14 October 2026.\n\nSource: clinicaltrials NCT07596173\nhttps://clinic altrials.gov/study/NCT07596173 URL:https://julienwillard.com/calendar/clinical#e-2577d3a0-febf-4a69-9309-0 ebce738abf2 END:VEVENT BEGIN:VEVENT UID:5df11da91f30bfccd7697ab37ca33018 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261015 DTEND;VALUE=DATE:20261016 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Alphamab Co.\, Ltd. KN057: Trial primary completion DESCRIPTION:As of 17 September 2025\, Suzhou Alphamab Co. estimated primary completion of a Phase 3 trial in Hemophilia A Without Inhibitor\, on 15 O ctober 2026.\n\nSource: clinicaltrials NCT06569108\nhttps://clinicaltrials .gov/study/NCT06569108 URL:https://julienwillard.com/calendar/clinical#e-a0480eb2-4001-402f-a375-6 e779e00c158 END:VEVENT BEGIN:VEVENT UID:b2ac9798060b388bcbc7f7ec22a6c4fb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261015 DTEND;VALUE=DATE:20261016 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals AAA617: Trial primary completion DESCRIPTION:As of 1 May 2026\, Novartis Pharmaceuticals estimated primary c ompletion of a Phase 2 trial in Metastatic Castration Resistant Prostate C ancer (mCRPC)\, on 15 October 2026.\n\nSource: clinicaltrials NCT06894511\ nhttps://clinicaltrials.gov/study/NCT06894511 URL:https://julienwillard.com/calendar/clinical#e-43aaa1f4-6424-4494-995f-b 204fb12b731 END:VEVENT BEGIN:VEVENT UID:53a551ef90a76953e42c50d70834926e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261015 DTEND;VALUE=DATE:20261016 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CanariaBio Inc. Oregovomab: Trial primary completion DESCRIPTION:As of 1 April 2026\, CanariaBio estimated primary completion of a Phase 2 trial in Ovarian Neoplasm Epithelial\, on 15 October 2026.\n\nS ource: clinicaltrials NCT05605535\nhttps://clinicaltrials.gov/study/NCT056 05535 URL:https://julienwillard.com/calendar/clinical#e-b522359a-556c-454f-b6b3-3 ce967d7abca END:VEVENT BEGIN:VEVENT UID:d9c532d256dbb1d88301a3a4bf7e0048 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261015 DTEND;VALUE=DATE:20261016 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Solid Biosciences Inc. SGT-001: Trial primary completion DESCRIPTION:As of 10 August 2026\, Solid Biosciences estimated primary comp letion of a Phase 2 trial in Duchenne Muscular Dystrophy\, on 15 October 2 026.\n\nSource: clinicaltrials NCT03368742\nhttps://clinicaltrials.gov/stu dy/NCT03368742 URL:https://julienwillard.com/calendar/clinical#e-25e134f3-7550-48b0-a254-9 96ed32e4daa END:VEVENT BEGIN:VEVENT UID:d43023f2a03b31e9856195fb265f4239 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261015 DTEND;VALUE=DATE:20261016 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD6489: Trial primary completion DESCRIPTION:As of 21 July 2026\, AstraZeneca estimated primary completion o f a Phase 2 trial in RSV Respiratory Syncytial Virus\, on 15 October 2026. \n\nSource: clinicaltrials NCT07717840\nhttps://clinicaltrials.gov/study/N CT07717840 URL:https://julienwillard.com/calendar/clinical#e-aae500ad-36c5-4db6-b3e7-3 c6f2c493dc6 END:VEVENT BEGIN:VEVENT UID:f086d270abc7c78eb6a9d014107f96eb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261015 DTEND;VALUE=DATE:20261016 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eccogene ECC4703: Trial primary completion DESCRIPTION:As of 25 June 2026\, Eccogene estimated primary completion of a Phase 2 trial in Adult Obesity\, on 15 October 2026.\n\nSource: clinicalt rials NCT07505303\nhttps://clinicaltrials.gov/study/NCT07505303 URL:https://julienwillard.com/calendar/clinical#e-c00bd783-658f-42f1-86ab-b 1d0559508fd END:VEVENT BEGIN:VEVENT UID:c00c9fcb63cf75513cdf2b02c76ad7be DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261015 DTEND;VALUE=DATE:20261016 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Birch BioMed Inc IP1 control cream (Vehicle base): Trial primary co mpletion DESCRIPTION:As of 4 May 2026\, Birch BioMed estimated primary completion of a Phase 3 trial in Burn Scar\, on 15 October 2026.\n\nSource: clinicaltri als NCT06807021\nhttps://clinicaltrials.gov/study/NCT06807021 URL:https://julienwillard.com/calendar/clinical#e-ed6f6fb7-6b23-4291-86e3-5 bd815232ae3 END:VEVENT BEGIN:VEVENT UID:ada024c9bc9c8e7eebf5af8f11083bf4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261016 DTEND;VALUE=DATE:20261017 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Glofitamab: Trial primary completion DESCRIPTION:As of 6 July 2026\, Hoffmann-La Roche estimated primary complet ion of a Phase 2 trial in Non-Hodgkins Lymphoma\, on 16 October 2026.\n\nS ource: clinicaltrials NCT03533283\nhttps://clinicaltrials.gov/study/NCT035 33283 URL:https://julienwillard.com/calendar/clinical#e-6e4f1309-fded-4e40-8d18-b 62e34c1a662 END:VEVENT BEGIN:VEVENT UID:b486d24f56a7cf75fcc2457e77fc2d83 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261018 DTEND;VALUE=DATE:20261019 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kunming Pharmaceuticals\, Inc. The KPCXM18 injection: Trial primary completion DESCRIPTION:As of 12 December 2025\, Kunming Pharmaceuticals estimated prim ary completion of a Phase 2 trial in Acute Ischemic Stroke\, on 18 October 2026.\n\nSource: clinicaltrials NCT07279493\nhttps://clinicaltrials.gov/s tudy/NCT07279493 URL:https://julienwillard.com/calendar/clinical#e-2c0e45c8-d8ad-4178-bf99-9 d3fe271dff4 END:VEVENT BEGIN:VEVENT UID:86260af7f7a3f2317dce211537c35f88 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261019 DTEND;VALUE=DATE:20261020 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer PF-07275315: Trial primary completion DESCRIPTION:As of 4 May 2026\, Pfizer estimated primary completion of a Pha se 2 trial in Atopic Dermatitis\, on 19 October 2026.\n\nSource: clinicalt rials NCT05995964\nhttps://clinicaltrials.gov/study/NCT05995964 URL:https://julienwillard.com/calendar/clinical#e-fc7b618e-df27-4bba-8221-e 1c4ade7ad38 END:VEVENT BEGIN:VEVENT UID:68b4aab86cf0304811ba13be08e01051 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261019 DTEND;VALUE=DATE:20261020 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Incyte Corporation Povorcitinib: Trial primary completion DESCRIPTION:As of 14 April 2026\, Incyte estimated primary completion of a Phase 3 trial in Prurigo Nodularis\, on 19 October 2026.\n\nSource: clinic altrials NCT06516965\nhttps://clinicaltrials.gov/study/NCT06516965 URL:https://julienwillard.com/calendar/clinical#e-2430b772-ad86-459d-a491-5 77785beae19 END:VEVENT BEGIN:VEVENT UID:04d942031366999cfc31a1fe76b21adc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261019 DTEND;VALUE=DATE:20261020 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bristol-Myers Squibb Deucravacitinib: Trial primary completion DESCRIPTION:As of 2 December 2025\, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Systemic Lupus Erythematosus\, on 19 Octo ber 2026.\n\nSource: clinicaltrials NCT05620407\nhttps://clinicaltrials.go v/study/NCT05620407 URL:https://julienwillard.com/calendar/clinical#e-9030cf52-85a4-482a-ae85-e 4f9c7a8c7cc END:VEVENT BEGIN:VEVENT UID:2836785133d50f3b13a373652d54dc35 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261019 DTEND;VALUE=DATE:20261020 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bristol-Myers Squibb Deucravacitinib: Trial primary completion DESCRIPTION:As of 3 December 2025\, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Systemic Lupus Erythematosus\, on 19 Octo ber 2026.\n\nSource: clinicaltrials NCT05617677\nhttps://clinicaltrials.go v/study/NCT05617677 URL:https://julienwillard.com/calendar/clinical#e-a249c50c-5e39-43e1-b657-e a2332ab5d75 END:VEVENT BEGIN:VEVENT UID:9cddf042d872fbee2fe8cfcb879609e7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261019 DTEND;VALUE=DATE:20261020 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Incyte Corporation Povorcitinib: Trial primary completion DESCRIPTION:As of 28 May 2026\, Incyte estimated primary completion of a Ph ase 3 trial in Prurigo Nodularis\, on 19 October 2026.\n\nSource: clinical trials NCT06516952\nhttps://clinicaltrials.gov/study/NCT06516952 URL:https://julienwillard.com/calendar/clinical#e-ff572c41-60e2-41a0-a50f-f 7f4eee14fa5 END:VEVENT BEGIN:VEVENT UID:c822c0ffa03c72010f629e07eef5be6a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261020 DTEND;VALUE=DATE:20261021 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biogen Litifilimab: Trial primary completion DESCRIPTION:As of 31 July 2026\, Biogen estimated primary completion of a P hase 3 trial in Subacute Cutaneous Lupus Erythematosus\, on 20 October 202 6.\n\nSource: clinicaltrials NCT05531565\nhttps://clinicaltrials.gov/study /NCT05531565 URL:https://julienwillard.com/calendar/clinical#e-4fd8c923-af51-4dca-91ff-d 35818ea2ff9 END:VEVENT BEGIN:VEVENT UID:8ffcabef8111ce768b73b7c06bcf5f1d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261020 DTEND;VALUE=DATE:20261021 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:LEO Pharma Tralokinumab + TCS: Trial primary completion DESCRIPTION:As of 7 July 2026\, LEO Pharma estimated primary completion of a Phase 3 trial in Atopic Dermatitis\, on 20 October 2026.\n\nSource: clin icaltrials NCT06311682\nhttps://clinicaltrials.gov/study/NCT06311682 URL:https://julienwillard.com/calendar/clinical#e-17471488-0813-4cf0-9eaa-6 dc43d25a0dd END:VEVENT BEGIN:VEVENT UID:5881f19e0748d073800bc9a02efd91d3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261020 DTEND;VALUE=DATE:20261021 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bioray Laboratories BRL-101: Trial primary completion DESCRIPTION:As of 21 July 2026\, Bioray Laboratories estimated primary comp letion of a Phase 2 trial in beta-Thalassemia\, on 20 October 2026.\n\nSou rce: clinicaltrials NCT05577312\nhttps://clinicaltrials.gov/study/NCT05577 312 URL:https://julienwillard.com/calendar/clinical#e-6d231794-652f-4ec7-ac8b-3 78a0dd07cf9 END:VEVENT BEGIN:VEVENT UID:3403360ef8af3063f3b7fd558dd30eaf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261020 DTEND;VALUE=DATE:20261021 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Daiichi Sankyo DS-3939a: Trial primary completion DESCRIPTION:As of 17 July 2026\, Daiichi Sankyo estimated primary completio n of a Phase 2 trial in Advanced Solid Tumor\, on 20 October 2026.\n\nSour ce: clinicaltrials NCT05875168\nhttps://clinicaltrials.gov/study/NCT058751 68 URL:https://julienwillard.com/calendar/clinical#e-bb48bb3a-e815-4653-baa4-5 2d15ebe46db END:VEVENT BEGIN:VEVENT UID:f94a1232db1fd864f84789c48a84d459 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261020 DTEND;VALUE=DATE:20261021 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Otsuka Pharmaceutical Development & Commercialization\, Inc. SEP-36 3856: Trial primary completion DESCRIPTION:As of 31 July 2026\, Otsuka Pharmaceutical Development & Commer cialization estimated primary completion of a Phase 3 trial in schizophren ia\, on 20 October 2026.\n\nSource: clinicaltrials NCT06894212\nhttps://cl inicaltrials.gov/study/NCT06894212 URL:https://julienwillard.com/calendar/clinical#e-5347e614-e6bf-4383-8a52-e 156e4168402 END:VEVENT BEGIN:VEVENT UID:1005aacff203d7580877b3611ace443e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261020 DTEND;VALUE=DATE:20261021 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Nanjing Leads Biolabs Co.\,Ltd LBL-034 for Injection: Trial primary completion DESCRIPTION:As of 4 December 2025\, Nanjing Leads Biolabs Co. estimated pri mary completion of a Phase 2 trial in Relapsed/Refractory Multiple Myeloma \, on 20 October 2026.\n\nSource: clinicaltrials NCT06049290\nhttps://clin icaltrials.gov/study/NCT06049290 URL:https://julienwillard.com/calendar/clinical#e-da6c2e92-f49d-4cbe-bac1-4 f21a123c841 END:VEVENT BEGIN:VEVENT UID:721ae93e85f7b77712146462b046e335 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261022 DTEND;VALUE=DATE:20261023 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amgen Dazodalibep: Trial primary completion DESCRIPTION:As of 8 January 2026\, Amgen estimated primary completion of a Phase 3 trial in Sjögren's Syndrome (SS)\, on 22 October 2026.\n\nSource: clinicaltrials NCT06245408\nhttps://clinicaltrials.gov/study/NCT06245408 URL:https://julienwillard.com/calendar/clinical#e-107290a7-c64c-42c6-808f-3 b0619df31c3 END:VEVENT BEGIN:VEVENT UID:66f7f869386c3c2348ab023859462031 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261022 DTEND;VALUE=DATE:20261023 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Henlius Biotech HLX10+chemo: Trial primary completion DESCRIPTION:As of 20 May 2026\, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in SCLC\, Extensive Stage\, on 22 October 20 26.\n\nSource: clinicaltrials NCT06812260\nhttps://clinicaltrials.gov/stud y/NCT06812260 URL:https://julienwillard.com/calendar/clinical#e-750242ae-f622-4d3a-9246-4 d7dc5c4583c END:VEVENT BEGIN:VEVENT UID:ab4c4ee54af41c6953861b38ee32488a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261022 DTEND;VALUE=DATE:20261023 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Ocrelizumab: Trial primary completion DESCRIPTION:As of 23 July 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 3 trial in Progressive Multiple Sclerosis (PMS)\, on 22 Oc tober 2026.\n\nSource: clinicaltrials NCT03523858\nhttps://clinicaltrials. gov/study/NCT03523858 URL:https://julienwillard.com/calendar/clinical#e-d25250be-6bdd-4970-baed-2 951219e22dd END:VEVENT BEGIN:VEVENT UID:3be770c0a2e23acd8b0f8cdcaf604de2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261023 DTEND;VALUE=DATE:20261024 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Durvalumab: Trial primary completion DESCRIPTION:As of 2 July 2026\, AstraZeneca estimated primary completion of a Phase 2 trial in Carcinoma\, Non-Small-Cell Lung\, on 23 October 2026.\ n\nSource: clinicaltrials NCT06008093\nhttps://clinicaltrials.gov/study/NC T06008093 URL:https://julienwillard.com/calendar/clinical#e-44ea339b-88fc-40bd-b2c9-b 5ff89758338 END:VEVENT BEGIN:VEVENT UID:c6fa998a0949c4a74a6ae8102d79d15a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261026 DTEND;VALUE=DATE:20261027 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CSL Behring Recombinant single-chain factor VIII (rVIII-SingleChain ): Trial primary completion DESCRIPTION:As of 23 April 2026\, CSL Behring estimated primary completion of a Phase 3 trial in Congenital Hemophilia A\, on 26 October 2026.\n\nSou rce: clinicaltrials NCT06738485\nhttps://clinicaltrials.gov/study/NCT06738 485 URL:https://julienwillard.com/calendar/clinical#e-f4ed4283-04ca-4841-94b9-e ad74ad96f2c END:VEVENT BEGIN:VEVENT UID:92e8c6a245d14f8bd05141f26c23f429 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261026 DTEND;VALUE=DATE:20261027 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Galderma R&D Nemolizumab: Trial primary completion DESCRIPTION:As of 12 November 2025\, Galderma R&D estimated primary complet ion of a Phase 3 trial in Prurigo Nodularis\, on 26 October 2026.\n\nSourc e: clinicaltrials NCT04204616\nhttps://clinicaltrials.gov/study/NCT0420461 6 URL:https://julienwillard.com/calendar/clinical#e-eecbe5ea-b568-4827-8000-2 ca1c6c239bd END:VEVENT BEGIN:VEVENT UID:6226797a577b0ce47dab96f5bcd0c510 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261026 DTEND;VALUE=DATE:20261027 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals Inclisiran sodium 300 mg: Trial primary co mpletion DESCRIPTION:As of 13 July 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Coronary Artery Disease\, on 26 October 2026.\n\nSource: clinicaltrials NCT05360446\nhttps://clinicaltrials.gov/st udy/NCT05360446 URL:https://julienwillard.com/calendar/clinical#e-3c5c5b55-ffce-4286-9661-0 1a34992cbc7 END:VEVENT BEGIN:VEVENT UID:1b361a6a6688dc3bb923e6b05140fe2c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261027 DTEND;VALUE=DATE:20261028 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Volrustomig: Trial primary completion DESCRIPTION:As of 2 July 2026\, AstraZeneca estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma\, on 27 October 2026.\n\nSour ce: clinicaltrials NCT05775159\nhttps://clinicaltrials.gov/study/NCT057751 59 URL:https://julienwillard.com/calendar/clinical#e-e02a9c94-f4ba-458f-b8c0-a 1a3b9a925f6 END:VEVENT BEGIN:VEVENT UID:340e3ed3adb1a517f9bd408009c0beea DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261028 DTEND;VALUE=DATE:20261029 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Boehringer Ingelheim BI 771716: Trial primary completion DESCRIPTION:As of 14 May 2026\, Boehringer Ingelheim estimated primary comp letion of a Phase 2 trial in Macular Degeneration\, Age-related\, on 28 Oc tober 2026.\n\nSource: clinicaltrials NCT06722157\nhttps://clinicaltrials. gov/study/NCT06722157 URL:https://julienwillard.com/calendar/clinical#e-24d44034-83d8-46b9-8fdb-a a4db1a8d80b END:VEVENT BEGIN:VEVENT UID:47a0b076a8e28de8c2cd6435ee712083 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261028 DTEND;VALUE=DATE:20261029 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Belzutifan: Trial primary completion DESCRIPTION:As of 15 May 2026\, Merck Sharp & Dohme estimated primary compl etion of a Phase 3 trial in Carcinoma\, Renal Cell\, on 28 October 2026.\n \nSource: clinicaltrials NCT05239728\nhttps://clinicaltrials.gov/study/NCT 05239728 URL:https://julienwillard.com/calendar/clinical#e-43d4546e-7d3e-48e9-8f1d-5 2984c3761c1 END:VEVENT BEGIN:VEVENT UID:6763a6813b31a542955da104a2115bf4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261028 DTEND;VALUE=DATE:20261029 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Akeso Cadonilimab (AK104): Trial primary completion DESCRIPTION:As of 12 March 2025\, Akeso estimated primary completion of a P hase 3 trial in NSCLC (Non-small Cell Lung Cancer)\, on 28 October 2026.\n \nSource: clinicaltrials NCT06617416\nhttps://clinicaltrials.gov/study/NCT 06617416 URL:https://julienwillard.com/calendar/clinical#e-51e732b4-e292-4424-a107-8 6720956ddda END:VEVENT BEGIN:VEVENT UID:ab6892ac419d9d88e3aabdc6c7e035b2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261028 DTEND;VALUE=DATE:20261029 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche RO7204239: Trial primary completion DESCRIPTION:As of 11 June 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 3 trial in Spinal Muscular Atrophy (SMA)\, on 28 October 2 026.\n\nSource: clinicaltrials NCT05115110\nhttps://clinicaltrials.gov/stu dy/NCT05115110 URL:https://julienwillard.com/calendar/clinical#e-5698d867-0bbf-4d94-b20a-8 2c326dccff7 END:VEVENT BEGIN:VEVENT UID:9fc48efd7086f42a0311755befc6d9c2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261029 DTEND;VALUE=DATE:20261030 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Pembrolizumab: Trial primary completion DESCRIPTION:As of 6 May 2026\, Merck Sharp & Dohme estimated primary comple tion of a Phase 3 trial in Carcinoma\, Renal Cell\, on 29 October 2026.\n\ nSource: clinicaltrials NCT04736706\nhttps://clinicaltrials.gov/study/NCT0 4736706 URL:https://julienwillard.com/calendar/clinical#e-6845d0f1-2ef0-4ca8-a3ae-b 0eac5ba3bdd END:VEVENT BEGIN:VEVENT UID:f14c7eb42601120d47c721e2943960af DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261029 DTEND;VALUE=DATE:20261030 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals Ianalumab: Trial primary completion DESCRIPTION:As of 15 June 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Primary Immune Thrombocytopenia (ITP)\, on 29 October 2026.\n\nSource: clinicaltrials NCT05653349\nhttps://clinica ltrials.gov/study/NCT05653349 URL:https://julienwillard.com/calendar/clinical#e-4a77f705-fbea-4f84-8150-1 91596fde54f END:VEVENT BEGIN:VEVENT UID:04b85db56f8c3c559b44f4b928a3b3bb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Antelope Surgical Solutions\, Inc AS1986NS: Trial primary completio n DESCRIPTION:As of 9 July 2026\, Antelope Surgical Solutions estimated prima ry completion of a Phase 2 trial in Prostate Cancer\, on 30 October 2026.\ n\nSource: clinicaltrials NCT06906471\nhttps://clinicaltrials.gov/study/NC T06906471 URL:https://julienwillard.com/calendar/clinical#e-bcec8e7a-af4c-40e0-a5ae-6 270c258167a END:VEVENT BEGIN:VEVENT UID:9ceaa60d8a7064f849bd8f9ce5562894 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vertex Pharmaceuticals Incorporated VX-121/TEZ/D-IVA: Trial primary completion DESCRIPTION:As of 21 July 2026\, Vertex Pharmaceuticals Incorporated estima ted primary completion of a Phase 3 trial in Cystic Fibrosis\, on 30 Octob er 2026.\n\nSource: clinicaltrials NCT05444257\nhttps://clinicaltrials.gov /study/NCT05444257 URL:https://julienwillard.com/calendar/clinical#e-267ff3d3-5aa6-48e7-bb8d-2 dfe0d8c486a END:VEVENT BEGIN:VEVENT UID:e654cb7acedf5783f2bed53f0410a128 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tyligand Pharmaceuticals (Suzhou) Limited TSN1611: Trial primary co mpletion DESCRIPTION:As of 24 April 2026\, Tyligand Pharmaceuticals (Suzhou) estimat ed primary completion of a Phase 2 trial in Malignant Neoplasm\, on 30 Oct ober 2026.\n\nSource: clinicaltrials NCT06385925\nhttps://clinicaltrials.g ov/study/NCT06385925 URL:https://julienwillard.com/calendar/clinical#e-f97d64ac-e9f2-4292-9e0a-a 559d97bdf62 END:VEVENT BEGIN:VEVENT UID:26e3b44049fade3d7c5f975292e72832 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Nouscom SRL GAd-209-FSP low dose: Trial primary completion DESCRIPTION:As of 13 February 2026\, Nouscom SRL estimated primary completi on of a Phase 2 trial in Solid Tumor\, Adult\, on 30 October 2026.\n\nSour ce: clinicaltrials NCT04041310\nhttps://clinicaltrials.gov/study/NCT040413 10 URL:https://julienwillard.com/calendar/clinical#e-8f86c6ff-3ceb-408d-9596-b 5ebf67691d8 END:VEVENT BEGIN:VEVENT UID:214eb8df228b156c30b864c2461b0c80 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmac euticals LLC) 18F-metaFluorobenzylguanidine: Trial primary completion DESCRIPTION:As of 1 July 2026\, Innervate Radiopharmaceuticals estimated pr imary completion of a Phase 2 trial in Heart Failure\, on 30 October 2026. \n\nSource: clinicaltrials NCT06965621\nhttps://clinicaltrials.gov/study/N CT06965621 URL:https://julienwillard.com/calendar/clinical#e-bb42612f-4112-45c5-a826-a 338ef9d0436 END:VEVENT BEGIN:VEVENT UID:a33912f7dc8b08e76cd7d410304d4962 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biotheus Inc. PM8002: Trial primary completion DESCRIPTION:As of 11 March 2025\, Biotheus estimated primary completion of a Phase 2 trial in tNBC\, on 30 October 2026.\n\nSource: clinicaltrials NC T05918133\nhttps://clinicaltrials.gov/study/NCT05918133 URL:https://julienwillard.com/calendar/clinical#e-3d3b20df-adc7-4372-971b-5 f198ee2f5bf END:VEVENT BEGIN:VEVENT UID:dd60f51075067e1dfec01320de6accb3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Natureceuticals Sdn Bhd Nuvastatic 300: Trial primary completion DESCRIPTION:As of 25 June 2026\, Natureceuticals Sdn Bhd estimated primary completion of a Phase 3 trial in Fatigue Related to Cancer Treatment\, on 30 October 2026.\n\nSource: clinicaltrials NCT07669467\nhttps://clinicaltr ials.gov/study/NCT07669467 URL:https://julienwillard.com/calendar/clinical#e-326a05cd-06c7-47d0-8b7b-c bb763a17776 END:VEVENT BEGIN:VEVENT UID:c9c2b2969168e2fed3679c40f46b47dd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kind Pharmaceuticals LLC AND017 capsules: Trial primary completion DESCRIPTION:As of 27 March 2026\, Kind Pharmaceuticals estimated primary co mpletion of a Phase 3 trial in Anemia Due to Chronic Kidney Disease\, on 3 0 October 2026.\n\nSource: clinicaltrials NCT07494409\nhttps://clinicaltri als.gov/study/NCT07494409 URL:https://julienwillard.com/calendar/clinical#e-38a27d04-36cf-4240-8a9f-3 9a319fbc865 END:VEVENT BEGIN:VEVENT UID:da6d40bb9ca6bbfa94e2e95a4043c19a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vidya Therapeutics Inc VT7208: Trial primary completion DESCRIPTION:As of 21 July 2026\, Vidya Therapeutics estimated primary compl etion of a Phase 2 trial in Multiple Sclerosis\, on 30 October 2026.\n\nSo urce: clinicaltrials NCT07085507\nhttps://clinicaltrials.gov/study/NCT0708 5507 URL:https://julienwillard.com/calendar/clinical#e-beac1b75-3f34-48a9-b41b-3 7cd1e3b3828 END:VEVENT BEGIN:VEVENT UID:216b5c4f0768b4ad3a4ba7206c28c204 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Laekna Limited Afuresertib: Trial primary completion DESCRIPTION:As of 2 April 2026\, Laekna estimated primary completion of a P hase 3 trial in Breast Cancer\, on 30 October 2026.\n\nSource: clinicaltri als NCT04851613\nhttps://clinicaltrials.gov/study/NCT04851613 URL:https://julienwillard.com/calendar/clinical#e-02d891c7-92d2-4a82-a7a1-4 2865140d967 END:VEVENT BEGIN:VEVENT UID:5275380f0cdbefacfb96b87662ffbc10 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shandong Suncadia Medicine Co.\, Ltd. HRS-2189: Trial primary compl etion DESCRIPTION:As of 2 March 2026\, Shandong Suncadia Medicine Co. estimated p rimary completion of a Phase 2 trial in Advanced Unresectable or Metastati c Breast Cancer\, on 30 October 2026.\n\nSource: clinicaltrials NCT0667903 6\nhttps://clinicaltrials.gov/study/NCT06679036 URL:https://julienwillard.com/calendar/clinical#e-e9c43eb6-e987-48e1-a06a-0 c59c2e58dc0 END:VEVENT BEGIN:VEVENT UID:9bc18b0b1a23aa3a80a77d6b9b52c921 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Abbisko Therapeutics Co\, Ltd ABSK021: Trial primary completion DESCRIPTION:As of 12 August 2024\, Abbisko Therapeutics Co estimated primar y completion of a Phase 2 trial in cGvHD\, on 30 October 2026.\n\nSource: clinicaltrials NCT06186804\nhttps://clinicaltrials.gov/study/NCT06186804 URL:https://julienwillard.com/calendar/clinical#e-587c42c7-b630-43fd-ac7f-e 053fc39b61d END:VEVENT BEGIN:VEVENT UID:f1c6645cc598fdfd36d3ba5d580098cf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmac euticals LLC) 18F-MFBG: Trial primary completion DESCRIPTION:As of 1 July 2026\, Innervate Radiopharmaceuticals estimated pr imary completion of a Phase 2 trial in Parkinson Disease (PD)\, on 30 Octo ber 2026.\n\nSource: clinicaltrials NCT07176286\nhttps://clinicaltrials.go v/study/NCT07176286 URL:https://julienwillard.com/calendar/clinical#e-88995124-28c6-4c16-a8e9-0 495eb93864f END:VEVENT BEGIN:VEVENT UID:3101c07a48efac4291e2b8e939d3be86 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CSPC Ouyi Pharmaceutical Co.\, Ltd. Prusogliptin\, Dapagliflozin(hi gh dose)\, Dapagliflozin (low dose) placebo\, plus metformin XR: Trial pri mary completion DESCRIPTION:As of 6 April 2026\, CSPC Ouyi Pharmaceutical Co. estimated pri mary completion of a Phase 3 trial in Type 2 Diabetes\, on 30 October 2026 .\n\nSource: clinicaltrials NCT07026968\nhttps://clinicaltrials.gov/study/ NCT07026968 URL:https://julienwillard.com/calendar/clinical#e-60b7075d-daf9-4928-bdfe-0 211f332d1fe END:VEVENT BEGIN:VEVENT UID:181e9d81654ebaf2f49812f42803b9c7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Henlius Biotech HLX43 dose 1: Trial primary completion DESCRIPTION:As of 17 November 2025\, Shanghai Henlius Biotech estimated pri mary completion of a Phase 2 trial in Solid Tumor Cancer\, on 30 October 2 026.\n\nSource: clinicaltrials NCT06848699\nhttps://clinicaltrials.gov/stu dy/NCT06848699 URL:https://julienwillard.com/calendar/clinical#e-f0bb9129-4706-4d8e-8368-9 bdbac67cae0 END:VEVENT BEGIN:VEVENT UID:e5ded424f3e7631e411ce2bf7b65e0e2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Genzyme\, a Sanofi Company venglustat (GZ402671): Trial primary com pletion DESCRIPTION:As of 10 July 2026\, Genzyme\, a Sanofi estimated primary compl etion of a Phase 2 trial in Gaucher Disease Type 1\, on 30 October 2026.\n \nSource: clinicaltrials NCT02843035\nhttps://clinicaltrials.gov/study/NCT 02843035 URL:https://julienwillard.com/calendar/clinical#e-4d87bfee-1002-4486-b462-f ab790375496 END:VEVENT BEGIN:VEVENT UID:c4273d706ccbb478ff7e660a49a33395 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261030 DTEND;VALUE=DATE:20261031 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing Continent Pharmaceutical Co\, Ltd. Hydronidone Capsules: Tr ial primary completion DESCRIPTION:As of 31 March 2026\, Beijing Continent Pharmaceutical Co estim ated primary completion of a Phase 3 trial in Chronic Hepatitis B With Hep atic Fibrosis\, on 30 October 2026.\n\nSource: clinicaltrials NCT07343778\ nhttps://clinicaltrials.gov/study/NCT07343778 URL:https://julienwillard.com/calendar/clinical#e-d9de27ba-9885-4e5c-b4e4-c efa1ffed506 END:VEVENT BEGIN:VEVENT UID:8bd4fe3d44d4e98fd596a7ec8e0aa6ef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sarepta Therapeutics\, Inc. Eteplirsen: Trial primary completion DESCRIPTION:As of 27 February 2026\, Sarepta Therapeutics estimated primary completion of a Phase 3 trial in Muscular Dystrophy\, Duchenne\, on 31 Oc tober 2026.\n\nSource: clinicaltrials NCT03992430\nhttps://clinicaltrials. gov/study/NCT03992430 URL:https://julienwillard.com/calendar/clinical#e-20cca7b3-4a19-40a0-adb7-7 b9c881d8150 END:VEVENT BEGIN:VEVENT UID:e3662d5c202f62d576d1666e40112053 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Topadur Pharma AG TOP-N53: Trial primary completion DESCRIPTION:As of 15 June 2026\, Topadur Pharma estimated primary completio n of a Phase 2 trial in Digital Ulcers in Systemic Sclerosis\, on 31 Octob er 2026.\n\nSource: clinicaltrials NCT06954597\nhttps://clinicaltrials.gov /study/NCT06954597 URL:https://julienwillard.com/calendar/clinical#e-786457ba-c2d3-46a7-b1a0-a 2f31cc1c4b9 END:VEVENT BEGIN:VEVENT UID:6b77d29cbcb5d67775c0588a3b0a23cd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Takeda TAK-788: Trial primary completion DESCRIPTION:As of 25 February 2026\, Takeda estimated primary completion of a Phase 2 trial in Carcinoma\, Non-Small-Cell Lung\, on 31 October 2026.\ n\nSource: clinicaltrials NCT02716116\nhttps://clinicaltrials.gov/study/NC T02716116 URL:https://julienwillard.com/calendar/clinical#e-a2c3606e-2b41-479a-abd0-8 aff5386865b END:VEVENT BEGIN:VEVENT UID:e10c5ef2c73e741f20193e8da183677d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Longboard Pharmaceuticals LP352: Trial primary completion DESCRIPTION:As of 17 July 2026\, Longboard Pharmaceuticals estimated primar y completion of a Phase 3 trial in Developmental and Epileptic Encephalopa thy\, on 31 October 2026.\n\nSource: clinicaltrials NCT06719141\nhttps://c linicaltrials.gov/study/NCT06719141 URL:https://julienwillard.com/calendar/clinical#e-4de6d9cf-465d-45fe-9edc-5 ec4f59a7eae END:VEVENT BEGIN:VEVENT UID:4652d19589e2c704b7ee3dbc13b32c3b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Tobemstomig: Trial primary completion DESCRIPTION:As of 11 June 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 2 trial in Breast Cancer\, on 31 October 2026.\n\nSource: clinicaltrials NCT05852691\nhttps://clinicaltrials.gov/study/NCT05852691 URL:https://julienwillard.com/calendar/clinical#e-6403d0a4-9f7e-4730-a77f-5 e119e622058 END:VEVENT BEGIN:VEVENT UID:1127ecb0b28b1eacd063549302645b50 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Neurimmune AG ALXN2220: Trial primary completion DESCRIPTION:As of 19 December 2025\, Neurimmune estimated primary completio n of a Phase 2 trial in Amyloid Transthyretin Cardiomyopathy\, on 31 Octob er 2026.\n\nSource: clinicaltrials NCT07213583\nhttps://clinicaltrials.gov /study/NCT07213583 URL:https://julienwillard.com/calendar/clinical#e-e6c9a764-be6d-47e7-a019-7 e89d99efbf9 END:VEVENT BEGIN:VEVENT UID:7e81cdc4461105d76323999f782e70cd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amgen anvumetostat: Trial primary completion DESCRIPTION:As of 28 May 2026\, Amgen estimated primary completion of a Pha se 2 trial in MTAP-deleted NSCLC\, on 31 October 2026.\n\nSource: clinical trials NCT06593522\nhttps://clinicaltrials.gov/study/NCT06593522 URL:https://julienwillard.com/calendar/clinical#e-f18ec4a6-23fd-48bb-a6f6-2 dcfea286583 END:VEVENT BEGIN:VEVENT UID:ceed518e8892813d0984e6e58c2debea DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Natureceuticals Sdn Bhd Nuvastatic 300: Trial primary completion DESCRIPTION:As of 25 June 2026\, Natureceuticals Sdn Bhd estimated primary completion of a Phase 3 trial in Fatigue Related to Cancer Treatment\, on 31 October 2026.\n\nSource: clinicaltrials NCT07669454\nhttps://clinicaltr ials.gov/study/NCT07669454 URL:https://julienwillard.com/calendar/clinical#e-68871dff-4e46-46a9-bac1-9 63a878b0060 END:VEVENT BEGIN:VEVENT UID:59242018de399b75af4697dca15586bc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Salubris Biotherapeutics Inc JK07: Trial primary completion DESCRIPTION:As of 22 May 2026\, Salubris Biotherapeutics estimated primary completion of a Phase 2 trial in Heart Failure With Reduced Ejection Fract ion\, on 31 October 2026.\n\nSource: clinicaltrials NCT06369298\nhttps://c linicaltrials.gov/study/NCT06369298 URL:https://julienwillard.com/calendar/clinical#e-19b435d9-042f-4fd8-91ed-f 501223a5d09 END:VEVENT BEGIN:VEVENT UID:975b05df9d0f99e830991feda42ad7b1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NEXTGEN Bioscience NXC736: Trial primary completion DESCRIPTION:As of 13 April 2026\, NEXTGEN Bioscience estimated primary comp letion of a Phase 2 trial in Alopecia Areata\, on 31 October 2026.\n\nSour ce: clinicaltrials NCT06104839\nhttps://clinicaltrials.gov/study/NCT061048 39 URL:https://julienwillard.com/calendar/clinical#e-4cdc74fc-ee61-4a2b-b049-0 5c36e128a55 END:VEVENT BEGIN:VEVENT UID:807ba05483182f238476faacf8386ad6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MaaT Pharma Pooled allogeneic fecal microbiotherapy: Trial primary completion DESCRIPTION:As of 27 December 2024\, MaaT Pharma estimated primary completi on of a Phase 2 trial in Transplant Complication\, on 31 October 2026.\n\n Source: clinicaltrials NCT05762211\nhttps://clinicaltrials.gov/study/NCT05 762211 URL:https://julienwillard.com/calendar/clinical#e-896eaf58-a29a-48d2-989a-9 7baf0c917f1 END:VEVENT BEGIN:VEVENT UID:10068b55a17d8d3753a26a178b5338c6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Adagene Inc ADG126: Trial primary completion DESCRIPTION:As of 7 January 2026\, Adagene estimated primary completion of a Phase 2 trial in Advanced/Metastatic Solid Tumors\, on 31 October 2026.\ n\nSource: clinicaltrials NCT05405595\nhttps://clinicaltrials.gov/study/NC T05405595 URL:https://julienwillard.com/calendar/clinical#e-9b218c1d-3043-4530-bede-d b6d9b343877 END:VEVENT BEGIN:VEVENT UID:845296a4bada5a8577c409f8543a2610 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Annexon\, Inc. Vonaprument: Trial primary completion DESCRIPTION:As of 4 May 2026\, Annexon estimated primary completion of a Ph ase 3 trial in Geographic Atrophy\, on 31 October 2026.\n\nSource: clinica ltrials NCT06510816\nhttps://clinicaltrials.gov/study/NCT06510816 URL:https://julienwillard.com/calendar/clinical#e-43c0284e-3aba-4cac-a103-3 26f4e0e2383 END:VEVENT BEGIN:VEVENT UID:03d24aeb88868b7868231426d8f2f34e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AskBio Inc AB-1002: Trial primary completion DESCRIPTION:As of 3 December 2025\, AskBio estimated primary completion of a Phase 2 trial in Congestive Heart Failure\, on 31 October 2026.\n\nSourc e: clinicaltrials NCT05598333\nhttps://clinicaltrials.gov/study/NCT0559833 3 URL:https://julienwillard.com/calendar/clinical#e-64786fb8-0d27-49b5-b70f-2 b1c2fd5456a END:VEVENT BEGIN:VEVENT UID:9fecfc914dd8d5908d01083b275f91d2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Henlius Biotech HLX43 DOSE 1: Trial primary completion DESCRIPTION:As of 10 March 2025\, Shanghai Henlius Biotech estimated primar y completion of a Phase 2 trial in Carcinoma\, Hepatocellular\, on 31 Octo ber 2026.\n\nSource: clinicaltrials NCT06742892\nhttps://clinicaltrials.go v/study/NCT06742892 URL:https://julienwillard.com/calendar/clinical#e-ddd6c460-f178-4bae-a884-b f7ced8860d2 END:VEVENT BEGIN:VEVENT UID:cc21d04d4bc375be7347c6ac1d9b4d61 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Viatris Innovation GmbH Cenerimod: Trial primary completion DESCRIPTION:As of 28 July 2026\, Viatris Innovation estimated primary compl etion of a Phase 3 trial in Lupus Erythematosus\, Systemic\, on 31 October 2026.\n\nSource: clinicaltrials NCT05648500\nhttps://clinicaltrials.gov/s tudy/NCT05648500 URL:https://julienwillard.com/calendar/clinical#e-bdfe2864-1852-40fb-89c0-c 98569b07528 END:VEVENT BEGIN:VEVENT UID:20970ecdc019bb97cf79c12dbc42cf2a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Changzhou Qianhong Bio-pharma Co.\, Ltd. QHRD106 Injection (Low-dos e group): Trial primary completion DESCRIPTION:As of 9 February 2026\, Changzhou Qianhong Bio-pharma Co. estim ated primary completion of a Phase 2 trial in Acute Ischemic Stroke\, on 3 1 October 2026.\n\nSource: clinicaltrials NCT07396337\nhttps://clinicaltri als.gov/study/NCT07396337 URL:https://julienwillard.com/calendar/clinical#e-2f35cbeb-d957-43e4-aaca-d 84f177cdcf5 END:VEVENT BEGIN:VEVENT UID:9b0dbc1d339e1c6114dc29b62a0353c9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Teva Branded Pharmaceutical Products R&D LLC TEV-56248: Trial prima ry completion DESCRIPTION:As of 24 July 2026\, Teva Branded Pharmaceutical Products R&D e stimated primary completion of a Phase 3 trial in asthma\, on 31 October 2 026.\n\nSource: clinicaltrials NCT06052267\nhttps://clinicaltrials.gov/stu dy/NCT06052267 URL:https://julienwillard.com/calendar/clinical#e-0df23a84-7bf8-4610-b23f-b 5dda1094cb2 END:VEVENT BEGIN:VEVENT UID:d77ef717c0453450d562c6200ff20d56 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Takeda TAK-788: Trial primary completion DESCRIPTION:As of 30 March 2026\, Takeda estimated primary completion of a Phase 3 trial in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)\, on 31 October 2026.\n\nSource: clinicaltrials NCT04129502\nhttps://clinica ltrials.gov/study/NCT04129502 URL:https://julienwillard.com/calendar/clinical#e-04fba133-5d41-4d71-b3a9-e feea2052159 END:VEVENT BEGIN:VEVENT UID:771c8e005a4b4bd3c082d90fa4f94709 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Rhythm Pharmaceuticals\, Inc. Setmelanotide: Trial primary completi on DESCRIPTION:As of 12 February 2026\, Rhythm Pharmaceuticals estimated prima ry completion of a Phase 2 trial in Prader-Willi Syndrome\, on 31 October 2026.\n\nSource: clinicaltrials NCT06772597\nhttps://clinicaltrials.gov/st udy/NCT06772597 URL:https://julienwillard.com/calendar/clinical#e-fc56adf6-d12e-4ecf-955f-8 6885c27a01c END:VEVENT BEGIN:VEVENT UID:b7c3098f9c2043b99511d2784f5a4cf6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Spyre Therapeutics\, Inc. SPY002-072: Trial primary completion DESCRIPTION:As of 5 June 2026\, Spyre Therapeutics estimated primary comple tion of a Phase 2 trial in Rheumatoid Arthritis\, on 31 October 2026.\n\nS ource: clinicaltrials NCT07148414\nhttps://clinicaltrials.gov/study/NCT071 48414 URL:https://julienwillard.com/calendar/clinical#e-b7e53e02-5f8b-4c86-b95a-7 81c97b8dbb9 END:VEVENT BEGIN:VEVENT UID:f3ab9890e92a962a533130f31aca5db2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Alectinib: Trial primary completion DESCRIPTION:As of 5 June 2026\, Hoffmann-La Roche estimated primary complet ion of a Phase 3 trial in Non-Small Cell Lung Cancer\, on 31 October 2026. \n\nSource: clinicaltrials NCT03178552\nhttps://clinicaltrials.gov/study/N CT03178552 URL:https://julienwillard.com/calendar/clinical#e-be159fc5-75cd-4aec-914f-2 8d7a4a1179c END:VEVENT BEGIN:VEVENT UID:b4a837dcf88ee4a61f5699f92ba6ad9a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Janssen Research & Development\, LLC Milvexian: Trial primary compl etion DESCRIPTION:As of 6 July 2026\, Janssen Research & Development estimated pr imary completion of a Phase 3 trial in Atrial Fibrillation\, on 31 October 2026.\n\nSource: clinicaltrials NCT05757869\nhttps://clinicaltrials.gov/s tudy/NCT05757869 URL:https://julienwillard.com/calendar/clinical#e-a739643a-df7c-4f7e-849c-3 fc9a5fa190e END:VEVENT BEGIN:VEVENT UID:9c85671d1b4dacca8aa5171fd2403b6d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Viatris Innovation GmbH Cenerimod: Trial primary completion DESCRIPTION:As of 28 July 2026\, Viatris Innovation estimated primary compl etion of a Phase 3 trial in Lupus Erythematosus\, Systemic\, on 31 October 2026.\n\nSource: clinicaltrials NCT05672576\nhttps://clinicaltrials.gov/s tudy/NCT05672576 URL:https://julienwillard.com/calendar/clinical#e-cf887eba-fcae-4899-bb55-e d2c33bb568a END:VEVENT BEGIN:VEVENT UID:b6e63156cae1ef3a0d568d5f786b19a9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Animuscure Inc. AMC6156 0.1mg: Trial primary completion DESCRIPTION:As of 3 August 2026\, Animuscure estimated primary completion o f a Phase 2 trial in Sarcopenia in Elderly\, on 31 October 2026.\n\nSource : clinicaltrials NCT07072195\nhttps://clinicaltrials.gov/study/NCT07072195 URL:https://julienwillard.com/calendar/clinical#e-b690014f-f415-4bae-868c-6 a179a1fc92a END:VEVENT BEGIN:VEVENT UID:547ca63a8d77e9a6d19ddd1403673a44 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Myosin Therapeutics Inc. MT-125: Trial primary completion DESCRIPTION:As of 14 April 2026\, Myosin Therapeutics estimated primary com pletion of a Phase 2 trial in glioblastoma (GBM)\, on 31 October 2026.\n\n Source: clinicaltrials NCT07185880\nhttps://clinicaltrials.gov/study/NCT07 185880 URL:https://julienwillard.com/calendar/clinical#e-41560feb-5c94-4bcc-8dc3-b 3b759a94758 END:VEVENT BEGIN:VEVENT UID:40a50ff02b624eec36afe0f4e2c529e6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Avistone Biotechnology Co.\, Ltd. Vebreltinib: Trial primary comple tion DESCRIPTION:As of 21 May 2025\, Avistone Biotechnology Co. estimated primar y completion of a Phase 2 trial in Non-Small-Cell Lung Cancer\, on 31 Octo ber 2026.\n\nSource: clinicaltrials NCT06574347\nhttps://clinicaltrials.go v/study/NCT06574347 URL:https://julienwillard.com/calendar/clinical#e-5050b46b-9681-43be-b6f7-a 2e29b614848 END:VEVENT BEGIN:VEVENT UID:e4715aaec6451708b80637a7087b8463 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. SHR6390: Trial primary completi on DESCRIPTION:As of 1 August 2024\, Jiangsu HengRui Medicine Co. estimated pr imary completion of a Phase 3 trial on 31 October 2026.\n\nSource: clinica ltrials NCT04842617\nhttps://clinicaltrials.gov/study/NCT04842617 URL:https://julienwillard.com/calendar/clinical#e-05d2bafd-8fbf-489c-ab66-2 c5df645dde9 END:VEVENT BEGIN:VEVENT UID:9cf1bb2d50911a360170edcd91618d6d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Henlius Biotech HLX43: Trial primary completion DESCRIPTION:As of 18 May 2026\, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Esophageal Cancer\, on 31 October 2026.\n \nSource: clinicaltrials NCT06769113\nhttps://clinicaltrials.gov/study/NCT 06769113 URL:https://julienwillard.com/calendar/clinical#e-61753490-66a9-44da-a408-8 84ea0ceac1e END:VEVENT BEGIN:VEVENT UID:89bb0fa3b5309d080705f8048b913eac DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. IBI3003: Trial primary complet ion DESCRIPTION:As of 13 December 2024\, Innovent Biologics (Suzhou) Co. estima ted primary completion of a Phase 2 trial in Multiple Myeloma\, on 31 Octo ber 2026.\n\nSource: clinicaltrials NCT06083207\nhttps://clinicaltrials.go v/study/NCT06083207 URL:https://julienwillard.com/calendar/clinical#e-598849fa-3767-4291-8795-5 8356bdb4606 END:VEVENT BEGIN:VEVENT UID:660328c6f46a564f941cab7456254d64 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TG Therapeutics\, Inc. Ublituximab: Trial primary completion DESCRIPTION:As of 17 July 2026\, TG Therapeutics estimated primary completi on of a Phase 3 trial in Relapsing Multiple Sclerosis\, on 31 October 2026 .\n\nSource: clinicaltrials NCT07211633\nhttps://clinicaltrials.gov/study/ NCT07211633 URL:https://julienwillard.com/calendar/clinical#e-be54f910-59e5-4ff3-8d13-c 91373db37a8 END:VEVENT BEGIN:VEVENT UID:2bfa01584dac4663c6083a9fe4bbdfc9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shandong Suncadia Medicine Co.\, Ltd. HRS-8080\; SHR-A1811: Trial p rimary completion DESCRIPTION:As of 25 November 2024\, Shandong Suncadia Medicine Co. estimat ed primary completion of a Phase 2 trial in Breast Cancer\, on 31 October 2026.\n\nSource: clinicaltrials NCT06222879\nhttps://clinicaltrials.gov/st udy/NCT06222879 URL:https://julienwillard.com/calendar/clinical#e-12aec0b0-2e3d-4648-91b7-2 64c6c649683 END:VEVENT BEGIN:VEVENT UID:aaed5266fb98de423ae248e85e49f7d3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Genentech\, Inc. Venetoclax: Trial primary completion DESCRIPTION:As of 25 February 2026\, Genentech estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia\, on 31 October 2026.\ n\nSource: clinicaltrials NCT06524375\nhttps://clinicaltrials.gov/study/NC T06524375 URL:https://julienwillard.com/calendar/clinical#e-35c4f604-2850-4751-bc0e-0 9e10c3b6f2c END:VEVENT BEGIN:VEVENT UID:a235382d351b47e3537d5b4707b41bc4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261031 DTEND;VALUE=DATE:20261101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Capivasertib: Trial primary completion DESCRIPTION:As of 27 March 2026\, AstraZeneca estimated primary completion of a Phase 3 trial in Breast Cancer\, on 31 October 2026.\n\nSource: clini caltrials NCT06635447\nhttps://clinicaltrials.gov/study/NCT06635447 URL:https://julienwillard.com/calendar/clinical#e-13f3877b-5df3-4e18-a18c-8 451ba903373 END:VEVENT BEGIN:VEVENT UID:9e65dec75ab97ccbf8e25ba55fb17b89 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Apogee Therapeutics\, Inc. APG777: Trial primary completion DESCRIPTION:As of 22 July 2026\, Apogee Therapeutics estimated primary comp letion of a Phase 2 trial in Atopic Dermatitis\, in November 2026.\n\nSour ce: clinicaltrials NCT06395948\nhttps://clinicaltrials.gov/study/NCT063959 48 URL:https://julienwillard.com/calendar/clinical#e-a77bf3f8-e144-4273-8d40-3 e8727f55d9c END:VEVENT BEGIN:VEVENT UID:3f5a48ade870eda91752a134165594f4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261102 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Erasca\, Inc. ERAS-007: Trial primary completion DESCRIPTION:As of 22 June 2026\, Erasca estimated primary completion of a P hase 2 trial in Advanced or Metastatic Solid Tumors\, on 1 November 2026.\ n\nSource: clinicaltrials NCT04866134\nhttps://clinicaltrials.gov/study/NC T04866134 URL:https://julienwillard.com/calendar/clinical#e-eafbd810-d485-4c2a-beaa-c bd6c17c80f9 END:VEVENT BEGIN:VEVENT UID:f72533c4d282687cda9d56158866b5a2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company Tirzepatide: Trial primary completion DESCRIPTION:As of 17 February 2026\, Eli Lilly and estimated primary comple tion of a Phase 3 trial in Type 1 Diabetes\, in November 2026.\n\nSource: clinicaltrials NCT06962280\nhttps://clinicaltrials.gov/study/NCT06962280 URL:https://julienwillard.com/calendar/clinical#e-100584e9-0c45-49f6-9ce2-f d35c567686c END:VEVENT BEGIN:VEVENT UID:16e2e0241bbdd1ca6e4f810d8a356891 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie Mirvetuximab soravtansine: Trial primary completion DESCRIPTION:As of 28 October 2025\, AbbVie estimated primary completion of a Phase 2 trial in High Grade Ovarian Cancer\, in November 2026.\n\nSource : clinicaltrials NCT05456685\nhttps://clinicaltrials.gov/study/NCT05456685 URL:https://julienwillard.com/calendar/clinical#e-d89bcee9-f5fd-40f6-93fa-d 33921765143 END:VEVENT BEGIN:VEVENT UID:7c4adf7a768ab3e3ef25dbc10a031e94 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company LY4515100: Trial primary completion DESCRIPTION:As of 1 May 2026\, Eli Lilly and estimated primary completion o f a Phase 2 trial in Acute Pain\, in November 2026.\n\nSource: clinicaltri als NCT07511816\nhttps://clinicaltrials.gov/study/NCT07511816 URL:https://julienwillard.com/calendar/clinical#e-dfb1728a-2d7d-49da-9da1-1 a5cbfe49a12 END:VEVENT BEGIN:VEVENT UID:ae0b85f5c6005bfd238fd0f36f5489b7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beckley Psytech Limited BPL-003: Trial primary completion DESCRIPTION:As of 6 July 2026\, Beckley Psytech estimated primary completio n of a Phase 2 trial in Treatment Resistant Depression\, in November 2026. \n\nSource: clinicaltrials NCT05660642\nhttps://clinicaltrials.gov/study/N CT05660642 URL:https://julienwillard.com/calendar/clinical#e-1cf556e7-116d-46cf-b195-7 5f64adc1c49 END:VEVENT BEGIN:VEVENT UID:e62a35843e19a1279f110c8080acf4be DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Xentria\, Inc. XTMAB-16: Trial primary completion DESCRIPTION:As of 30 July 2026\, Xentria estimated primary completion of a Phase 2 trial in Pulmonary Sarcoidosis\, in November 2026.\n\nSource: clin icaltrials NCT06169397\nhttps://clinicaltrials.gov/study/NCT06169397 URL:https://julienwillard.com/calendar/clinical#e-53ff4c6f-92cf-4531-8cbb-5 10801358f39 END:VEVENT BEGIN:VEVENT UID:2365666a768082a1a5711ceb2424f410 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NeuShen Therapeutics NS-136: Trial primary completion DESCRIPTION:As of 13 April 2026\, NeuShen Therapeutics estimated primary co mpletion of a Phase 2 trial in schizophrenia(Acute)\, in November 2026.\n\ nSource: clinicaltrials NCT07521683\nhttps://clinicaltrials.gov/study/NCT0 7521683 URL:https://julienwillard.com/calendar/clinical#e-94602679-bc0e-4102-8a29-3 ec51a2a52f1 END:VEVENT BEGIN:VEVENT UID:2862ae7edd78690307b5c0b78f6a3dc9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BeiGene Tislelizumab (BGB-A317): Trial primary completion DESCRIPTION:As of 10 July 2026\, BeiGene estimated primary completion of a Phase 2 trial in MSI-H/dMMR Solid Tumors\, in November 2026.\n\nSource: cl inicaltrials NCT03736889\nhttps://clinicaltrials.gov/study/NCT03736889 URL:https://julienwillard.com/calendar/clinical#e-1b74b6ab-d284-4ca8-9fd4-3 1637bed7ab8 END:VEVENT BEGIN:VEVENT UID:99e56f69dfa5ecb50a13a2305e6a01a5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ferrer Internacional S.A. FNP-223: Trial primary completion DESCRIPTION:As of 15 October 2025\, Ferrer Internacional estimated primary completion of a Phase 2 trial in Progressive Supranuclear Palsy\, in Novem ber 2026.\n\nSource: clinicaltrials NCT06355531\nhttps://clinicaltrials.go v/study/NCT06355531 URL:https://julienwillard.com/calendar/clinical#e-6eb78fb2-23e7-4a04-8898-6 0f685650aa5 END:VEVENT BEGIN:VEVENT UID:6e2fb38f28a97bf4e1a6999ce9f7d386 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Camurus AB CAM2029: Trial primary completion DESCRIPTION:As of 28 July 2026\, Camurus estimated primary completion of a Phase 3 trial in Gastro-enteropancreatic Neuroendocrine Tumor\, in Novembe r 2026.\n\nSource: clinicaltrials NCT05050942\nhttps://clinicaltrials.gov/ study/NCT05050942 URL:https://julienwillard.com/calendar/clinical#e-3aea50ce-5f2d-4638-9fde-0 db4c984e1bd END:VEVENT BEGIN:VEVENT UID:8b53026b500ca91d86963722d201338c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Waterstone Pharmaceutical (Wuhan) Co.\, LTD. WS016: Trial primary c ompletion DESCRIPTION:As of 26 November 2025\, Waterstone Pharmaceutical (Wuhan) Co. estimated primary completion of a Phase 3 trial in hyperkalemia\, in Novem ber 2026.\n\nSource: clinicaltrials NCT07251309\nhttps://clinicaltrials.go v/study/NCT07251309 URL:https://julienwillard.com/calendar/clinical#e-4e0e9d5b-0aba-44c1-aa44-6 e66504166c6 END:VEVENT BEGIN:VEVENT UID:d12b2652356dea73a553949c281006b7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie Venetoclax: Trial primary completion DESCRIPTION:As of 9 February 2026\, AbbVie estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia (CLL)\, in November 2026.\ n\nSource: clinicaltrials NCT04895436\nhttps://clinicaltrials.gov/study/NC T04895436 URL:https://julienwillard.com/calendar/clinical#e-9c778da3-e70e-4394-8eab-9 5ad181edee9 END:VEVENT BEGIN:VEVENT UID:6adbcf36601133c64158b60edd22bd3a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Immunic AG IMU-838 tablets: Trial primary completion DESCRIPTION:As of 23 February 2026\, Immunic estimated primary completion o f a Phase 3 trial in Multiple Sclerosis\, Relapsing-Remitting\, in Novembe r 2026.\n\nSource: clinicaltrials NCT05201638\nhttps://clinicaltrials.gov/ study/NCT05201638 URL:https://julienwillard.com/calendar/clinical#e-8b2ee574-e7bb-4690-a78d-4 91448dd3244 END:VEVENT BEGIN:VEVENT UID:db6cc6eb34150e971a52ee785dbb960f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pacira Pharmaceuticals\, Inc Enekinragene Inzadenovec (PCRX-201): T rial primary completion DESCRIPTION:As of 7 August 2026\, Pacira Pharmaceuticals estimated primary completion of a Phase 2 trial in Osteoarthritis (OA) of the Knee\, in Nove mber 2026.\n\nSource: clinicaltrials NCT06884865\nhttps://clinicaltrials.g ov/study/NCT06884865 URL:https://julienwillard.com/calendar/clinical#e-e38332fe-d60e-4720-a645-a f1ca1ac6005 END:VEVENT BEGIN:VEVENT UID:f6ec7dd670a6ae8069934b569c732fc6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Forge Biologics\, Inc FBX-101: Trial primary completion DESCRIPTION:As of 2 June 2026\, Forge Biologics estimated primary completio n of a Phase 2 trial in Krabbe Disease\, in November 2026.\n\nSource: clin icaltrials NCT04693598\nhttps://clinicaltrials.gov/study/NCT04693598 URL:https://julienwillard.com/calendar/clinical#e-b1c808e0-3ec4-4fb4-bb8f-2 9bc1b7785e8 END:VEVENT BEGIN:VEVENT UID:81f34d21a19c3927d26de3663f816744 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Zura Bio Inc Tibulizumab Dose A: Trial primary completion DESCRIPTION:As of 30 June 2026\, Zura Bio estimated primary completion of a Phase 2 trial in Hidradenitis Suppurativa (HS)\, in November 2026.\n\nSou rce: clinicaltrials NCT06993610\nhttps://clinicaltrials.gov/study/NCT06993 610 URL:https://julienwillard.com/calendar/clinical#e-33bc7f2c-e366-4c39-a359-8 1b434666617 END:VEVENT BEGIN:VEVENT UID:fd1a67632fe771330316893753c84cab DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261102 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Epygenix Clemizole HCl: Trial primary completion DESCRIPTION:As of 2 July 2026\, Epygenix estimated primary completion of a Phase 3 trial in Lennox Gastaut Syndrome\, on 1 November 2026.\n\nSource: clinicaltrials NCT05066217\nhttps://clinicaltrials.gov/study/NCT05066217 URL:https://julienwillard.com/calendar/clinical#e-00110ffb-52ac-449f-a883-9 8b0fe7e49da END:VEVENT BEGIN:VEVENT UID:d99d81480e4ea6a25168d993112882c6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BeOne Medicines Sonrotoclax: Trial primary completion DESCRIPTION:As of 9 July 2026\, BeOne Medicines estimated primary completio n of a Phase 2 trial in Chronic Lymphocytic Leukemia\, in November 2026.\n \nSource: clinicaltrials NCT06637501\nhttps://clinicaltrials.gov/study/NCT 06637501 URL:https://julienwillard.com/calendar/clinical#e-d65a8098-5ef4-47ba-a21c-6 d4cd0fe3c6c END:VEVENT BEGIN:VEVENT UID:9c73aa80fd5f111278c0029526294f26 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NewAmsterdam Pharma obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks: Trial primary completion DESCRIPTION:As of 9 April 2026\, NewAmsterdam Pharma estimated primary comp letion of a Phase 2 trial in dyslipidemias\, in November 2026.\n\nSource: clinicaltrials NCT06496243\nhttps://clinicaltrials.gov/study/NCT06496243 URL:https://julienwillard.com/calendar/clinical#e-85961f5d-df09-4fda-afd6-b a3c7ec339e0 END:VEVENT BEGIN:VEVENT UID:41cf0dd378363ba1313f13eeab65f5d6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Stemline Therapeutics\, Inc. Elacestrant: Trial primary completion DESCRIPTION:As of 7 May 2026\, Stemline Therapeutics estimated primary comp letion of a Phase 2 trial in Metastatic Breast Cancer\, in November 2026.\ n\nSource: clinicaltrials NCT05596409\nhttps://clinicaltrials.gov/study/NC T05596409 URL:https://julienwillard.com/calendar/clinical#e-a1991adf-30fa-4e2e-a160-1 3bb5d88b4b6 END:VEVENT BEGIN:VEVENT UID:16c843f88351b275ffa022dec3502406 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Aptose Biosciences Inc. Tuspetinib: Trial primary completion DESCRIPTION:As of 26 August 2025\, Aptose Biosciences estimated primary com pletion of a Phase 2 trial in Leukemia\, Myeloid\, Acute\, in November 202 6.\n\nSource: clinicaltrials NCT03850574\nhttps://clinicaltrials.gov/study /NCT03850574 URL:https://julienwillard.com/calendar/clinical#e-0a9e6539-4c4b-4aa6-9d67-d a06c5520a6d END:VEVENT BEGIN:VEVENT UID:423f0d7b20dacc7ca751bffa25f0a67c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Reunion Neuroscience Inc RE104 for Injection: Trial primary complet ion DESCRIPTION:As of 6 August 2026\, Reunion Neuroscience estimated primary co mpletion of a Phase 2 trial in Adjustment Disorder\, in November 2026.\n\n Source: clinicaltrials NCT07002034\nhttps://clinicaltrials.gov/study/NCT07 002034 URL:https://julienwillard.com/calendar/clinical#e-073668d4-e37b-46c6-b49b-1 13dd488e52e END:VEVENT BEGIN:VEVENT UID:3e8496f46ccb9b682a39c91cd743002c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MediLink Therapeutics (Suzhou) Co.\, Ltd. YL202 should be intraveno usly infused: Trial primary completion DESCRIPTION:As of 26 November 2025\, MediLink Therapeutics (Suzhou) Co. est imated primary completion of a Phase 2 trial in nSCLC\, in November 2026.\ n\nSource: clinicaltrials NCT06107686\nhttps://clinicaltrials.gov/study/NC T06107686 URL:https://julienwillard.com/calendar/clinical#e-a91dea23-acd1-4546-bc7f-4 922312c4c6f END:VEVENT BEGIN:VEVENT UID:4a2ae11290780a71d8717a42ed01c2ba DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BeOne Medicines BGB-16673: Trial primary completion DESCRIPTION:As of 6 August 2026\, BeOne Medicines estimated primary complet ion of a Phase 2 trial in B-cell Malignancy\, in November 2026.\n\nSource: clinicaltrials NCT05006716\nhttps://clinicaltrials.gov/study/NCT05006716 URL:https://julienwillard.com/calendar/clinical#e-7965bdc5-7562-4a1b-9f6e-d 9052b673b33 END:VEVENT BEGIN:VEVENT UID:f21a0d635388ce476cf4af430436cea8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company Retatrutide: Trial primary completion DESCRIPTION:As of 20 July 2026\, Eli Lilly and estimated primary completion of a Phase 3 trial in obesity\, in November 2026.\n\nSource: clinicaltria ls NCT06662383\nhttps://clinicaltrials.gov/study/NCT06662383 URL:https://julienwillard.com/calendar/clinical#e-76702912-1192-436d-ab3d-0 f88d405201e END:VEVENT BEGIN:VEVENT UID:f7c35e6cd5670775e19d2ba297b3102c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie ABBV-932: Trial primary completion DESCRIPTION:As of 17 June 2026\, AbbVie estimated primary completion of a P hase 2 trial in Generalized Anxiety Disorder (GAD)\, in November 2026.\n\n Source: clinicaltrials NCT06846320\nhttps://clinicaltrials.gov/study/NCT06 846320 URL:https://julienwillard.com/calendar/clinical#e-f5d4f311-10c5-4a6c-b5c6-2 a5bd3f75029 END:VEVENT BEGIN:VEVENT UID:d7dda4ac6ed86f92cbb1bc3bbdc262dd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:LG Chem LBVD: Trial primary completion DESCRIPTION:As of 3 July 2025\, LG Chem estimated primary completion of a P hase 3 trial in diphtheria\, in November 2026.\n\nSource: clinicaltrials N CT06947499\nhttps://clinicaltrials.gov/study/NCT06947499 URL:https://julienwillard.com/calendar/clinical#e-025f4948-0f33-4f77-91f0-a b438c77303f END:VEVENT BEGIN:VEVENT UID:032183df3f55dbfe9233cba684822ad2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Colgate Palmolive Colgate SNaP Total 10/10\, 1.5 Taurate: Trial pri mary completion DESCRIPTION:As of 27 May 2026\, Colgate Palmolive estimated primary complet ion of a Phase 3 trial in Plaque\, Dental\, in November 2026.\n\nSource: c linicaltrials NCT07605338\nhttps://clinicaltrials.gov/study/NCT07605338 URL:https://julienwillard.com/calendar/clinical#e-1886bd65-7ecf-4595-b80a-4 f096bc2d32d END:VEVENT BEGIN:VEVENT UID:d8087eb7b9392233a99ac1919cd2abc8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. Bupivacaine Liposome Injection: Trial primary completion DESCRIPTION:As of 12 March 2026\, Jiangsu HengRui Medicine Co. estimated pr imary completion of a Phase 2 trial in Local Analgesia Via Nerve Block\, i n November 2026.\n\nSource: clinicaltrials NCT06529432\nhttps://clinicaltr ials.gov/study/NCT06529432 URL:https://julienwillard.com/calendar/clinical#e-3cee7160-ce80-4e1a-baff-3 e94a008990d END:VEVENT BEGIN:VEVENT UID:47c857b1b89a8e93ab5161b876d39e0f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 17 April 2026\, Sichuan Baili Pharmaceutical Co. estimate d primary completion of a Phase 3 trial in Nasopharyngeal Carcinoma\, in N ovember 2026.\n\nSource: clinicaltrials NCT06118333\nhttps://clinicaltrial s.gov/study/NCT06118333 URL:https://julienwillard.com/calendar/clinical#e-ab2f26d9-8f6f-427e-8e80-1 287e30159d9 END:VEVENT BEGIN:VEVENT UID:824b320e5e48e7431d5484fb5a50723d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Lynk Pharmaceuticals Co.\, Ltd LNK01001: Trial primary completion DESCRIPTION:As of 20 November 2025\, Lynk Pharmaceuticals Co. estimated pri mary completion of a Phase 3 trial in Ankylosing Spondylitis\, in November 2026.\n\nSource: clinicaltrials NCT07237568\nhttps://clinicaltrials.gov/s tudy/NCT07237568 URL:https://julienwillard.com/calendar/clinical#e-8e694a7e-0952-41e7-a1a8-3 65440de3fd0 END:VEVENT BEGIN:VEVENT UID:61992cff1f0fdd8fc9e7b9bc42e9f555 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:DBV Technologies DBV712 250 mcg: Trial primary completion DESCRIPTION:As of 22 July 2026\, DBV Technologies estimated primary complet ion of a Phase 3 trial in allergy\, in November 2026.\n\nSource: clinicalt rials NCT07003919\nhttps://clinicaltrials.gov/study/NCT07003919 URL:https://julienwillard.com/calendar/clinical#e-8f1c6c2f-2565-40e3-9272-a f2c82808ab9 END:VEVENT BEGIN:VEVENT UID:c5e06e696f45d83b0891e56b0fdc4e2b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vir Biotechnology\, Inc. Tobevibart: Trial primary completion DESCRIPTION:As of 16 January 2026\, Vir Biotechnology estimated primary com pletion of a Phase 2 trial in Viral Hepatitis\, in November 2026.\n\nSourc e: clinicaltrials NCT07142811\nhttps://clinicaltrials.gov/study/NCT0714281 1 URL:https://julienwillard.com/calendar/clinical#e-158817da-fc05-49c3-8039-f a84e91ef0e5 END:VEVENT BEGIN:VEVENT UID:691ab8ad326afd7f7a504a57787093f4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CG Oncology\, Inc. Cretostimogene Grenadenorepvec: Trial primary co mpletion DESCRIPTION:As of 1 July 2026\, CG Oncology estimated primary completion of a Phase 3 trial in Non Muscle Invasive Bladder Cancer\, in November 2026. \n\nSource: clinicaltrials NCT06111235\nhttps://clinicaltrials.gov/study/N CT06111235 URL:https://julienwillard.com/calendar/clinical#e-82e60e1d-63a6-4fe6-8894-5 d600b9a03c9 END:VEVENT BEGIN:VEVENT UID:bb088c7a79d43910cd92c303d3409746 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Avistone Biotechnology Co.\, Ltd. PLB1004: Trial primary completion DESCRIPTION:As of 20 March 2026\, Avistone Biotechnology Co. estimated prim ary completion of a Phase 2 trial in Non-Small-Cell Lung Cancer\, in Novem ber 2026.\n\nSource: clinicaltrials NCT07336732\nhttps://clinicaltrials.go v/study/NCT07336732 URL:https://julienwillard.com/calendar/clinical#e-72dde625-d3f4-4175-8280-3 60e39be9248 END:VEVENT BEGIN:VEVENT UID:6561820a1e8a135bde0bb55b4154a12a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261102 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Zelgen Biopharmaceuticals Co.\,Ltd ZGGS18 for Injection: Tri al primary completion DESCRIPTION:As of 5 January 2026\, Suzhou Zelgen Biopharmaceuticals Co. est imated primary completion of a Phase 2 trial in Advanced Solid Tumor\, on 1 November 2026.\n\nSource: clinicaltrials NCT05584800\nhttps://clinicaltr ials.gov/study/NCT05584800 URL:https://julienwillard.com/calendar/clinical#e-b38b2f65-d32b-401b-b052-6 184ddcf8172 END:VEVENT BEGIN:VEVENT UID:a7f8f0ac672fd14a195d7d91c6ebc145 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. SHR-1681: Trial prima ry completion DESCRIPTION:As of 9 January 2026\, Suzhou Suncadia Biopharmaceuticals Co. e stimated primary completion of a Phase 2 trial in Malignant Solid Tumors\, in November 2026.\n\nSource: clinicaltrials NCT06737731\nhttps://clinical trials.gov/study/NCT06737731 URL:https://julienwillard.com/calendar/clinical#e-9540dafa-0303-4e83-a813-9 f315ca96e81 END:VEVENT BEGIN:VEVENT UID:19d54f476f0cfb3ec4ca25937d9ac719 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Anbogen Therapeutics\, Inc. ABT-101: Trial primary completion DESCRIPTION:As of 24 June 2024\, Anbogen Therapeutics estimated primary com pletion of a Phase 2 trial in Advanced Solid Tumor\, in November 2026.\n\n Source: clinicaltrials NCT05532696\nhttps://clinicaltrials.gov/study/NCT05 532696 URL:https://julienwillard.com/calendar/clinical#e-64fff16e-382d-45e1-a975-f 12cdf3d9991 END:VEVENT BEGIN:VEVENT UID:2f0ba26759b67bed9d5ffbe00a02a35b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NewAmsterdam Pharma Obicetrapib: Trial primary completion DESCRIPTION:As of 4 June 2024\, NewAmsterdam Pharma estimated primary compl etion of a Phase 3 trial in Atherosclerotic Cardiovascular Disease\, in No vember 2026.\n\nSource: clinicaltrials NCT05202509\nhttps://clinicaltrials .gov/study/NCT05202509 URL:https://julienwillard.com/calendar/clinical#e-9dd0a376-2272-49e9-8fd2-c 1d4d92a1d6b END:VEVENT BEGIN:VEVENT UID:6f9f97848f75e4621c40ca9a780210cb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tyra Biosciences\, Inc TYRA-300: Trial primary completion DESCRIPTION:As of 12 January 2026\, Tyra Biosciences estimated primary comp letion of a Phase 2 trial in Locally Advanced Urothelial Carcinoma\, in No vember 2026.\n\nSource: clinicaltrials NCT05544552\nhttps://clinicaltrials .gov/study/NCT05544552 URL:https://julienwillard.com/calendar/clinical#e-57daeb2e-5309-4245-a76f-a b545272c121 END:VEVENT BEGIN:VEVENT UID:ea37cf6b3745645a3f7a4f2d8abb6c4d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie Budigalimab: Trial primary completion DESCRIPTION:As of 14 August 2025\, AbbVie estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma\, in November 2026.\n\nSource: clinicaltrials NCT05822752\nhttps://clinicaltrials.gov/study/NCT05822752 URL:https://julienwillard.com/calendar/clinical#e-9c648010-50d4-4bbe-97ce-3 82cbb7c0592 END:VEVENT BEGIN:VEVENT UID:2215ed3cab6d26dead779ab88277f86c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd. SKB264: Trial pr imary completion DESCRIPTION:As of 8 May 2026\, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Can cer\, in November 2026.\n\nSource: clinicaltrials NCT06448312\nhttps://cli nicaltrials.gov/study/NCT06448312 URL:https://julienwillard.com/calendar/clinical#e-e2f4bd63-0ff8-461b-a495-f a2b8c7eab9d END:VEVENT BEGIN:VEVENT UID:f106bc9237d05532bdb2c18c1b70ebe3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pharming Technologies B.V. Leniolisib: Trial primary completion DESCRIPTION:As of 13 February 2026\, Pharming Technologies B.V. estimated p rimary completion of a Phase 2 trial in Primary Immunodeficiency Disorders (PIDs)\, in November 2026.\n\nSource: clinicaltrials NCT06549114\nhttps:/ /clinicaltrials.gov/study/NCT06549114 URL:https://julienwillard.com/calendar/clinical#e-34748fbd-d6d4-41d2-a7a3-b 747d5364832 END:VEVENT BEGIN:VEVENT UID:e9e0252779ca6bd6d34c9d007765b026 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company Tirzepatide: Trial primary completion DESCRIPTION:As of 12 May 2026\, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 1 Diabetes\, in November 2026.\n\nSource: clini caltrials NCT06914895\nhttps://clinicaltrials.gov/study/NCT06914895 URL:https://julienwillard.com/calendar/clinical#e-ac7d928b-5587-4794-99a9-3 75a3a83b9a9 END:VEVENT BEGIN:VEVENT UID:16d62920f440e6d5e1486013264337ac DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Acesion Pharma AP31969: Trial primary completion DESCRIPTION:As of 12 June 2026\, Acesion Pharma estimated primary completio n of a Phase 2 trial in Atrial Fibrillation (AF)\, in November 2026.\n\nSo urce: clinicaltrials NCT07267949\nhttps://clinicaltrials.gov/study/NCT0726 7949 URL:https://julienwillard.com/calendar/clinical#e-7470a3c9-5571-4ac5-be41-4 c59453eb8e3 END:VEVENT BEGIN:VEVENT UID:fb31fdcf6828b2de953b24a1e82fd151 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Admetsys Corporation glucose and insulin infusions: Trial primary c ompletion DESCRIPTION:As of 30 July 2024\, Admetsys estimated primary completion of a Phase 2 trial in hyperglycemia\, in November 2026.\n\nSource: clinicaltri als NCT01291719\nhttps://clinicaltrials.gov/study/NCT01291719 URL:https://julienwillard.com/calendar/clinical#e-b72234f8-c3bb-446c-9e0d-3 c432e638180 END:VEVENT BEGIN:VEVENT UID:22b6bb042d197bce91574698de455b44 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Atossa Therapeutics\, Inc. (Z)-endoxifen: Trial primary completion DESCRIPTION:As of 8 July 2026\, Atossa Therapeutics estimated primary compl etion of a Phase 2 trial in Breast Neoplasms\, in November 2026.\n\nSource : clinicaltrials NCT05607004\nhttps://clinicaltrials.gov/study/NCT05607004 URL:https://julienwillard.com/calendar/clinical#e-20987765-473a-4e68-bbe0-2 1ce0575590f END:VEVENT BEGIN:VEVENT UID:91bb194d5ffb9c9bcf0529f6fee74a9d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Wooshin Labottach Co.\, Ltd. Cosmetic patch containing urea applica ted daily for 3 months: Trial primary completion DESCRIPTION:As of 26 January 2026\, Wooshin Labottach Co. estimated primary completion of a Phase 3 trial in Nail Psoriasis\, in November 2026.\n\nSo urce: clinicaltrials NCT07029516\nhttps://clinicaltrials.gov/study/NCT0702 9516 URL:https://julienwillard.com/calendar/clinical#e-bb8663dc-c2f3-47c4-90bf-1 f55a2e23108 END:VEVENT BEGIN:VEVENT UID:339bb6e93069219deb6029a8ff8159a2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261102 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ML Bio Solutions\, Inc. BBP-418: Trial primary completion DESCRIPTION:As of 21 July 2026\, ML Bio Solutions estimated primary complet ion of a Phase 2 trial in lGMD2I\, on 1 November 2026.\n\nSource: clinical trials NCT04800874\nhttps://clinicaltrials.gov/study/NCT04800874 URL:https://julienwillard.com/calendar/clinical#e-a8a18174-e723-4037-9184-4 620f6160a53 END:VEVENT BEGIN:VEVENT UID:1816549db1b29c5427898137c34fe929 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Immunic AG IMU-838 tablets: Trial primary completion DESCRIPTION:As of 23 February 2026\, Immunic estimated primary completion o f a Phase 3 trial in Multiple Sclerosis\, in November 2026.\n\nSource: cli nicaltrials NCT05134441\nhttps://clinicaltrials.gov/study/NCT05134441 URL:https://julienwillard.com/calendar/clinical#e-8de46229-cfca-4c7a-adc7-f 4868da0d935 END:VEVENT BEGIN:VEVENT UID:5f9fd2b71c943a29749e117a03db7013 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Alkermes\, Inc. ALKS 2680: Trial primary completion DESCRIPTION:As of 24 June 2026\, Alkermes estimated primary completion of a Phase 2 trial in Idiopathic Hypersomnia\, in November 2026.\n\nSource: cl inicaltrials NCT06843590\nhttps://clinicaltrials.gov/study/NCT06843590 URL:https://julienwillard.com/calendar/clinical#e-95af9072-a81b-4b15-b4e6-a ffec8c851b2 END:VEVENT BEGIN:VEVENT UID:172611a3602ab15549be475d81dc276a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Forge Biologics\, Inc FBX-101: Trial primary completion DESCRIPTION:As of 20 November 2025\, Forge Biologics estimated primary comp letion of a Phase 2 trial in Krabbe Disease\, in November 2026.\n\nSource: clinicaltrials NCT05739643\nhttps://clinicaltrials.gov/study/NCT05739643 URL:https://julienwillard.com/calendar/clinical#e-f53ace6f-3a89-4619-92e5-c e9684364e1d END:VEVENT BEGIN:VEVENT UID:65b46c6f2868ddd64fa6468a82fe18f4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BioNTech SE RO7198457 intravenous (IV): Trial primary completion DESCRIPTION:As of 15 July 2026\, BioNTech SE estimated primary completion o f a Phase 2 trial in Colorectal Cancer Stage II\, in November 2026.\n\nSou rce: clinicaltrials NCT04486378\nhttps://clinicaltrials.gov/study/NCT04486 378 URL:https://julienwillard.com/calendar/clinical#e-17fad844-a3b9-491b-84f7-3 2374572043f END:VEVENT BEGIN:VEVENT UID:7e9f06d10eaedfcbc43e1c420ad80d1b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261102 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Corbus Pharmaceuticals Inc. CRB-601 monoclonal antibody: Trial prim ary completion DESCRIPTION:As of 3 June 2025\, Corbus Pharmaceuticals estimated primary co mpletion of a Phase 2 trial in Solid Tumor\, on 1 November 2026.\n\nSource : clinicaltrials NCT06603844\nhttps://clinicaltrials.gov/study/NCT06603844 URL:https://julienwillard.com/calendar/clinical#e-f868ee3c-12e5-4902-bb02-c 0de22548aa1 END:VEVENT BEGIN:VEVENT UID:f454cefe9d4e1a41ef1aff9f018e5509 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Nuance Hearing Spectacle Hearing Aid: Trial primary completion DESCRIPTION:As of 15 December 2025\, Nuance Hearing estimated primary compl etion of a Phase 3 trial in Hearing Loss Mixed\, in November 2026.\n\nSour ce: clinicaltrials NCT07282028\nhttps://clinicaltrials.gov/study/NCT072820 28 URL:https://julienwillard.com/calendar/clinical#e-6220624d-2fa8-4214-8b84-b 9c8e4280b3a END:VEVENT BEGIN:VEVENT UID:ed7ef22191329b6ccfb1962b1d1bcb40 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company LY3938577: Trial primary completion DESCRIPTION:As of 13 July 2026\, Eli Lilly and estimated primary completion of a Phase 2 trial in Diabetes Mellitus\, Type 2\, in November 2026.\n\nS ource: clinicaltrials NCT07215312\nhttps://clinicaltrials.gov/study/NCT072 15312 URL:https://julienwillard.com/calendar/clinical#e-030f5da8-e6a2-4f1d-91e1-5 e13ee6f1e2d END:VEVENT BEGIN:VEVENT UID:050cd0a22e7b437c2b849b1b8c123107 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Medicure Pyridoxal Phosphate: Trial primary completion DESCRIPTION:As of 16 October 2025\, Medicure estimated primary completion o f a Phase 3 trial in Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency\, in N ovember 2026.\n\nSource: clinicaltrials NCT04706013\nhttps://clinicaltrial s.gov/study/NCT04706013 URL:https://julienwillard.com/calendar/clinical#e-f3bc0786-7076-46cc-9a0b-6 ab0e4214686 END:VEVENT BEGIN:VEVENT UID:d70ffbdb01029e308c4c72b4aaba498b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Arthrosi Therapeutics AR882 75 mg: Trial primary completion DESCRIPTION:As of 15 May 2026\, Arthrosi Therapeutics estimated primary com pletion of a Phase 2 trial in gout\, in November 2026.\n\nSource: clinical trials NCT07116746\nhttps://clinicaltrials.gov/study/NCT07116746 URL:https://julienwillard.com/calendar/clinical#e-58a02d37-5e4b-4336-9acf-3 b7814ac9941 END:VEVENT BEGIN:VEVENT UID:ddd4e679b14e0d6983073ed7a590688a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutic al Co.\, Ltd. TQB2868 injection: Trial primary completion DESCRIPTION:As of 19 September 2025\, Chia Tai Tianqing Pharmaceutical Grou p Nanjing Shunxin Pharmaceutical Co. estimated primary completion of a Pha se 2 trial in Pancreatic Neoplasms\, in November 2026.\n\nSource: clinical trials NCT06767813\nhttps://clinicaltrials.gov/study/NCT06767813 URL:https://julienwillard.com/calendar/clinical#e-d2dc154e-acbe-4a14-b586-a 830df01b750 END:VEVENT BEGIN:VEVENT UID:6dcc9a4908b3aef722f65fbb00af9a78 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:medac GmbH Methotrexate: Trial primary completion DESCRIPTION:As of 27 August 2025\, medac estimated primary completion of a Phase 3 trial in Moderate to Severe Atopic Dermatitis\, in November 2026.\ n\nSource: clinicaltrials NCT06239311\nhttps://clinicaltrials.gov/study/NC T06239311 URL:https://julienwillard.com/calendar/clinical#e-c84648a9-0069-40aa-9281-0 ce26dc83776 END:VEVENT BEGIN:VEVENT UID:22fa4a44e6833e0894fa9987308fc547 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co .\, Ltd. TQH2722 injection: Trial primary completion DESCRIPTION:As of 27 March 2026\, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co. estimated primary completion of a Phase 2 tria l in Seasonal Allergic Rhinitis\, in November 2026.\n\nSource: clinicaltri als NCT07398859\nhttps://clinicaltrials.gov/study/NCT07398859 URL:https://julienwillard.com/calendar/clinical#e-af8bafb8-05a6-40ae-acbd-b 8480a769638 END:VEVENT BEGIN:VEVENT UID:9dbbf7bacbe278db5d48d10e0c227e27 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. SHR-A1811 combined with Pyrotin ib.: Trial primary completion DESCRIPTION:As of 5 August 2024\, Jiangsu HengRui Medicine Co. estimated pr imary completion of a Phase 2 trial in HER2-expressing Advanced Solid Tumo rs\, in November 2026.\n\nSource: clinicaltrials NCT06015048\nhttps://clin icaltrials.gov/study/NCT06015048 URL:https://julienwillard.com/calendar/clinical#e-630823e6-4368-4c34-a0b3-3 0a980efb1ed END:VEVENT BEGIN:VEVENT UID:c83457ffcdf3640604e8006284d252ae DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Calluna Pharma AS CAL101: Trial primary completion DESCRIPTION:As of 27 April 2026\, Calluna Pharma AS estimated primary compl etion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis\, in November 20 26.\n\nSource: clinicaltrials NCT06736990\nhttps://clinicaltrials.gov/stud y/NCT06736990 URL:https://julienwillard.com/calendar/clinical#e-4b676def-3056-420f-ab62-7 8a4ff5d9d12 END:VEVENT BEGIN:VEVENT UID:45230a91d598a335c175c1c04ddf3df1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kiora Pharmaceuticals\, Inc. KIO-104: Trial primary completion DESCRIPTION:As of 16 June 2026\, Kiora Pharmaceuticals estimated primary co mpletion of a Phase 2 trial in Macular Edema\, in November 2026.\n\nSource : clinicaltrials NCT06825702\nhttps://clinicaltrials.gov/study/NCT06825702 URL:https://julienwillard.com/calendar/clinical#e-e10d77fb-8a85-472b-8d94-7 3ec2932f3d2 END:VEVENT BEGIN:VEVENT UID:a18254ff3a67131b2f75be91a1036ba1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:SK Life Science\, Inc. Xcopri: Trial primary completion DESCRIPTION:As of 3 April 2026\, SK Life Science estimated primary completi on of a Phase 3 trial in Partial Epilepsy\, in November 2026.\n\nSource: c linicaltrials NCT05067634\nhttps://clinicaltrials.gov/study/NCT05067634 URL:https://julienwillard.com/calendar/clinical#e-14576b1f-280e-44f4-89e9-b aab58334772 END:VEVENT BEGIN:VEVENT UID:a38f845cd68e1afa580c7065b91d71b3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sinovac Biotech Co.\, Ltd experimental vaccine: Trial primary compl etion DESCRIPTION:As of 10 August 2026\, Sinovac Biotech Co. estimated primary co mpletion of a Phase 3 trial in Epidemic Meningitis\, in November 2026.\n\n Source: clinicaltrials NCT07505888\nhttps://clinicaltrials.gov/study/NCT07 505888 URL:https://julienwillard.com/calendar/clinical#e-c6328b87-6064-40ed-a6fb-f ade98eac439 END:VEVENT BEGIN:VEVENT UID:570ffca345fdba86cd0e07d66f0f43c9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company Orforglipron: Trial primary completion DESCRIPTION:As of 29 September 2025\, Eli Lilly and estimated primary compl etion of a Phase 3 trial in oSA\, in November 2026.\n\nSource: clinicaltri als NCT06649045\nhttps://clinicaltrials.gov/study/NCT06649045 URL:https://julienwillard.com/calendar/clinical#e-9b94232f-6df8-404a-82ec-e 9fd3b1fe000 END:VEVENT BEGIN:VEVENT UID:76fc1a7ccebed0f401f0b6a09b2b91db DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BeOne Medicines Sonrotoclax: Trial primary completion DESCRIPTION:As of 7 August 2026\, BeOne Medicines estimated primary complet ion of a Phase 2 trial in Relapsed/Refractory Multiple Myeloma\, in Novemb er 2026.\n\nSource: clinicaltrials NCT04973605\nhttps://clinicaltrials.gov /study/NCT04973605 URL:https://julienwillard.com/calendar/clinical#e-984335fc-3b5c-48c7-9fd4-8 2e090718012 END:VEVENT BEGIN:VEVENT UID:1f9938d2801d08f1a5a38302bd27dcb6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261102 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bristol-Myers Squibb KarXT: Trial primary completion DESCRIPTION:As of 27 July 2026\, Bristol-Myers Squibb estimated primary com pletion of a Phase 3 trial on 1 November 2026.\n\nSource: clinicaltrials N CT06951698\nhttps://clinicaltrials.gov/study/NCT06951698 URL:https://julienwillard.com/calendar/clinical#e-948df9e4-9ea5-4196-a228-c a76d00c66ff END:VEVENT BEGIN:VEVENT UID:9afbaeea862e5e6461e43d84a2e7e58c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:KeyBioscience AG KBP-336: Trial primary completion DESCRIPTION:As of 19 February 2025\, KeyBioscience estimated primary comple tion of a Phase 2 trial in Osteoarthritis in the Knee\, in November 2026.\ n\nSource: clinicaltrials NCT06833749\nhttps://clinicaltrials.gov/study/NC T06833749 URL:https://julienwillard.com/calendar/clinical#e-3e700ba2-7e91-4488-97c0-0 a6155fb710b END:VEVENT BEGIN:VEVENT UID:e5c915ce126cc4eff1ebeab950f55c6a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sandoz CYB704: Trial primary completion DESCRIPTION:As of 29 May 2026\, Sandoz estimated primary completion of a Ph ase 3 trial in Relapsing Multiple Sclerosis\, in November 2026.\n\nSource: clinicaltrials NCT06847724\nhttps://clinicaltrials.gov/study/NCT06847724 URL:https://julienwillard.com/calendar/clinical#e-06f3ef94-c60f-4b3a-8dca-9 cd793183d1f END:VEVENT BEGIN:VEVENT UID:c0a7a525afc46767b88fc251538758d5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Akeso cadonilimab: Trial primary completion DESCRIPTION:As of 24 June 2024\, Akeso estimated primary completion of a Ph ase 3 trial in Gastric and Gastroesophageal Junction Adenocarcinoma\, in N ovember 2026.\n\nSource: clinicaltrials NCT06341335\nhttps://clinicaltrial s.gov/study/NCT06341335 URL:https://julienwillard.com/calendar/clinical#e-f9091d3a-be96-4c7f-8a58-9 64e3a8d272f END:VEVENT BEGIN:VEVENT UID:7f9a9a2a7ddb42e310c2c27de46d2fc4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pharmazz\, Inc. Normal Saline along with standard treatment: Trial primary completion DESCRIPTION:As of 31 December 2025\, Pharmazz estimated primary completion of a Phase 2 trial in Hypoxic-Ischemic Encephalopathy\, in November 2026.\ n\nSource: clinicaltrials NCT05514340\nhttps://clinicaltrials.gov/study/NC T05514340 URL:https://julienwillard.com/calendar/clinical#e-f1122ce9-e373-4f86-896d-8 857c639e504 END:VEVENT BEGIN:VEVENT UID:9b942bcf6a1a3b075fc76a06db7b924e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cardiff Oncology Onvansertib: Trial primary completion DESCRIPTION:As of 16 June 2026\, Cardiff Oncology estimated primary complet ion of a Phase 2 trial in Metastatic Colorectal Cancer\, in November 2026. \n\nSource: clinicaltrials NCT06106308\nhttps://clinicaltrials.gov/study/N CT06106308 URL:https://julienwillard.com/calendar/clinical#e-df3dd1ce-4701-47b1-bb85-1 bec28f3f8a4 END:VEVENT BEGIN:VEVENT UID:b7882511a51e0d81b1247dd9f5a23f6e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shandong Suncadia Medicine Co.\, Ltd. HRS-1780 Tablets: Trial prima ry completion DESCRIPTION:As of 30 April 2026\, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Primary Aldosteronism\, in Novemb er 2026.\n\nSource: clinicaltrials NCT07470983\nhttps://clinicaltrials.gov /study/NCT07470983 URL:https://julienwillard.com/calendar/clinical#e-d0e78d2b-cad9-4fe4-9595-0 51c5bc7e1fd END:VEVENT BEGIN:VEVENT UID:71f67bc7ac83a86ffee10815e6067858 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261102 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Scholar Rock\, Inc. Apitegromab: Trial primary completion DESCRIPTION:As of 25 May 2025\, Scholar Rock estimated primary completion o f a Phase 3 trial in Spinal Muscular Atrophy\, on 1 November 2026.\n\nSour ce: clinicaltrials NCT05626855\nhttps://clinicaltrials.gov/study/NCT056268 55 URL:https://julienwillard.com/calendar/clinical#e-344be7af-398e-490b-aa7c-c 80fedc50bd7 END:VEVENT BEGIN:VEVENT UID:179d01f93c6f1555363d735b539cabab DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:argenx Empasiprubart IV: Trial primary completion DESCRIPTION:As of 25 September 2025\, argenx estimated primary completion o f a Phase 2 trial in dermatomyositis\, in November 2026.\n\nSource: clinic altrials NCT06284954\nhttps://clinicaltrials.gov/study/NCT06284954 URL:https://julienwillard.com/calendar/clinical#e-fad39a2b-1253-4286-896b-9 45e1a9cd2bb END:VEVENT BEGIN:VEVENT UID:85aea89ea81a33d7fd885667b2569141 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261101 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. SI-B001: Trial primary comp letion DESCRIPTION:As of 21 January 2026\, Sichuan Baili Pharmaceutical Co. estima ted primary completion of a Phase 2 trial in Head and Neck Squamous Cell C arcinoma\, in November 2026.\n\nSource: clinicaltrials NCT06668961\nhttps: //clinicaltrials.gov/study/NCT06668961 URL:https://julienwillard.com/calendar/clinical#e-5b8bc856-e77e-4969-8f78-3 3bd6a77ca3b END:VEVENT BEGIN:VEVENT UID:57f14011e35a413f6de6ef618d09b105 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261102 DTEND;VALUE=DATE:20261103 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Dostarlimab: Trial primary completion DESCRIPTION:As of 26 May 2026\, GlaxoSmithKline estimated primary completio n of a Phase 2 trial in Neoplasms\, Rectal\, on 2 November 2026.\n\nSource : clinicaltrials NCT05723562\nhttps://clinicaltrials.gov/study/NCT05723562 URL:https://julienwillard.com/calendar/clinical#e-14318c10-4c66-41be-917e-5 389ade0ced8 END:VEVENT BEGIN:VEVENT UID:90d094226a621fb3f28a25e638a392c6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261102 DTEND;VALUE=DATE:20261103 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Keymed Biosciences Co.Ltd CM512 injection: Trial primary completion DESCRIPTION:As of 9 April 2026\, Keymed Biosciences Co. estimated primary c ompletion of a Phase 2 trial in Chronic Spontaneous Urticaria (CSU)\, on 2 November 2026.\n\nSource: clinicaltrials NCT07166211\nhttps://clinicaltri als.gov/study/NCT07166211 URL:https://julienwillard.com/calendar/clinical#e-d96e923b-203e-4c89-8b42-0 baa50cdb5a8 END:VEVENT BEGIN:VEVENT UID:f63945a3d11071d1e499de9d0de163c9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261102 DTEND;VALUE=DATE:20261103 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Regeneron Pharmaceuticals cemiplimab: Trial primary completion DESCRIPTION:As of 10 February 2026\, Regeneron Pharmaceuticals estimated pr imary completion of a Phase 2 trial in melanoma\, on 2 November 2026.\n\nS ource: clinicaltrials NCT06190951\nhttps://clinicaltrials.gov/study/NCT061 90951 URL:https://julienwillard.com/calendar/clinical#e-f74ead14-9d87-475f-9033-6 4a79392ec3d END:VEVENT BEGIN:VEVENT UID:26995533f66b6f1549ba74c77480aa7c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261102 DTEND;VALUE=DATE:20261103 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Anifrolumab: Trial primary completion DESCRIPTION:As of 29 July 2026\, AstraZeneca estimated primary completion o f a Phase 3 trial in Cutaneous Lupus Erythematosus\, on 2 November 2026.\n \nSource: clinicaltrials NCT06015737\nhttps://clinicaltrials.gov/study/NCT 06015737 URL:https://julienwillard.com/calendar/clinical#e-49218fcd-94bd-49c6-9151-0 9d4735fe2bb END:VEVENT BEGIN:VEVENT UID:98c1c1c66205873ba55057b8f7e1e209 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261102 DTEND;VALUE=DATE:20261103 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bristol-Myers Squibb KarXT: Trial primary completion DESCRIPTION:As of 20 July 2026\, Bristol-Myers Squibb estimated primary com pletion of a Phase 3 trial on 2 November 2026.\n\nSource: clinicaltrials N CT06951711\nhttps://clinicaltrials.gov/study/NCT06951711 URL:https://julienwillard.com/calendar/clinical#e-e4201c20-3757-4af6-8b9f-6 4047e73e217 END:VEVENT BEGIN:VEVENT UID:8a65c4554254b7af5f86ca327b8d7dbd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261103 DTEND;VALUE=DATE:20261104 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals LOU064 (blinded): Trial primary completion DESCRIPTION:As of 20 July 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Chronic Spontaneous Urticaria\, on 3 Nov ember 2026.\n\nSource: clinicaltrials NCT05677451\nhttps://clinicaltrials. gov/study/NCT05677451 URL:https://julienwillard.com/calendar/clinical#e-42d8ef7d-25a3-4f2a-bcac-3 33ee5deca94 END:VEVENT BEGIN:VEVENT UID:866a54d9167839223f368818061fdef4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261104 DTEND;VALUE=DATE:20261105 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CMG Pharmaceutical Co. Ltd CMG190303(Dapagliflozin/Rosuvastatin): T rial primary completion DESCRIPTION:As of 15 January 2026\, CMG Pharmaceutical Co. estimated primar y completion of a Phase 3 trial in dyslipidemia\, on 4 November 2026.\n\nS ource: clinicaltrials NCT06772168\nhttps://clinicaltrials.gov/study/NCT067 72168 URL:https://julienwillard.com/calendar/clinical#e-09dc482a-fdf9-41b9-9d07-d 9415b6492c3 END:VEVENT BEGIN:VEVENT UID:b9d64774f0b3f8559d6412ac197f1f0a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261105 DTEND;VALUE=DATE:20261106 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Incyte Corporation Parsaclisib: Trial primary completion DESCRIPTION:As of 25 June 2026\, Incyte estimated primary completion of a P hase 2 trial in B-Cell Malignancies\, on 5 November 2026.\n\nSource: clini caltrials NCT04509700\nhttps://clinicaltrials.gov/study/NCT04509700 URL:https://julienwillard.com/calendar/clinical#e-8d6f2124-9413-426f-a77e-2 4db7433e1e9 END:VEVENT BEGIN:VEVENT UID:2e96562994ce649c8f43a4928dc339e9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261105 DTEND;VALUE=DATE:20261106 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Genzyme\, a Sanofi Company Fitusiran: Trial primary completion DESCRIPTION:As of 17 December 2025\, Genzyme\, a Sanofi estimated primary c ompletion of a Phase 3 trial in hemophilia\, on 5 November 2026.\n\nSource : clinicaltrials NCT03754790\nhttps://clinicaltrials.gov/study/NCT03754790 URL:https://julienwillard.com/calendar/clinical#e-4138cee3-f37b-4f24-b850-b e707e2fa63c END:VEVENT BEGIN:VEVENT UID:b02f6dd48d4448d3022139d1769b55e8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261106 DTEND;VALUE=DATE:20261107 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi Itepekimab (SAR440340): Trial primary completion DESCRIPTION:As of 2 June 2026\, Sanofi estimated primary completion of a Ph ase 3 trial in Chronic Rhinosinusitis With Nasal Polyps\, on 6 November 20 26.\n\nSource: clinicaltrials NCT06834360\nhttps://clinicaltrials.gov/stud y/NCT06834360 URL:https://julienwillard.com/calendar/clinical#e-cb637451-036e-458c-bb7b-d 991d4a35170 END:VEVENT BEGIN:VEVENT UID:95024be858c9731437e846635fbab83a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261106 DTEND;VALUE=DATE:20261107 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC pembrolizumab: Trial primary completion DESCRIPTION:As of 19 February 2026\, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Hodgkin Lymphoma\, on 6 November 2026.\n\ nSource: clinicaltrials NCT03407144\nhttps://clinicaltrials.gov/study/NCT0 3407144 URL:https://julienwillard.com/calendar/clinical#e-63491608-1a64-496c-a048-b b38288dd4b4 END:VEVENT BEGIN:VEVENT UID:0437ad922c3d56394266145adf43294b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261109 DTEND;VALUE=DATE:20261110 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Pembrolizumab: Trial primary completion DESCRIPTION:As of 15 June 2026\, GlaxoSmithKline estimated primary completi on of a Phase 2 trial in Lung Cancer\, Non-Small Cell\, on 9 November 2026 .\n\nSource: clinicaltrials NCT05565378\nhttps://clinicaltrials.gov/study/ NCT05565378 URL:https://julienwillard.com/calendar/clinical#e-621da785-181e-44ed-ba4f-1 115fdd250ce END:VEVENT BEGIN:VEVENT UID:4a4044bb2056eb4754804f4a8efde4f3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261109 DTEND;VALUE=DATE:20261110 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bio-Thera Solutions BAT8010 for Injection: Trial primary completion DESCRIPTION:As of 13 August 2025\, Bio-Thera Solutions estimated primary co mpletion of a Phase 2 trial in Advanced Solid Tumors\, on 9 November 2026. \n\nSource: clinicaltrials NCT06376136\nhttps://clinicaltrials.gov/study/N CT06376136 URL:https://julienwillard.com/calendar/clinical#e-c6849c50-47cd-4afd-86e5-2 9482d3b168f END:VEVENT BEGIN:VEVENT UID:6544ed1719cdc045454fe1891a5f459e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261110 DTEND;VALUE=DATE:20261111 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gan & Lee Pharmaceuticals. GZR4: Trial primary completion DESCRIPTION:As of 25 November 2025\, Gan & Lee Pharmaceuticals. estimated p rimary completion of a Phase 3 trial in diabetes\, on 10 November 2026.\n\ nSource: clinicaltrials NCT07165223\nhttps://clinicaltrials.gov/study/NCT0 7165223 URL:https://julienwillard.com/calendar/clinical#e-28c858a4-4d04-43be-9a87-d 2c2e251c360 END:VEVENT BEGIN:VEVENT UID:cf71dec7da544ae3de12b01ec81f4060 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261110 DTEND;VALUE=DATE:20261111 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:HELP Therapeutics Co.\, Ltd. HiCM-188 therapy: Trial primary comple tion DESCRIPTION:As of 10 February 2026\, HELP Therapeutics Co. estimated primar y completion of a Phase 2 trial in Heart Failure\, on 10 November 2026.\n\ nSource: clinicaltrials NCT06340048\nhttps://clinicaltrials.gov/study/NCT0 6340048 URL:https://julienwillard.com/calendar/clinical#e-cf4af585-d863-4640-8773-1 b89de438a5a END:VEVENT BEGIN:VEVENT UID:a2114d46d80beef0a0d3c5e527113f33 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261111 DTEND;VALUE=DATE:20261112 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Janssen Research & Development\, LLC Milvexian: Trial primary compl etion DESCRIPTION:As of 31 July 2026\, Janssen Research & Development estimated p rimary completion of a Phase 3 trial in Ischemic Stroke\; Ischemic Attack\ , Transient\, on 11 November 2026.\n\nSource: clinicaltrials NCT05702034\n https://clinicaltrials.gov/study/NCT05702034 URL:https://julienwillard.com/calendar/clinical#e-eaf19ceb-a3c0-4494-ae07-e 3d46e7dc9b7 END:VEVENT BEGIN:VEVENT UID:e572b87bf10dfa6b2f8e0df7da9b19ca DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261111 DTEND;VALUE=DATE:20261112 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Precigen\, Inc PRGN-2009 plus Pembrolizumab: Trial primary completi on DESCRIPTION:As of 23 April 2026\, Precigen estimated primary completion of a Phase 2 trial in Cervical Cancer\, on 11 November 2026.\n\nSource: clini caltrials NCT06157151\nhttps://clinicaltrials.gov/study/NCT06157151 URL:https://julienwillard.com/calendar/clinical#e-0106dc7a-c205-4505-8e1a-3 f2b66e99bbb END:VEVENT BEGIN:VEVENT UID:be2665b71a3b6f08ec3ed9ae9777cbd3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261111 DTEND;VALUE=DATE:20261112 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Trastuzumab deruxtecan: Trial primary completion DESCRIPTION:As of 30 July 2026\, AstraZeneca estimated primary completion o f a Phase 3 trial in Breast Cancer\; HER2-positive\; Metastatic\, on 11 No vember 2026.\n\nSource: clinicaltrials NCT04784715\nhttps://clinicaltrials .gov/study/NCT04784715 URL:https://julienwillard.com/calendar/clinical#e-5bbc8a13-55f0-4a73-bc7b-8 c78b92c260c END:VEVENT BEGIN:VEVENT UID:f50b840969432862ea0d41f0d1443959 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261112 DTEND;VALUE=DATE:20261113 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Qilu Pharmaceutical Co.\, Ltd. Relugolix: Trial primary completion DESCRIPTION:As of 2 February 2026\, Qilu Pharmaceutical Co. estimated prima ry completion of a Phase 3 trial in Heavy Menstrual Bleeding\, on 12 Novem ber 2026.\n\nSource: clinicaltrials NCT06671548\nhttps://clinicaltrials.go v/study/NCT06671548 URL:https://julienwillard.com/calendar/clinical#e-d3aa281f-ea9d-46db-9afd-9 a221254adb6 END:VEVENT BEGIN:VEVENT UID:f713fa2abb965c4c03497ce2c4f5f80d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261113 DTEND;VALUE=DATE:20261114 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Inavolisib: Trial primary completion DESCRIPTION:As of 24 June 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 3 trial in Breast Cancer\, on 13 November 2026.\n\nSource: clinicaltrials NCT05646862\nhttps://clinicaltrials.gov/study/NCT05646862 URL:https://julienwillard.com/calendar/clinical#e-3d9d5306-8393-42f9-b0eb-e 013bd83399e END:VEVENT BEGIN:VEVENT UID:cd290e425226a1d32352f42a36cb29f4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261113 DTEND;VALUE=DATE:20261114 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Regeneron Pharmaceuticals Olatorepatide: Trial primary completion DESCRIPTION:As of 17 June 2026\, Regeneron Pharmaceuticals estimated primar y completion of a Phase 2 trial in Overweight or Obesity\, on 13 November 2026.\n\nSource: clinicaltrials NCT07431086\nhttps://clinicaltrials.gov/st udy/NCT07431086 URL:https://julienwillard.com/calendar/clinical#e-cb9fb371-eb09-480e-abe3-0 79d185722a3 END:VEVENT BEGIN:VEVENT UID:f5cc54119dafff5b86d1933629ccaf78 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261113 DTEND;VALUE=DATE:20261114 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Regeneron Pharmaceuticals REGN7075: Trial primary completion DESCRIPTION:As of 2 July 2026\, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Advanced Solid Tumors\, on 13 November 2 026.\n\nSource: clinicaltrials NCT04626635\nhttps://clinicaltrials.gov/stu dy/NCT04626635 URL:https://julienwillard.com/calendar/clinical#e-bbb93cff-6742-4d06-99df-a 13eb770604e END:VEVENT BEGIN:VEVENT UID:eb601aa6dfdb77b0d9902706767f4215 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261113 DTEND;VALUE=DATE:20261114 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD0486: Trial primary completion DESCRIPTION:As of 27 May 2026\, AstraZeneca estimated primary completion of a Phase 2 trial in B-cell Acute Lymphoblastic Leukemia (B-ALL)\, on 13 No vember 2026.\n\nSource: clinicaltrials NCT06137118\nhttps://clinicaltrials .gov/study/NCT06137118 URL:https://julienwillard.com/calendar/clinical#e-7c123273-c418-46af-ba22-8 8f70a9cf1a3 END:VEVENT BEGIN:VEVENT UID:f9acbd9aa325bd6ebc746cba95895ecd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261115 DTEND;VALUE=DATE:20261116 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:PolyActiva Pty Ltd PA5108 Ocular Implant low dose: Trial primary co mpletion DESCRIPTION:As of 8 July 2026\, PolyActiva Pty estimated primary completion of a Phase 2 trial in Glaucoma\, Open-Angle\, on 15 November 2026.\n\nSou rce: clinicaltrials NCT06964191\nhttps://clinicaltrials.gov/study/NCT06964 191 URL:https://julienwillard.com/calendar/clinical#e-f1a0825b-eafc-435a-a7c4-e aae7b72a024 END:VEVENT BEGIN:VEVENT UID:dc4ff06a0e2055f68db6ce4d022d52ee DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261116 DTEND;VALUE=DATE:20261117 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Tulisokibart: Trial primary completion DESCRIPTION:As of 20 January 2026\, Merck Sharp & Dohme estimated primary c ompletion of a Phase 2 trial in Hidradenitis Suppurativa\, on 16 November 2026.\n\nSource: clinicaltrials NCT06956235\nhttps://clinicaltrials.gov/st udy/NCT06956235 URL:https://julienwillard.com/calendar/clinical#e-e729d350-75b1-4432-8f43-0 df483d7c32c END:VEVENT BEGIN:VEVENT UID:88b63f5be008ad863007b845ac683d2c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261116 DTEND;VALUE=DATE:20261117 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:UCB Biopharma SRL Zilucoplan: Trial primary completion DESCRIPTION:As of 31 July 2026\, UCB Biopharma SRL estimated primary comple tion of a Phase 3 trial in Generalized Myasthenia Gravis\, on 16 November 2026.\n\nSource: clinicaltrials NCT06055959\nhttps://clinicaltrials.gov/st udy/NCT06055959 URL:https://julienwillard.com/calendar/clinical#e-8163c546-13e7-4f1f-85b3-c e552340d7fe END:VEVENT BEGIN:VEVENT UID:42d8beb219cefbfd10df9f774951a38a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261117 DTEND;VALUE=DATE:20261118 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD0901: Trial primary completion DESCRIPTION:As of 29 July 2026\, AstraZeneca estimated primary completion o f a Phase 2 trial in Gastric Cancer\, on 17 November 2026.\n\nSource: clin icaltrials NCT06219941\nhttps://clinicaltrials.gov/study/NCT06219941 URL:https://julienwillard.com/calendar/clinical#e-20854563-a7fc-45ff-9b80-4 67208f0cfad END:VEVENT BEGIN:VEVENT UID:dfc8f3816b3a3ae0eb64900ffbd4396a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261118 DTEND;VALUE=DATE:20261119 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bristol-Myers Squibb Deucravacitinib: Trial primary completion DESCRIPTION:As of 1 April 2026\, Bristol-Myers Squibb estimated primary com pletion of a Phase 3 trial in Sjögren's Syndrome\, on 18 November 2026.\n \nSource: clinicaltrials NCT05946941\nhttps://clinicaltrials.gov/study/NCT 05946941 URL:https://julienwillard.com/calendar/clinical#e-b21210a1-45ad-4506-bfe6-0 c8993047d28 END:VEVENT BEGIN:VEVENT UID:275530763021ae3b56f2b28e07cc7d0c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261118 DTEND;VALUE=DATE:20261119 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CSL Behring BE1116: Trial primary completion DESCRIPTION:As of 11 May 2026\, CSL Behring estimated primary completion of a Phase 3 trial in Complex Cardiovascular Surgery With Cardiopulmonary By pass\, on 18 November 2026.\n\nSource: clinicaltrials NCT07094087\nhttps:/ /clinicaltrials.gov/study/NCT07094087 URL:https://julienwillard.com/calendar/clinical#e-6ab012d8-8f9a-4d29-921d-6 8a92d0cc344 END:VEVENT BEGIN:VEVENT UID:52d687ffe233b5dc9ae2b14032301a80 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261118 DTEND;VALUE=DATE:20261119 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ToLymph Inc. SMS001: Trial primary completion DESCRIPTION:As of 6 March 2026\, ToLymph estimated primary completion of a Phase 2 trial in Carcinoma\, Non-Small-Cell Lung Cancer (NSCLC)\, on 18 No vember 2026.\n\nSource: clinicaltrials NCT06693336\nhttps://clinicaltrials .gov/study/NCT06693336 URL:https://julienwillard.com/calendar/clinical#e-f608047b-43cb-4196-89c4-3 fc0bb34a3e2 END:VEVENT BEGIN:VEVENT UID:ff6dcef679fd903447adcaa0c252e659 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261118 DTEND;VALUE=DATE:20261119 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Han Xu\, M.D.\, Ph.D.\, FAPCR\, Sponsor-Investigator\, IRB Chair Ab iraterone - Usual: Trial primary completion DESCRIPTION:As of 10 June 2026\, Han Xu\, M.D.\, Ph.D.\, FAPCR\, Sponsor-In vestigator\, IRB Chair estimated primary completion of a Phase 3 trial in Prostate Cancer\, on 18 November 2026.\n\nSource: clinicaltrials NCT033486 70\nhttps://clinicaltrials.gov/study/NCT03348670 URL:https://julienwillard.com/calendar/clinical#e-a7d97d54-3e99-4832-adf1-e 06a351d7dd0 END:VEVENT BEGIN:VEVENT UID:5e70bbd798762f309c8e0deb804d2510 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261119 DTEND;VALUE=DATE:20261120 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche RO7269162: Trial primary completion DESCRIPTION:As of 18 May 2026\, Hoffmann-La Roche estimated primary complet ion of a Phase 2 trial in Alzheimer's Disease\, on 19 November 2026.\n\nSo urce: clinicaltrials NCT06402838\nhttps://clinicaltrials.gov/study/NCT0640 2838 URL:https://julienwillard.com/calendar/clinical#e-f85b7701-0fc6-4d82-abd0-6 130d4367a36 END:VEVENT BEGIN:VEVENT UID:0bb906efca19c475aeeb1801f3483acb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261119 DTEND;VALUE=DATE:20261120 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Janssen Research & Development\, LLC JNJ-95597528: Trial primary co mpletion DESCRIPTION:As of 31 July 2026\, Janssen Research & Development estimated p rimary completion of a Phase 2 trial in Dermatitis\, Atopic\, on 19 Novemb er 2026.\n\nSource: clinicaltrials NCT07230860\nhttps://clinicaltrials.gov /study/NCT07230860 URL:https://julienwillard.com/calendar/clinical#e-2d792856-277f-4a05-93c3-0 30d8509aede END:VEVENT BEGIN:VEVENT UID:2380ecbb5b0f559b534d287b95d1641e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261120 DTEND;VALUE=DATE:20261121 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Incyte Corporation povorcitinib: Trial primary completion DESCRIPTION:As of 7 July 2026\, Incyte estimated primary completion of a Ph ase 2 trial in Moderate to Severe Asthma\, on 20 November 2026.\n\nSource: clinicaltrials NCT05851443\nhttps://clinicaltrials.gov/study/NCT05851443 URL:https://julienwillard.com/calendar/clinical#e-6b70bb2e-a18f-408f-8973-e 8538a2d872f END:VEVENT BEGIN:VEVENT UID:14843d6a3ff3b122c2244c5a54d0901d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261120 DTEND;VALUE=DATE:20261121 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Skye Bioscience\, Inc. Nimacimab injection: Trial primary completio n DESCRIPTION:As of 14 January 2026\, Skye Bioscience estimated primary compl etion of a Phase 2 trial in obesity\, on 20 November 2026.\n\nSource: clin icaltrials NCT06577090\nhttps://clinicaltrials.gov/study/NCT06577090 URL:https://julienwillard.com/calendar/clinical#e-7985ed6d-a800-4f4f-91aa-0 66df7c35eae END:VEVENT BEGIN:VEVENT UID:2fcae095641884d4a2f9b3f7bef67c0e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261121 DTEND;VALUE=DATE:20261122 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Changchun GeneScience Pharmaceutical Co.\, Ltd. Cabergoline tablets : Trial primary completion DESCRIPTION:As of 2 October 2025\, Changchun GeneScience Pharmaceutical Co. estimated primary completion of a Phase 3 trial in hyperprolactinemia\, o n 21 November 2026.\n\nSource: clinicaltrials NCT07124221\nhttps://clinica ltrials.gov/study/NCT07124221 URL:https://julienwillard.com/calendar/clinical#e-fe365ad1-15a1-484e-af00-e 4c7afbdeb64 END:VEVENT BEGIN:VEVENT UID:80e8bac251fda3f2e1f765b606f9accb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261122 DTEND;VALUE=DATE:20261123 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Haisco Pharmaceutical Group Co.\, Ltd. HSK55718 dose level1: Trial primary completion DESCRIPTION:As of 28 May 2026\, Haisco Pharmaceutical Group Co. estimated p rimary completion of a Phase 2 trial in Pain After Surgery\, on 22 Novembe r 2026.\n\nSource: clinicaltrials NCT07533786\nhttps://clinicaltrials.gov/ study/NCT07533786 URL:https://julienwillard.com/calendar/clinical#e-03add45c-d2d2-4c02-86ce-d 99facdceab9 END:VEVENT BEGIN:VEVENT UID:667b1836613bb94eb95ae87ff2bcb524 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261122 DTEND;VALUE=DATE:20261123 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Henlius Biotech HLX43 DOSE 1: Trial primary completion DESCRIPTION:As of 24 November 2025\, Shanghai Henlius Biotech estimated pri mary completion of a Phase 2 trial in Nasopharyngeal Carcinoma (NPC)\, on 22 November 2026.\n\nSource: clinicaltrials NCT06839066\nhttps://clinicalt rials.gov/study/NCT06839066 URL:https://julienwillard.com/calendar/clinical#e-b5b883e4-a08a-4f43-9d27-5 d9c21c5c379 END:VEVENT BEGIN:VEVENT UID:7997fd871aad5b9b7ea8dc4f2f52fc91 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261123 DTEND;VALUE=DATE:20261124 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Dostarlimab: Trial primary completion DESCRIPTION:As of 22 May 2026\, GlaxoSmithKline estimated primary completio n of a Phase 2 trial in Neoplasms\, Colon\, on 23 November 2026.\n\nSource : clinicaltrials NCT06567782\nhttps://clinicaltrials.gov/study/NCT06567782 URL:https://julienwillard.com/calendar/clinical#e-66b09fee-5b4e-46fc-9e05-f d569602a77f END:VEVENT BEGIN:VEVENT UID:c2a46481e8943a9ef68b152cf0ed28c8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261123 DTEND;VALUE=DATE:20261124 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Investigational varicella vaccine: Trial primary co mpletion DESCRIPTION:As of 29 May 2026\, GlaxoSmithKline estimated primary completio n of a Phase 3 trial in chickenpox\, on 23 November 2026.\n\nSource: clini caltrials NCT06693895\nhttps://clinicaltrials.gov/study/NCT06693895 URL:https://julienwillard.com/calendar/clinical#e-8380a5b5-8183-44c1-b5ac-9 d74c5e1a242 END:VEVENT BEGIN:VEVENT UID:c5889c1a4b315452620a3933fdecb01f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261124 DTEND;VALUE=DATE:20261125 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tectonic Therapeutic TX000045- Dose A: Trial primary completion DESCRIPTION:As of 7 July 2026\, Tectonic Therapeutic estimated primary comp letion of a Phase 2 trial in Pulmonary Hypertension\, on 24 November 2026. \n\nSource: clinicaltrials NCT06616974\nhttps://clinicaltrials.gov/study/N CT06616974 URL:https://julienwillard.com/calendar/clinical#e-d2266495-0c33-4502-acd5-4 4a0b42f739b END:VEVENT BEGIN:VEVENT UID:a8f18d2abc7376a581ffdc25be3ea907 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261124 DTEND;VALUE=DATE:20261125 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CanSino Biologics Inc. 24-valent pneumococcal polysaccharide conjug ate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M): Trial primary completion DESCRIPTION:As of 5 August 2026\, CanSino Biologics estimated primary compl etion of a Phase 2 trial in Streptococcus Pneumoniae Infection\, on 24 Nov ember 2026.\n\nSource: clinicaltrials NCT07600983\nhttps://clinicaltrials. gov/study/NCT07600983 URL:https://julienwillard.com/calendar/clinical#e-2d58b7ed-cc4c-4e96-a2af-4 b2a628cab08 END:VEVENT BEGIN:VEVENT UID:060f7ea7b118675c3756707133a4edfe DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261124 DTEND;VALUE=DATE:20261125 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:HTA Co.\, Ltd. 177Lu-DOTATATE injection: Trial primary completion DESCRIPTION:As of 10 July 2025\, HTA Co. estimated primary completion of a Phase 3 trial in NETS Ga68 Lu177\, on 24 November 2026.\n\nSource: clinica ltrials NCT07057622\nhttps://clinicaltrials.gov/study/NCT07057622 URL:https://julienwillard.com/calendar/clinical#e-333b8d80-5fed-462d-a8e9-e e1057a221be END:VEVENT BEGIN:VEVENT UID:bf9158646c7891fe1a0cd2ba0df91e91 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261124 DTEND;VALUE=DATE:20261125 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Karuna Therapeutics\, Inc.\, a Bristol Myers Squibb company KarXT: Trial primary completion DESCRIPTION:As of 30 July 2026\, Karuna Therapeutics\, Inc.\, a Bristol Mye rs Squibb estimated primary completion of a Phase 3 trial in Alzheimer Dis ease\, on 24 November 2026.\n\nSource: clinicaltrials NCT06585787\nhttps:/ /clinicaltrials.gov/study/NCT06585787 URL:https://julienwillard.com/calendar/clinical#e-88266ca3-1467-44f6-97c0-1 c9a68017cf7 END:VEVENT BEGIN:VEVENT UID:f1c99d010ab8981e2489311a7fb00fce DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261124 DTEND;VALUE=DATE:20261125 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD0754: Trial primary completion DESCRIPTION:As of 23 February 2026\, AstraZeneca estimated primary completi on of a Phase 2 trial in Metastatic Prostate Cancer\, on 24 November 2026. \n\nSource: clinicaltrials NCT06267729\nhttps://clinicaltrials.gov/study/N CT06267729 URL:https://julienwillard.com/calendar/clinical#e-65f78f96-4c70-4d45-bb24-6 bf04f9f9c28 END:VEVENT BEGIN:VEVENT UID:1d57220a404d0cbeb9178ff7f47e87ce DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261125 DTEND;VALUE=DATE:20261126 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing InnoCare Pharma Tech Co.\, Ltd. ICP-332 Tablets: Trial prim ary completion DESCRIPTION:As of 8 September 2025\, Beijing InnoCare Pharma Tech Co. estim ated primary completion of a Phase 3 trial in Atopic Dermatitis\, on 25 No vember 2026.\n\nSource: clinicaltrials NCT06775860\nhttps://clinicaltrials .gov/study/NCT06775860 URL:https://julienwillard.com/calendar/clinical#e-ffc5b4f0-1ad4-4bbb-b68d-3 fd93bba3765 END:VEVENT BEGIN:VEVENT UID:0a69e174de538eafad4ea890b167660f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261126 DTEND;VALUE=DATE:20261127 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shaanxi Micot Pharmaceutical Technology Co.\, Ltd. MT1013: Trial pr imary completion DESCRIPTION:As of 1 October 2025\, Shaanxi Micot Pharmaceutical Technology Co. estimated primary completion of a Phase 3 trial in Secondary Hyperpara thyroidism\, Chronic Kidney Disease\, on 26 November 2026.\n\nSource: clin icaltrials NCT07122401\nhttps://clinicaltrials.gov/study/NCT07122401 URL:https://julienwillard.com/calendar/clinical#e-d2933aa0-4e32-4ac2-9c2b-a 5ee625ca8a4 END:VEVENT BEGIN:VEVENT UID:0e6d488754f8a0e7a7535b3a22d24245 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261126 DTEND;VALUE=DATE:20261127 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tesaro\, Inc. Dostarlimab: Trial primary completion DESCRIPTION:As of 3 September 2025\, Tesaro estimated primary completion of a Phase 3 trial in neoplasms\, on 26 November 2026.\n\nSource: clinicaltr ials NCT03981796\nhttps://clinicaltrials.gov/study/NCT03981796 URL:https://julienwillard.com/calendar/clinical#e-1ffb5c23-d7b4-4cd2-a708-d db8704e5663 END:VEVENT BEGIN:VEVENT UID:175013df00ff73d840275bb3f9475a61 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261127 DTEND;VALUE=DATE:20261128 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche RO7795081: Trial primary completion DESCRIPTION:As of 7 July 2026\, Hoffmann-La Roche estimated primary complet ion of a Phase 2 trial in Type 2 Diabetes Mellitus\, on 27 November 2026.\ n\nSource: clinicaltrials NCT07112872\nhttps://clinicaltrials.gov/study/NC T07112872 URL:https://julienwillard.com/calendar/clinical#e-8b07b0a0-856f-4ae8-8145-5 3e0b73ae23d END:VEVENT BEGIN:VEVENT UID:586b88f3b225165a3c27cc22b1f292ef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261128 DTEND;VALUE=DATE:20261129 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TrueBinding\, Inc. TB006: Trial primary completion DESCRIPTION:As of 23 April 2026\, TrueBinding estimated primary completion of a Phase 2 trial in Parkinson's Disease (PD)\, on 28 November 2026.\n\nS ource: clinicaltrials NCT06773962\nhttps://clinicaltrials.gov/study/NCT067 73962 URL:https://julienwillard.com/calendar/clinical#e-2f061d56-f6fb-4332-916c-7 364ab0a562f END:VEVENT BEGIN:VEVENT UID:429f04cf7dcfa3de0ebd77a5e867e8b3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261128 DTEND;VALUE=DATE:20261129 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Haisco Pharmaceutical Group Co.\, Ltd. HSK31858\, tablet: Trial pri mary completion DESCRIPTION:As of 28 October 2024\, Haisco Pharmaceutical Group Co. estimat ed primary completion of a Phase 3 trial in Non-cystic Fibrosis Bronchiect asis\, on 28 November 2026.\n\nSource: clinicaltrials NCT06660992\nhttps:/ /clinicaltrials.gov/study/NCT06660992 URL:https://julienwillard.com/calendar/clinical#e-33163082-51e9-4e0d-9ce7-a 058d753b7c6 END:VEVENT BEGIN:VEVENT UID:e43e6a3aa409eb38b0e7a5ca517a4cfb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261129 DTEND;VALUE=DATE:20261130 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer Rimegepant: Trial primary completion DESCRIPTION:As of 9 July 2026\, Pfizer estimated primary completion of a Ph ase 3 trial in Menstrual Migraine\, on 29 November 2026.\n\nSource: clinic altrials NCT06641466\nhttps://clinicaltrials.gov/study/NCT06641466 URL:https://julienwillard.com/calendar/clinical#e-efdf291c-9652-4ca9-a343-0 f65772c575f END:VEVENT BEGIN:VEVENT UID:0fc53288f931b9559e15d1ec03fdbb2f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BeyondBio Inc. BEY1107: Trial primary completion DESCRIPTION:As of 10 March 2025\, BeyondBio estimated primary completion of a Phase 2 trial in Metastatic Colorectal Cancer\, on 30 November 2026.\n\ nSource: clinicaltrials NCT05093907\nhttps://clinicaltrials.gov/study/NCT0 5093907 URL:https://julienwillard.com/calendar/clinical#e-0f164896-bcc5-4645-a16d-5 d27f8975408 END:VEVENT BEGIN:VEVENT UID:307b1178b45d5e8b95cab3ec26ef846d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bavarian Nordic Jynneos: Trial primary completion DESCRIPTION:As of 8 April 2026\, Bavarian Nordic estimated primary completi on of a Phase 2 trial in monkeypox (Mpox)\, on 30 November 2026.\n\nSource : clinicaltrials NCT07199569\nhttps://clinicaltrials.gov/study/NCT07199569 URL:https://julienwillard.com/calendar/clinical#e-1fd02064-efbb-47a2-a919-6 579bde4ae78 END:VEVENT BEGIN:VEVENT UID:99b395256832e02128c4d891908f6af6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AUG Therapeutics AVTX-803 (L-Fucose): Trial primary completion DESCRIPTION:As of 1 May 2026\, AUG Therapeutics estimated primary completio n of a Phase 3 trial in Leukocyte Adhesion Deficiency\, on 30 November 202 6.\n\nSource: clinicaltrials NCT05462587\nhttps://clinicaltrials.gov/study /NCT05462587 URL:https://julienwillard.com/calendar/clinical#e-7b7b1fbc-b424-429b-b823-7 10754fb31d9 END:VEVENT BEGIN:VEVENT UID:45766f586845631d9025b15819216830 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:OriCell Therapeutics Co.\, Ltd. OriCAR-017: Trial primary completio n DESCRIPTION:As of 31 May 2024\, OriCell Therapeutics Co. estimated primary completion of a Phase 2 trial in Relapsed and/or Refractory Multiple Myelo ma\, on 30 November 2026.\n\nSource: clinicaltrials NCT06182696\nhttps://c linicaltrials.gov/study/NCT06182696 URL:https://julienwillard.com/calendar/clinical#e-e5f85d38-b153-4fb2-96d4-b a0e2a2c0a57 END:VEVENT BEGIN:VEVENT UID:8be822be20898b387e219b4a0df96694 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Verdiva Bio Dev Limited VRB-101: Trial primary completion DESCRIPTION:As of 4 August 2026\, Verdiva Bio Dev estimated primary complet ion of a Phase 2 trial in obesity\, on 30 November 2026.\n\nSource: clinic altrials NCT07553299\nhttps://clinicaltrials.gov/study/NCT07553299 URL:https://julienwillard.com/calendar/clinical#e-1f38fdf0-4532-4b01-b2ce-1 a86fb76a828 END:VEVENT BEGIN:VEVENT UID:eae5052a58eef63a7811b2457e073776 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Celgene CC-92480: Trial primary completion DESCRIPTION:As of 29 November 2024\, Celgene estimated primary completion o f a Phase 2 trial in Multiple Myeloma\, on 30 November 2026.\n\nSource: cl inicaltrials NCT03989414\nhttps://clinicaltrials.gov/study/NCT03989414 URL:https://julienwillard.com/calendar/clinical#e-1a1292f9-f1a8-4fd9-bb2a-d 955755ab9ee END:VEVENT BEGIN:VEVENT UID:55d34698af7d4eeaff16a717eb60cc66 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Durvalumab: Trial primary completion DESCRIPTION:As of 12 May 2026\, AstraZeneca estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma\, on 30 November 2026.\n\nSou rce: clinicaltrials NCT07081633\nhttps://clinicaltrials.gov/study/NCT07081 633 URL:https://julienwillard.com/calendar/clinical#e-e545da37-2dff-41ff-b444-4 82cfb50622d END:VEVENT BEGIN:VEVENT UID:dd639201cccdc5d3c1365144e75f7c1e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Mylan Pharmaceuticals Inc MR-130A-01 contraceptive transdermal patc h\, containing norelgestromin (NGMN): Trial primary completion DESCRIPTION:As of 26 January 2026\, Mylan Pharmaceuticals estimated primary completion of a Phase 2 trial in contraception\, on 30 November 2026.\n\n Source: clinicaltrials NCT07365904\nhttps://clinicaltrials.gov/study/NCT07 365904 URL:https://julienwillard.com/calendar/clinical#e-152e99f6-65c0-49eb-ac82-7 3d136ec09a3 END:VEVENT BEGIN:VEVENT UID:fb5f137753a92ff653cff2ea4701d10d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Mirati Therapeutics Inc. Adagrasib: Trial primary completion DESCRIPTION:As of 4 August 2026\, Mirati Therapeutics estimated primary com pletion of a Phase 2 trial in Advanced Cancer\, on 30 November 2026.\n\nSo urce: clinicaltrials NCT05853575\nhttps://clinicaltrials.gov/study/NCT0585 3575 URL:https://julienwillard.com/calendar/clinical#e-9e2b8165-69bd-49cb-b661-8 b23453180fe END:VEVENT BEGIN:VEVENT UID:e28f3f9177a38419732ad5de6e46a129 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Immunocore Ltd IMC-R117C: Trial primary completion DESCRIPTION:As of 28 January 2026\, Immunocore estimated primary completion of a Phase 2 trial in cancer\, on 30 November 2026.\n\nSource: clinicaltr ials NCT06840119\nhttps://clinicaltrials.gov/study/NCT06840119 URL:https://julienwillard.com/calendar/clinical#e-f875613f-b7eb-4123-be69-5 dd7d9ec77cf END:VEVENT BEGIN:VEVENT UID:73acfeff70ce7dfaa439dbb0715fa9ed DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Aura Biosciences AU-011: Trial primary completion DESCRIPTION:As of 13 March 2026\, Aura Biosciences estimated primary comple tion of a Phase 2 trial in Eye Cancer\, on 30 November 2026.\n\nSource: cl inicaltrials NCT06643884\nhttps://clinicaltrials.gov/study/NCT06643884 URL:https://julienwillard.com/calendar/clinical#e-88888793-194a-4a19-910a-7 60c8de92b03 END:VEVENT BEGIN:VEVENT UID:d6952e6c9ee422131486e9ee4584ce1e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:InventisBio Co.\, Ltd D-0502: Trial primary completion DESCRIPTION:As of 31 March 2026\, InventisBio Co. estimated primary complet ion of a Phase 3 trial in Breast Cancer\, on 30 November 2026.\n\nSource: clinicaltrials NCT06954961\nhttps://clinicaltrials.gov/study/NCT06954961 URL:https://julienwillard.com/calendar/clinical#e-ae94f483-4bc6-40d7-8258-b 6cd1bc7e385 END:VEVENT BEGIN:VEVENT UID:4332ca1b2dcc76c12e125255c7c40b1b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd. A166: Trial prim ary completion DESCRIPTION:As of 8 May 2026\, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in HER2-positive Breast Ca ncer\, on 30 November 2026.\n\nSource: clinicaltrials NCT06968585\nhttps:/ /clinicaltrials.gov/study/NCT06968585 URL:https://julienwillard.com/calendar/clinical#e-067346cd-a202-4e5a-ab06-8 1eedc65b7c7 END:VEVENT BEGIN:VEVENT UID:e403ebff8aade233863edde46c69c902 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Mundipharma Research Limited Rezafungin Acetate: Trial primary comp letion DESCRIPTION:As of 14 May 2026\, Mundipharma Research estimated primary comp letion of a Phase 2 trial in Chronic Pulmonary Aspergillosis\, on 30 Novem ber 2026.\n\nSource: clinicaltrials NCT06794554\nhttps://clinicaltrials.go v/study/NCT06794554 URL:https://julienwillard.com/calendar/clinical#e-b05b350d-a56b-4d2f-9320-a ddac237a979 END:VEVENT BEGIN:VEVENT UID:ae86307c479dc60728a5451cc2524081 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Saol Therapeutics Inc SL1002: Trial primary completion DESCRIPTION:As of 21 July 2026\, Saol Therapeutics estimated primary comple tion of a Phase 3 trial in Osteoarthritis Knee Pain\, on 30 November 2026. \n\nSource: clinicaltrials NCT07226258\nhttps://clinicaltrials.gov/study/N CT07226258 URL:https://julienwillard.com/calendar/clinical#e-db4e59eb-8575-468e-bc31-8 cc263ad60a0 END:VEVENT BEGIN:VEVENT UID:7e64093124391679eb255c83db55a211 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cytopeutics Sdn. Bhd. Neuroncell-EX: Trial primary completion DESCRIPTION:As of 2 January 2026\, Cytopeutics Sdn. Bhd. estimated primary completion of a Phase 3 trial in Acute Ischemic Stroke\, on 30 November 20 26.\n\nSource: clinicaltrials NCT06129175\nhttps://clinicaltrials.gov/stud y/NCT06129175 URL:https://julienwillard.com/calendar/clinical#e-595f8df0-b7c9-49f5-b16e-5 8db4e5b0429 END:VEVENT BEGIN:VEVENT UID:5d5b49cbf31be7ebe330b3e538bed48d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:UniQure Biopharma B.V. AAV9-hSyn1-miGRIK2: Trial primary completion DESCRIPTION:As of 29 July 2026\, UniQure Biopharma B.V. estimated primary c ompletion of a Phase 2 trial in Mesial Temporal Lobe Epilepsy\, on 30 Nove mber 2026.\n\nSource: clinicaltrials NCT06063850\nhttps://clinicaltrials.g ov/study/NCT06063850 URL:https://julienwillard.com/calendar/clinical#e-9b224f7c-011d-4e73-88db-e 1af80e981f8 END:VEVENT BEGIN:VEVENT UID:54be773f975591bf9e451762cb279bc9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ranok Therapeutics (Hangzhou) Co.\, Ltd. RNK08954: Trial primary co mpletion DESCRIPTION:As of 24 December 2025\, Ranok Therapeutics (Hangzhou) Co. esti mated primary completion of a Phase 2 trial in KRAS G12D Mutations\, on 30 November 2026.\n\nSource: clinicaltrials NCT07303465\nhttps://clinicaltri als.gov/study/NCT07303465 URL:https://julienwillard.com/calendar/clinical#e-6624b452-bcf2-4a7b-ae36-6 f3a10deb542 END:VEVENT BEGIN:VEVENT UID:1d3cb9d74f5be1a103411317b74ea2f2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Genentech\, Inc. Alectinib: Trial primary completion DESCRIPTION:As of 11 August 2026\, Genentech estimated primary completion o f a Phase 2 trial in Non-small Cell Lung Cancer\, on 30 November 2026.\n\n Source: clinicaltrials NCT04302025\nhttps://clinicaltrials.gov/study/NCT04 302025 URL:https://julienwillard.com/calendar/clinical#e-0775ac25-5ada-4c7d-9376-6 673e8dee6a7 END:VEVENT BEGIN:VEVENT UID:8c3fd41140cc56077137b4f69246961a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cartesian Therapeutics Decartes-08: Trial primary completion DESCRIPTION:As of 24 March 2026\, Cartesian Therapeutics estimated primary completion of a Phase 3 trial in Myasthaenia Gravis\, on 30 November 2026. \n\nSource: clinicaltrials NCT06799247\nhttps://clinicaltrials.gov/study/N CT06799247 URL:https://julienwillard.com/calendar/clinical#e-b2090292-9d69-4da5-9cf0-c b254a9710b2 END:VEVENT BEGIN:VEVENT UID:8243e7d2c84640be037feb434e3bc40a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BeyondBio Inc. BEY1107: Trial primary completion DESCRIPTION:As of 10 March 2025\, BeyondBio estimated primary completion of a Phase 2 trial in Locally Advanced or Metastatic Pancreatic Cancer\, on 30 November 2026.\n\nSource: clinicaltrials NCT03579836\nhttps://clinicalt rials.gov/study/NCT03579836 URL:https://julienwillard.com/calendar/clinical#e-468de375-5b25-4e26-8ee7-5 bab2b7ae969 END:VEVENT BEGIN:VEVENT UID:11a2273772e88d24e06c837413ec526d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gritgen Therapeutics Co.\, Ltd. GS1191-0445 injection: Trial primar y completion DESCRIPTION:As of 9 December 2025\, Gritgen Therapeutics Co. estimated prim ary completion of a Phase 3 trial in Hemophilia A\, on 30 November 2026.\n \nSource: clinicaltrials NCT06833983\nhttps://clinicaltrials.gov/study/NCT 06833983 URL:https://julienwillard.com/calendar/clinical#e-c2334fdd-1073-40f6-aa1c-0 d40bc9cb54c END:VEVENT BEGIN:VEVENT UID:b5899ea03e1e04c514658de68021443b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amgen Anvumetostat: Trial primary completion DESCRIPTION:As of 28 May 2026\, Amgen estimated primary completion of a Pha se 2 trial in Advanced MTAP-null Solid Tumors\, on 30 November 2026.\n\nSo urce: clinicaltrials NCT05094336\nhttps://clinicaltrials.gov/study/NCT0509 4336 URL:https://julienwillard.com/calendar/clinical#e-87e67402-62e8-4fff-9a74-6 8d4b981f846 END:VEVENT BEGIN:VEVENT UID:6cbac24721e72ea5ab343e58ba9254d6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi rilzabrutinib: Trial primary completion DESCRIPTION:As of 6 November 2025\, Sanofi estimated primary completion of a Phase 3 trial in Immune Thrombocytopenia\, on 30 November 2026.\n\nSourc e: clinicaltrials NCT07216079\nhttps://clinicaltrials.gov/study/NCT0721607 9 URL:https://julienwillard.com/calendar/clinical#e-db0ffbbd-747e-43b4-8e02-2 73aef391567 END:VEVENT BEGIN:VEVENT UID:b10f41dfdda773d6f3acb98ef1c0dd18 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pharming Technologies B.V. Leniolisib: Trial primary completion DESCRIPTION:As of 6 May 2026\, Pharming Technologies B.V. estimated primary completion of a Phase 3 trial in aPDS\, on 30 November 2026.\n\nSource: c linicaltrials NCT05438407\nhttps://clinicaltrials.gov/study/NCT05438407 URL:https://julienwillard.com/calendar/clinical#e-c2b47552-6978-4059-9626-c f8d6b2b5a6e END:VEVENT BEGIN:VEVENT UID:4467a2bee22ab20a6fac42f33c7a78bc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai JMT-Bio Inc. JMT108: Trial primary completion DESCRIPTION:As of 7 January 2026\, Shanghai JMT-Bio estimated primary compl etion of a Phase 2 trial in Unresectable Locally Advanced or Metastatic Me lanoma\, on 30 November 2026.\n\nSource: clinicaltrials NCT07280832\nhttps ://clinicaltrials.gov/study/NCT07280832 URL:https://julienwillard.com/calendar/clinical#e-0731059e-7dc2-4ccc-b9d6-d 0cdf82833c1 END:VEVENT BEGIN:VEVENT UID:94ac3c4f8bb1452ce73b8afe1b92f0c7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ModernaTX\, Inc. mRNA-3745: Trial primary completion DESCRIPTION:As of 15 December 2025\, ModernaTX estimated primary completion of a Phase 2 trial in Glycogen Storage Disease\, on 30 November 2026.\n\n Source: clinicaltrials NCT05095727\nhttps://clinicaltrials.gov/study/NCT05 095727 URL:https://julienwillard.com/calendar/clinical#e-9297d33d-8213-444e-aa1a-4 7322bcaab8f END:VEVENT BEGIN:VEVENT UID:0b3755c37fd0c630b1659ea7900864ff DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Taisho Pharmaceutical Co.\, Ltd. TS-172 20~60 mg/day: Trial primary completion DESCRIPTION:As of 15 May 2026\, Taisho Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Hyperphosphatemia Patients on Hemodialys is\, on 30 November 2026.\n\nSource: clinicaltrials NCT07548840\nhttps://c linicaltrials.gov/study/NCT07548840 URL:https://julienwillard.com/calendar/clinical#e-cdb55452-9f36-429c-b3ef-d c42cc09e326 END:VEVENT BEGIN:VEVENT UID:9e1b24392309551e3e3d3a35a06f7e9c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Takeda TAK-360: Trial primary completion DESCRIPTION:As of 15 July 2026\, Takeda estimated primary completion of a P hase 2 trial in Idiopathic Hypersomnia\, on 30 November 2026.\n\nSource: c linicaltrials NCT06812078\nhttps://clinicaltrials.gov/study/NCT06812078 URL:https://julienwillard.com/calendar/clinical#e-745d1349-00a8-416f-a02f-b ae817e528fa END:VEVENT BEGIN:VEVENT UID:8d3175115e4064ad141e55ab9597f11e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:OncoC4\, Inc. ONC-392 low: Trial primary completion DESCRIPTION:As of 22 May 2026\, OncoC4 estimated primary completion of a Ph ase 2 trial in Metastatic Castration-resistant Prostate Cancer\, on 30 Nov ember 2026.\n\nSource: clinicaltrials NCT05682443\nhttps://clinicaltrials. gov/study/NCT05682443 URL:https://julienwillard.com/calendar/clinical#e-6e151d44-2e90-4fd3-bcd1-c 4c2050fe1da END:VEVENT BEGIN:VEVENT UID:a5dfd8fe171a8dad4ff5eec3be072381 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BioAge Labs\, Inc. Oral BGE-102: Trial primary completion DESCRIPTION:As of 18 June 2026\, BioAge Labs estimated primary completion o f a Phase 2 trial in Obesity and Cardiovascular Risk\, on 30 November 2026 .\n\nSource: clinicaltrials NCT07656727\nhttps://clinicaltrials.gov/study/ NCT07656727 URL:https://julienwillard.com/calendar/clinical#e-148f1509-03e9-4627-a458-9 7881e6d3b03 END:VEVENT BEGIN:VEVENT UID:77e126967db5d3c1103e9885a0b7b5c2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261130 DTEND;VALUE=DATE:20261201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Takeda TAK-360: Trial primary completion DESCRIPTION:As of 16 July 2026\, Takeda estimated primary completion of a P hase 2 trial in Narcolepsy Type 2\, on 30 November 2026.\n\nSource: clinic altrials NCT06952699\nhttps://clinicaltrials.gov/study/NCT06952699 URL:https://julienwillard.com/calendar/clinical#e-5babbbd8-9ce9-49cc-a319-4 f50e03a1e54 END:VEVENT BEGIN:VEVENT UID:cd2a634826391b5b63b45ca7ed19ecab DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 26 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Urothelial Carcinoma\, in D ecember 2026.\n\nSource: clinicaltrials NCT05965856\nhttps://clinicaltrial s.gov/study/NCT05965856 URL:https://julienwillard.com/calendar/clinical#e-145c70ef-f9c7-4c67-af8d-a e2ff3822ac9 END:VEVENT BEGIN:VEVENT UID:b2f2b5e8cdc3ce9eedcae8d5d3ba7fa2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Qilu Pharmaceutical Co.\, Ltd. QLC5508: Trial primary completion DESCRIPTION:As of 2 June 2026\, Qilu Pharmaceutical Co. estimated primary c ompletion of a Phase 2 trial in Advanced Prostate Cancer\, in December 202 6.\n\nSource: clinicaltrials NCT07198633\nhttps://clinicaltrials.gov/study /NCT07198633 URL:https://julienwillard.com/calendar/clinical#e-60379447-bd5e-4c3b-b7db-f 3738ce8f3bd END:VEVENT BEGIN:VEVENT UID:f89623d17cbf6ca0af31888fc37db67c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi Itepekimab (SAR440340): Trial primary completion DESCRIPTION:As of 18 May 2026\, Sanofi estimated primary completion of a Ph ase 3 trial in Chronic Obstructive Pulmonary Disease\, on 1 December 2026. \n\nSource: clinicaltrials NCT06208306\nhttps://clinicaltrials.gov/study/N CT06208306 URL:https://julienwillard.com/calendar/clinical#e-58122035-ccf0-4091-ad25-8 1227301538f END:VEVENT BEGIN:VEVENT UID:2084e118d9a6f12fc45314de44ce8f88 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Pharmaceuticals Holding Co.\, Ltd SPH4336 Tablets: Trial p rimary completion DESCRIPTION:As of 14 January 2026\, Shanghai Pharmaceuticals Holding Co. es timated primary completion of a Phase 3 trial in Locally Advanced or Metas tatic Breast Cancer\, on 1 December 2026.\n\nSource: clinicaltrials NCT058 60465\nhttps://clinicaltrials.gov/study/NCT05860465 URL:https://julienwillard.com/calendar/clinical#e-a7a9834a-fdb8-4cb5-b5d9-4 85cdf8f5573 END:VEVENT BEGIN:VEVENT UID:595a6d5aac2d98fba41f981317922438 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Praxis Precision Medicines 1.0mg/kg/day PRAX-562: Trial primary com pletion DESCRIPTION:As of 4 August 2026\, Praxis Precision Medicines estimated prim ary completion of a Phase 3 trial in Developmental and Epileptic Encephalo pathy 1\, in December 2026.\n\nSource: clinicaltrials NCT07010471\nhttps:/ /clinicaltrials.gov/study/NCT07010471 URL:https://julienwillard.com/calendar/clinical#e-8e21398c-7402-456e-89fb-6 ec332597e8f END:VEVENT BEGIN:VEVENT UID:58d4c17649723ace654f0f910cb0f337 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TBF Genie Tissulaire SclerFIX-IP: Trial primary completion DESCRIPTION:As of 30 September 2025\, TBF Genie Tissulaire estimated primar y completion of a Phase 2 trial in Osteoarthritis Hand\, in December 2026. \n\nSource: clinicaltrials NCT06038331\nhttps://clinicaltrials.gov/study/N CT06038331 URL:https://julienwillard.com/calendar/clinical#e-0d5b59d9-a036-4a5b-a780-1 1dc149b3f78 END:VEVENT BEGIN:VEVENT UID:c2cc961c273fc66fe3090c3a7739f9ab DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Intra-IMMUSG Pte Ltd PRL3-ZUMAB: Trial primary completion DESCRIPTION:As of 16 April 2026\, Intra-IMMUSG Pte estimated primary comple tion of a Phase 3 trial in Advanced Solid Cancers\, in December 2026.\n\nS ource: clinicaltrials NCT07290088\nhttps://clinicaltrials.gov/study/NCT072 90088 URL:https://julienwillard.com/calendar/clinical#e-fa18a0d2-f609-4bc7-a47d-0 5d5f8e58555 END:VEVENT BEGIN:VEVENT UID:83cc0b57943bcca9bb4b6c35afea6b6e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Technophage\, SA Eletriptan HBr 40 mg: Trial primary completion DESCRIPTION:As of 9 September 2025\, Technophage\, SA estimated primary com pletion of a Phase 2 trial in Acute Spinal Cord Injury (SCI)\, in December 2026.\n\nSource: clinicaltrials NCT06677229\nhttps://clinicaltrials.gov/s tudy/NCT06677229 URL:https://julienwillard.com/calendar/clinical#e-2ed0f8a8-6aad-4a79-aec6-2 0aa5fa7de4e END:VEVENT BEGIN:VEVENT UID:da5c6d2916ba7adcfdbc3ff7feb867a8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NoNO Inc. NoNO-42: Trial primary completion DESCRIPTION:As of 15 July 2025\, NoNO estimated primary completion of a Pha se 2 trial in Acute Ischemic Stroke\, in December 2026.\n\nSource: clinica ltrials NCT06403267\nhttps://clinicaltrials.gov/study/NCT06403267 URL:https://julienwillard.com/calendar/clinical#e-9b223018-da7b-427d-86ee-5 49625b0886c END:VEVENT BEGIN:VEVENT UID:1f48271dbe24f7909ccca6d883826b7a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pulmovant\, Inc. inhaled mosliciguat: Trial primary completion DESCRIPTION:As of 22 April 2026\, Pulmovant estimated primary completion of a Phase 2 trial in Pulmonary Hypertension\, in December 2026.\n\nSource: clinicaltrials NCT07333183\nhttps://clinicaltrials.gov/study/NCT07333183 URL:https://julienwillard.com/calendar/clinical#e-acac3771-f742-457a-9268-9 c3e97a14683 END:VEVENT BEGIN:VEVENT UID:624d4d5365e11b357803c8148a340093 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Minovia Therapeutics Ltd. MNV-201: Trial primary completion DESCRIPTION:As of 22 June 2025\, Minovia Therapeutics estimated primary com pletion of a Phase 2 trial in Mitochondrial Diseases\, in December 2026.\n \nSource: clinicaltrials NCT06017869\nhttps://clinicaltrials.gov/study/NCT 06017869 URL:https://julienwillard.com/calendar/clinical#e-45f11ef0-14cc-4e6a-9db8-6 5e78fad0370 END:VEVENT BEGIN:VEVENT UID:b3ad0b8fddf7cec9b2f3ae31ec0e25a0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. TQB3616 capsules\ , Letrozole\, Anastrozole\, Tamoxifen: Trial primary completion DESCRIPTION:As of 17 April 2026\, Chia Tai Tianqing Pharmaceutical Group Co . estimated primary completion of a Phase 3 trial in Breast Cancer\, in De cember 2026.\n\nSource: clinicaltrials NCT05780567\nhttps://clinicaltrials .gov/study/NCT05780567 URL:https://julienwillard.com/calendar/clinical#e-292ddf99-1977-45d4-9b50-7 2952452e87d END:VEVENT BEGIN:VEVENT UID:4c9a0a625b8b72140192e5830ebdce22 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cook MyoSite Iltamiocel: Trial primary completion DESCRIPTION:As of 21 July 2026\, Cook MyoSite estimated primary completion of a Phase 3 trial in Fecal Incontinence\, in December 2026.\n\nSource: cl inicaltrials NCT05776277\nhttps://clinicaltrials.gov/study/NCT05776277 URL:https://julienwillard.com/calendar/clinical#e-6a2ac680-55b0-40dc-97d2-0 c0dd355689c END:VEVENT BEGIN:VEVENT UID:2400ce07cfa89dacdef639a81bfea546 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 26 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Head and Neck Squamous Cell Carcinoma\, in December 2026.\n\nSource: clinicaltrials NCT06006169\nhttp s://clinicaltrials.gov/study/NCT06006169 URL:https://julienwillard.com/calendar/clinical#e-f796d7ab-d48e-457d-b8aa-6 cfe6973a2ef END:VEVENT BEGIN:VEVENT UID:647c170994799ef8099988a8249cbf75 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 23 July 2026\, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Urothelial Carcinoma\, in Decemb er 2026.\n\nSource: clinicaltrials NCT06405425\nhttps://clinicaltrials.gov /study/NCT06405425 URL:https://julienwillard.com/calendar/clinical#e-6e3ec064-cd59-49c9-96ab-d c8766c9107f END:VEVENT BEGIN:VEVENT UID:008c650f023921305e801be6ad1acc73 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Rottapharm Biotech CR6086: Trial primary completion DESCRIPTION:As of 29 October 2025\, Rottapharm Biotech estimated primary co mpletion of a Phase 2 trial in Refractory Metastatic Colorectal Cancer\, i n December 2026.\n\nSource: clinicaltrials NCT05205330\nhttps://clinicaltr ials.gov/study/NCT05205330 URL:https://julienwillard.com/calendar/clinical#e-3295f158-0f76-4b70-8bca-7 3ac2836a45d END:VEVENT BEGIN:VEVENT UID:1e59533e8687d186f6d5966bc4cb530a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CellARTs Inc. Stem cell: Trial primary completion DESCRIPTION:As of 24 February 2025\, CellARTs estimated primary completion of a Phase 2 trial in Infertility\, Male\, on 1 December 2026.\n\nSource: clinicaltrials NCT06841861\nhttps://clinicaltrials.gov/study/NCT06841861 URL:https://julienwillard.com/calendar/clinical#e-f3933623-4e6b-4843-a1d1-9 4e796071f3c END:VEVENT BEGIN:VEVENT UID:f65872bb7631a082f9efe765466f0cbc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vanda Pharmaceuticals VQW-765: Trial primary completion DESCRIPTION:As of 20 July 2026\, Vanda Pharmaceuticals estimated primary co mpletion of a Phase 3 trial in Social Anxiety Disorder (SAD)\, in December 2026.\n\nSource: clinicaltrials NCT07221578\nhttps://clinicaltrials.gov/s tudy/NCT07221578 URL:https://julienwillard.com/calendar/clinical#e-3628b567-6bdf-4d64-a166-5 72eab3682f7 END:VEVENT BEGIN:VEVENT UID:a6e8a63503cc114cbb87a3cd5a5ab6bd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Vitalgen BioPharma Co.\, Ltd. VGR-R01: Trial primary compl etion DESCRIPTION:As of 24 December 2025\, Shanghai Vitalgen BioPharma Co. estima ted primary completion of a Phase 3 trial in Bietti Crystalline Dystrophy\ , on 1 December 2026.\n\nSource: clinicaltrials NCT06699108\nhttps://clini caltrials.gov/study/NCT06699108 URL:https://julienwillard.com/calendar/clinical#e-075cd82a-5835-46a1-b178-c 49e1f7c3534 END:VEVENT BEGIN:VEVENT UID:ca8e2e8327a1780779e78ca1dcfb6926 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. SI-B003: Trial primary comp letion DESCRIPTION:As of 26 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Esophageal Cancer\, in Dece mber 2026.\n\nSource: clinicaltrials NCT06008054\nhttps://clinicaltrials.g ov/study/NCT06008054 URL:https://julienwillard.com/calendar/clinical#e-a2cf32b5-b0ae-4ef0-9b4f-0 dfe410216cf END:VEVENT BEGIN:VEVENT UID:68c33740c2eb659601d35c178edd6123 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sunhawk Vision Biotech\, Inc. SHJ002: Trial primary completion DESCRIPTION:As of 23 January 2026\, Sunhawk Vision Biotech estimated primar y completion of a Phase 2 trial in Myopia\, Progressive\, in December 2026 .\n\nSource: clinicaltrials NCT06579287\nhttps://clinicaltrials.gov/study/ NCT06579287 URL:https://julienwillard.com/calendar/clinical#e-667a527d-3fe9-4111-bc1b-6 de813e5b4af END:VEVENT BEGIN:VEVENT UID:7b8c49aaf8cc91382eadf49551bbc54e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 23 July 2026\, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Triple-negative Breast Cancer\, in December 2026.\n\nSource: clinicaltrials NCT06471205\nhttps://clinicalt rials.gov/study/NCT06471205 URL:https://julienwillard.com/calendar/clinical#e-63678e71-efdb-449f-b91c-5 a9f48b930b1 END:VEVENT BEGIN:VEVENT UID:bb1b02f0469aefba80fe2fc30a2631ca DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Design Therapeutics\, Inc. DT-216P2: Trial primary completion DESCRIPTION:As of 18 May 2025\, Design Therapeutics estimated primary compl etion of a Phase 2 trial in Friedreich Ataxia\, in December 2026.\n\nSourc e: clinicaltrials NCT06874010\nhttps://clinicaltrials.gov/study/NCT0687401 0 URL:https://julienwillard.com/calendar/clinical#e-50edfc8f-6032-4222-84a5-6 8ccaba51b65 END:VEVENT BEGIN:VEVENT UID:5b01179a8995cbbafb87892fa29d7647 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Resolve Therapeutics RSLV-132: Trial primary completion DESCRIPTION:As of 18 July 2025\, Resolve Therapeutics estimated primary com pletion of a Phase 2 trial in Primary Sjögren Syndrome\, on 1 December 20 26.\n\nSource: clinicaltrials NCT06440525\nhttps://clinicaltrials.gov/stud y/NCT06440525 URL:https://julienwillard.com/calendar/clinical#e-b65d27af-8b05-4c16-8ffe-d 1a6ab9c351a END:VEVENT BEGIN:VEVENT UID:c37ebfb633739debe1cf3b76ba009093 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:A2 Biotherapeutics Inc. A2B530: Trial primary completion DESCRIPTION:As of 25 April 2025\, A2 Biotherapeutics estimated primary comp letion of a Phase 2 trial in Solid Tumor\, Adult\, in December 2026.\n\nSo urce: clinicaltrials NCT05736731\nhttps://clinicaltrials.gov/study/NCT0573 6731 URL:https://julienwillard.com/calendar/clinical#e-b56af958-0a08-4b71-9ffd-6 ce6109ec15c END:VEVENT BEGIN:VEVENT UID:1b821030ebd6538b73a238558163b606 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Janssen Research & Development\, LLC Apalutamide: Trial primary com pletion DESCRIPTION:As of 31 July 2026\, Janssen Research & Development estimated p rimary completion of a Phase 3 trial in Prostatic Neoplasms\, on 1 Decembe r 2026.\n\nSource: clinicaltrials NCT03767244\nhttps://clinicaltrials.gov/ study/NCT03767244 URL:https://julienwillard.com/calendar/clinical#e-6356f1e5-211e-4aca-8edf-d 89872950490 END:VEVENT BEGIN:VEVENT UID:82c1f760a85234b805a2914f51b5373b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:858 Therapeutics\, Inc. ETX-19477: Trial primary completion DESCRIPTION:As of 27 March 2026\, 858 Therapeutics estimated primary comple tion of a Phase 2 trial in Advanced or Metastatic Solid Tumors\, in Decemb er 2026.\n\nSource: clinicaltrials NCT06395519\nhttps://clinicaltrials.gov /study/NCT06395519 URL:https://julienwillard.com/calendar/clinical#e-5b33edc9-e7a9-49d4-beb7-2 b82f9fdfb0b END:VEVENT BEGIN:VEVENT UID:6577a1c98b9b90f9b5fdc58d49ed5ce5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ryvu Therapeutics SA MEN1703: Trial primary completion DESCRIPTION:As of 29 September 2025\, Ryvu Therapeutics SA estimated primar y completion of a Phase 2 trial in Non-Hodgkin Lymphoma\, B-cell\, in Dece mber 2026.\n\nSource: clinicaltrials NCT06534437\nhttps://clinicaltrials.g ov/study/NCT06534437 URL:https://julienwillard.com/calendar/clinical#e-bf8eba2a-163c-4021-848b-e 797c7275a31 END:VEVENT BEGIN:VEVENT UID:8c966177a4e91935f39dc4c1784f9825 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GeneCradle Inc GC301: Trial primary completion DESCRIPTION:As of 3 July 2025\, GeneCradle estimated primary completion of a Phase 2 trial in Pompe Disease (Late-onset)\, in December 2026.\n\nSourc e: clinicaltrials NCT06391736\nhttps://clinicaltrials.gov/study/NCT0639173 6 URL:https://julienwillard.com/calendar/clinical#e-11da08f2-89dd-4494-909b-4 18f65b620c2 END:VEVENT BEGIN:VEVENT UID:d04316965b96f5996e34ed8a2e4777fd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shandong Suncadia Medicine Co.\, Ltd. HRS-7058 + SHR-1316: Trial pr imary completion DESCRIPTION:As of 26 January 2026\, Shandong Suncadia Medicine Co. estimate d primary completion of a Phase 2 trial in Advanced Malignant Tumour\, in December 2026.\n\nSource: clinicaltrials NCT06915142\nhttps://clinicaltria ls.gov/study/NCT06915142 URL:https://julienwillard.com/calendar/clinical#e-089acecf-28d3-48cf-9b58-e 2b906f77c51 END:VEVENT BEGIN:VEVENT UID:cbb6f0ee5cb2b5c99d3af036b7048e0b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:VIS\, Inc. Optimal laser keratoplasty: Trial primary completion DESCRIPTION:As of 5 September 2024\, VIS estimated primary completion of a Phase 3 trial in presbyopia\, in December 2026.\n\nSource: clinicaltrials NCT06487897\nhttps://clinicaltrials.gov/study/NCT06487897 URL:https://julienwillard.com/calendar/clinical#e-b70d7c5f-f656-489a-a21d-c df7529dfe05 END:VEVENT BEGIN:VEVENT UID:1d67586945532528f25a97ae37501fd8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi Pandemic flu H5 HA mRNA SD2 vaccine: Trial primary completio n DESCRIPTION:As of 16 January 2026\, Sanofi estimated primary completion of a Phase 2 trial in Pandemic Influenza Immunization\, on 1 December 2026.\n \nSource: clinicaltrials NCT06907511\nhttps://clinicaltrials.gov/study/NCT 06907511 URL:https://julienwillard.com/calendar/clinical#e-40f845a6-047b-4680-b8bd-1 84434869848 END:VEVENT BEGIN:VEVENT UID:30c7893fc9efa85c37f47586f3f1f8ae DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Priovant Therapeutics\, Inc. Oral Brepocitinib: Trial primary compl etion DESCRIPTION:As of 18 May 2025\, Priovant Therapeutics estimated primary com pletion of a Phase 2 trial in Cutaneous Sarcoidosis\, in December 2026.\n\ nSource: clinicaltrials NCT06978725\nhttps://clinicaltrials.gov/study/NCT0 6978725 URL:https://julienwillard.com/calendar/clinical#e-eceecf99-c057-4a83-93b4-6 63770e5d19d END:VEVENT BEGIN:VEVENT UID:a193617848c130480ef4174a2c1c5817 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Karyopharm Therapeutics Inc Selinexor: Trial primary completion DESCRIPTION:As of 2 July 2026\, Karyopharm Therapeutics estimated primary c ompletion of a Phase 2 trial in Diffuse Large B-cell Lymphoma\, in Decembe r 2026.\n\nSource: clinicaltrials NCT02227251\nhttps://clinicaltrials.gov/ study/NCT02227251 URL:https://julienwillard.com/calendar/clinical#e-d4c2ee90-2f7e-4aec-b9ec-5 6ae08970ae1 END:VEVENT BEGIN:VEVENT UID:b21b1f6aba75c5448fa685a67050dd7b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Heron Neutron Medical Corp. F18 FBPA Injection: Trial primary compl etion DESCRIPTION:As of 9 July 2026\, Heron Neutron Medical estimated primary com pletion of a Phase 2 trial in Solid Tumor\, in December 2026.\n\nSource: c linicaltrials NCT07691775\nhttps://clinicaltrials.gov/study/NCT07691775 URL:https://julienwillard.com/calendar/clinical#e-8029557e-f8e4-44a6-8cd4-a c1e8c43ba43 END:VEVENT BEGIN:VEVENT UID:ae891cb014a8cc520f796e9ed7b61acb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Atea Pharmaceuticals\, Inc. Bemnifosbuvir-Ruzasvir: Trial primary c ompletion DESCRIPTION:As of 29 June 2026\, Atea Pharmaceuticals estimated primary com pletion of a Phase 3 trial in HEPATITIS C VIRUS CHRONIC INFECTION\, in Dec ember 2026.\n\nSource: clinicaltrials NCT07037277\nhttps://clinicaltrials. gov/study/NCT07037277 URL:https://julienwillard.com/calendar/clinical#e-693f7de3-4ba2-4be1-bb4d-d fb1a825ada0 END:VEVENT BEGIN:VEVENT UID:eb0d3dd96d232e8bc1f375beaa00637b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Dr. Falk Pharma GmbH Budesonide: Trial primary completion DESCRIPTION:As of 10 July 2026\, Dr. Falk Pharma estimated primary completi on of a Phase 3 trial in Eosinophilic Esophagitis\, in December 2026.\n\nS ource: clinicaltrials NCT06596252\nhttps://clinicaltrials.gov/study/NCT065 96252 URL:https://julienwillard.com/calendar/clinical#e-e8e944a2-5bff-4555-bdc5-9 3b58c3fb5c4 END:VEVENT BEGIN:VEVENT UID:7737cf27f9d42f19573b26ea99d477b6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 23 July 2026\, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Extensive-stage Small-cell Lung Cancer\, in December 2026.\n\nSource: clinicaltrials NCT06437509\nhttps:// clinicaltrials.gov/study/NCT06437509 URL:https://julienwillard.com/calendar/clinical#e-906c4d8f-03d6-4b25-9e88-0 27a681a61fc END:VEVENT BEGIN:VEVENT UID:1a6c35579117643206039d29af8f47cf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NS Pharma\, Inc. NS-229: Trial primary completion DESCRIPTION:As of 26 May 2026\, NS Pharma estimated primary completion of a Phase 2 trial in Eosinophilic Granulomatosis With Polyangiitis\, in Decem ber 2026.\n\nSource: clinicaltrials NCT06046222\nhttps://clinicaltrials.go v/study/NCT06046222 URL:https://julienwillard.com/calendar/clinical#e-53835fa3-c7a5-47fa-9807-e e97a216c1a0 END:VEVENT BEGIN:VEVENT UID:ef7a7d20d194afd467ed30596ef5fa34 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shandong Suncadia Medicine Co.\, Ltd. HRS-7535 tablet: Trial primar y completion DESCRIPTION:As of 29 December 2025\, Shandong Suncadia Medicine Co. estimat ed primary completion of a Phase 2 trial in December 2026.\n\nSource: clin icaltrials NCT06820099\nhttps://clinicaltrials.gov/study/NCT06820099 URL:https://julienwillard.com/calendar/clinical#e-fbc6dd34-f920-4eba-98b1-e c8ac750d3a6 END:VEVENT BEGIN:VEVENT UID:93fc1d491237d5db792881239b45c2d1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sound Pharmaceuticals\, Incorporated Ebselen: Trial primary complet ion DESCRIPTION:As of 26 June 2026\, Sound Pharmaceuticals\, Incorporated estim ated primary completion of a Phase 2 trial in Hearing Loss\, in December 2 026.\n\nSource: clinicaltrials NCT06340633\nhttps://clinicaltrials.gov/stu dy/NCT06340633 URL:https://julienwillard.com/calendar/clinical#e-9497f0e4-8b67-4684-9d00-b 5cb8631051a END:VEVENT BEGIN:VEVENT UID:e1cc542426e50de4ca4e17bf2ee5a5ea DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Huiyu Pharmaceutical Co.\, Ltd Test product: HYP-2090PTSA: Trial primary completion DESCRIPTION:As of 29 January 2026\, Sichuan Huiyu Pharmaceutical Co. estima ted primary completion of a Phase 2 trial in safety\, in December 2026.\n\ nSource: clinicaltrials NCT06243354\nhttps://clinicaltrials.gov/study/NCT0 6243354 URL:https://julienwillard.com/calendar/clinical#e-a52e621c-70ac-4508-96af-7 65acff83bbe END:VEVENT BEGIN:VEVENT UID:dedb12d96f8275d4eb5bdaff7f87882e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Centessa Pharmaceuticals (UK) Limited ORX750: Trial primary complet ion DESCRIPTION:As of 27 April 2026\, Centessa Pharmaceuticals (UK) estimated p rimary completion of a Phase 2 trial in Narcolepsy Type 1\, in December 20 26.\n\nSource: clinicaltrials NCT06752668\nhttps://clinicaltrials.gov/stud y/NCT06752668 URL:https://julienwillard.com/calendar/clinical#e-1e17b4a9-f7fa-4571-9005-6 e0511ea0a51 END:VEVENT BEGIN:VEVENT UID:65db6cbdcf0ef437fb5f2c922c529e52 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Qilu Pharmaceutical Co.\, Ltd. Dose 1 of QLS1410: Trial primary com pletion DESCRIPTION:As of 22 May 2026\, Qilu Pharmaceutical Co. estimated primary c ompletion of a Phase 2 trial in hypertension (HTN)\, in December 2026.\n\n Source: clinicaltrials NCT07489612\nhttps://clinicaltrials.gov/study/NCT07 489612 URL:https://julienwillard.com/calendar/clinical#e-fdf9a2af-491d-4acb-aee5-d 3e8dfe0431c END:VEVENT BEGIN:VEVENT UID:32f1483f713cc1b1030165f4c52b432f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Astria Therapeutics\, Inc. navenibart: Trial primary completion DESCRIPTION:As of 30 June 2026\, Astria Therapeutics estimated primary comp letion of a Phase 3 trial in Hereditary Angioedema (HAE)\, in December 202 6.\n\nSource: clinicaltrials NCT06842823\nhttps://clinicaltrials.gov/study /NCT06842823 URL:https://julienwillard.com/calendar/clinical#e-baf6bbfd-2319-4edf-8066-1 156fb265a7b END:VEVENT BEGIN:VEVENT UID:f8a4525a64c5a9e4b5c4ccfccdaf83ff DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:RayzeBio\, Inc. RYZ101: Trial primary completion DESCRIPTION:As of 30 March 2026\, RayzeBio estimated primary completion of a Phase 3 trial in gEP-NET\, in December 2026.\n\nSource: clinicaltrials N CT05477576\nhttps://clinicaltrials.gov/study/NCT05477576 URL:https://julienwillard.com/calendar/clinical#e-5d902738-38a8-4b12-ba92-f 0eaeee65b37 END:VEVENT BEGIN:VEVENT UID:8b5d70f6666565bb8bd6ba7a23831c60 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:jCyte\, Inc human retinal progenitor cells: Trial primary completio n DESCRIPTION:As of 30 July 2026\, jCyte estimated primary completion of a Ph ase 2 trial in Retinitis Pigmentosa\, in December 2026.\n\nSource: clinica ltrials NCT06912633\nhttps://clinicaltrials.gov/study/NCT06912633 URL:https://julienwillard.com/calendar/clinical#e-f092bc88-1178-4f1b-83f5-a 787f87a98ce END:VEVENT BEGIN:VEVENT UID:e3f624a77640e91418c66d19532353b2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amydis Inc. AMDX-2011P: Trial primary completion DESCRIPTION:As of 13 February 2026\, Amydis estimated primary completion of a Phase 2 trial in Cerebral Amyloid Angiopathy\, in December 2026.\n\nSou rce: clinicaltrials NCT05709314\nhttps://clinicaltrials.gov/study/NCT05709 314 URL:https://julienwillard.com/calendar/clinical#e-973f474c-9d09-479e-be11-e 38bc5dcf547 END:VEVENT BEGIN:VEVENT UID:9420c16b9a1781bfcbfeeed643afd4c2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kind Pharmaceuticals LLC AND017: Trial primary completion DESCRIPTION:As of 27 March 2026\, Kind Pharmaceuticals estimated primary co mpletion of a Phase 3 trial in Anemia Due to Chronic Kidney Disease\, on 1 December 2026.\n\nSource: clinicaltrials NCT07487727\nhttps://clinicaltri als.gov/study/NCT07487727 URL:https://julienwillard.com/calendar/clinical#e-bf40d59b-41ab-43b4-9e5b-a 133d644060b END:VEVENT BEGIN:VEVENT UID:c184a0ca7bd1e0adb89c11638abb8d40 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Mabwell (Shanghai) Bioscience Co.\, Ltd. 9MW3811 Injection: Trial p rimary completion DESCRIPTION:As of 8 May 2026\, Mabwell (Shanghai) Bioscience Co. estimated primary completion of a Phase 2 trial in scar\, in December 2026.\n\nSourc e: clinicaltrials NCT07576608\nhttps://clinicaltrials.gov/study/NCT0757660 8 URL:https://julienwillard.com/calendar/clinical#e-8f3f342d-1b56-40be-887d-7 6cd377ed1cb END:VEVENT BEGIN:VEVENT UID:474fc72006a927791bbc6c16e24940b2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 26 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer\ , in December 2026.\n\nSource: clinicaltrials NCT05956587\nhttps://clinica ltrials.gov/study/NCT05956587 URL:https://julienwillard.com/calendar/clinical#e-2da8486c-cead-4643-8875-b d50bb42b2ac END:VEVENT BEGIN:VEVENT UID:3f09ce22422bd8c5bb5e07a0daa02a71 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Octapharma Atenativ: Trial primary completion DESCRIPTION:As of 3 June 2026\, Octapharma estimated primary completion of a Phase 3 trial in Congenital Antithrombin Deficiency\, on 1 December 2026 .\n\nSource: clinicaltrials NCT04918173\nhttps://clinicaltrials.gov/study/ NCT04918173 URL:https://julienwillard.com/calendar/clinical#e-6972f29a-c0c3-4804-a8b5-9 1701f0ef00b END:VEVENT BEGIN:VEVENT UID:cea5675ae1952a6f5004b23636c6d48d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Genelux Corporation olvimulogene nanivacirepvec: Trial primary comp letion DESCRIPTION:As of 10 July 2026\, Genelux estimated primary completion of a Phase 3 trial in Platinum-resistant Ovarian Cancer\, in December 2026.\n\n Source: clinicaltrials NCT05281471\nhttps://clinicaltrials.gov/study/NCT05 281471 URL:https://julienwillard.com/calendar/clinical#e-34575a0f-6fd7-4831-a910-1 9720ea253cc END:VEVENT BEGIN:VEVENT UID:9640bf33a89eedaa510d60ebfaad0b34 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eikon Therapeutics EIK1001: Trial primary completion DESCRIPTION:As of 28 May 2026\, Eikon Therapeutics estimated primary comple tion of a Phase 2 trial in nSCLC\, in December 2026.\n\nSource: clinicaltr ials NCT06246110\nhttps://clinicaltrials.gov/study/NCT06246110 URL:https://julienwillard.com/calendar/clinical#e-38b3ecb9-5334-4f40-816b-5 c7e1d6ff94d END:VEVENT BEGIN:VEVENT UID:321d6ce9e19b397e0d1f3cbf7e0e4225 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Enveda Therapeutics ENV-294: Trial primary completion DESCRIPTION:As of 29 July 2026\, Enveda Therapeutics estimated primary comp letion of a Phase 2 trial in asthma\, in December 2026.\n\nSource: clinica ltrials NCT07301255\nhttps://clinicaltrials.gov/study/NCT07301255 URL:https://julienwillard.com/calendar/clinical#e-db319def-4b0d-4f5c-99a7-5 fa810ce4257 END:VEVENT BEGIN:VEVENT UID:b4093d9e58fe663497d0d49f5905cd0d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Aldeyra Therapeutics\, Inc. ICM ADX-2191 injection: Trial primary c ompletion DESCRIPTION:As of 11 February 2026\, Aldeyra Therapeutics estimated primary completion of a Phase 3 trial in Primary Vitreoretinal Lymphoma\, in Dece mber 2026.\n\nSource: clinicaltrials NCT07402876\nhttps://clinicaltrials.g ov/study/NCT07402876 URL:https://julienwillard.com/calendar/clinical#e-e047af00-1366-497c-8a99-7 199065e455a END:VEVENT BEGIN:VEVENT UID:c66ec61fa525c3f3caf57995fc8f2063 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Oculis Artificial Tear Run-in: Trial primary completion DESCRIPTION:As of 6 July 2026\, Oculis estimated primary completion of a Ph ase 3 trial in Dry Eye Disease (DED)\, in December 2026.\n\nSource: clinic altrials NCT07548632\nhttps://clinicaltrials.gov/study/NCT07548632 URL:https://julienwillard.com/calendar/clinical#e-5fc920ba-9fe9-4b1b-84b8-b ddd9e1c45c5 END:VEVENT BEGIN:VEVENT UID:850f285255f361cb69f8fd9c5ca2283b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ASTEROGENE Biomedical Co. Ltd. aNPC: Trial primary completion DESCRIPTION:As of 3 April 2026\, ASTEROGENE Biomedical Co. estimated primar y completion of a Phase 2 trial in Intervertebral Disc Degeneration\, on 1 December 2026.\n\nSource: clinicaltrials NCT07168603\nhttps://clinicaltri als.gov/study/NCT07168603 URL:https://julienwillard.com/calendar/clinical#e-2e34a95b-5903-4331-b69b-e 10d39f64499 END:VEVENT BEGIN:VEVENT UID:e8e7cedd4c0b5c3a70cc6f400751973f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TolerogenixX GmbH MIC: Trial primary completion DESCRIPTION:As of 11 April 2025\, TolerogenixX estimated primary completion of a Phase 2 trial in Kidney Transplantation\, in December 2026.\n\nSourc e: clinicaltrials NCT05365672\nhttps://clinicaltrials.gov/study/NCT0536567 2 URL:https://julienwillard.com/calendar/clinical#e-e9661c09-bd27-4610-b4ba-2 7e4f9e76bd3 END:VEVENT BEGIN:VEVENT UID:87ae598588eec737b28436386a66bfd3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GeneCradle Inc GC101: Trial primary completion DESCRIPTION:As of 3 July 2025\, GeneCradle estimated primary completion of a Phase 2 trial in Spinal Muscular Atrophy\, in December 2026.\n\nSource: clinicaltrials NCT05824169\nhttps://clinicaltrials.gov/study/NCT05824169 URL:https://julienwillard.com/calendar/clinical#e-4d6ef217-78a2-4609-bbe2-4 ad587a2c037 END:VEVENT BEGIN:VEVENT UID:95eb2f64dae8034121d215593b84bb76 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. SI-B001: Trial primary comp letion DESCRIPTION:As of 26 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Squamous Cell Carcinoma of Head and Neck\, in December 2026.\n\nSource: clinicaltrials NCT05668858\nh ttps://clinicaltrials.gov/study/NCT05668858 URL:https://julienwillard.com/calendar/clinical#e-6168e15a-7fe0-4cea-aa15-0 c5d482bd7b5 END:VEVENT BEGIN:VEVENT UID:8eeb8b408dd1d6eb150109eff2b20f86 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Angitia Biopharmaceuticals AGA2118: Trial primary completion DESCRIPTION:As of 10 February 2026\, Angitia Biopharmaceuticals estimated p rimary completion of a Phase 2 trial in Postmenopausal Osteoporosis\, in D ecember 2026.\n\nSource: clinicaltrials NCT06577935\nhttps://clinicaltrial s.gov/study/NCT06577935 URL:https://julienwillard.com/calendar/clinical#e-a69e3e87-0b6c-42f6-9daa-7 95a1c978721 END:VEVENT BEGIN:VEVENT UID:087388f496b3818335b14f6d52c73fa3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 26 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Small Cell Lung Cancer\, in December 2026.\n\nSource: clinicaltrials NCT05924841\nhttps://clinicaltri als.gov/study/NCT05924841 URL:https://julienwillard.com/calendar/clinical#e-9c3cc713-6f92-4f6c-8d79-b ecbf7a1d3ba END:VEVENT BEGIN:VEVENT UID:b07ef557ce4376c29c29f248a638047c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sinew Pharma Inc. TYNADOTE: Trial primary completion DESCRIPTION:As of 10 January 2024\, Sinew Pharma estimated primary completi on of a Phase 2 trial in hepatitis\, in December 2026.\n\nSource: clinical trials NCT05557448\nhttps://clinicaltrials.gov/study/NCT05557448 URL:https://julienwillard.com/calendar/clinical#e-c8a29cc8-0e31-4d7a-ab95-3 d7521e6e1be END:VEVENT BEGIN:VEVENT UID:2d776642da12f6e6e28999521f843aaa DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:United Therapeutics Ralinepag: Trial primary completion DESCRIPTION:As of 20 February 2026\, United Therapeutics estimated primary completion of a Phase 3 trial in pAH\, in December 2026.\n\nSource: clinic altrials NCT03683186\nhttps://clinicaltrials.gov/study/NCT03683186 URL:https://julienwillard.com/calendar/clinical#e-24dfea8c-4974-48b1-b252-e 60a4b07c0d6 END:VEVENT BEGIN:VEVENT UID:4bbac11c3c4c1c43bae9ebcc122bfefd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MediWound Ltd EscharEx (EX-03): Trial primary completion DESCRIPTION:As of 2 April 2026\, MediWound estimated primary completion of a Phase 3 trial in Venous Leg Ulcer (VLU)\, in December 2026.\n\nSource: c linicaltrials NCT06568627\nhttps://clinicaltrials.gov/study/NCT06568627 URL:https://julienwillard.com/calendar/clinical#e-cc1df79e-ab7b-432f-b118-5 e421de1c642 END:VEVENT BEGIN:VEVENT UID:08c30a3f618137cae1b387896616e2e7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eupraxia Pharmaceuticals Inc. EP-104GI: Trial primary completion DESCRIPTION:As of 19 March 2026\, Eupraxia Pharmaceuticals estimated primar y completion of a Phase 2 trial in Eosinophilic Esophagitis\, in December 2026.\n\nSource: clinicaltrials NCT05608681\nhttps://clinicaltrials.gov/st udy/NCT05608681 URL:https://julienwillard.com/calendar/clinical#e-5c7e60cf-5fba-430f-b437-d 51a2573e2b6 END:VEVENT BEGIN:VEVENT UID:670272c056bdce2f84cc35d29f4c41c3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Nanjing Leads Biolabs Co.\,Ltd LBL-024 for Injection: Trial primary completion DESCRIPTION:As of 30 June 2026\, Nanjing Leads Biolabs Co. estimated primar y completion of a Phase 2 trial in Advanced Solid Tumor\, in December 2026 .\n\nSource: clinicaltrials NCT05170958\nhttps://clinicaltrials.gov/study/ NCT05170958 URL:https://julienwillard.com/calendar/clinical#e-028a7dcc-69c0-4972-873a-9 e9a6f0b4e49 END:VEVENT BEGIN:VEVENT UID:7e5aa299c8498e8c04f8dfa60512e006 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Italfarmaco givinostat: Trial primary completion DESCRIPTION:As of 30 April 2025\, Italfarma estimated primary completion of a Phase 2 trial in Chronic Myeloproliferative Neoplasms\, in December 202 6.\n\nSource: clinicaltrials NCT01761968\nhttps://clinicaltrials.gov/study /NCT01761968 URL:https://julienwillard.com/calendar/clinical#e-292138f6-6184-40c1-affa-f f71029bd891 END:VEVENT BEGIN:VEVENT UID:203267e1b1874b18d89b524152225081 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutic al Co.\, Ltd. TQA2225/AP025 or TQA2225/AP025 Placebo 25mg: Trial primary c ompletion DESCRIPTION:As of 26 August 2024\, Chia Tai Tianqing Pharmaceutical Group N anjing Shunxin Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-alcoholic Steatohepatitis\, in December 2026.\n\nSource: cl inicaltrials NCT06569524\nhttps://clinicaltrials.gov/study/NCT06569524 URL:https://julienwillard.com/calendar/clinical#e-35c5148a-3f28-41df-b5a9-2 b2e03b61483 END:VEVENT BEGIN:VEVENT UID:24eb403f50c2dcc14c6913e0c24fc251 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. SHR-A2009 monotherapy : Trial primary completion DESCRIPTION:As of 19 March 2026\, Suzhou Suncadia Biopharmaceuticals Co. es timated primary completion of a Phase 3 trial in Non-small Cell Lung Cance r\, in December 2026.\n\nSource: clinicaltrials NCT06671379\nhttps://clini caltrials.gov/study/NCT06671379 URL:https://julienwillard.com/calendar/clinical#e-b4397911-cef1-4cd7-90dd-c 93ffd39373f END:VEVENT BEGIN:VEVENT UID:53e050ce3f1ff0914fde42eecf540b29 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GE Healthcare Regadenoson: Trial primary completion DESCRIPTION:As of 6 May 2026\, GE Healthcare estimated primary completion o f a Phase 2 trial in Myocardial Ischemia\, in December 2026.\n\nSource: cl inicaltrials NCT04604782\nhttps://clinicaltrials.gov/study/NCT04604782 URL:https://julienwillard.com/calendar/clinical#e-0c68e635-8259-4352-9587-6 827e1bed185 END:VEVENT BEGIN:VEVENT UID:108f3c1058cafad517796581c90a39da DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. AK105 Injection: Trial primary completion DESCRIPTION:As of 20 February 2025\, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Advanced Hepatocel lular Carcinoma (HCC)\, in December 2026.\n\nSource: clinicaltrials NCT043 44158\nhttps://clinicaltrials.gov/study/NCT04344158 URL:https://julienwillard.com/calendar/clinical#e-3a2857d9-15e0-4c1b-a147-8 b8b9f9c4c25 END:VEVENT BEGIN:VEVENT UID:93b68488a679c984bf943d4736bfa983 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gossamer Bio USA\, Inc. Seralutinib: Trial primary completion DESCRIPTION:As of 29 July 2026\, Gossamer Bio USA estimated primary complet ion of a Phase 3 trial in Pulmonary Arterial Hypertension\, in December 20 26.\n\nSource: clinicaltrials NCT06274801\nhttps://clinicaltrials.gov/stud y/NCT06274801 URL:https://julienwillard.com/calendar/clinical#e-4983b8bd-c99a-4f72-9c3a-a c4b271a7a9a END:VEVENT BEGIN:VEVENT UID:87efe782a4ab9ddf983529f1d3e49266 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-M07D1: Trial primary com pletion DESCRIPTION:As of 8 April 2026\, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Her2-positive/Low-expression Uri nary and Digestive Tract Tumors\, in December 2026.\n\nSource: clinicaltri als NCT06031584\nhttps://clinicaltrials.gov/study/NCT06031584 URL:https://julienwillard.com/calendar/clinical#e-0ac913e5-0634-4a22-82aa-b a0bbd38ff38 END:VEVENT BEGIN:VEVENT UID:9baad491f84db0b904017e1841d575a9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie ABBV-RGX-314: Trial primary completion DESCRIPTION:As of 28 April 2026\, AbbVie estimated primary completion of a Phase 3 trial in aMD\, in December 2026.\n\nSource: clinicaltrials NCT0470 4921\nhttps://clinicaltrials.gov/study/NCT04704921 URL:https://julienwillard.com/calendar/clinical#e-c9c6a6ef-05fb-4514-ae49-4 4530d85f9b6 END:VEVENT BEGIN:VEVENT UID:f1a0f73d86f1eb1f3e23b9135a86f5ad DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ionis Pharmaceuticals\, Inc. Donidalorsen: Trial primary completion DESCRIPTION:As of 12 December 2025\, Ionis Pharmaceuticals estimated primar y completion of a Phase 3 trial in Hereditary Angioedema\, in December 202 6.\n\nSource: clinicaltrials NCT05392114\nhttps://clinicaltrials.gov/study /NCT05392114 URL:https://julienwillard.com/calendar/clinical#e-aee4ca71-06b6-4019-82b8-d 097cf5ad36c END:VEVENT BEGIN:VEVENT UID:a60efcc1ab85415adc09e3e80106203c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. TQB3454 tablets: Trial primary completion DESCRIPTION:As of 11 March 2026\, Chia Tai Tianqing Pharmaceutical Group Co . estimated primary completion of a Phase 3 trial in Biliary Carcinoma\, i n December 2026.\n\nSource: clinicaltrials NCT05987358\nhttps://clinicaltr ials.gov/study/NCT05987358 URL:https://julienwillard.com/calendar/clinical#e-da120f74-79f4-48a7-8281-d e0d9d2132e0 END:VEVENT BEGIN:VEVENT UID:b2ffccce61c28b35d584af4e51d13931 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-M07D1: Trial primary com pletion DESCRIPTION:As of 23 July 2026\, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer\, in December 2026.\n\nSource: clinicaltrials NCT06114511\nhttps://clinicaltria ls.gov/study/NCT06114511 URL:https://julienwillard.com/calendar/clinical#e-366f27ee-d10a-4c38-b405-d 69e41d8be97 END:VEVENT BEGIN:VEVENT UID:5d6776dd379075a9b5f3c473c7db5c1e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:SynDevRx\, Inc. Evexomostat: Trial primary completion DESCRIPTION:As of 22 April 2026\, SynDevRx estimated primary completion of a Phase 2 trial in HR+/HER2-negative Breast Cancer\, in December 2026.\n\n Source: clinicaltrials NCT05455619\nhttps://clinicaltrials.gov/study/NCT05 455619 URL:https://julienwillard.com/calendar/clinical#e-a6801888-edd2-4bdd-815a-1 b99af7260b3 END:VEVENT BEGIN:VEVENT UID:cd4c7857215745867823685d1b36110b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CivaTech Oncology CivaSheet: Trial primary completion DESCRIPTION:As of 4 April 2025\, CivaTech Oncology estimated primary comple tion of a Phase 2 trial in Lung Cancer\, in December 2026.\n\nSource: clin icaltrials NCT03290534\nhttps://clinicaltrials.gov/study/NCT03290534 URL:https://julienwillard.com/calendar/clinical#e-17977b31-83df-4854-a834-6 f267661ba77 END:VEVENT BEGIN:VEVENT UID:59ab4d74ee475804987b7e4d9dd476a9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TVAX Biomedical TVI-Brain-1: Trial primary completion DESCRIPTION:As of 1 July 2025\, TVAX Biomedical estimated primary completio n of a Phase 3 trial in Glioblastoma Multiforme of Brain\, in December 202 6.\n\nSource: clinicaltrials NCT05685004\nhttps://clinicaltrials.gov/study /NCT05685004 URL:https://julienwillard.com/calendar/clinical#e-7a809f3b-0ae8-4ad6-adcb-1 b874b2e5df1 END:VEVENT BEGIN:VEVENT UID:e9941e3557b62b3641c70731001ac484 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Zenith Epigenetics ZEN003694: Trial primary completion DESCRIPTION:As of 8 May 2026\, Zenith Epigenetics estimated primary complet ion of a Phase 2 trial in Metastatic Castration-Resistant Prostate Cancer\ , in December 2026.\n\nSource: clinicaltrials NCT04986423\nhttps://clinica ltrials.gov/study/NCT04986423 URL:https://julienwillard.com/calendar/clinical#e-7d35cb09-7328-4dd2-8483-f 40eb4c6ae5c END:VEVENT BEGIN:VEVENT UID:64b422c80d0df5a06d429fc257da86f9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ReAlta Life Sciences\, Inc. RLS-0071: Trial primary completion DESCRIPTION:As of 24 November 2025\, ReAlta Life Sciences estimated primary completion of a Phase 2 trial in Steroid Refractory GVHD\, in December 20 26.\n\nSource: clinicaltrials NCT06343792\nhttps://clinicaltrials.gov/stud y/NCT06343792 URL:https://julienwillard.com/calendar/clinical#e-fc1a103a-5a90-4122-96ca-a ad119857ede END:VEVENT BEGIN:VEVENT UID:86388a8be1e7a4c31095ff09e09a7573 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sapience Therapeutics ST101: Trial primary completion DESCRIPTION:As of 9 February 2026\, Sapience Therapeutics estimated primary completion of a Phase 2 trial in glioblastoma\, in December 2026.\n\nSour ce: clinicaltrials NCT04478279\nhttps://clinicaltrials.gov/study/NCT044782 79 URL:https://julienwillard.com/calendar/clinical#e-3e79bb92-2203-4c7d-950d-6 a74318d12e2 END:VEVENT BEGIN:VEVENT UID:6163e3693ffe12545525e8efc1a0c614 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Axsome Therapeutics\, Inc. Solriamfetol 150 mg: Trial primary compl etion DESCRIPTION:As of 24 July 2026\, Axsome Therapeutics estimated primary comp letion of a Phase 3 trial in Excessive Sleepiness\, in December 2026.\n\nS ource: clinicaltrials NCT06568367\nhttps://clinicaltrials.gov/study/NCT065 68367 URL:https://julienwillard.com/calendar/clinical#e-16f11e9b-289a-4176-85de-4 87893ed5108 END:VEVENT BEGIN:VEVENT UID:8e49af506f3a5a6e22efe0b44d4a7542 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Brii Biosciences Limited BRII-179: Trial primary completion DESCRIPTION:As of 30 December 2024\, Brii Biosciences estimated primary com pletion of a Phase 2 trial in For Treatment of Chronic Hepatitis B Virus I nfection\, in December 2026.\n\nSource: clinicaltrials NCT06491563\nhttps: //clinicaltrials.gov/study/NCT06491563 URL:https://julienwillard.com/calendar/clinical#e-ce5245ca-f342-44d1-aeb1-4 b5101add5ed END:VEVENT BEGIN:VEVENT UID:02109d51f45cdf5d227bc3cbe176c461 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Panafina\, Inc. RABI-767: Trial primary completion DESCRIPTION:As of 5 August 2026\, Panafina estimated primary completion of a Phase 2 trial in Acute Pancreatitis\, in December 2026.\n\nSource: clini caltrials NCT06080789\nhttps://clinicaltrials.gov/study/NCT06080789 URL:https://julienwillard.com/calendar/clinical#e-1544fc7e-efda-4ae1-b5c5-d 03e520ce735 END:VEVENT BEGIN:VEVENT UID:6623643e92a717d63510da2efb28a3f3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:One-carbon Therapeutics AB TH9619: Trial primary completion DESCRIPTION:As of 28 January 2026\, One-carbon Therapeutics estimated prima ry completion of a Phase 2 trial in Solid Tumor\, in December 2026.\n\nSou rce: clinicaltrials NCT07151040\nhttps://clinicaltrials.gov/study/NCT07151 040 URL:https://julienwillard.com/calendar/clinical#e-dac2a2f7-fb94-4d30-8542-e 09b4fed59fa END:VEVENT BEGIN:VEVENT UID:1c290aef364452fc57da78ca4c6dd1e7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Denali Therapeutics Inc. DNL593: Trial primary completion DESCRIPTION:As of 15 January 2026\, Denali Therapeutics estimated primary c ompletion of a Phase 2 trial in Frontotemporal Dementia\, in December 2026 .\n\nSource: clinicaltrials NCT05262023\nhttps://clinicaltrials.gov/study/ NCT05262023 URL:https://julienwillard.com/calendar/clinical#e-601ec669-cc9c-47a7-b00f-f fe0dfa7c4e6 END:VEVENT BEGIN:VEVENT UID:54dc175171f295261fb23f5c225f4965 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Lexeo Therapeutics LX2020: Trial primary completion DESCRIPTION:As of 12 November 2025\, Lexeo Therapeutics estimated primary c ompletion of a Phase 2 trial in Arrhythmogenic Cardiomyopathy\, in Decembe r 2026.\n\nSource: clinicaltrials NCT06109181\nhttps://clinicaltrials.gov/ study/NCT06109181 URL:https://julienwillard.com/calendar/clinical#e-69b84a78-23b0-446f-bd0b-c 6f8b24f217c END:VEVENT BEGIN:VEVENT UID:55b90b480668ef333dab292dd1a6a545 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Newsoara HYK Biopharmaceutical (Shanghai) Co.\, Ltd. Olvi-Vec: Tria l primary completion DESCRIPTION:As of 3 December 2025\, Newsoara HYK Biopharmaceutical (Shangha i) Co. estimated primary completion of a Phase 2 trial in SCLC\, Extensive Stage\, in December 2026.\n\nSource: clinicaltrials NCT07136285\nhttps:// clinicaltrials.gov/study/NCT07136285 URL:https://julienwillard.com/calendar/clinical#e-3003e0b5-6f1b-40a3-99ef-f 9620be82ef0 END:VEVENT BEGIN:VEVENT UID:d623ebdc88a27d6ee41e94cefbc1741d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Krystal Biotech\, Inc. KB801: Trial primary completion DESCRIPTION:As of 27 February 2026\, Krystal Biotech estimated primary comp letion of a Phase 2 trial in Neurotrophic Keratitis\, in December 2026.\n\ nSource: clinicaltrials NCT06999733\nhttps://clinicaltrials.gov/study/NCT0 6999733 URL:https://julienwillard.com/calendar/clinical#e-ebf90380-c494-42e4-b79d-d 0c86b8ff8e4 END:VEVENT BEGIN:VEVENT UID:dbe19cd367c0c88408941e26e0c037e1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:EicOsis Human Health Inc. EC5026 oral tablet: Trial primary complet ion DESCRIPTION:As of 10 July 2026\, EicOsis Human Health estimated primary com pletion of a Phase 2 trial in Parkinson'\;s Disease (PD)\, in December 2026.\n\nSource: clinicaltrials NCT07142044\nhttps://clinicaltrials.gov/st udy/NCT07142044 URL:https://julienwillard.com/calendar/clinical#e-7e959ca2-c92a-4f3e-998c-6 5a04df06cde END:VEVENT BEGIN:VEVENT UID:242fee359f1e9412bbe2130566f45d82 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Alyssum Therapeutics AT-1965 Liposome Injection: Trial primary comp letion DESCRIPTION:As of 23 July 2026\, Alyssum Therapeutics estimated primary com pletion of a Phase 2 trial in Solid Tumor\, in December 2026.\n\nSource: c linicaltrials NCT06234098\nhttps://clinicaltrials.gov/study/NCT06234098 URL:https://julienwillard.com/calendar/clinical#e-a5b911cd-1c02-4a37-9529-c fc17535e414 END:VEVENT BEGIN:VEVENT UID:ed0d4fc6f10c58b583b1bd3d65e328af DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company LY3457263: Trial primary completion DESCRIPTION:As of 6 August 2026\, Eli Lilly and estimated primary completio n of a Phase 2 trial in Type 2 Diabetes\, in December 2026.\n\nSource: cli nicaltrials NCT06897475\nhttps://clinicaltrials.gov/study/NCT06897475 URL:https://julienwillard.com/calendar/clinical#e-f9e3e887-dce3-46e4-98e4-1 04019a57feb END:VEVENT BEGIN:VEVENT UID:f0f0fbe41096c32449e4c62aa6ec3f33 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Songqi Gao MT218 injection: Trial primary completion DESCRIPTION:As of 19 December 2025\, Songqi Gao estimated primary completio n of a Phase 2 trial in MRI Scan\, in December 2026.\n\nSource: clinicaltr ials NCT06262139\nhttps://clinicaltrials.gov/study/NCT06262139 URL:https://julienwillard.com/calendar/clinical#e-acffb208-8875-40ff-851a-5 a26eb0976ac END:VEVENT BEGIN:VEVENT UID:57928489e325f66e120fb9103df1ae2d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 26 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Breast Cancer\, in December 2026.\n\nSource: clinicaltrials NCT06042894\nhttps://clinicaltrials.gov/s tudy/NCT06042894 URL:https://julienwillard.com/calendar/clinical#e-246d23f3-1ba0-454f-b926-d 493208570d9 END:VEVENT BEGIN:VEVENT UID:0a3d71100c1c5fd7b83e8cfc516ceea6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Taiho Oncology\, Inc. TAS-120: Trial primary completion DESCRIPTION:As of 28 July 2026\, Taiho Oncology estimated primary completio n of a Phase 2 trial in Advanced Cholangiocarcinoma\, in December 2026.\n\ nSource: clinicaltrials NCT05727176\nhttps://clinicaltrials.gov/study/NCT0 5727176 URL:https://julienwillard.com/calendar/clinical#e-c0bfc9f8-1b31-44e0-8b3e-4 e53d2f5964c END:VEVENT BEGIN:VEVENT UID:7ccd86e2872377014427d36d3c30b195 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Intra-IMMUSG Pte Ltd PRL3-zumab: Trial primary completion DESCRIPTION:As of 22 April 2026\, Intra-IMMUSG Pte estimated primary comple tion of a Phase 2 trial in Solid Tumor\, on 1 December 2026.\n\nSource: cl inicaltrials NCT04452955\nhttps://clinicaltrials.gov/study/NCT04452955 URL:https://julienwillard.com/calendar/clinical#e-a2c2c87a-4b10-496c-ba2e-2 430974a2a56 END:VEVENT BEGIN:VEVENT UID:fc23d6b4f28fe76efba59b227d845d13 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vergent Bioscience\, Inc. Abenacianine: Trial primary completion DESCRIPTION:As of 29 May 2026\, Vergent Bioscience estimated primary comple tion of a Phase 3 trial in Lung Cancer\, in December 2026.\n\nSource: clin icaltrials NCT07499674\nhttps://clinicaltrials.gov/study/NCT07499674 URL:https://julienwillard.com/calendar/clinical#e-715aaeaf-2806-40e9-8209-f a05fc43d0b0 END:VEVENT BEGIN:VEVENT UID:1b94cbaaca7f285d9233994ed39d2166 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Aadi Bioscience\, Inc. nab-sirolimus: Trial primary completion DESCRIPTION:As of 13 November 2025\, Aadi Bioscience estimated primary comp letion of a Phase 2 trial in Endometrial Cancer\, in December 2026.\n\nSou rce: clinicaltrials NCT05997017\nhttps://clinicaltrials.gov/study/NCT05997 017 URL:https://julienwillard.com/calendar/clinical#e-1fd698a3-fdd1-4c64-b3a4-7 534765880f1 END:VEVENT BEGIN:VEVENT UID:c1faa87e4be84e569eeee0d802d49d41 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Avalyn Pharma Inc. AP02: Trial primary completion DESCRIPTION:As of 10 August 2026\, Avalyn Pharma estimated primary completi on of a Phase 2 trial in Idiopathic Pulmonary Fibrosis (IPF)\, in December 2026.\n\nSource: clinicaltrials NCT07194382\nhttps://clinicaltrials.gov/s tudy/NCT07194382 URL:https://julienwillard.com/calendar/clinical#e-d96bb84d-6bc4-490f-ac78-1 52248e0a331 END:VEVENT BEGIN:VEVENT UID:93ab4ae0fd456257b89a368fe0263cf6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cancer Vaccines Limited ACIT-1: Trial primary completion DESCRIPTION:As of 20 January 2026\, Cancer Vaccines estimated primary compl etion of a Phase 2 trial in cancer\, in December 2026.\n\nSource: clinical trials NCT03096093\nhttps://clinicaltrials.gov/study/NCT03096093 URL:https://julienwillard.com/calendar/clinical#e-745a6c2e-d334-49ac-aafd-2 a7372c45d16 END:VEVENT BEGIN:VEVENT UID:b889fc1a0c9aeb57582b9ca6df92391b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vanda Pharmaceuticals Tradipitant: Trial primary completion DESCRIPTION:As of 20 April 2026\, Vanda Pharmaceuticals estimated primary c ompletion of a Phase 3 trial in Nausea and Vomiting\, on 1 December 2026.\ n\nSource: clinicaltrials NCT07446439\nhttps://clinicaltrials.gov/study/NC T07446439 URL:https://julienwillard.com/calendar/clinical#e-870fd06b-c7f7-44a9-9ad8-8 03b67af0223 END:VEVENT BEGIN:VEVENT UID:61a52f2294c44d2a137e8e3126397a51 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kite\, A Gilead Company anitocabtagene-autoleucel: Trial primary co mpletion DESCRIPTION:As of 11 February 2026\, Kite\, A Gilead estimated primary comp letion of a Phase 2 trial in Multiple Myeloma\, in December 2026.\n\nSourc e: clinicaltrials NCT05396885\nhttps://clinicaltrials.gov/study/NCT0539688 5 URL:https://julienwillard.com/calendar/clinical#e-dd67a9b6-ced2-45d7-832e-1 e1891a13022 END:VEVENT BEGIN:VEVENT UID:0bee4745cc4f1f7edbab07ca5bda24e7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pacira Pharmaceuticals\, Inc ZILRETTA: Trial primary completion DESCRIPTION:As of 29 May 2026\, Pacira Pharmaceuticals estimated primary co mpletion of a Phase 3 trial in Glenohumeral Osteoarthritis\, in December 2 026.\n\nSource: clinicaltrials NCT06269705\nhttps://clinicaltrials.gov/stu dy/NCT06269705 URL:https://julienwillard.com/calendar/clinical#e-1eb5421c-ff6d-4561-b1cc-4 b9df1767e9d END:VEVENT BEGIN:VEVENT UID:5dee983ca8dfb490affbe76bc1196e4b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NKGen Biotech\, Inc. SNK01: Trial primary completion DESCRIPTION:As of 2 July 2026\, NKGen Biotech estimated primary completion of a Phase 2 trial in Moderate Alzheimer Disease\, in December 2026.\n\nSo urce: clinicaltrials NCT06189963\nhttps://clinicaltrials.gov/study/NCT0618 9963 URL:https://julienwillard.com/calendar/clinical#e-11b2c1b9-50df-4607-957f-a 80a8d5d9762 END:VEVENT BEGIN:VEVENT UID:dbfad420899e6969efceaea54b7fee7d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie Lutikizumab: Trial primary completion DESCRIPTION:As of 16 July 2026\, AbbVie estimated primary completion of a P hase 3 trial in Hidradenitis Suppurativa\, in December 2026.\n\nSource: cl inicaltrials NCT06468228\nhttps://clinicaltrials.gov/study/NCT06468228 URL:https://julienwillard.com/calendar/clinical#e-3ddf62c3-a8da-4ca7-98b1-e 4ae0c14d656 END:VEVENT BEGIN:VEVENT UID:fd0eb88deefd10bc5c85038ea5a27dae DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Elion Therapeutics\, Inc. EL219: Trial primary completion DESCRIPTION:As of 5 August 2026\, Elion Therapeutics estimated primary comp letion of a Phase 2 trial in Invasive Mould Infection\, in December 2026.\ n\nSource: clinicaltrials NCT07215273\nhttps://clinicaltrials.gov/study/NC T07215273 URL:https://julienwillard.com/calendar/clinical#e-fbb9f48b-2c65-4e99-baab-5 db77a1d4df7 END:VEVENT BEGIN:VEVENT UID:b4720c38d4e1930855c54c61aa5cdd48 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:VapeAway VapeAway filter system: Trial primary completion DESCRIPTION:As of 7 January 2026\, VapeAway estimated primary completion of a Phase 2 trial in Addiction Nicotine\, in December 2026.\n\nSource: clin icaltrials NCT07322432\nhttps://clinicaltrials.gov/study/NCT07322432 URL:https://julienwillard.com/calendar/clinical#e-9b277f47-13ed-4de9-b438-a ef0cc609af4 END:VEVENT BEGIN:VEVENT UID:e713246c877c580e89db1924b630ac46 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Iperboreal Pharma Srl PolyCore (Polydextrin\, L-Carnitine\, D-xylit ol): Trial primary completion DESCRIPTION:As of 16 May 2025\, Iperboreal Pharma Srl estimated primary com pletion of a Phase 2 trial in Congestive Heart Failure\, in December 2026. \n\nSource: clinicaltrials NCT03994874\nhttps://clinicaltrials.gov/study/N CT03994874 URL:https://julienwillard.com/calendar/clinical#e-55e5353f-46c2-4c2e-a3ee-2 df359470ec0 END:VEVENT BEGIN:VEVENT UID:6e02d1ccc50603a6712663a62e723796 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Aveta Biomics\, Inc. APG-157: Trial primary completion DESCRIPTION:As of 16 January 2026\, Aveta Biomics estimated primary complet ion of a Phase 2 trial in Head and Neck Cancer\, in December 2026.\n\nSour ce: clinicaltrials NCT05312710\nhttps://clinicaltrials.gov/study/NCT053127 10 URL:https://julienwillard.com/calendar/clinical#e-41b4233f-6d5e-4193-960c-5 75d17a29983 END:VEVENT BEGIN:VEVENT UID:168e09ea4b728629f42bde93f2de489a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Dianthus Therapeutics Claseprubart: Trial primary completion DESCRIPTION:As of 10 August 2026\, Dianthus Therapeutics estimated primary completion of a Phase 2 trial in Multifocal Motor Neuropathy\, in December 2026.\n\nSource: clinicaltrials NCT06537999\nhttps://clinicaltrials.gov/s tudy/NCT06537999 URL:https://julienwillard.com/calendar/clinical#e-4ac00c9e-e1d5-47f5-adf3-b 59e9fe0151c END:VEVENT BEGIN:VEVENT UID:a491afcfcf1cea414e399e6c98130bb1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Enveda Therapeutics ENV-294: Trial primary completion DESCRIPTION:As of 29 July 2026\, Enveda Therapeutics estimated primary comp letion of a Phase 2 trial in Atopic Dermatitis (AD)\, in December 2026.\n\ nSource: clinicaltrials NCT07298395\nhttps://clinicaltrials.gov/study/NCT0 7298395 URL:https://julienwillard.com/calendar/clinical#e-a018f4b0-aa6b-4afa-8bad-e 0d786ac6446 END:VEVENT BEGIN:VEVENT UID:73ac23685c357b8ded3250c8a2d35d66 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Theralase® Technologies Inc. Ruvidar® (TLD-1433) bladder infusion and PDT: Trial primary completion DESCRIPTION:As of 24 November 2025\, Theralase® Technologies estimated pri mary completion of a Phase 2 trial in Non-Muscle Invasive Bladder Cancer ( "NMIBC") Unresponsive/Intolerant to BCG\, in December 2026.\n\nSource: cli nicaltrials NCT03945162\nhttps://clinicaltrials.gov/study/NCT03945162 URL:https://julienwillard.com/calendar/clinical#e-7d00f5d7-c40b-4b96-9909-1 06940ce81e2 END:VEVENT BEGIN:VEVENT UID:85c7a193f4e602add82b9c57b80c212d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. GNC-035: Trial primary comp letion DESCRIPTION:As of 1 October 2025\, Sichuan Baili Pharmaceutical Co. estimat ed primary completion of a Phase 2 trial in Non-hodgkin's Lymphoma\, in De cember 2026.\n\nSource: clinicaltrials NCT06066203\nhttps://clinicaltrials .gov/study/NCT06066203 URL:https://julienwillard.com/calendar/clinical#e-ce468367-d8d7-4335-8f53-5 a17bf1ac7f7 END:VEVENT BEGIN:VEVENT UID:d8f34d4fd2ddfdf5367d0e962e831c8d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vantive Health LLC Prismocitrate 18: Trial primary completion DESCRIPTION:As of 27 July 2026\, Vantive Health estimated primary completio n of a Phase 3 trial in Regional Citrate Anticoagulation (RCA)\, in Decemb er 2026.\n\nSource: clinicaltrials NCT05399537\nhttps://clinicaltrials.gov /study/NCT05399537 URL:https://julienwillard.com/calendar/clinical#e-0363d244-410e-4064-8a4b-8 cbdb6fb2ab7 END:VEVENT BEGIN:VEVENT UID:c59683e005ad940d2567be53af94773d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Fujian Shengdi Pharmaceutical Co.\, Ltd. HRS9531: Trial primary com pletion DESCRIPTION:As of 26 January 2026\, Fujian Shengdi Pharmaceutical Co. estim ated primary completion of a Phase 3 trial in December 2026.\n\nSource: cl inicaltrials NCT06994650\nhttps://clinicaltrials.gov/study/NCT06994650 URL:https://julienwillard.com/calendar/clinical#e-0b221cbe-4d22-41d5-a3dd-1 1be1b62b1f8 END:VEVENT BEGIN:VEVENT UID:5e7f8d185859e31aca70f4337c26a108 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 26 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Cervical Cancer\, in Decemb er 2026.\n\nSource: clinicaltrials NCT05990803\nhttps://clinicaltrials.gov /study/NCT05990803 URL:https://julienwillard.com/calendar/clinical#e-d12b427f-09c2-4945-9376-a 2849f17f3ca END:VEVENT BEGIN:VEVENT UID:4420624fbec8473964fd49a1029442cc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BioRestorative Therapies BRTX-100: Trial primary completion DESCRIPTION:As of 26 August 2025\, BioRestorative Therapies estimated prima ry completion of a Phase 2 trial in Lumbar Disc Disease\, in December 2026 .\n\nSource: clinicaltrials NCT04042844\nhttps://clinicaltrials.gov/study/ NCT04042844 URL:https://julienwillard.com/calendar/clinical#e-5cd5f9e4-f5b2-4c90-953a-2 a5ac8afb4bf END:VEVENT BEGIN:VEVENT UID:53ada4bfcc35bd98d91dc60b221c8d05 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Akeso AK119: Trial primary completion DESCRIPTION:As of 18 March 2026\, Akeso estimated primary completion of a P hase 2 trial in Solid Tumor\, Adult\, in December 2026.\n\nSource: clinica ltrials NCT05689853\nhttps://clinicaltrials.gov/study/NCT05689853 URL:https://julienwillard.com/calendar/clinical#e-354ee598-fc31-441e-8c03-e 29244cd4f7b END:VEVENT BEGIN:VEVENT UID:a0a8cdfb5c32cd9796e2a75546a8a0f0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biocomposites Ltd STIMULAN VG: Trial primary completion DESCRIPTION:As of 6 May 2026\, Biocomposites estimated primary completion o f a Phase 2 trial in Pressure Ulcer\, Stage IV\, on 1 December 2026.\n\nSo urce: clinicaltrials NCT06283979\nhttps://clinicaltrials.gov/study/NCT0628 3979 URL:https://julienwillard.com/calendar/clinical#e-0e36dee3-2bc5-4504-ab2a-2 1e93ec46e61 END:VEVENT BEGIN:VEVENT UID:5dc945431cad94e640e795f14e9b328f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company LY3537021: Trial primary completion DESCRIPTION:As of 6 August 2026\, Eli Lilly and estimated primary completio n of a Phase 2 trial in nausea\, in December 2026.\n\nSource: clinicaltria ls NCT07169851\nhttps://clinicaltrials.gov/study/NCT07169851 URL:https://julienwillard.com/calendar/clinical#e-96e51698-4604-4e2c-9ea5-3 8c5db95cf08 END:VEVENT BEGIN:VEVENT UID:02060dec548894964317bc10944ea904 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AP Biosciences Inc. AP203: Trial primary completion DESCRIPTION:As of 26 March 2025\, AP Biosciences estimated primary completi on of a Phase 2 trial in Locally Advanced or Metastatic Solid Tumors\, in December 2026.\n\nSource: clinicaltrials NCT05473156\nhttps://clinicaltria ls.gov/study/NCT05473156 URL:https://julienwillard.com/calendar/clinical#e-352a7e72-3dbe-4426-ba31-f a8968c8fff7 END:VEVENT BEGIN:VEVENT UID:ccaa9983cd5428c0149b9fb6361a1be3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Alkeus Pharmaceuticals\, Inc. ALK-001: Trial primary completion DESCRIPTION:As of 27 April 2025\, Alkeus Pharmaceuticals estimated primary completion of a Phase 2 trial in Stargardt Disease\, in December 2026.\n\n Source: clinicaltrials NCT04239625\nhttps://clinicaltrials.gov/study/NCT04 239625 URL:https://julienwillard.com/calendar/clinical#e-54d3f9ea-5d26-447d-aca5-6 5a2e265c03f END:VEVENT BEGIN:VEVENT UID:5409004dc8b560ccb0b2d9a8eee2de71 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Institut de Recherches Internationales Servier (I.R.I.S.) BN104 mon otherapy: Trial primary completion DESCRIPTION:As of 25 February 2026\, Institut de Recherches Internationales Servier estimated primary completion of a Phase 2 trial in ALL\, Adult\, in December 2026.\n\nSource: clinicaltrials NCT06052813\nhttps://clinicalt rials.gov/study/NCT06052813 URL:https://julienwillard.com/calendar/clinical#e-eca190d5-6e2d-4f28-ae27-a 4a3efa02dfd END:VEVENT BEGIN:VEVENT UID:641a9ecf6e7aeffda40eb260743fe59b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Wuxi Cellular Biopharmaceutical Group Ltd. Mesenchymal Stem Cells: Trial primary completion DESCRIPTION:As of 16 July 2025\, Wuxi Cellular Biopharmaceutical Group esti mated primary completion of a Phase 3 trial in Knee Osteoarthritis\, in De cember 2026.\n\nSource: clinicaltrials NCT06570291\nhttps://clinicaltrials .gov/study/NCT06570291 URL:https://julienwillard.com/calendar/clinical#e-2c8e34f9-8484-481b-a52e-0 50809f59afb END:VEVENT BEGIN:VEVENT UID:226bd20eb1e0009597d981cd1d3e93e1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TransThera Sciences (Nanjing)\, Inc. Tinengotinib 8 mg: Trial prima ry completion DESCRIPTION:As of 6 July 2026\, TransThera Sciences (Nanjing) estimated pri mary completion of a Phase 3 trial in cholangiocarcinoma\, in December 202 6.\n\nSource: clinicaltrials NCT05948475\nhttps://clinicaltrials.gov/study /NCT05948475 URL:https://julienwillard.com/calendar/clinical#e-5596eae5-e821-4f97-a56e-9 8d9966ffd3d END:VEVENT BEGIN:VEVENT UID:90e8ce08149cbea674e039d743546b3a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Galderma R&D nemolizumab: Trial primary completion DESCRIPTION:As of 27 July 2026\, Galderma R&D estimated primary completion of a Phase 2 trial in Chronic Pruritus of Unknown Origin\, in December 202 6.\n\nSource: clinicaltrials NCT07074977\nhttps://clinicaltrials.gov/study /NCT07074977 URL:https://julienwillard.com/calendar/clinical#e-c272c778-1d50-4dd6-a3fc-2 a20d5521246 END:VEVENT BEGIN:VEVENT UID:67afaf8fc330d2ab9f556799da913016 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. FCN-3 38 + Azacitidine: Trial primary completion DESCRIPTION:As of 5 March 2025\, Shanghai Fosun Pharmaceutical Industrial D evelopment Co. estimated primary completion of a Phase 2 trial in safety\, on 1 December 2026.\n\nSource: clinicaltrials NCT06858618\nhttps://clinic altrials.gov/study/NCT06858618 URL:https://julienwillard.com/calendar/clinical#e-827b6088-db59-40c5-9b9f-0 10d16ef3083 END:VEVENT BEGIN:VEVENT UID:22d1d273fcb8b2313bbaf98984ec878a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Verona Pharma\, Inc.\, a subsidiary of Merck & Co.\, Inc. (Rahway\, New Jersey USA Ensifentrine: Trial primary completion DESCRIPTION:As of 13 May 2026\, Verona Pharma estimated primary completion of a Phase 2 trial in cOPD\, in December 2026.\n\nSource: clinicaltrials N CT05270525\nhttps://clinicaltrials.gov/study/NCT05270525 URL:https://julienwillard.com/calendar/clinical#e-59e84151-3ddc-4792-8f83-2 d0241fc7713 END:VEVENT BEGIN:VEVENT UID:66efd40f15ab169ea154174f5472bcab DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 17 April 2026\, Sichuan Baili Pharmaceutical Co. estimate d primary completion of a Phase 3 trial in Small Cell Lung Cancer\, in Dec ember 2026.\n\nSource: clinicaltrials NCT06500026\nhttps://clinicaltrials. gov/study/NCT06500026 URL:https://julienwillard.com/calendar/clinical#e-3071ebdb-3ad1-4c20-a3de-a 009e143528b END:VEVENT BEGIN:VEVENT UID:7fc61dd10a1eae395c5dcba6bf113c3e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gilead Sciences Sacituzumab Govitecan-hziy: Trial primary completio n DESCRIPTION:As of 9 February 2026\, Gilead Sciences estimated primary compl etion of a Phase 3 trial in Metastatic Breast Cancer\, in December 2026.\n \nSource: clinicaltrials NCT04639986\nhttps://clinicaltrials.gov/study/NCT 04639986 URL:https://julienwillard.com/calendar/clinical#e-e5d060a0-3820-4d44-8f6b-9 d12b00b45d0 END:VEVENT BEGIN:VEVENT UID:ac885211c33ab58cef55bd245af46b5d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Dren Bio DR-01: Trial primary completion DESCRIPTION:As of 17 June 2026\, Dren Bio estimated primary completion of a Phase 2 trial in LGLL - Large Granular Lymphocytic Leukemia\, in December 2026.\n\nSource: clinicaltrials NCT05475925\nhttps://clinicaltrials.gov/s tudy/NCT05475925 URL:https://julienwillard.com/calendar/clinical#e-05c46f9b-dd55-49e2-9e48-a 21dc9889a1a END:VEVENT BEGIN:VEVENT UID:70b753d42552ee1900f0f77310a6e974 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ascentage Pharma Group Inc. APG2575: Trial primary completion DESCRIPTION:As of 27 March 2026\, Ascentage Pharma Group estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia\, in Decembe r 2026.\n\nSource: clinicaltrials NCT05147467\nhttps://clinicaltrials.gov/ study/NCT05147467 URL:https://julienwillard.com/calendar/clinical#e-ccc6a76c-04c7-4b57-87c2-3 760ae503591 END:VEVENT BEGIN:VEVENT UID:ad8b4bf98ef22da3b7feae6300c38e58 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GC Cell Corporation Immuncell-LC: Trial primary completion DESCRIPTION:As of 22 November 2021\, GC Cell estimated primary completion o f a Phase 3 trial in Pancreatic Ductal Adenocarcinoma\, in December 2026.\ n\nSource: clinicaltrials NCT04969731\nhttps://clinicaltrials.gov/study/NC T04969731 URL:https://julienwillard.com/calendar/clinical#e-bb94f429-c35b-4fca-a983-4 0463781ca7e END:VEVENT BEGIN:VEVENT UID:14a24820862aac3a25dee898a0cf2eda DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Qilu Pharmaceutical Co.\, Ltd. QL2107: Trial primary completion DESCRIPTION:As of 10 June 2025\, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in nSCLC\, in December 2026.\n\nSource: clin icaltrials NCT06754644\nhttps://clinicaltrials.gov/study/NCT06754644 URL:https://julienwillard.com/calendar/clinical#e-df90586e-2022-493f-aabb-a 64abc75bd92 END:VEVENT BEGIN:VEVENT UID:e78417cea5755210027a5c2b16f44bd7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Latticon Antibody Therapeutics\, Inc LAT010: Trial primary completi on DESCRIPTION:As of 8 July 2025\, Latticon Antibody Therapeutics estimated pr imary completion of a Phase 2 trial in Advanced Solid Tumor\, in December 2026.\n\nSource: clinicaltrials NCT06277219\nhttps://clinicaltrials.gov/st udy/NCT06277219 URL:https://julienwillard.com/calendar/clinical#e-847009bb-bb9f-49ce-b698-b 18b35d790ba END:VEVENT BEGIN:VEVENT UID:3e66b58497f574121abe5827877e99de DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pulmovant\, Inc. Mosliciguat: Trial primary completion DESCRIPTION:As of 20 February 2026\, Pulmovant estimated primary completion of a Phase 2 trial in Pulmonary Hypertension\, in December 2026.\n\nSourc e: clinicaltrials NCT06635850\nhttps://clinicaltrials.gov/study/NCT0663585 0 URL:https://julienwillard.com/calendar/clinical#e-b5fb4f84-6905-40c3-bd72-f 76032eeab04 END:VEVENT BEGIN:VEVENT UID:88e21586f166ac1d8b865156ffbf151c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 26 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Gynecological Malignant Tum or\, in December 2026.\n\nSource: clinicaltrials NCT05803018\nhttps://clin icaltrials.gov/study/NCT05803018 URL:https://julienwillard.com/calendar/clinical#e-87459ee8-43d8-484d-a163-c 2541451a2b4 END:VEVENT BEGIN:VEVENT UID:e28fe602e4ceeabf480c799db8f7b493 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Luxa Biotechnology\, LLC RPESC-RPE-4W: Trial primary completion DESCRIPTION:As of 15 October 2025\, Luxa Biotechnology estimated primary co mpletion of a Phase 2 trial in Dry Age-related Macular Degeneration\, on 1 December 2026.\n\nSource: clinicaltrials NCT04627428\nhttps://clinicaltri als.gov/study/NCT04627428 URL:https://julienwillard.com/calendar/clinical#e-f170b539-9d3a-4ea5-b835-1 9c59fa28e3a END:VEVENT BEGIN:VEVENT UID:2bc7736fd93b4ed0fa54d73369cc76a7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NMD Pharma A/S NMD670: Trial primary completion DESCRIPTION:As of 1 July 2026\, NMD Pharma estimated primary completion of a Phase 2 trial in Myasthenia Gravis\, in December 2026.\n\nSource: clinic altrials NCT06414954\nhttps://clinicaltrials.gov/study/NCT06414954 URL:https://julienwillard.com/calendar/clinical#e-6909f41a-e29e-44ac-89c6-9 dc49ad92f95 END:VEVENT BEGIN:VEVENT UID:3a6de2232c24d183d583e901e5ad2c4c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ReAlta Life Sciences\, Inc. RLS-0071: Trial primary completion DESCRIPTION:As of 13 April 2026\, ReAlta Life Sciences estimated primary co mpletion of a Phase 2 trial in Hypoxic-Ischemic Encephalopathy\, in Decemb er 2026.\n\nSource: clinicaltrials NCT05778188\nhttps://clinicaltrials.gov /study/NCT05778188 URL:https://julienwillard.com/calendar/clinical#e-77ed5667-6526-42d1-b050-5 8c647609919 END:VEVENT BEGIN:VEVENT UID:4f8fafa0adf8260c0abaa21549da046e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Xenothera SAS XON7: Trial primary completion DESCRIPTION:As of 22 June 2025\, Xenothera estimated primary completion of a Phase 2 trial in Advanced Solid Tumor\, in December 2026.\n\nSource: cli nicaltrials NCT06154291\nhttps://clinicaltrials.gov/study/NCT06154291 URL:https://julienwillard.com/calendar/clinical#e-42d10add-f58a-4942-b009-d f17a79b2cbb END:VEVENT BEGIN:VEVENT UID:b992352277059b30e9b5dd096e94f343 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:3D Medicines (Sichuan) Co.\, Ltd. Envafolimab+Lenvatinib: Trial pri mary completion DESCRIPTION:As of 25 March 2026\, 3D Medicines (Sichuan) Co. estimated prim ary completion of a Phase 2 trial in Advanced Endometrial Cancer\, in Dece mber 2026.\n\nSource: clinicaltrials NCT05112991\nhttps://clinicaltrials.g ov/study/NCT05112991 URL:https://julienwillard.com/calendar/clinical#e-211c3528-7319-4816-9935-7 c1cda85f3ab END:VEVENT BEGIN:VEVENT UID:55c7355722fa2b19a5475ead91a70f9c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cartesian Therapeutics Descartes-08: Trial primary completion DESCRIPTION:As of 27 March 2026\, Cartesian Therapeutics estimated primary completion of a Phase 2 trial in Systemic Lupus Erythematosus (SLE)\, on 1 December 2026.\n\nSource: clinicaltrials NCT06038474\nhttps://clinicaltri als.gov/study/NCT06038474 URL:https://julienwillard.com/calendar/clinical#e-516bfa7b-eb61-49dc-91b6-e 9d86a90d510 END:VEVENT BEGIN:VEVENT UID:5e5df97cb362bd48b8e2b238fb402018 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Protara Therapeutics TARA-002: Trial primary completion DESCRIPTION:As of 18 May 2026\, Protara Therapeutics estimated primary comp letion of a Phase 2 trial in Lymphatic Malformation\, in December 2026.\n\ nSource: clinicaltrials NCT05871970\nhttps://clinicaltrials.gov/study/NCT0 5871970 URL:https://julienwillard.com/calendar/clinical#e-e0c60b72-f23f-4b16-863a-9 51ab50cef80 END:VEVENT BEGIN:VEVENT UID:57a0ce643e860d167098fc4613e978bc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:RDC Clinical Pty Ltd life'sTM omega O1035DS nTG: Trial primary comp letion DESCRIPTION:As of 2 July 2026\, RDC Clinical Pty estimated primary completi on of a Phase 3 trial in Absorption of Omega-3\, in December 2026.\n\nSour ce: clinicaltrials NCT07241377\nhttps://clinicaltrials.gov/study/NCT072413 77 URL:https://julienwillard.com/calendar/clinical#e-ce695ed0-ddfb-42ff-9531-1 6ca1d1e5fc1 END:VEVENT BEGIN:VEVENT UID:b1b66898af86a6d14ef086d5d20de430 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kind Pharmaceuticals LLC AND017: Trial primary completion DESCRIPTION:As of 27 February 2026\, Kind Pharmaceuticals estimated primary completion of a Phase 2 trial in Myelodysplastic Syndromes\, in December 2026.\n\nSource: clinicaltrials NCT06304103\nhttps://clinicaltrials.gov/st udy/NCT06304103 URL:https://julienwillard.com/calendar/clinical#e-edef4c56-ca3f-46b5-b964-b d05d5573908 END:VEVENT BEGIN:VEVENT UID:73e0be5a6e06f438f4154755cfb9a779 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Alto Neuroscience ALTO-300: Trial primary completion DESCRIPTION:As of 24 July 2025\, Alto Neuroscience estimated primary comple tion of a Phase 2 trial in Major Depressive Disorder\, in December 2026.\n \nSource: clinicaltrials NCT05922878\nhttps://clinicaltrials.gov/study/NCT 05922878 URL:https://julienwillard.com/calendar/clinical#e-e8d5dcfd-5d95-46d2-970a-2 2513efefef6 END:VEVENT BEGIN:VEVENT UID:8ec89e017b490c2b5d4414e609ad0a6d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TR Therapeutics TR987 0.1% gel + Standard of Care: Trial primary co mpletion DESCRIPTION:As of 2 April 2025\, TR Therapeutics estimated primary completi on of a Phase 3 trial in Venous Leg Ulcer\, in December 2026.\n\nSource: c linicaltrials NCT06707103\nhttps://clinicaltrials.gov/study/NCT06707103 URL:https://julienwillard.com/calendar/clinical#e-983c7e56-e185-45d0-b02f-6 5030462840a END:VEVENT BEGIN:VEVENT UID:728f3cb692a19a73e4315beada91dd34 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Traws Pharma\, Inc. TRX-100: Trial primary completion DESCRIPTION:As of 27 March 2026\, Traws Pharma estimated primary completion of a Phase 2 trial in influenza\, in December 2026.\n\nSource: clinicaltr ials NCT07371650\nhttps://clinicaltrials.gov/study/NCT07371650 URL:https://julienwillard.com/calendar/clinical#e-e9a5053e-3da6-4d67-84cc-9 7d4259e63cd END:VEVENT BEGIN:VEVENT UID:e87ba74cf091286edbc3d97e47698df0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Akeso AK112: Trial primary completion DESCRIPTION:As of 16 March 2026\, Akeso estimated primary completion of a P hase 3 trial in Triple-Negative Breast Cancer (TNBC)\, in December 2026.\n \nSource: clinicaltrials NCT06767527\nhttps://clinicaltrials.gov/study/NCT 06767527 URL:https://julienwillard.com/calendar/clinical#e-040bcfbc-212f-4540-a35c-f 209c3941843 END:VEVENT BEGIN:VEVENT UID:165c2f4bc45932d28fece3ff470cb032 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Zucara Therapeutics Inc. ZT-01\, 7 mg: Trial primary completion DESCRIPTION:As of 29 April 2026\, Zucara Therapeutics estimated primary com pletion of a Phase 2 trial in Type 1 Diabetes Mellitus With Hypoglycemia\, in December 2026.\n\nSource: clinicaltrials NCT05762107\nhttps://clinical trials.gov/study/NCT05762107 URL:https://julienwillard.com/calendar/clinical#e-31a11610-fbdc-43b1-bc43-2 8d6674b1435 END:VEVENT BEGIN:VEVENT UID:275b5447bb53478ca187df37d69addf9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:LaNova Medicines Limited LM-299: Trial primary completion DESCRIPTION:As of 2 May 2025\, LaNova Medicines estimated primary completio n of a Phase 2 trial in Malignant Tumors\, in December 2026.\n\nSource: cl inicaltrials NCT06650566\nhttps://clinicaltrials.gov/study/NCT06650566 URL:https://julienwillard.com/calendar/clinical#e-b3dab1bb-1eca-4f34-acf8-3 f3ab237aee6 END:VEVENT BEGIN:VEVENT UID:3bbe68d3e722b6a188ff034184edc3d3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Enanta Pharmaceuticals\, Inc zelicapavir: Trial primary completion DESCRIPTION:As of 20 July 2026\, Enanta Pharmaceuticals estimated primary c ompletion of a Phase 2 trial in RSV Infection\, in December 2026.\n\nSourc e: clinicaltrials NCT07482657\nhttps://clinicaltrials.gov/study/NCT0748265 7 URL:https://julienwillard.com/calendar/clinical#e-94891087-7aa8-4f33-95af-0 c45a5f164b8 END:VEVENT BEGIN:VEVENT UID:52fbaf63867e6b66d9a8dcb04a68f39f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Red de Terapia Celular Mesenchymal stem cells (MSC): Trial primary completion DESCRIPTION:As of 24 July 2025\, Red de Terapia Celular estimated primary c ompletion of a Phase 2 trial in Lupus Nephritis\, in December 2026.\n\nSou rce: clinicaltrials NCT03673748\nhttps://clinicaltrials.gov/study/NCT03673 748 URL:https://julienwillard.com/calendar/clinical#e-0c48e8fe-786e-46bb-bd7b-3 10b6e8d8742 END:VEVENT BEGIN:VEVENT UID:78c747e88a7070c75cd4fda708f06ed5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biohaven Therapeutics Ltd. BHV-7000: Trial primary completion DESCRIPTION:As of 1 May 2026\, Biohaven Therapeutics estimated primary comp letion of a Phase 2 trial in Focal Epilepsy\, in December 2026.\n\nSource: clinicaltrials NCT06443463\nhttps://clinicaltrials.gov/study/NCT06443463 URL:https://julienwillard.com/calendar/clinical#e-ed548f44-9ea5-47f0-814f-3 b920fe05884 END:VEVENT BEGIN:VEVENT UID:11ec5add11a5fc64e7a6e632d93985bf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing Scitech-Mq Pharmaceuticals Limited ST-1898 tablets: Trial p rimary completion DESCRIPTION:As of 24 August 2025\, Beijing Scitech-Mq Pharmaceuticals estim ated primary completion of a Phase 2 trial in Unresectable or Metastatic M elanoma\, in December 2026.\n\nSource: clinicaltrials NCT06359860\nhttps:/ /clinicaltrials.gov/study/NCT06359860 URL:https://julienwillard.com/calendar/clinical#e-9843d9df-9f98-4588-9dde-a 4fcbfab6741 END:VEVENT BEGIN:VEVENT UID:7c5735a72fcbfc94b905716c128a742b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biohaven Therapeutics Ltd. BHV-7000: Trial primary completion DESCRIPTION:As of 1 May 2026\, Biohaven Therapeutics estimated primary comp letion of a Phase 3 trial in Focal Epilepsy\, in December 2026.\n\nSource: clinicaltrials NCT06132893\nhttps://clinicaltrials.gov/study/NCT06132893 URL:https://julienwillard.com/calendar/clinical#e-e7e73b3f-ffe9-4e84-bdcc-a 4f577f23e5c END:VEVENT BEGIN:VEVENT UID:8a8e117cd00e9f01c0098d242b9a6706 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AP Biosciences Inc. AP402 (Part 1 Dose esclation): Trial primary co mpletion DESCRIPTION:As of 25 April 2025\, AP Biosciences estimated primary completi on of a Phase 2 trial in Advanced Solid Tumor\, on 1 December 2026.\n\nSou rce: clinicaltrials NCT06669975\nhttps://clinicaltrials.gov/study/NCT06669 975 URL:https://julienwillard.com/calendar/clinical#e-1c73d318-ab2a-4328-a288-0 2fee16904de END:VEVENT BEGIN:VEVENT UID:31d8631c8c09209d3f9e04a2720f022e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. TQ05105 Tablets: Trial primary completion DESCRIPTION:As of 8 December 2025\, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in myelofibrosis\, in December 2026.\n\nSource: clinicaltrials NCT06122831\nhttps://clinicaltria ls.gov/study/NCT06122831 URL:https://julienwillard.com/calendar/clinical#e-74c6670f-1f97-4be8-aaa3-2 4201dfbceea END:VEVENT BEGIN:VEVENT UID:edd848b86d5bf4171bec6dd535a6ea98 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:OriCell Therapeutics Co.\, Ltd. Ori-C101: Trial primary completion DESCRIPTION:As of 3 April 2024\, OriCell Therapeutics Co. estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma\, in December 2 026.\n\nSource: clinicaltrials NCT05652920\nhttps://clinicaltrials.gov/stu dy/NCT05652920 URL:https://julienwillard.com/calendar/clinical#e-583fe4a8-d138-4355-b240-2 213305ebcf1 END:VEVENT BEGIN:VEVENT UID:870cebb8e0dd7b5d6c2bf1dbe3b10b1c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd. SKB264: Trial pr imary completion DESCRIPTION:As of 8 July 2026\, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Ca ncer\, in December 2026.\n\nSource: clinicaltrials NCT06711900\nhttps://cl inicaltrials.gov/study/NCT06711900 URL:https://julienwillard.com/calendar/clinical#e-44c371ca-3536-44e5-b358-d df8394df6dd END:VEVENT BEGIN:VEVENT UID:f508000e1c98d78e5103b484ed761e56 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-M07D1: Trial primary com pletion DESCRIPTION:As of 26 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Gynecological Malignancies\ , in December 2026.\n\nSource: clinicaltrials NCT06131450\nhttps://clinica ltrials.gov/study/NCT06131450 URL:https://julienwillard.com/calendar/clinical#e-203bd779-b149-41be-88bb-8 189a5ba7b9b END:VEVENT BEGIN:VEVENT UID:6b073d2c84eaead6e923545d935f3fb8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Axsome Therapeutics\, Inc. Solriamfetol 150 mg: Trial primary compl etion DESCRIPTION:As of 28 July 2026\, Axsome Therapeutics estimated primary comp letion of a Phase 3 trial in Binge-Eating Disorder\, in December 2026.\n\n Source: clinicaltrials NCT06413433\nhttps://clinicaltrials.gov/study/NCT06 413433 URL:https://julienwillard.com/calendar/clinical#e-660bf3a0-94e6-4c8b-8d26-9 5b7b08269dc END:VEVENT BEGIN:VEVENT UID:442f4e9717d801db1bd39ed14d3672e0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Guangzhou Gloria Biosciences Co.\, Ltd. GLS-012: Trial primary comp letion DESCRIPTION:As of 18 June 2023\, Guangzhou Gloria Biosciences Co. estimated primary completion of a Phase 2 trial in Solid Tumor\, in December 2026.\ n\nSource: clinicaltrials NCT05909436\nhttps://clinicaltrials.gov/study/NC T05909436 URL:https://julienwillard.com/calendar/clinical#e-d09233d7-1712-46df-8383-0 260d6315728 END:VEVENT BEGIN:VEVENT UID:14feee091dbd17b14abdc2a050b77f1e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Celltrion Metformin: Trial primary completion DESCRIPTION:As of 11 August 2025\, Celltrion estimated primary completion o f a Phase 3 trial in t2DM\, in December 2026.\n\nSource: clinicaltrials NC T07093476\nhttps://clinicaltrials.gov/study/NCT07093476 URL:https://julienwillard.com/calendar/clinical#e-5959e88e-20d8-495b-a695-d 402974ff322 END:VEVENT BEGIN:VEVENT UID:5080bc76b2164cc47625e3dc9b5f04ad DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ambrx\, Inc. ARX788: Trial primary completion DESCRIPTION:As of 9 March 2026\, Ambrx estimated primary completion of a Ph ase 2 trial in HER2 Positive Metastatic Breast Cancer\, in December 2026.\ n\nSource: clinicaltrials NCT04829604\nhttps://clinicaltrials.gov/study/NC T04829604 URL:https://julienwillard.com/calendar/clinical#e-f99e2950-b359-439d-a654-d 8b45c40064f END:VEVENT BEGIN:VEVENT UID:ea89e33a8e5a69773101d4c3ebda3df6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Frantz Viral Therapeutics\, LLC Artesunate ointment: Trial primary completion DESCRIPTION:As of 14 August 2025\, Frantz Viral Therapeutics estimated prim ary completion of a Phase 2 trial in Vulvar Diseases\, in December 2026.\n \nSource: clinicaltrials NCT06075264\nhttps://clinicaltrials.gov/study/NCT 06075264 URL:https://julienwillard.com/calendar/clinical#e-a7b45be6-1c0a-407f-8220-6 a146461208f END:VEVENT BEGIN:VEVENT UID:04108b4b777edd6896c4af24f0d980fc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi Pasteur\, a Sanofi Company PCV21: Trial primary completion DESCRIPTION:As of 6 October 2025\, Sanofi Pasteur\, a Sanofi estimated prim ary completion of a Phase 3 trial in Pneumococcal Infections\, on 1 Decemb er 2026.\n\nSource: clinicaltrials NCT06838000\nhttps://clinicaltrials.gov /study/NCT06838000 URL:https://julienwillard.com/calendar/clinical#e-732b5197-eadb-47a2-9e1a-c 828db470c69 END:VEVENT BEGIN:VEVENT UID:da5b90155319592b2af51bbe8237737d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Meribank Biotech Co.\, Ltd. umbilical cord mesenchymal stem cells: Trial primary completion DESCRIPTION:As of 15 July 2024\, Meribank Biotech Co. estimated primary com pletion of a Phase 2 trial in Pathologic Processes\, in December 2026.\n\n Source: clinicaltrials NCT06501066\nhttps://clinicaltrials.gov/study/NCT06 501066 URL:https://julienwillard.com/calendar/clinical#e-6ff9a73f-c5ca-4245-8949-7 71af5879bae END:VEVENT BEGIN:VEVENT UID:0a65f32b51569b448ec99a198551ba3b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 17 April 2026\, Sichuan Baili Pharmaceutical Co. estimate d primary completion of a Phase 3 trial in Non-small Cell Lung Cancer\, in December 2026.\n\nSource: clinicaltrials NCT06382129\nhttps://clinicaltri als.gov/study/NCT06382129 URL:https://julienwillard.com/calendar/clinical#e-7af7884c-c440-4008-838b-4 108e1b7313f END:VEVENT BEGIN:VEVENT UID:ff7b4daf6a49d9c06b3c6e0006bf8946 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:K-Group\, Beta\, Inc.\, a wholly owned subsidiary of Zentalis Pharm aceuticals\, Inc azenosertib: Trial primary completion DESCRIPTION:As of 1 July 2026\, K-Group\, Beta estimated primary completion of a Phase 2 trial on 1 December 2026.\n\nSource: clinicaltrials NCT05128 825\nhttps://clinicaltrials.gov/study/NCT05128825 URL:https://julienwillard.com/calendar/clinical#e-15a7dcd6-b1a7-49a1-8668-3 5e1a8cfbbd9 END:VEVENT BEGIN:VEVENT UID:26e4b6962bb4014952587b9c8a906491 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. SI-B001: Trial primary comp letion DESCRIPTION:As of 26 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer\ , in December 2026.\n\nSource: clinicaltrials NCT05949606\nhttps://clinica ltrials.gov/study/NCT05949606 URL:https://julienwillard.com/calendar/clinical#e-6cd44428-a8d3-440a-9b45-2 a8afce9a7ab END:VEVENT BEGIN:VEVENT UID:ced1e4637ccad1faf30c976cb9f5c8fa DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Fujian Shengdi Pharmaceutical Co.\, Ltd. HRS9531: Trial primary com pletion DESCRIPTION:As of 17 November 2025\, Fujian Shengdi Pharmaceutical Co. esti mated primary completion of a Phase 3 trial in Bstructive Sleep Apnea (OSA ) and Obesity\, in December 2026.\n\nSource: clinicaltrials NCT06974851\nh ttps://clinicaltrials.gov/study/NCT06974851 URL:https://julienwillard.com/calendar/clinical#e-f4569427-ac09-40a0-94b7-b c50333d4812 END:VEVENT BEGIN:VEVENT UID:48371007267e8dece9451246ac6bf6ec DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Mabscale\, LLC Bevacizumab: Trial primary completion DESCRIPTION:As of 16 August 2024\, Mabscale estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer\, in December 2026.\n\nSour ce: clinicaltrials NCT05654454\nhttps://clinicaltrials.gov/study/NCT056544 54 URL:https://julienwillard.com/calendar/clinical#e-581b9a15-cc4a-46aa-a705-9 eff72ff1240 END:VEVENT BEGIN:VEVENT UID:4b8959e6da7bd6a5dc103b414f59f6bf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Georgiamune Inc GIM-531: Trial primary completion DESCRIPTION:As of 27 March 2026\, Georgiamune estimated primary completion of a Phase 2 trial in Melanoma Stage IV\, in December 2026.\n\nSource: cli nicaltrials NCT06425926\nhttps://clinicaltrials.gov/study/NCT06425926 URL:https://julienwillard.com/calendar/clinical#e-7fa803ed-35a1-4c8c-a251-3 19354b09e61 END:VEVENT BEGIN:VEVENT UID:738142bd88aeb48b89cc7931421725ac DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. HRS-6209 Capsules: Trial primar y completion DESCRIPTION:As of 12 June 2026\, Jiangsu HengRui Medicine Co. estimated pri mary completion of a Phase 2 trial in Breast Cancer\, in December 2026.\n\ nSource: clinicaltrials NCT06974929\nhttps://clinicaltrials.gov/study/NCT0 6974929 URL:https://julienwillard.com/calendar/clinical#e-2425a7b8-316f-4305-9eda-3 ddbfd6686bb END:VEVENT BEGIN:VEVENT UID:d58287d8208246f5378a58238c3d1d55 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Qilu Pharmaceutical Co.\, Ltd. Meropenem and Pralurbactam: Trial pr imary completion DESCRIPTION:As of 30 July 2025\, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Hospital-acquired Bacterial Pneumonia (HA BP)\, in December 2026.\n\nSource: clinicaltrials NCT07089186\nhttps://cli nicaltrials.gov/study/NCT07089186 URL:https://julienwillard.com/calendar/clinical#e-7aa4c620-caa8-4204-992b-c 9a97c0532f4 END:VEVENT BEGIN:VEVENT UID:505d81eb2391a6e75471fff84599e3c0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sound Pharmaceuticals\, Incorporated Ebselen: Trial primary complet ion DESCRIPTION:As of 13 July 2026\, Sound Pharmaceuticals\, Incorporated estim ated primary completion of a Phase 3 trial in Meniere's Disease\, in Decem ber 2026.\n\nSource: clinicaltrials NCT06859788\nhttps://clinicaltrials.go v/study/NCT06859788 URL:https://julienwillard.com/calendar/clinical#e-20ceb622-dad2-4158-8925-8 13569ab8271 END:VEVENT BEGIN:VEVENT UID:09d24330a9f35b9fc4e3d3b0ad729a3e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kedrion S.p.A. Kedrion IVIG 10%: Trial primary completion DESCRIPTION:As of 29 May 2026\, Kedrion S.p.A. estimated primary completion of a Phase 3 trial in Primary Immunodeficiency Disease\, in December 2026 .\n\nSource: clinicaltrials NCT04944979\nhttps://clinicaltrials.gov/study/ NCT04944979 URL:https://julienwillard.com/calendar/clinical#e-8ed26047-e0ad-4a6d-a39a-e 026599228be END:VEVENT BEGIN:VEVENT UID:d01de149dd3d58c0e91b26c3db81f79f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Delcath Systems Inc. Melphalan/HDS Followed by Consolidation Treatm ent with Trifluridine-tipiracil plus Bevacizumab: Trial primary completion DESCRIPTION:As of 1 June 2026\, Delcath Systems estimated primary completio n of a Phase 2 trial in Refractory Metastatic Colorectal Cancer\, in Decem ber 2026.\n\nSource: clinicaltrials NCT06607458\nhttps://clinicaltrials.go v/study/NCT06607458 URL:https://julienwillard.com/calendar/clinical#e-f3cff238-bd57-429b-b20e-5 11d85b27431 END:VEVENT BEGIN:VEVENT UID:6e68fc86efcd19cc01375d3436e71366 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Toll Biotech Co. Ltd. (Beijing) Group 1: TollB-001 100mg qd po\; Gr oup 2: TollB-001 200mg qd po\; Group 3: TollB-001400mg qd po: Trial primar y completion DESCRIPTION:As of 17 February 2026\, Toll Biotech Co. estimated primary com pletion of a Phase 2 trial in Rheumatoid Arthritis (RA)\, in December 2026 .\n\nSource: clinicaltrials NCT07408024\nhttps://clinicaltrials.gov/study/ NCT07408024 URL:https://julienwillard.com/calendar/clinical#e-a90f826d-ea98-43f9-993d-5 d41cdedb273 END:VEVENT BEGIN:VEVENT UID:25492eec8c7d2a20718b165eabf0c859 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Napo Pharmaceuticals\, Inc. Crofelemer Powder for Oral Solution: Tr ial primary completion DESCRIPTION:As of 9 June 2026\, Napo Pharmaceuticals estimated primary comp letion of a Phase 3 trial in Microvillus Inclusion Disease\, in December 2 026.\n\nSource: clinicaltrials NCT06721871\nhttps://clinicaltrials.gov/stu dy/NCT06721871 URL:https://julienwillard.com/calendar/clinical#e-8a2b0004-0aeb-4387-930a-2 7566833a3d8 END:VEVENT BEGIN:VEVENT UID:f4fc4e8316340f4a2c1b9fcd6f726eee DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Omeros Corporation OMS906 study drug: Trial primary completion DESCRIPTION:As of 16 July 2026\, Omeros estimated primary completion of a P hase 2 trial in Paroxysmal Nocturnal Hemoglobinuria\, in December 2026.\n\ nSource: clinicaltrials NCT06298955\nhttps://clinicaltrials.gov/study/NCT0 6298955 URL:https://julienwillard.com/calendar/clinical#e-7af87ef7-1da7-4443-83d2-0 23ccb152d66 END:VEVENT BEGIN:VEVENT UID:af2df17303d5d892d31c45db76c9d341 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Henan Genuine Biotech Co.\, Ltd. CL-197 capsules: Trial primary com pletion DESCRIPTION:As of 6 January 2026\, Henan Genuine Biotech Co. estimated prim ary completion of a Phase 2 trial in HIV-1 Infection\, in December 2026.\n \nSource: clinicaltrials NCT07308782\nhttps://clinicaltrials.gov/study/NCT 07308782 URL:https://julienwillard.com/calendar/clinical#e-2504b73e-1141-4661-bea0-0 bd8dd88625f END:VEVENT BEGIN:VEVENT UID:1cff6ca992c338052773075c20bda89c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. GNC-038: Trial primary comp letion DESCRIPTION:As of 29 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Non-hodgkin's Lymphoma\, in December 2026.\n\nSource: clinicaltrials NCT05623982\nhttps://clinicaltri als.gov/study/NCT05623982 URL:https://julienwillard.com/calendar/clinical#e-a257343b-b53a-402d-865c-4 a6c19cceefe END:VEVENT BEGIN:VEVENT UID:858810c8e025f6b8892e893483bfbd39 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:SynerGene Therapeutics\, Inc. SGT-53: Trial primary completion DESCRIPTION:As of 30 May 2025\, SynerGene Therapeutics estimated primary co mpletion of a Phase 2 trial in Metastatic Pancreatic Cancer\, in December 2026.\n\nSource: clinicaltrials NCT02340117\nhttps://clinicaltrials.gov/st udy/NCT02340117 URL:https://julienwillard.com/calendar/clinical#e-1d76e235-fdc5-4ec1-b3e0-7 bdf79dc5b4e END:VEVENT BEGIN:VEVENT UID:16febf2c8d961b5bffc6a71431ed19ce DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Madrigal Pharmaceuticals\, Inc. Resmetirom: Trial primary completio n DESCRIPTION:As of 8 July 2026\, Madrigal Pharmaceuticals estimated primary completion of a Phase 3 trial in nASH\, in December 2026.\n\nSource: clini caltrials NCT05500222\nhttps://clinicaltrials.gov/study/NCT05500222 URL:https://julienwillard.com/calendar/clinical#e-da316791-392c-4327-bc8c-0 5f285df9008 END:VEVENT BEGIN:VEVENT UID:c609496ec33581a5f8b6839c0160ac27 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BioCardia\, Inc. CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs): Trial primary completion DESCRIPTION:As of 12 December 2025\, BioCardia estimated primary completion of a Phase 2 trial in Heart Failure\, Systolic\, in December 2026.\n\nSou rce: clinicaltrials NCT05925608\nhttps://clinicaltrials.gov/study/NCT05925 608 URL:https://julienwillard.com/calendar/clinical#e-a092b8b2-7414-4ae9-ae0b-1 c49f130f638 END:VEVENT BEGIN:VEVENT UID:df66695d91c0e0b25d24403bf9a34748 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide: Trial primary completion DESCRIPTION:As of 19 May 2026\, Jiangsu HengRui Medicine Co. estimated prim ary completion of a Phase 3 trial in Advanced Gastroenteropancreatic Neuro endocrine Tumor\, in December 2026.\n\nSource: clinicaltrials NCT05884255\ nhttps://clinicaltrials.gov/study/NCT05884255 URL:https://julienwillard.com/calendar/clinical#e-278d9e9f-8fc9-47a5-b3d5-7 0666c57c917 END:VEVENT BEGIN:VEVENT UID:30af048bb2a34903761ef191ee3a4077 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suven Life Sciences Limited Masupirdine 50 mg: Trial primary comple tion DESCRIPTION:As of 12 January 2026\, Suven Life Sciences estimated primary c ompletion of a Phase 3 trial in agitation\, in December 2026.\n\nSource: c linicaltrials NCT05397639\nhttps://clinicaltrials.gov/study/NCT05397639 URL:https://julienwillard.com/calendar/clinical#e-36f934a5-1408-4da6-ac59-f d8e3dbae350 END:VEVENT BEGIN:VEVENT UID:d7d09b9fe176d7338cf54283b9624c29 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Krystal Biotech\, Inc. KB803: Trial primary completion DESCRIPTION:As of 12 March 2026\, Krystal Biotech estimated primary complet ion of a Phase 3 trial in Dystrophic Epidermolysis Bullosa\, in December 2 026.\n\nSource: clinicaltrials NCT07016750\nhttps://clinicaltrials.gov/stu dy/NCT07016750 URL:https://julienwillard.com/calendar/clinical#e-bb9dce72-6407-497d-91c7-3 7e0a5dd0352 END:VEVENT BEGIN:VEVENT UID:1869af97fcdb86cfd08f92fcc1469000 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kedrion S.p.A. Kedrion IVIG 10%: Trial primary completion DESCRIPTION:As of 6 August 2026\, Kedrion S.p.A. estimated primary completi on of a Phase 3 trial in Chronic Primary Immune Thrombocytopenia (ITP)\, i n December 2026.\n\nSource: clinicaltrials NCT07059000\nhttps://clinicaltr ials.gov/study/NCT07059000 URL:https://julienwillard.com/calendar/clinical#e-73ae2cd4-8c3d-45fe-9878-2 804519bac67 END:VEVENT BEGIN:VEVENT UID:0c14f2b8e74e011b07c047cf8bba8dc6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Lantern Pharma Inc. LP-300: Trial primary completion DESCRIPTION:As of 4 May 2026\, Lantern Pharma estimated primary completion of a Phase 2 trial in Adenocarcinoma of Lung\, in December 2026.\n\nSource : clinicaltrials NCT05456256\nhttps://clinicaltrials.gov/study/NCT05456256 URL:https://julienwillard.com/calendar/clinical#e-46f59450-e5b0-4dab-8b61-6 709bcb9765d END:VEVENT BEGIN:VEVENT UID:227bb02c7f41604ed5eb39a0f70c0d7b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shandong Suncadia Medicine Co.\, Ltd. HRS-7085: Trial primary compl etion DESCRIPTION:As of 2 June 2026\, Shandong Suncadia Medicine Co. estimated pr imary completion of a Phase 2 trial in December 2026.\n\nSource: clinicalt rials NCT07229950\nhttps://clinicaltrials.gov/study/NCT07229950 URL:https://julienwillard.com/calendar/clinical#e-46123a3b-3ef0-4330-988f-d ee0eac3d44c END:VEVENT BEGIN:VEVENT UID:ebef3014d44db28bb1092e56c748d035 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Step Pharma\, SAS STP938: Trial primary completion DESCRIPTION:As of 16 June 2026\, Step Pharma estimated primary completion o f a Phase 2 trial in Lymphoma\, B-Cell\, in December 2026.\n\nSource: clin icaltrials NCT05463263\nhttps://clinicaltrials.gov/study/NCT05463263 URL:https://julienwillard.com/calendar/clinical#e-3c2aad7a-d5b3-4846-baac-1 9327048b4bf END:VEVENT BEGIN:VEVENT UID:80bd9d03a8ebf8628b766636f3e327d6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:RemeGen Co.\, Ltd. Disitamab Vedotin Injection: Trial primary compl etion DESCRIPTION:As of 3 April 2024\, RemeGen Co. estimated primary completion o f a Phase 3 trial in Gastric Cancer\, in December 2026.\n\nSource: clinica ltrials NCT06221748\nhttps://clinicaltrials.gov/study/NCT06221748 URL:https://julienwillard.com/calendar/clinical#e-28156148-f736-4377-b99d-8 3cf4daba384 END:VEVENT BEGIN:VEVENT UID:dabff8315e25d1de3cb819d11823e05c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shandong Suncadia Medicine Co.\, Ltd. HRS-8080 Tablet: Trial primar y completion DESCRIPTION:As of 26 January 2026\, Shandong Suncadia Medicine Co. estimate d primary completion of a Phase 3 trial in Locally Advanced Breast Cancer\ , in December 2026.\n\nSource: clinicaltrials NCT07024173\nhttps://clinica ltrials.gov/study/NCT07024173 URL:https://julienwillard.com/calendar/clinical#e-8313d0e5-f3d6-47b2-ad9f-0 270adb6411d END:VEVENT BEGIN:VEVENT UID:a6ebcbb55646b72fc0fae5d386f08867 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GeneCradle Inc GC101: Trial primary completion DESCRIPTION:As of 3 July 2025\, GeneCradle estimated primary completion of a Phase 2 trial in Spinal Muscular Atrophy Type 3\, in December 2026.\n\nS ource: clinicaltrials NCT06421831\nhttps://clinicaltrials.gov/study/NCT064 21831 URL:https://julienwillard.com/calendar/clinical#e-a57e9900-6849-447b-839c-1 4f07b77479f END:VEVENT BEGIN:VEVENT UID:bbca25ba45c3af83a67c4513ec8d0788 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Praxis Precision Medicines 1mg elsunersen: Trial primary completion DESCRIPTION:As of 3 August 2026\, Praxis Precision Medicines estimated prim ary completion of a Phase 3 trial in Epileptic Encephalopathy\, in Decembe r 2026.\n\nSource: clinicaltrials NCT07019922\nhttps://clinicaltrials.gov/ study/NCT07019922 URL:https://julienwillard.com/calendar/clinical#e-2712b3b5-3c3b-4cd3-b483-6 9cf0969e3fd END:VEVENT BEGIN:VEVENT UID:fde03cdc76b9844f1d5a9bed8ccd93db DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Nexcella Inc. NXC-201 CAR-T: Trial primary completion DESCRIPTION:As of 14 July 2026\, Nexcella estimated primary completion of a Phase 2 trial in Light Chain (AL) Amyloidosis\, in December 2026.\n\nSour ce: clinicaltrials NCT06097832\nhttps://clinicaltrials.gov/study/NCT060978 32 URL:https://julienwillard.com/calendar/clinical#e-721f37c7-2ddf-4255-9d9c-9 ad86a889683 END:VEVENT BEGIN:VEVENT UID:e34f5ddd7801ae989e7768dd3138a621 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Baili Pharmaceutical Co.\, Ltd. BL-B01D1: Trial primary com pletion DESCRIPTION:As of 26 September 2025\, Sichuan Baili Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Urinary System Tumor\, in D ecember 2026.\n\nSource: clinicaltrials NCT05785039\nhttps://clinicaltrial s.gov/study/NCT05785039 URL:https://julienwillard.com/calendar/clinical#e-aa402d1d-2a38-44f1-beea-c ad471461928 END:VEVENT BEGIN:VEVENT UID:6b1ef6bf4ae887bebff4f3a7103b78a1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Regenerative Ocular Immunobiologics LLC d-MAPPS: Trial primary comp letion DESCRIPTION:As of 8 July 2026\, Regenerative Ocular Immunobiologics estimat ed primary completion of a Phase 2 trial in oGHVD\, in December 2026.\n\nS ource: clinicaltrials NCT06852768\nhttps://clinicaltrials.gov/study/NCT068 52768 URL:https://julienwillard.com/calendar/clinical#e-e0ff6b3c-086b-40fd-af9d-4 20e39fd33d8 END:VEVENT BEGIN:VEVENT UID:55fc374dc53814e1d2fc7cd6246d22d7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie Eluxadoline: Trial primary completion DESCRIPTION:As of 19 September 2025\, AbbVie estimated primary completion o f a Phase 2 trial in Irritable Bowel Syndrome\, in December 2026.\n\nSourc e: clinicaltrials NCT03339128\nhttps://clinicaltrials.gov/study/NCT0333912 8 URL:https://julienwillard.com/calendar/clinical#e-aba5b3b3-ca5e-4276-8c35-6 7736278c69f END:VEVENT BEGIN:VEVENT UID:b1865eebcc9a1f85b4007a5465e54e19 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:PT. Prodia Stem Cell Indonesia Control (NaCl 0.9%): Trial primary c ompletion DESCRIPTION:As of 27 February 2026\, PT. Prodia Stem Cell Indonesia estimat ed primary completion of a Phase 2 trial in Acute Respiratory Distress Syn drome\, in December 2026.\n\nSource: clinicaltrials NCT07439848\nhttps://c linicaltrials.gov/study/NCT07439848 URL:https://julienwillard.com/calendar/clinical#e-97b35224-e645-4e70-aa80-8 ab5c0064abf END:VEVENT BEGIN:VEVENT UID:70bde79125d0ca40b3e42e2b98c3e5ba DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Veradermics\, Inc. VDPHL01: Trial primary completion DESCRIPTION:As of 12 February 2026\, Veradermics estimated primary completi on of a Phase 3 trial in Androgenetic Alopecia\, in December 2026.\n\nSour ce: clinicaltrials NCT06972264\nhttps://clinicaltrials.gov/study/NCT069722 64 URL:https://julienwillard.com/calendar/clinical#e-04a1c851-b5d5-435d-b940-9 d4750f5fe1e END:VEVENT BEGIN:VEVENT UID:0c235d0e59290fdc5d537b27fd6f4cfd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Keymed Biosciences Co.Ltd CM336_group 1: Trial primary completion DESCRIPTION:As of 15 October 2024\, Keymed Biosciences Co. estimated primar y completion of a Phase 2 trial in Multiple Myeloma\, in December 2026.\n\ nSource: clinicaltrials NCT05299424\nhttps://clinicaltrials.gov/study/NCT0 5299424 URL:https://julienwillard.com/calendar/clinical#e-3da6dbc1-7907-4c5f-9def-3 fe32b611b3a END:VEVENT BEGIN:VEVENT UID:f94e6b6727d3c6f8917a119251eec171 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biogen Felzartamab: Trial primary completion DESCRIPTION:As of 5 June 2026\, Biogen estimated primary completion of a Ph ase 3 trial in Antibody-mediated Rejection\, on 1 December 2026.\n\nSource : clinicaltrials NCT06685757\nhttps://clinicaltrials.gov/study/NCT06685757 URL:https://julienwillard.com/calendar/clinical#e-6f758232-5b14-4d67-a53a-0 ce24f1a2036 END:VEVENT BEGIN:VEVENT UID:d4982c910f4fe3f7bdba664614aa877a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:3D Medicines (Sichuan) Co.\, Ltd. Lenvatinib + Envafolimab: Trial p rimary completion DESCRIPTION:As of 25 March 2026\, 3D Medicines (Sichuan) Co. estimated prim ary completion of a Phase 2 trial in Solid Tumors\, in December 2026.\n\nS ource: clinicaltrials NCT05024214\nhttps://clinicaltrials.gov/study/NCT050 24214 URL:https://julienwillard.com/calendar/clinical#e-c7e1b606-c042-4338-8e61-1 42777c8a01b END:VEVENT BEGIN:VEVENT UID:e7001996e2cf5b2df42642a924ef753b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Karyopharm Therapeutics Inc Selinexor (combination therapy): Trial primary completion DESCRIPTION:As of 2 July 2026\, Karyopharm Therapeutics estimated primary c ompletion of a Phase 3 trial in Relapsed/Refractory Diffuse Large B-cell L ymphoma\, in December 2026.\n\nSource: clinicaltrials NCT04442022\nhttps:/ /clinicaltrials.gov/study/NCT04442022 URL:https://julienwillard.com/calendar/clinical#e-f2f9ffdc-fbf5-42db-8cee-f 587372652a8 END:VEVENT BEGIN:VEVENT UID:51b0cee912c0960889abf14340449d0d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:COUR Pharmaceutical Development Company\, Inc. CNP-103: Trial prima ry completion DESCRIPTION:As of 6 August 2026\, COUR Pharmaceutical Development Company e stimated primary completion of a Phase 2 trial in Type 1 Diabetes Mellitus \, in December 2026.\n\nSource: clinicaltrials NCT06783309\nhttps://clinic altrials.gov/study/NCT06783309 URL:https://julienwillard.com/calendar/clinical#e-ce9e11a7-68f8-4051-85e7-b 49a0315af07 END:VEVENT BEGIN:VEVENT UID:57174db6a114f4ec4e599d0d5b6cf9de DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tasly Pharmaceuticals\, Inc. T89 capsule: Trial primary completion DESCRIPTION:As of 9 April 2025\, Tasly Pharmaceuticals estimated primary co mpletion of a Phase 3 trial in Chronic Stable Angina Pectoris\, in Decembe r 2026.\n\nSource: clinicaltrials NCT03789552\nhttps://clinicaltrials.gov/ study/NCT03789552 URL:https://julienwillard.com/calendar/clinical#e-2b31f0af-37d5-480e-b912-0 62e2d0f81c6 END:VEVENT BEGIN:VEVENT UID:5455a3529629cece0fcf9a2c95615356 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beam Therapeutics Inc. BEAM-201: Trial primary completion DESCRIPTION:As of 13 January 2025\, Beam Therapeutics estimated primary com pletion of a Phase 2 trial in Lymphoblastic Lymphoma\, in December 2026.\n \nSource: clinicaltrials NCT05885464\nhttps://clinicaltrials.gov/study/NCT 05885464 URL:https://julienwillard.com/calendar/clinical#e-6643f97c-97ae-4d89-9ae1-0 a3d4e4202cc END:VEVENT BEGIN:VEVENT UID:2b59aa5d09e92b01cd5148bb83733a3d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ranok Therapeutics (Hangzhou) Co.\, Ltd. RNK08954-01: Trial primary completion DESCRIPTION:As of 30 October 2025\, Ranok Therapeutics (Hangzhou) Co. estim ated primary completion of a Phase 2 trial in KRAS G12D Mutation\, in Dece mber 2026.\n\nSource: clinicaltrials NCT06667544\nhttps://clinicaltrials.g ov/study/NCT06667544 URL:https://julienwillard.com/calendar/clinical#e-d4c3e029-8d56-448c-a735-e 5fbbfa6f031 END:VEVENT BEGIN:VEVENT UID:7b8c697d385b8c48d6016754348ed090 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Zhejiang Haichang Biotech Co.\, Ltd. WGI-0301 at MTD/RP2D dose IV i nfusion\, QW: Trial primary completion DESCRIPTION:As of 19 March 2026\, Zhejiang Haichang Biotech Co. estimated p rimary completion of a Phase 2 trial in Advanced Hepatocellular Carcinoma (HCC)\, in December 2026.\n\nSource: clinicaltrials NCT06309485\nhttps://c linicaltrials.gov/study/NCT06309485 URL:https://julienwillard.com/calendar/clinical#e-1856f9f0-b25f-49cd-9aa8-6 462b8ff1fce END:VEVENT BEGIN:VEVENT UID:dba0d54da5379bed8bd18532a0424943 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Abivax S.A. Obefazimod: Trial primary completion DESCRIPTION:As of 27 April 2026\, Abivax estimated primary completion of a Phase 2 trial in Moderately to Severely Active Crohn Disease\, in December 2026.\n\nSource: clinicaltrials NCT06456593\nhttps://clinicaltrials.gov/s tudy/NCT06456593 URL:https://julienwillard.com/calendar/clinical#e-b5db6875-2a3c-482a-8f3e-f d81eafafd6c END:VEVENT BEGIN:VEVENT UID:992cbdccf5b2b255ea17048026457f94 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kardigan\, Inc. Tonlamarsen: Trial primary completion DESCRIPTION:As of 1 July 2026\, Kardigan estimated primary completion of a Phase 2 trial in hypertension\, in December 2026.\n\nSource: clinicaltrial s NCT07511361\nhttps://clinicaltrials.gov/study/NCT07511361 URL:https://julienwillard.com/calendar/clinical#e-f4e53932-da23-4060-a6fd-6 7808b14411a END:VEVENT BEGIN:VEVENT UID:b567ac699a8c6d741d0dcd5031f790eb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. SHR-3167 Injection: Trial prima ry completion DESCRIPTION:As of 4 June 2026\, Jiangsu HengRui Medicine Co. estimated prim ary completion of a Phase 2 trial in Diabetes Mellitus\, Type 2\, in Decem ber 2026.\n\nSource: clinicaltrials NCT07472725\nhttps://clinicaltrials.go v/study/NCT07472725 URL:https://julienwillard.com/calendar/clinical#e-e57ef7b0-cae9-4ac4-b64f-5 7540d85b64d END:VEVENT BEGIN:VEVENT UID:78b0b61fb694ed516f726d7c29335811 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Fujian Akeylink Biotechnology Co.\, Ltd. GST-HG141: Trial primary c ompletion DESCRIPTION:As of 23 January 2026\, Fujian Akeylink Biotechnology Co. estim ated primary completion of a Phase 3 trial in Chronic Hepatitis b\, on 1 D ecember 2026.\n\nSource: clinicaltrials NCT07090759\nhttps://clinicaltrial s.gov/study/NCT07090759 URL:https://julienwillard.com/calendar/clinical#e-74913fa2-8ffa-4a6b-8ded-f efa276a406f END:VEVENT BEGIN:VEVENT UID:b6ce68802d5ba81b41019963a81992bd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Lumicell\, Inc. LUM015: Trial primary completion DESCRIPTION:As of 16 January 2026\, Lumicell estimated primary completion o f a Phase 2 trial in Colorectal Cancer\, in December 2026.\n\nSource: clin icaltrials NCT02584244\nhttps://clinicaltrials.gov/study/NCT02584244 URL:https://julienwillard.com/calendar/clinical#e-52ed28d4-8654-4863-88f8-9 e40129494f2 END:VEVENT BEGIN:VEVENT UID:1655beb0307755a03c80bc939bdf9030 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Phoenix Molecular Designs PMD-026: Trial primary completion DESCRIPTION:As of 16 July 2026\, Phoenix Molecular Designs estimated primar y completion of a Phase 2 trial in Metastatic Breast Cancer\, in December 2026.\n\nSource: clinicaltrials NCT04115306\nhttps://clinicaltrials.gov/st udy/NCT04115306 URL:https://julienwillard.com/calendar/clinical#e-c48a7dd1-30b6-4d47-90bc-f 9a4dcf05aaf END:VEVENT BEGIN:VEVENT UID:2bb838d7aa983595d0cd19dd53ea2ea8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Fujian Shengdi Pharmaceutical Co.\, Ltd. HRS-9563 Injection: Trial primary completion DESCRIPTION:As of 31 July 2026\, Fujian Shengdi Pharmaceutical Co. estimate d primary completion of a Phase 2 trial in Mild to Moderate Hypertension\, in December 2026.\n\nSource: clinicaltrials NCT07297797\nhttps://clinical trials.gov/study/NCT07297797 URL:https://julienwillard.com/calendar/clinical#e-0b26f6ae-dde5-406a-9f2a-0 0b46bcbff05 END:VEVENT BEGIN:VEVENT UID:f4ea5d6c281c3eac53a8a2b9100d8761 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. TQB2930 for injec tion: Trial primary completion DESCRIPTION:As of 12 March 2024\, Chia Tai Tianqing Pharmaceutical Group Co . estimated primary completion of a Phase 2 trial in Metastatic Breast Can cer\, in December 2026.\n\nSource: clinicaltrials NCT06202261\nhttps://cli nicaltrials.gov/study/NCT06202261 URL:https://julienwillard.com/calendar/clinical#e-6817c394-c879-470f-b5f3-c 94fa4e15ad5 END:VEVENT BEGIN:VEVENT UID:bbccc9d74c6e58f6f373377c1741e451 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Corcept Therapeutics relacorilant: Trial primary completion DESCRIPTION:As of 21 April 2026\, Corcept Therapeutics estimated primary co mpletion of a Phase 2 trial in Cushing Syndrome\, in December 2026.\n\nSou rce: clinicaltrials NCT03604198\nhttps://clinicaltrials.gov/study/NCT03604 198 URL:https://julienwillard.com/calendar/clinical#e-91e0ac14-5656-4dd3-b16b-7 77eb7ff2661 END:VEVENT BEGIN:VEVENT UID:27203e57222cf88d5651c8b401e7b580 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Yidian Pharmaceutical Technology Development Co.\, Ltd. YD 0743: Trial primary completion DESCRIPTION:As of 17 February 2026\, Shanghai Yidian Pharmaceutical Technol ogy Development Co. estimated primary completion of a Phase 2 trial in sep sis\, in December 2026.\n\nSource: clinicaltrials NCT07413094\nhttps://cli nicaltrials.gov/study/NCT07413094 URL:https://julienwillard.com/calendar/clinical#e-91a76d5b-7942-4602-a9c0-9 51c124c4a0b END:VEVENT BEGIN:VEVENT UID:f2f51fe0ab3d4d6add7a76160b243148 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Grand Shuyang Life Sciences (Chengdu) Co.\, Ltd. Human immunoglobul in (pH4) for intravenous injection: Trial primary completion DESCRIPTION:As of 8 April 2026\, Grand Shuyang Life Sciences (Chengdu) Co. estimated primary completion of a Phase 3 trial in Primary Immune Thromboc ytopenia (ITP)\, in December 2026.\n\nSource: clinicaltrials NCT07233213\n https://clinicaltrials.gov/study/NCT07233213 URL:https://julienwillard.com/calendar/clinical#e-256612f8-27dd-4a7f-9dc1-a 3e9b40dd878 END:VEVENT BEGIN:VEVENT UID:7c65eadeb7558c79277a24d5a33c7479 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Aspeya\, Inc. ASY202: Trial primary completion DESCRIPTION:As of 21 July 2026\, Aspeya estimated primary completion of a P hase 2 trial in migraine\, in December 2026.\n\nSource: clinicaltrials NCT 07646613\nhttps://clinicaltrials.gov/study/NCT07646613 URL:https://julienwillard.com/calendar/clinical#e-ff534f37-e355-4b6d-aa67-a 30d340b6f16 END:VEVENT BEGIN:VEVENT UID:e66ee87440bb37ea9698499d153ff376 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:DiaMedica Therapeutics Inc Recombinant human tissue kallikrein: Tri al primary completion DESCRIPTION:As of 28 April 2026\, DiaMedica Therapeutics estimated primary completion of a Phase 3 trial in Acute Stroke\, in December 2026.\n\nSourc e: clinicaltrials NCT05065216\nhttps://clinicaltrials.gov/study/NCT0506521 6 URL:https://julienwillard.com/calendar/clinical#e-0a39b3ec-da8c-480b-8eee-4 a44fde67ebe END:VEVENT BEGIN:VEVENT UID:6de36c2592613bcc432b82fc5f1b79ba DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kind Pharmaceuticals LLC AND017 capsules: Trial primary completion DESCRIPTION:As of 27 February 2026\, Kind Pharmaceuticals estimated primary completion of a Phase 2 trial in β -Thalassemia\, in December 2026.\n\nS ource: clinicaltrials NCT06302491\nhttps://clinicaltrials.gov/study/NCT063 02491 URL:https://julienwillard.com/calendar/clinical#e-d90fb1fd-e2ef-4cc4-97d4-7 a2112d91064 END:VEVENT BEGIN:VEVENT UID:2b1e3aae04f384555f50a5eaddf9fe8a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Elixiron Immunotherapeutics Inc. EI-1071 tablet\, oral: Trial prima ry completion DESCRIPTION:As of 9 June 2026\, Elixiron Immunotherapeutics estimated prima ry completion of a Phase 2 trial in Mild\, Moderate\, or Severe Alzheimer' s Disease\, in December 2026.\n\nSource: clinicaltrials NCT06745583\nhttps ://clinicaltrials.gov/study/NCT06745583 URL:https://julienwillard.com/calendar/clinical#e-27c8c735-fa18-47b4-a381-3 513a71dce96 END:VEVENT BEGIN:VEVENT UID:ac0a31108ec5fe49e4326ede45c5cb89 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tasly Pharmaceutical Group Co.\, Ltd Jitongning tablets: Trial prim ary completion DESCRIPTION:As of 21 November 2024\, Tasly Pharmaceutical Group Co. estimat ed primary completion of a Phase 3 trial in Ankylosing Spondylitis\, on 1 December 2026.\n\nSource: clinicaltrials NCT06000956\nhttps://clinicaltria ls.gov/study/NCT06000956 URL:https://julienwillard.com/calendar/clinical#e-82d4995c-94d2-49c5-882b-a c7466e2c713 END:VEVENT BEGIN:VEVENT UID:dd4ee4e1165e98b64013120f81cf17ed DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:SERDA bv SN514-066b: Trial primary completion DESCRIPTION:As of 7 August 2026\, SERDA bv estimated primary completion of a Phase 2 trial in Burn Injury\, in December 2026.\n\nSource: clinicaltria ls NCT06628037\nhttps://clinicaltrials.gov/study/NCT06628037 URL:https://julienwillard.com/calendar/clinical#e-b9ba0c88-8916-4ea3-9334-8 7ebb555905f END:VEVENT BEGIN:VEVENT UID:1734855110b2950214dd4e49a4aeb07c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Akeso AK129(dose 1): Trial primary completion DESCRIPTION:As of 3 June 2025\, Akeso estimated primary completion of a Pha se 2 trial in Non-small Cell Lung Cancer Stage IIIB/IV\, in December 2026. \n\nSource: clinicaltrials NCT06943820\nhttps://clinicaltrials.gov/study/N CT06943820 URL:https://julienwillard.com/calendar/clinical#e-c61f0733-43e5-45fc-827b-6 371947d9b95 END:VEVENT BEGIN:VEVENT UID:6d7e6b22e53a228fe9fff87cffed58be DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Inmunotek S.L. 10\,000 MM09: Trial primary completion DESCRIPTION:As of 13 May 2025\, Inmunotek S.L. estimated primary completion of a Phase 3 trial in Rhinitis\, Allergic\, in December 2026.\n\nSource: clinicaltrials NCT04435990\nhttps://clinicaltrials.gov/study/NCT04435990 URL:https://julienwillard.com/calendar/clinical#e-c82a384a-ed87-44be-b6cc-a cb41f63db08 END:VEVENT BEGIN:VEVENT UID:27f81f0fd3b6727beaeaed802604eb16 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vir Biotechnology\, Inc. Tobevibart: Trial primary completion DESCRIPTION:As of 13 July 2026\, Vir Biotechnology estimated primary comple tion of a Phase 3 trial in Viral Hepatitis\, in December 2026.\n\nSource: clinicaltrials NCT07128550\nhttps://clinicaltrials.gov/study/NCT07128550 URL:https://julienwillard.com/calendar/clinical#e-1eb9723e-7c59-4cec-b2a2-7 0c8b8b4042f END:VEVENT BEGIN:VEVENT UID:1bfcdf50b8224a7e3f326271facc4c46 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:EpicentRx\, Inc. AdAPT-001: Trial primary completion DESCRIPTION:As of 26 June 2026\, EpicentRx estimated primary completion of a Phase 2 trial in Solid Tumor\, Adult\, on 1 December 2026.\n\nSource: cl inicaltrials NCT04673942\nhttps://clinicaltrials.gov/study/NCT04673942 URL:https://julienwillard.com/calendar/clinical#e-f4db22a6-1113-4a11-b739-0 3429dbfcd51 END:VEVENT BEGIN:VEVENT UID:3a6aaa3dfef16cf2ad5c1071c0dc387b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Dizal Pharmaceuticals DZD9008+AZD4205: Trial primary completion DESCRIPTION:As of 31 December 2025\, Dizal Pharmaceuticals estimated primar y completion of a Phase 2 trial in Non-small Cell Lung Cancer\, in Decembe r 2026.\n\nSource: clinicaltrials NCT06295432\nhttps://clinicaltrials.gov/ study/NCT06295432 URL:https://julienwillard.com/calendar/clinical#e-ebcf836e-907f-4bf8-9ba5-6 dfd25ee8c69 END:VEVENT BEGIN:VEVENT UID:bf6a8ab51baf24d49dd8605dcfe5f3ae DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316: Trial primary completion DESCRIPTION:As of 20 April 2026\, Jiangsu HengRui Medicine Co. estimated pr imary completion of a Phase 2 trial in Advanced Non-small Cell Lung Cancer \, in December 2026.\n\nSource: clinicaltrials NCT05482568\nhttps://clinic altrials.gov/study/NCT05482568 URL:https://julienwillard.com/calendar/clinical#e-39f55bed-7db8-4636-bd8c-3 77ae131bf0d END:VEVENT BEGIN:VEVENT UID:f3fbb3c2792d242314795b136a9036ef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie ABBV-400: Trial primary completion DESCRIPTION:As of 12 December 2025\, AbbVie estimated primary completion of a Phase 2 trial in Unresectable Metastatic Colorectal Cancer\, in Decembe r 2026.\n\nSource: clinicaltrials NCT06107413\nhttps://clinicaltrials.gov/ study/NCT06107413 URL:https://julienwillard.com/calendar/clinical#e-7bb10289-de25-47f4-9ddb-e 766d23e6130 END:VEVENT BEGIN:VEVENT UID:36fd29ab7ed6f493c03244ac259bc7f6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:JYAMS PET Research & Development Limited [18F]-APN-1607: Trial prim ary completion DESCRIPTION:As of 20 February 2026\, JYAMS PET Research & Development estim ated primary completion of a Phase 3 trial on 1 December 2026.\n\nSource: clinicaltrials NCT07422857\nhttps://clinicaltrials.gov/study/NCT07422857 URL:https://julienwillard.com/calendar/clinical#e-c9b1d157-f967-48ad-9254-f 639e3c59ee0 END:VEVENT BEGIN:VEVENT UID:f9d20d2b546afbc8aa029b65aab34701 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Octapharma OCTA-C1-INH: Trial primary completion DESCRIPTION:As of 6 August 2026\, Octapharma estimated primary completion o f a Phase 3 trial in Acute Hereditary Angio Edema\, in December 2026.\n\nS ource: clinicaltrials NCT06361537\nhttps://clinicaltrials.gov/study/NCT063 61537 URL:https://julienwillard.com/calendar/clinical#e-b80bdb85-8789-4b36-abdb-b bd1942cc6ac END:VEVENT BEGIN:VEVENT UID:8b2a17570169dad2c3c8d5fe3988ded4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Alzamend Neuro\, Inc. AL001: Trial primary completion DESCRIPTION:As of 28 July 2026\, Alzamend Neuro estimated primary completio n of a Phase 2 trial in Bipolar I Disorder\, in December 2026.\n\nSource: clinicaltrials NCT07540338\nhttps://clinicaltrials.gov/study/NCT07540338 URL:https://julienwillard.com/calendar/clinical#e-71bfa4c2-8fb5-41ed-8e23-c 08ca669f14e END:VEVENT BEGIN:VEVENT UID:c853934977dcd143bf59aeaf3aed20f1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TiumBio Co.\, Ltd. TU2218 + KEYTRUDA® (Pembrolizumab): Trial prima ry completion DESCRIPTION:As of 30 March 2025\, TiumBio Co. estimated primary completion of a Phase 2 trial in Solid Tumor\, in December 2026.\n\nSource: clinicalt rials NCT05784688\nhttps://clinicaltrials.gov/study/NCT05784688 URL:https://julienwillard.com/calendar/clinical#e-575da50a-6e6d-4df3-9155-c 6a88320a7c6 END:VEVENT BEGIN:VEVENT UID:e9c6dc2c3c857af5179fa98fab08e4d4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Imbria Pharmaceuticals\, Inc. Ninerafaxstat 200mg MR: Trial primary completion DESCRIPTION:As of 18 May 2026\, Imbria Pharmaceuticals estimated primary co mpletion of a Phase 2 trial in Non-obstructive Hypertrophic Cardiomyopathy \, in December 2026.\n\nSource: clinicaltrials NCT07023614\nhttps://clinic altrials.gov/study/NCT07023614 URL:https://julienwillard.com/calendar/clinical#e-2a511603-3ad9-4fc6-b1dd-3 bc8936d7913 END:VEVENT BEGIN:VEVENT UID:5c116c6c0619f4209eaa6bf45ac7490c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. Herombopag tablets: Trial prima ry completion DESCRIPTION:As of 17 July 2026\, Jiangsu HengRui Medicine Co. estimated pri mary completion of a Phase 3 trial in December 2026.\n\nSource: clinicaltr ials NCT06507436\nhttps://clinicaltrials.gov/study/NCT06507436 URL:https://julienwillard.com/calendar/clinical#e-7de6fefa-07d3-464c-b135-e bf9cba7e221 END:VEVENT BEGIN:VEVENT UID:df9794757c0d4e0d554fec0677da1c5a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20261202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Compass Therapeutics CTX-009: Trial primary completion DESCRIPTION:As of 7 May 2026\, Compass Therapeutics estimated primary compl etion of a Phase 3 trial in Biliary Tract Cancer\, on 1 December 2026.\n\n Source: clinicaltrials NCT05506943\nhttps://clinicaltrials.gov/study/NCT05 506943 URL:https://julienwillard.com/calendar/clinical#e-985b58a5-e26d-410c-80c7-2 a81bfd78e51 END:VEVENT BEGIN:VEVENT UID:34bf79d6c107f2c9f538985a5ed5905f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai BDgene Co.\, Ltd. BD111 Injection (investigational new dru g): Trial primary completion DESCRIPTION:As of 18 May 2025\, Shanghai BDgene Co. estimated primary compl etion of a Phase 2 trial in Herpes Simplex Virus Type I Stromal Keratitis\ , in December 2026.\n\nSource: clinicaltrials NCT06474442\nhttps://clinica ltrials.gov/study/NCT06474442 URL:https://julienwillard.com/calendar/clinical#e-4cc058b3-93e9-4fb5-90d4-8 c2ee9241dce END:VEVENT BEGIN:VEVENT UID:cf54d929d3634445902976d251e5ab3e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Stemline Therapeutics\, Inc. Elacestrant: Trial primary completion DESCRIPTION:As of 6 August 2026\, Stemline Therapeutics estimated primary c ompletion of a Phase 2 trial in Breast Neoplasms\, in December 2026.\n\nSo urce: clinicaltrials NCT05386108\nhttps://clinicaltrials.gov/study/NCT0538 6108 URL:https://julienwillard.com/calendar/clinical#e-e605628e-76e2-4be7-8be1-e cd8b9591104 END:VEVENT BEGIN:VEVENT UID:5fc40768c7d2016e810c9955de72ff96 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261201 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sunshine Lake Pharma Co.\, Ltd. HEC585 dose A: Trial primary comple tion DESCRIPTION:As of 24 April 2026\, Sunshine Lake Pharma Co. estimated primar y completion of a Phase 2 trial in December 2026.\n\nSource: clinicaltrial s NCT05139719\nhttps://clinicaltrials.gov/study/NCT05139719 URL:https://julienwillard.com/calendar/clinical#e-b22fefc3-444d-4061-910a-f 0bdd8eedf4b END:VEVENT BEGIN:VEVENT UID:f682fbe06ccc53fda8b075af45050c9d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261202 DTEND;VALUE=DATE:20261203 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer Ritlecitinib higher dose: Trial primary completion DESCRIPTION:As of 17 June 2026\, Pfizer estimated primary completion of a P hase 3 trial in Severe Alopecia Areata\, on 2 December 2026.\n\nSource: cl inicaltrials NCT07029711\nhttps://clinicaltrials.gov/study/NCT07029711 URL:https://julienwillard.com/calendar/clinical#e-1084d8fc-cd17-4dbe-b57c-5 4034625fe72 END:VEVENT BEGIN:VEVENT UID:534977f4612faaeafb4faa80d1df5d90 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261202 DTEND;VALUE=DATE:20261203 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer PF-06821497: Trial primary completion DESCRIPTION:As of 29 July 2026\, Pfizer estimated primary completion of a P hase 3 trial in Metastatic Castration-Resistant Prostate Cancer\, on 2 Dec ember 2026.\n\nSource: clinicaltrials NCT06629779\nhttps://clinicaltrials. gov/study/NCT06629779 URL:https://julienwillard.com/calendar/clinical#e-789986e5-5406-4408-b1f8-9 8f8ca7ad8c2 END:VEVENT BEGIN:VEVENT UID:e8475a27ee249ba129f9dd393cde2c4a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261203 DTEND;VALUE=DATE:20261204 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Regeneron Pharmaceuticals REGN7999: Trial primary completion DESCRIPTION:As of 1 July 2026\, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Non-Transfusion Dependent Beta-Thalassem ia (NTDT)\, on 3 December 2026.\n\nSource: clinicaltrials NCT06421636\nhtt ps://clinicaltrials.gov/study/NCT06421636 URL:https://julienwillard.com/calendar/clinical#e-c4b536ad-6bd7-4d5d-980d-1 0d68b7dcd61 END:VEVENT BEGIN:VEVENT UID:73281cd39d6b35ca2068285a1846ee64 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261203 DTEND;VALUE=DATE:20261204 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eisai Inc. E2814: Trial primary completion DESCRIPTION:As of 11 February 2026\, Eisai estimated primary completion of a Phase 2 trial in Alzheimer's Disease\, on 3 December 2026.\n\nSource: cl inicaltrials NCT06602258\nhttps://clinicaltrials.gov/study/NCT06602258 URL:https://julienwillard.com/calendar/clinical#e-8a05f109-434b-45a1-be84-a d9fc6c700de END:VEVENT BEGIN:VEVENT UID:433c13b335504b9700d28fcb1c051c00 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261204 DTEND;VALUE=DATE:20261205 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer VLA15: Trial primary completion DESCRIPTION:As of 6 May 2026\, Pfizer estimated primary completion of a Pha se 3 trial in Lyme Disease\, on 4 December 2026.\n\nSource: clinicaltrials NCT07500506\nhttps://clinicaltrials.gov/study/NCT07500506 URL:https://julienwillard.com/calendar/clinical#e-1d0d267b-7046-47c2-8980-6 1ce8bd0e977 END:VEVENT BEGIN:VEVENT UID:9ea9445275b6907063e0f6e36bed5411 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261205 DTEND;VALUE=DATE:20261206 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Forlong Biotechnology Co.\, Ltd FL115+PD-1: Trial primary co mpletion DESCRIPTION:As of 8 January 2026\, Suzhou Forlong Biotechnology Co. estimat ed primary completion of a Phase 2 trial in Advanced Solid Tumors\, on 5 D ecember 2026.\n\nSource: clinicaltrials NCT07131202\nhttps://clinicaltrial s.gov/study/NCT07131202 URL:https://julienwillard.com/calendar/clinical#e-b5a65199-a6d9-43c8-b83c-e 93120d24d1f END:VEVENT BEGIN:VEVENT UID:ba84dfa2b20a76cd8908ae651e1445ec DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261205 DTEND;VALUE=DATE:20261206 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Haisco Pharmaceutical Group Co.\, Ltd. HSK39297 200mgQD: Trial prim ary completion DESCRIPTION:As of 1 June 2026\, Haisco Pharmaceutical Group Co. estimated p rimary completion of a Phase 2 trial in IgA Nephropathy (IgAN)\, on 5 Dece mber 2026.\n\nSource: clinicaltrials NCT07616700\nhttps://clinicaltrials.g ov/study/NCT07616700 URL:https://julienwillard.com/calendar/clinical#e-d550d559-4ba1-4ccc-a126-4 144a0e41fae END:VEVENT BEGIN:VEVENT UID:fe20547df55ddb01e66761e59fd2d124 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261207 DTEND;VALUE=DATE:20261208 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Alexion Pharmaceuticals\, Inc. eculizumab: Trial primary completion DESCRIPTION:As of 19 December 2025\, Alexion Pharmaceuticals estimated prim ary completion of a Phase 3 trial in nMOSD\, on 7 December 2026.\n\nSource : clinicaltrials NCT06724809\nhttps://clinicaltrials.gov/study/NCT06724809 URL:https://julienwillard.com/calendar/clinical#e-ff8cb29e-5b45-45c3-b34c-3 b818f2dadab END:VEVENT BEGIN:VEVENT UID:0f117198e3c996a0dff43d3035202ba0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261209 DTEND;VALUE=DATE:20261210 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:SK Bioscience Co.\, Ltd. Test Drug 1-1 (GBP511 low dose): Trial pri mary completion DESCRIPTION:As of 14 May 2026\, SK Bioscience Co. estimated primary complet ion of a Phase 2 trial in Healthy Participants\, on 9 December 2026.\n\nSo urce: clinicaltrials NCT07280858\nhttps://clinicaltrials.gov/study/NCT0728 0858 URL:https://julienwillard.com/calendar/clinical#e-b7a0d958-5dfd-466b-a3fa-2 7a94b93e40e END:VEVENT BEGIN:VEVENT UID:516b43d7f42fd56df78d7066345edf47 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261210 DTEND;VALUE=DATE:20261211 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Pharmaceuticals Holding Co.\, Ltd LT3001 Drug:high dose: T rial primary completion DESCRIPTION:As of 30 April 2026\, Shanghai Pharmaceuticals Holding Co. esti mated primary completion of a Phase 2 trial in Acute Ischemic Stroke\, on 10 December 2026.\n\nSource: clinicaltrials NCT05686642\nhttps://clinicalt rials.gov/study/NCT05686642 URL:https://julienwillard.com/calendar/clinical#e-d9bd3e65-bf9f-4732-b8d6-a fbcbdc2b317 END:VEVENT BEGIN:VEVENT UID:e20fe37e49a5bdada7341f50e471ac7d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261211 DTEND;VALUE=DATE:20261212 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gan & Lee Pharmaceuticals. GZR18: Trial primary completion DESCRIPTION:As of 25 November 2025\, Gan & Lee Pharmaceuticals. estimated p rimary completion of a Phase 3 trial in Type 2 Diabetes Mellitus (T2DM)\, on 11 December 2026.\n\nSource: clinicaltrials NCT06778967\nhttps://clinic altrials.gov/study/NCT06778967 URL:https://julienwillard.com/calendar/clinical#e-bbf8a62c-aeb7-4b78-b605-9 d1277a67457 END:VEVENT BEGIN:VEVENT UID:b0c8f6405da3b85b1de40c9a1e4707cb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261211 DTEND;VALUE=DATE:20261212 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline dTpa: Trial primary completion DESCRIPTION:As of 28 July 2026\, GlaxoSmithKline estimated primary completi on of a Phase 3 trial in Diphtheria-Tetanus-acellular Pertussis Vaccines\, on 11 December 2026.\n\nSource: clinicaltrials NCT07596199\nhttps://clini caltrials.gov/study/NCT07596199 URL:https://julienwillard.com/calendar/clinical#e-d7e34549-d48a-421d-a56c-e 426a4aee192 END:VEVENT BEGIN:VEVENT UID:1ef8a47947d4ffe6c0b1ddaaf38e3bef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261211 DTEND;VALUE=DATE:20261212 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline MMB: Trial primary completion DESCRIPTION:As of 18 June 2026\, GlaxoSmithKline estimated primary completi on of a Phase 2 trial in neoplasms\, on 11 December 2026.\n\nSource: clini caltrials NCT03441113\nhttps://clinicaltrials.gov/study/NCT03441113 URL:https://julienwillard.com/calendar/clinical#e-1de861ca-a6d9-4c98-b3a3-9 d8565fea42c END:VEVENT BEGIN:VEVENT UID:7cdee3004ac39c873f91bffff2067c18 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261211 DTEND;VALUE=DATE:20261212 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Seagen\, a wholly owned subsidiary of Pfizer disitamab vedotin: Tri al primary completion DESCRIPTION:As of 22 July 2026\, Seagen estimated primary completion of a P hase 2 trial in Urothelial Carcinoma\, on 11 December 2026.\n\nSource: cli nicaltrials NCT04879329\nhttps://clinicaltrials.gov/study/NCT04879329 URL:https://julienwillard.com/calendar/clinical#e-2d0458a3-b37e-437f-a1d0-c a7d23fe9f59 END:VEVENT BEGIN:VEVENT UID:7764d3167a8505dc32bfb9fc66b22f4d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261212 DTEND;VALUE=DATE:20261213 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ausper Biopharma Co.\, Ltd. AHB-137: Trial primary completion DESCRIPTION:As of 5 August 2026\, Ausper Biopharma Co. estimated primary co mpletion of a Phase 2 trial in Chronic Hepatitis B\, on 12 December 2026.\ n\nSource: clinicaltrials NCT07137910\nhttps://clinicaltrials.gov/study/NC T07137910 URL:https://julienwillard.com/calendar/clinical#e-130d9c68-6976-4e1a-8b46-7 18d56a874fb END:VEVENT BEGIN:VEVENT UID:f16669d53f269c016e66707b5ff60793 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261212 DTEND;VALUE=DATE:20261213 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing QL Biopharmaceutical Co.\,Ltd ZT006: Trial primary completi on DESCRIPTION:As of 12 June 2026\, Beijing QL Biopharmaceutical Co. estimated primary completion of a Phase 2 trial in Overweight \, Obesity\, on 12 De cember 2026.\n\nSource: clinicaltrials NCT07230132\nhttps://clinicaltrials .gov/study/NCT07230132 URL:https://julienwillard.com/calendar/clinical#e-705612d4-e4b9-4cc6-a609-8 f9a18a40458 END:VEVENT BEGIN:VEVENT UID:04facecb2b920c950b065dfcefa98d50 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261214 DTEND;VALUE=DATE:20261215 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novo Nordisk A/S NNC0662-0419: Trial primary completion DESCRIPTION:As of 7 May 2026\, Novo Nordisk estimated primary completion of a Phase 2 trial in overweight\, on 14 December 2026.\n\nSource: clinicalt rials NCT07184632\nhttps://clinicaltrials.gov/study/NCT07184632 URL:https://julienwillard.com/calendar/clinical#e-15fb244f-054f-4725-b6e6-4 9c9dab9dc29 END:VEVENT BEGIN:VEVENT UID:7a61c3782430402d869f6c19936c6add DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261214 DTEND;VALUE=DATE:20261215 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novo Nordisk A/S Ziltivekimab: Trial primary completion DESCRIPTION:As of 14 April 2026\, Novo Nordisk estimated primary completion of a Phase 3 trial in Cardiovascular Risk\, on 14 December 2026.\n\nSourc e: clinicaltrials NCT06118281\nhttps://clinicaltrials.gov/study/NCT0611828 1 URL:https://julienwillard.com/calendar/clinical#e-b03aee0a-d86d-4865-951c-f b396cb2b218 END:VEVENT BEGIN:VEVENT UID:97f5f0bbaa7816c37eea7ae0f56df0f3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261214 DTEND;VALUE=DATE:20261215 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals AAA617: Trial primary completion DESCRIPTION:As of 10 July 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC)\, on 14 December 2026.\n\nSource: clinicaltrials NCT060046 61\nhttps://clinicaltrials.gov/study/NCT06004661 URL:https://julienwillard.com/calendar/clinical#e-0642ac76-26d1-451f-a8a2-0 f8496fa64e6 END:VEVENT BEGIN:VEVENT UID:687c16e9216d9c76d3af60a91ded9d0f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261214 DTEND;VALUE=DATE:20261215 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Investigational varicella vaccine: Trial primary co mpletion DESCRIPTION:As of 29 May 2026\, GlaxoSmithKline estimated primary completio n of a Phase 3 trial in chickenpox\, on 14 December 2026.\n\nSource: clini caltrials NCT06806137\nhttps://clinicaltrials.gov/study/NCT06806137 URL:https://julienwillard.com/calendar/clinical#e-fb628899-4291-4c42-89d6-7 f2f5ee85ccd END:VEVENT BEGIN:VEVENT UID:ca87023653c3fa3a0c1ee0dcb1cbaf71 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261214 DTEND;VALUE=DATE:20261215 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:LEO Pharma Delgocitinib cream: Trial primary completion DESCRIPTION:As of 21 July 2026\, LEO Pharma estimated primary completion of a Phase 2 trial in Palmoplantar Pustulosis\, on 14 December 2026.\n\nSour ce: clinicaltrials NCT07013201\nhttps://clinicaltrials.gov/study/NCT070132 01 URL:https://julienwillard.com/calendar/clinical#e-9f19e67c-534b-4765-9392-6 0288214c9d7 END:VEVENT BEGIN:VEVENT UID:dfe3da8b75afccbc696562560bc1e519 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261214 DTEND;VALUE=DATE:20261215 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amgen ABP 234: Trial primary completion DESCRIPTION:As of 1 April 2026\, Amgen estimated primary completion of a Ph ase 3 trial in Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) \, on 14 December 2026.\n\nSource: clinicaltrials NCT06430866\nhttps://cli nicaltrials.gov/study/NCT06430866 URL:https://julienwillard.com/calendar/clinical#e-b047fa9a-98f2-4c0f-af55-2 4d881998880 END:VEVENT BEGIN:VEVENT UID:79a816458019a1616e802817d251087b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261214 DTEND;VALUE=DATE:20261215 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bristol-Myers Squibb BMS-986435: Trial primary completion DESCRIPTION:As of 30 July 2026\, Bristol-Myers Squibb estimated primary com pletion of a Phase 2 trial in Heart Failure\, on 14 December 2026.\n\nSour ce: clinicaltrials NCT06122779\nhttps://clinicaltrials.gov/study/NCT061227 79 URL:https://julienwillard.com/calendar/clinical#e-73fc205d-51f2-456d-81ab-3 030b9f18796 END:VEVENT BEGIN:VEVENT UID:c0283a6022dc5c3e6fc873fea66256f7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261215 DTEND;VALUE=DATE:20261216 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Alexion Pharmaceuticals\, Inc. Gefurulimab: Trial primary completio n DESCRIPTION:As of 1 April 2026\, Alexion Pharmaceuticals estimated primary completion of a Phase 3 trial in Generalized Myasthenia Gravis\, on 15 Dec ember 2026.\n\nSource: clinicaltrials NCT06607627\nhttps://clinicaltrials. gov/study/NCT06607627 URL:https://julienwillard.com/calendar/clinical#e-60292c9e-7721-4398-aae8-0 84b094744e6 END:VEVENT BEGIN:VEVENT UID:d4b8c522cf9bc25e217c2c00f5488a63 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261215 DTEND;VALUE=DATE:20261216 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gedeon Richter Plc. Cariprazine: Trial primary completion DESCRIPTION:As of 8 October 2025\, Gedeon Richter estimated primary complet ion of a Phase 3 trial in schizophrenia\, on 15 December 2026.\n\nSource: clinicaltrials NCT03817502\nhttps://clinicaltrials.gov/study/NCT03817502 URL:https://julienwillard.com/calendar/clinical#e-672ffca5-968c-4da1-bb8f-a 7e6ddfb9bfe END:VEVENT BEGIN:VEVENT UID:6eb93bd3894c7293b442ba7279d6780a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261215 DTEND;VALUE=DATE:20261216 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:EXACT Therapeutics AS Acoustic Cluster Therapy: Trial primary compl etion DESCRIPTION:As of 3 April 2026\, EXACT Therapeutics AS estimated primary co mpletion of a Phase 2 trial in Locally Advanced Pancreatic Adenocarcinoma\ , on 15 December 2026.\n\nSource: clinicaltrials NCT06850623\nhttps://clin icaltrials.gov/study/NCT06850623 URL:https://julienwillard.com/calendar/clinical#e-032299d9-4a5b-4cdc-9033-6 4707c8fe7db END:VEVENT BEGIN:VEVENT UID:8297695060e760b8b7435cf357a8bcaa DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261215 DTEND;VALUE=DATE:20261216 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Exelixis XL092: Trial primary completion DESCRIPTION:As of 29 July 2026\, Exelixis estimated primary completion of a Phase 3 trial in Non-Clear Cell Renal Cell Carcinoma\, on 15 December 202 6.\n\nSource: clinicaltrials NCT05678673\nhttps://clinicaltrials.gov/study /NCT05678673 URL:https://julienwillard.com/calendar/clinical#e-6e687a12-9eb1-4a84-8146-3 065cb016398 END:VEVENT BEGIN:VEVENT UID:c6eb17d6375e2476cb8ee00e00a39e0e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261215 DTEND;VALUE=DATE:20261216 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ipsen Corabotase: Trial primary completion DESCRIPTION:As of 28 July 2026\, Ipsen estimated primary completion of a Ph ase 3 trial in Moderate to Severe Glabellar Lines\, on 15 December 2026.\n \nSource: clinicaltrials NCT07427797\nhttps://clinicaltrials.gov/study/NCT 07427797 URL:https://julienwillard.com/calendar/clinical#e-ecdbf10d-57a5-4752-8835-3 7315d2aa34c END:VEVENT BEGIN:VEVENT UID:b719d93768237613d8a6fa9eb84c2340 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261215 DTEND;VALUE=DATE:20261216 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GV20 Therapeutics GV20-0251: Trial primary completion DESCRIPTION:As of 13 February 2025\, GV20 Therapeutics estimated primary co mpletion of a Phase 2 trial in Solid Tumor\, Adult\, on 15 December 2026.\ n\nSource: clinicaltrials NCT05669430\nhttps://clinicaltrials.gov/study/NC T05669430 URL:https://julienwillard.com/calendar/clinical#e-d0a9351c-50d6-47b0-aecb-1 cdf5cdf9325 END:VEVENT BEGIN:VEVENT UID:3b541d4de39a71fd335f17cd305a08dc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261215 DTEND;VALUE=DATE:20261216 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ipsen Corabotase: Trial primary completion DESCRIPTION:As of 28 July 2026\, Ipsen estimated primary completion of a Ph ase 3 trial in Moderate to Severe Glabellar Lines\, on 15 December 2026.\n \nSource: clinicaltrials NCT07435428\nhttps://clinicaltrials.gov/study/NCT 07435428 URL:https://julienwillard.com/calendar/clinical#e-4b740617-654e-41cb-9702-d b6430bc1512 END:VEVENT BEGIN:VEVENT UID:b2e6e905d96ba985893837445fad71aa DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261216 DTEND;VALUE=DATE:20261217 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Posaconazole IV 6 mg/kg: Trial primary comp letion DESCRIPTION:As of 18 September 2025\, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Invasive Fungal Infection\, on 16 Decemb er 2026.\n\nSource: clinicaltrials NCT04665037\nhttps://clinicaltrials.gov /study/NCT04665037 URL:https://julienwillard.com/calendar/clinical#e-821cbbf0-3a2f-4a83-8560-3 b9d944c9d10 END:VEVENT BEGIN:VEVENT UID:d5fe1a0780208c1ff0b70914ea8e9ace DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261216 DTEND;VALUE=DATE:20261217 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Satralizumab: Trial primary completion DESCRIPTION:As of 10 July 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 3 trial in NMDAR Autoimmune Encephalitis\, on 16 December 2026.\n\nSource: clinicaltrials NCT05503264\nhttps://clinicaltrials.gov/st udy/NCT05503264 URL:https://julienwillard.com/calendar/clinical#e-5a8b864b-7575-4fef-a975-d 7bcdda2e667 END:VEVENT BEGIN:VEVENT UID:9fd6235c0adcb47d88da991a47ae26dc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261216 DTEND;VALUE=DATE:20261217 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai JMT-Bio Inc. KN026: Trial primary completion DESCRIPTION:As of 7 July 2026\, Shanghai JMT-Bio estimated primary completi on of a Phase 3 trial in Early or Locally Advanced HER2-positive Breast Ca ncer\, on 16 December 2026.\n\nSource: clinicaltrials NCT06747338\nhttps:/ /clinicaltrials.gov/study/NCT06747338 URL:https://julienwillard.com/calendar/clinical#e-e951f644-571d-40cb-a505-9 a0534f28170 END:VEVENT BEGIN:VEVENT UID:06e39118630d5e24a54305f8d8391ce9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261217 DTEND;VALUE=DATE:20261218 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi SAR442970: Trial primary completion DESCRIPTION:As of 23 April 2026\, Sanofi estimated primary completion of a Phase 2 trial in Ulcerative Colitis\, on 17 December 2026.\n\nSource: clin icaltrials NCT06975722\nhttps://clinicaltrials.gov/study/NCT06975722 URL:https://julienwillard.com/calendar/clinical#e-b6e5006c-cb08-4dfc-a455-b a40562de02c END:VEVENT BEGIN:VEVENT UID:d9c182986437b0d865c4ece7562e39ed DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261217 DTEND;VALUE=DATE:20261218 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi SAR442970: Trial primary completion DESCRIPTION:As of 27 March 2026\, Sanofi estimated primary completion of a Phase 2 trial in Crohn's Disease\, on 17 December 2026.\n\nSource: clinica ltrials NCT06958536\nhttps://clinicaltrials.gov/study/NCT06958536 URL:https://julienwillard.com/calendar/clinical#e-2e524f6d-3d5b-438b-bfa9-f 93f8cbcee8d END:VEVENT BEGIN:VEVENT UID:3dffef51c567926972fb9daf624ec580 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261217 DTEND;VALUE=DATE:20261218 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ipsen Elafibranor: Trial primary completion DESCRIPTION:As of 3 August 2026\, Ipsen estimated primary completion of a P hase 3 trial in Primary Biliary Cholangitis\, on 17 December 2026.\n\nSour ce: clinicaltrials NCT06730061\nhttps://clinicaltrials.gov/study/NCT067300 61 URL:https://julienwillard.com/calendar/clinical#e-6f256095-a7ec-4ee8-8499-5 dfb18b47f05 END:VEVENT BEGIN:VEVENT UID:54332b92110d256c74aba713148f7ade DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261218 DTEND;VALUE=DATE:20261219 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ausper Biopharma Co.\, Ltd. AHB-137: Trial primary completion DESCRIPTION:As of 4 May 2026\, Ausper Biopharma Co. estimated primary compl etion of a Phase 3 trial in Chronic Hepatitis B\, on 18 December 2026.\n\n Source: clinicaltrials NCT07246889\nhttps://clinicaltrials.gov/study/NCT07 246889 URL:https://julienwillard.com/calendar/clinical#e-2859c600-4c82-43b1-b7b7-3 6ac37c1c5ca END:VEVENT BEGIN:VEVENT UID:85505a850301ffebff809cc7a7619edd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261218 DTEND;VALUE=DATE:20261219 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie MEDI0618: Trial primary completion DESCRIPTION:As of 19 May 2026\, AbbVie estimated primary completion of a Ph ase 2 trial in migraine\, on 18 December 2026.\n\nSource: clinicaltrials N CT06602479\nhttps://clinicaltrials.gov/study/NCT06602479 URL:https://julienwillard.com/calendar/clinical#e-ce355ea1-3d32-42de-8003-c f7764a837b9 END:VEVENT BEGIN:VEVENT UID:046a01fec5b2eb4a9d7892ca72107393 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261218 DTEND;VALUE=DATE:20261219 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Han Xu\, M.D.\, Ph.D.\, FAPCR\, Sponsor-Investigator\, IRB Chair Ra loxifene - Usual: Trial primary completion DESCRIPTION:As of 23 April 2026\, Han Xu\, M.D.\, Ph.D.\, FAPCR\, Sponsor-I nvestigator\, IRB Chair estimated primary completion of a Phase 3 trial in Breast Cancer\, on 18 December 2026.\n\nSource: clinicaltrials NCT0606281 0\nhttps://clinicaltrials.gov/study/NCT06062810 URL:https://julienwillard.com/calendar/clinical#e-86e1c90a-6015-468e-b701-c 65d806ca7f3 END:VEVENT BEGIN:VEVENT UID:cf5041aec5413e830dad0615a856fdac DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261220 DTEND;VALUE=DATE:20261221 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TJ Biopharma Co.\, Ltd. Plonmarlimab: Trial primary completion DESCRIPTION:As of 20 July 2026\, TJ Biopharma Co. estimated primary complet ion of a Phase 3 trial in Relapsed/Refractory Rheumatic and Immunologic Di sease-associated Haemophagocytic Lympho\, on 20 December 2026.\n\nSource: clinicaltrials NCT07208058\nhttps://clinicaltrials.gov/study/NCT07208058 URL:https://julienwillard.com/calendar/clinical#e-0436762c-06db-48b3-9855-c d0e5f0bf6b7 END:VEVENT BEGIN:VEVENT UID:9cedab28c0921eb6e9df4588c7647012 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261221 DTEND;VALUE=DATE:20261222 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:UCB Biopharma SRL Bimekizumab: Trial primary completion DESCRIPTION:As of 31 July 2026\, UCB Biopharma SRL estimated primary comple tion of a Phase 3 trial in Hidradenitis Suppurativa\, on 21 December 2026. \n\nSource: clinicaltrials NCT06921850\nhttps://clinicaltrials.gov/study/N CT06921850 URL:https://julienwillard.com/calendar/clinical#e-92df3234-976b-421d-b827-a 77a7e45064f END:VEVENT BEGIN:VEVENT UID:a90f9e6069c0bb763774c783f81b16e0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261221 DTEND;VALUE=DATE:20261222 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer Ritlecitinib 100 mg: Trial primary completion DESCRIPTION:As of 13 May 2026\, Pfizer estimated primary completion of a Ph ase 3 trial in Alopecia Areata\, on 21 December 2026.\n\nSource: clinicalt rials NCT06873945\nhttps://clinicaltrials.gov/study/NCT06873945 URL:https://julienwillard.com/calendar/clinical#e-9171c754-354d-4686-9313-f 204c620c892 END:VEVENT BEGIN:VEVENT UID:0c350c8a378f071cb82e7228c14d77bb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261222 DTEND;VALUE=DATE:20261223 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Taisho Pharmaceutical Co.\, Ltd. TS-172 20~60 mg/day: Trial primary completion DESCRIPTION:As of 17 April 2026\, Taisho Pharmaceutical Co. estimated prima ry completion of a Phase 3 trial in Hyperphosphatemia Patients on Hemodial ysis\, on 22 December 2026.\n\nSource: clinicaltrials NCT07285291\nhttps:/ /clinicaltrials.gov/study/NCT07285291 URL:https://julienwillard.com/calendar/clinical#e-1996deff-779e-4ac0-8e7a-3 1c25acb7c7f END:VEVENT BEGIN:VEVENT UID:ffb47108c5cc0135cb56bc7a3d4a817a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261222 DTEND;VALUE=DATE:20261223 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Adverum Biotechnologies\, Inc. Ixo-vec: Trial primary completion DESCRIPTION:As of 22 May 2026\, Adverum Biotechnologies estimated primary c ompletion of a Phase 3 trial in Neovascular Age-Related Macular Degenerati on (nAMD)\, on 22 December 2026.\n\nSource: clinicaltrials NCT06856577\nht tps://clinicaltrials.gov/study/NCT06856577 URL:https://julienwillard.com/calendar/clinical#e-329b325c-7a40-402c-8e0b-c f45fbbead1c END:VEVENT BEGIN:VEVENT UID:7dc265b2c8948a70c2cae7db56a7ed72 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261222 DTEND;VALUE=DATE:20261223 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Janssen Pharmaceutica N.V.\, Belgium JNJ-64042056: Trial primary co mpletion DESCRIPTION:As of 31 July 2026\, Janssen Pharmaceutica N.V.\, Belgium estim ated primary completion of a Phase 2 trial in Alzheimer Disease\, on 22 De cember 2026.\n\nSource: clinicaltrials NCT06544616\nhttps://clinicaltrials .gov/study/NCT06544616 URL:https://julienwillard.com/calendar/clinical#e-0ea0aab5-6db5-4e76-8190-0 f2f4ca740bb END:VEVENT BEGIN:VEVENT UID:abce4b55249c89db7771f8f3539fa361 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261223 DTEND;VALUE=DATE:20261224 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals AAA617: Trial primary completion DESCRIPTION:As of 17 July 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Prostatic Neoplasm\, on 23 December 2026 .\n\nSource: clinicaltrials NCT05849298\nhttps://clinicaltrials.gov/study/ NCT05849298 URL:https://julienwillard.com/calendar/clinical#e-74403865-4c52-48cd-97d8-2 8bd02bbe2fe END:VEVENT BEGIN:VEVENT UID:9dd232aeba6a50d4ee3b130c8cac8225 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261223 DTEND;VALUE=DATE:20261224 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Corxel Pharmaceuticals CX11: Trial primary completion DESCRIPTION:As of 28 May 2026\, Corxel Pharmaceuticals estimated primary co mpletion of a Phase 2 trial in Type II Diabetes Mellitus\, on 23 December 2026.\n\nSource: clinicaltrials NCT07340320\nhttps://clinicaltrials.gov/st udy/NCT07340320 URL:https://julienwillard.com/calendar/clinical#e-c92932d0-47f1-4563-81e9-8 df39f0784b4 END:VEVENT BEGIN:VEVENT UID:5c6c15a7cf8eba114d5baa9d826e7b8f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261223 DTEND;VALUE=DATE:20261224 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi frexalimab: Trial primary completion DESCRIPTION:As of 20 July 2026\, Sanofi estimated primary completion of a P hase 2 trial in Focal Segmental Glomerulosclerosis\, on 23 December 2026.\ n\nSource: clinicaltrials NCT06500702\nhttps://clinicaltrials.gov/study/NC T06500702 URL:https://julienwillard.com/calendar/clinical#e-9d8eb846-e315-4580-86d4-e 8ff0a349ddf END:VEVENT BEGIN:VEVENT UID:6653cd68dd3f8944fdad28b76a925de9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261223 DTEND;VALUE=DATE:20261224 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cho Pharma Inc. CHO-H01: Trial primary completion DESCRIPTION:As of 3 March 2026\, Cho Pharma estimated primary completion of a Phase 2 trial in Non-Hodgkin Lymphoma\, on 23 December 2026.\n\nSource: clinicaltrials NCT05950165\nhttps://clinicaltrials.gov/study/NCT05950165 URL:https://julienwillard.com/calendar/clinical#e-e8fae385-39b7-443f-9735-3 d06464a142d END:VEVENT BEGIN:VEVENT UID:c93585535b945774d3c424dad17cd5fc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261223 DTEND;VALUE=DATE:20261224 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:OncoZenge AB BupiZenge 25 mg: Trial primary completion DESCRIPTION:As of 13 July 2026\, OncoZenge estimated primary completion of a Phase 3 trial in Head & Neck Cancer\, on 23 December 2026.\n\nSource: cl inicaltrials NCT07672236\nhttps://clinicaltrials.gov/study/NCT07672236 URL:https://julienwillard.com/calendar/clinical#e-4e6bcb41-d0a0-44b3-ba12-a 7351459dae4 END:VEVENT BEGIN:VEVENT UID:f337c658fb4021ee0285b68f18867de8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261223 DTEND;VALUE=DATE:20261224 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Fusion Pharmaceuticals Inc. FPI-2265: Trial primary completion DESCRIPTION:As of 8 April 2026\, Fusion Pharmaceuticals estimated primary c ompletion of a Phase 2 trial in Metastatic Castration-resistant Prostate C ancer\, on 23 December 2026.\n\nSource: clinicaltrials NCT06402331\nhttps: //clinicaltrials.gov/study/NCT06402331 URL:https://julienwillard.com/calendar/clinical#e-b07e5c03-240d-4f0a-9a91-7 6c1a588c538 END:VEVENT BEGIN:VEVENT UID:4f7d7949951a11e940d7b2eb0d01571a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261223 DTEND;VALUE=DATE:20261224 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:R-Bio JOINTSTEM: Trial primary completion DESCRIPTION:As of 10 July 2023\, R-Bio estimated primary completion of a Ph ase 3 trial in Knee Osteoarthritis\, on 23 December 2026.\n\nSource: clini caltrials NCT04427930\nhttps://clinicaltrials.gov/study/NCT04427930 URL:https://julienwillard.com/calendar/clinical#e-ead89d46-a910-4d4c-9203-a 607352b60b7 END:VEVENT BEGIN:VEVENT UID:b8f1ff9203da9ffa80ec2576a8870a78 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261223 DTEND;VALUE=DATE:20261224 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Changchun GeneScience Pharmaceutical Co.\, Ltd. PEG-rhGH Injection: Trial primary completion DESCRIPTION:As of 17 February 2026\, Changchun GeneScience Pharmaceutical C o. estimated primary completion of a Phase 2 trial on 23 December 2026.\n\ nSource: clinicaltrials NCT07260500\nhttps://clinicaltrials.gov/study/NCT0 7260500 URL:https://julienwillard.com/calendar/clinical#e-6eaf0337-e4be-4c81-831c-0 5bfb20fd71a END:VEVENT BEGIN:VEVENT UID:b71c03dcfae6587cbf799056e0d1e4a2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261224 DTEND;VALUE=DATE:20261225 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:InxMed (Shanghai) Co.\, Ltd. IN10018: Trial primary completion DESCRIPTION:As of 30 April 2025\, InxMed (Shanghai) Co. estimated primary c ompletion of a Phase 2 trial in Ovarian Cancer Recurrent\, on 24 December 2026.\n\nSource: clinicaltrials NCT06014528\nhttps://clinicaltrials.gov/st udy/NCT06014528 URL:https://julienwillard.com/calendar/clinical#e-7acb1340-f4e1-4541-8205-c 948a892702d END:VEVENT BEGIN:VEVENT UID:f10767412d7caeed2bb8657ed6db26e3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261224 DTEND;VALUE=DATE:20261225 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Kechow Pharma\, Inc. Tunlametinib plus Vemurafenib: Trial primary completion DESCRIPTION:As of 18 September 2025\, Shanghai Kechow Pharma estimated prim ary completion of a Phase 3 trial in Colorectal Cancer Metastatic\, on 24 December 2026.\n\nSource: clinicaltrials NCT06008119\nhttps://clinicaltria ls.gov/study/NCT06008119 URL:https://julienwillard.com/calendar/clinical#e-80255472-fae2-4edd-8d84-7 300e2c07e19 END:VEVENT BEGIN:VEVENT UID:db551050b0dc79fc9329c9e3df473f24 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261224 DTEND;VALUE=DATE:20261225 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Nanjing Leads Biolabs Co.\,Ltd LBL-024 for Injection: Trial primary completion DESCRIPTION:As of 18 May 2026\, Nanjing Leads Biolabs Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumour\, on 24 December 2 026.\n\nSource: clinicaltrials NCT06783647\nhttps://clinicaltrials.gov/stu dy/NCT06783647 URL:https://julienwillard.com/calendar/clinical#e-ba727d83-da9c-41ce-a4ac-a 23f8f39db68 END:VEVENT BEGIN:VEVENT UID:26c444968c45b6bacba77d48e87825cc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261225 DTEND;VALUE=DATE:20261226 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Investigational varicella vaccine_Lot 1: Trial prim ary completion DESCRIPTION:As of 29 May 2026\, GlaxoSmithKline estimated primary completio n of a Phase 3 trial in chickenpox\, on 25 December 2026.\n\nSource: clini caltrials NCT06740630\nhttps://clinicaltrials.gov/study/NCT06740630 URL:https://julienwillard.com/calendar/clinical#e-7f3b3fd5-d04e-4d75-a22c-2 3ca0e45b35a END:VEVENT BEGIN:VEVENT UID:06a90e4a1a46bca5750b19e7a873406a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261225 DTEND;VALUE=DATE:20261226 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer Ritlecitinib 50 mg: Trial primary completion DESCRIPTION:As of 17 June 2026\, Pfizer estimated primary completion of a P hase 2 trial in Chronic Spontaneous Urticaria\, on 25 December 2026.\n\nSo urce: clinicaltrials NCT07219615\nhttps://clinicaltrials.gov/study/NCT0721 9615 URL:https://julienwillard.com/calendar/clinical#e-3c818ec6-1169-4f94-9a36-b f33e72ffa1f END:VEVENT BEGIN:VEVENT UID:8481dc0c18d280d3603f3d2301b74cee DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261225 DTEND;VALUE=DATE:20261226 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Boehringer Ingelheim BI 1584862: Trial primary completion DESCRIPTION:As of 28 July 2026\, Boehringer Ingelheim estimated primary com pletion of a Phase 2 trial in Geographic Atrophy\, on 25 December 2026.\n\ nSource: clinicaltrials NCT06769048\nhttps://clinicaltrials.gov/study/NCT0 6769048 URL:https://julienwillard.com/calendar/clinical#e-07f87f10-5afb-4128-a5aa-e e1547fc6ba5 END:VEVENT BEGIN:VEVENT UID:f810afa69c6b1f3a02a7d01bdd00fc1b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261226 DTEND;VALUE=DATE:20261227 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Incyte Corporation Povorcitinib: Trial primary completion DESCRIPTION:As of 23 March 2026\, Incyte estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa (HS)\, on 26 December 2026.\n\nS ource: clinicaltrials NCT06212999\nhttps://clinicaltrials.gov/study/NCT062 12999 URL:https://julienwillard.com/calendar/clinical#e-e544e857-c529-407c-acf3-7 e5f5257e58c END:VEVENT BEGIN:VEVENT UID:165d51bf27a82a94664de8554c02ef7f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261226 DTEND;VALUE=DATE:20261227 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CanariaBio Inc. Oregovomab: Trial primary completion DESCRIPTION:As of 1 April 2026\, CanariaBio estimated primary completion of a Phase 3 trial in Carcinoma\, Ovarian Epithelial\, on 26 December 2026.\ n\nSource: clinicaltrials NCT04498117\nhttps://clinicaltrials.gov/study/NC T04498117 URL:https://julienwillard.com/calendar/clinical#e-aaacebea-c0e2-4356-99e8-1 9828b4c44b5 END:VEVENT BEGIN:VEVENT UID:efcc94b15e0327aa596bf6ae92d40fdb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261227 DTEND;VALUE=DATE:20261228 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Stemline Therapeutics\, Inc. Elacestrant: Trial primary completion DESCRIPTION:As of 12 June 2026\, Stemline Therapeutics estimated primary co mpletion of a Phase 2 trial in Breast Cancer\, on 27 December 2026.\n\nSou rce: clinicaltrials NCT05563220\nhttps://clinicaltrials.gov/study/NCT05563 220 URL:https://julienwillard.com/calendar/clinical#e-f9a75594-c125-4573-87d3-f ce1de597916 END:VEVENT BEGIN:VEVENT UID:b68aacbc6ef3fde7816a11dfbd05a0c5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261227 DTEND;VALUE=DATE:20261228 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amplexd Therapeutics\, Inc. EGCG and Quinine Sulfate Vaginal Suppos itory: Trial primary completion DESCRIPTION:As of 14 May 2026\, Amplexd Therapeutics estimated primary comp letion of a Phase 2 trial in High-risk HPV (Any Strain)\, on 27 December 2 026.\n\nSource: clinicaltrials NCT07572396\nhttps://clinicaltrials.gov/stu dy/NCT07572396 URL:https://julienwillard.com/calendar/clinical#e-62c78072-3d92-402d-b182-b eaaff59c2fd END:VEVENT BEGIN:VEVENT UID:1ebc49c171f62629dcfd69c7d87542d9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261228 DTEND;VALUE=DATE:20261229 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Niraparib: Trial primary completion DESCRIPTION:As of 24 June 2026\, GlaxoSmithKline estimated primary completi on of a Phase 2 trial in Ovarian Neoplasms\, on 28 December 2026.\n\nSourc e: clinicaltrials NCT04641247\nhttps://clinicaltrials.gov/study/NCT0464124 7 URL:https://julienwillard.com/calendar/clinical#e-a4030ac9-5016-4468-8879-e b1a201a5b19 END:VEVENT BEGIN:VEVENT UID:e9bcbac8a1b2b2103b1633a4cd25a03e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261228 DTEND;VALUE=DATE:20261229 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer PF-06821497: Trial primary completion DESCRIPTION:As of 11 August 2026\, Pfizer estimated primary completion of a Phase 3 trial in Metastatic Castrate Resistant Prostate Cancer (mCRPC)\, on 28 December 2026.\n\nSource: clinicaltrials NCT06551324\nhttps://clinic altrials.gov/study/NCT06551324 URL:https://julienwillard.com/calendar/clinical#e-c7c05677-11c0-48bf-815f-8 0cb7690bab2 END:VEVENT BEGIN:VEVENT UID:0f660181e0cb286d2e6057ebd9531f84 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261228 DTEND;VALUE=DATE:20261229 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing InnoCare Pharma Tech Co.\, Ltd. CM355: Trial primary comple tion DESCRIPTION:As of 27 January 2022\, Beijing InnoCare Pharma Tech Co. estima ted primary completion of a Phase 2 trial in hematoma\, on 28 December 202 6.\n\nSource: clinicaltrials NCT05210868\nhttps://clinicaltrials.gov/study /NCT05210868 URL:https://julienwillard.com/calendar/clinical#e-baeef214-c8e9-48a8-a791-d fdd323d65c1 END:VEVENT BEGIN:VEVENT UID:9199c5e6376a93c9b282595634fd02d6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261228 DTEND;VALUE=DATE:20261229 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Frantz Viral Therapeutics\, LLC Artesunate: Trial primary completio n DESCRIPTION:As of 18 May 2025\, Frantz Viral Therapeutics estimated primary completion of a Phase 2 trial in Anal High Grade Squamous Intraepithelial Lesion\, on 28 December 2026.\n\nSource: clinicaltrials NCT05555862\nhttp s://clinicaltrials.gov/study/NCT05555862 URL:https://julienwillard.com/calendar/clinical#e-2455bedd-0e50-44fd-8dc7-d 015693e38ef END:VEVENT BEGIN:VEVENT UID:adfb1c0c2a503468821e589b4bf3c973 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261228 DTEND;VALUE=DATE:20261229 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chengdu Origen Biotechnology Co.\, Ltd. KH631: Trial primary comple tion DESCRIPTION:As of 27 November 2024\, Chengdu Origen Biotechnology Co. estim ated primary completion of a Phase 2 trial in Age-Related Macular Degenera tion\, on 28 December 2026.\n\nSource: clinicaltrials NCT05672121\nhttps:/ /clinicaltrials.gov/study/NCT05672121 URL:https://julienwillard.com/calendar/clinical#e-c518ad62-720b-44e2-8bea-1 34e136cb885 END:VEVENT BEGIN:VEVENT UID:ba913b9cfbb4688311071ea6c2c834bc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261228 DTEND;VALUE=DATE:20261229 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu Topcel-KH Pharmaceutical Co.\, Ltd. Human TH-SC01 cell inje ction: Trial primary completion DESCRIPTION:As of 13 April 2025\, Jiangsu Topcel-KH Pharmaceutical Co. esti mated primary completion of a Phase 3 trial in Crohn's Disease\, on 28 Dec ember 2026.\n\nSource: clinicaltrials NCT06925594\nhttps://clinicaltrials. gov/study/NCT06925594 URL:https://julienwillard.com/calendar/clinical#e-d6f19ca3-2c71-4cd6-adda-1 5a44bc7cc97 END:VEVENT BEGIN:VEVENT UID:9c7720859835097f1158b945489c32b9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261228 DTEND;VALUE=DATE:20261229 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Nanjing Leads Biolabs Co.\,Ltd LBL-024 for Injection: Trial primary completion DESCRIPTION:As of 12 March 2026\, Nanjing Leads Biolabs Co. estimated prima ry completion of a Phase 2 trial in Advanced Neuroendocrine Carcinoma\, on 28 December 2026.\n\nSource: clinicaltrials NCT06157827\nhttps://clinical trials.gov/study/NCT06157827 URL:https://julienwillard.com/calendar/clinical#e-6d7af0e4-c473-4f3e-bbd4-7 f9f62ab1046 END:VEVENT BEGIN:VEVENT UID:405dd0c3aee243693e65b364901c85e3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261229 DTEND;VALUE=DATE:20261230 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Arctic Therapeutics NACA: Trial primary completion DESCRIPTION:As of 21 July 2026\, Arctic Therapeutics estimated primary comp letion of a Phase 2 trial in Hereditary Cystatin C Amyloid Angiopathy (HCC AA)\, on 29 December 2026.\n\nSource: clinicaltrials NCT07716865\nhttps:// clinicaltrials.gov/study/NCT07716865 URL:https://julienwillard.com/calendar/clinical#e-551d7dd7-f183-4496-a988-f b0e72183316 END:VEVENT BEGIN:VEVENT UID:2bf2fd7dfdd902337dd89e6c372b0774 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261229 DTEND;VALUE=DATE:20261230 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Regeneron Pharmaceuticals Alirocumab: Trial primary completion DESCRIPTION:As of 22 July 2026\, Regeneron Pharmaceuticals estimated primar y completion of a Phase 2 trial in hypercholesterolemia\, on 29 December 2 026.\n\nSource: clinicaltrials NCT07477704\nhttps://clinicaltrials.gov/stu dy/NCT07477704 URL:https://julienwillard.com/calendar/clinical#e-7e65e4e2-ca07-4d44-8b4b-d 89c23fe7165 END:VEVENT BEGIN:VEVENT UID:abeea528c6aeba04b0e39c31ae4fbe1c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Astellas Pharma Global Development\, Inc. XNW27011: Trial primary c ompletion DESCRIPTION:As of 11 August 2026\, Astellas Pharma Global Development estim ated primary completion of a Phase 2 trial in Pancreatic Adenocarcinoma Me tastatic\, on 30 December 2026.\n\nSource: clinicaltrials NCT06792435\nhtt ps://clinicaltrials.gov/study/NCT06792435 URL:https://julienwillard.com/calendar/clinical#e-db3905cb-4235-4a77-b9ce-2 446a17571ae END:VEVENT BEGIN:VEVENT UID:daa614d4563f5d8a36ab9f63f12d4966 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals Iptacopan: Trial primary completion DESCRIPTION:As of 23 June 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Anti-Neutrophil Cytoplasm Antibodies (AN CA) Associated Vasculitis\, on 30 December 2026.\n\nSource: clinicaltrials NCT06388941\nhttps://clinicaltrials.gov/study/NCT06388941 URL:https://julienwillard.com/calendar/clinical#e-9991f8c2-34cf-431a-97ad-3 3ec0278149a END:VEVENT BEGIN:VEVENT UID:54fe90bb937372188ef3e2993012e18a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vertex Pharmaceuticals Incorporated Inaxaplin: Trial primary comple tion DESCRIPTION:As of 5 May 2026\, Vertex Pharmaceuticals Incorporated estimate d primary completion of a Phase 2 trial in Proteinuric Kidney Disease\, on 30 December 2026.\n\nSource: clinicaltrials NCT06794996\nhttps://clinical trials.gov/study/NCT06794996 URL:https://julienwillard.com/calendar/clinical#e-a7c059ac-1a48-497a-b92f-9 75383c3f7d1 END:VEVENT BEGIN:VEVENT UID:3a75282817be265fc405415397d76ac8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AskGene Pharma\, Inc. ASKB589: Trial primary completion DESCRIPTION:As of 27 January 2026\, AskGene Pharma estimated primary comple tion of a Phase 3 trial in Gastroesophageal Junction Adenocarcinoma\, on 3 0 December 2026.\n\nSource: clinicaltrials NCT06206733\nhttps://clinicaltr ials.gov/study/NCT06206733 URL:https://julienwillard.com/calendar/clinical#e-909d7aea-4398-40a1-bad3-0 57fc8b8fb0b END:VEVENT BEGIN:VEVENT UID:62146bd6f7f320178575bb881ef1d43f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu vcare pharmaceutical technology co.\, LTD VC004 Capsules: T rial primary completion DESCRIPTION:As of 27 July 2026\, Jiangsu vcare pharmaceutical technology co . estimated primary completion of a Phase 3 trial in Locally Advanced Soli d Tumor\, on 30 December 2026.\n\nSource: clinicaltrials NCT06658353\nhttp s://clinicaltrials.gov/study/NCT06658353 URL:https://julienwillard.com/calendar/clinical#e-0cdf8938-9231-476a-a08d-b f0335e07d19 END:VEVENT BEGIN:VEVENT UID:845a5b476c6fbc374357c046d923eddf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Swedish Orphan Biovitrum Pacritinib: Trial primary completion DESCRIPTION:As of 24 April 2026\, Swedish Orphan Biovitrum estimated primar y completion of a Phase 2 trial in vEXAS\, on 30 December 2026.\n\nSource: clinicaltrials NCT06782373\nhttps://clinicaltrials.gov/study/NCT06782373 URL:https://julienwillard.com/calendar/clinical#e-53336d8b-0b91-46e7-b76f-2 6ca50a93151 END:VEVENT BEGIN:VEVENT UID:5945523c91491d161a325292bdfe1d38 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Supernus Pharmaceuticals\, Inc. BIS-001ER: Trial primary completion DESCRIPTION:As of 30 August 2022\, Supernus Pharmaceuticals estimated prima ry completion of a Phase 2 trial in Focal Impaired Awareness Seizures\, on 30 December 2026.\n\nSource: clinicaltrials NCT03474770\nhttps://clinical trials.gov/study/NCT03474770 URL:https://julienwillard.com/calendar/clinical#e-c9ac93ef-4668-4dad-bfab-f e18c2596178 END:VEVENT BEGIN:VEVENT UID:f8453319d3fbee0076feb462ec9d8410 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sunshine Lake Pharma Co.\, Ltd. HEC169096: Trial primary completion DESCRIPTION:As of 28 April 2026\, Sunshine Lake Pharma Co. estimated primar y completion of a Phase 2 trial in Advanced Solid Tumor\, on 30 December 2 026.\n\nSource: clinicaltrials NCT05451602\nhttps://clinicaltrials.gov/stu dy/NCT05451602 URL:https://julienwillard.com/calendar/clinical#e-6eeb0385-744f-494c-b74d-e 4711a3bb232 END:VEVENT BEGIN:VEVENT UID:c10c8495dd9a14ddf0dd3986dd839c12 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chengdu Zenitar Biomedical Technology Co.\, Ltd PM 8.4 mg/m^2: Tria l primary completion DESCRIPTION:As of 4 February 2026\, Chengdu Zenitar Biomedical Technology C o. estimated primary completion of a Phase 2 trial in Diffuse Large B Cell Lymphoma，DLBCL\, on 30 December 2026.\n\nSource: clinicaltrials NCT0556 3844\nhttps://clinicaltrials.gov/study/NCT05563844 URL:https://julienwillard.com/calendar/clinical#e-c61ff8eb-93a7-4d5c-bc74-c 36888bffa34 END:VEVENT BEGIN:VEVENT UID:f3b560661a418a5c135d040314d947da DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Xynomic Pharmaceuticals\, Inc. Pazopanib: Trial primary completion DESCRIPTION:As of 13 April 2025\, Xynomic Pharmaceuticals estimated primary completion of a Phase 3 trial in Renal Cell Carcinoma\, on 30 December 20 26.\n\nSource: clinicaltrials NCT03592472\nhttps://clinicaltrials.gov/stud y/NCT03592472 URL:https://julienwillard.com/calendar/clinical#e-50a94459-4cfa-41a3-af84-d 122251dc4ef END:VEVENT BEGIN:VEVENT UID:c8c894f97077ec4033e9e3166ccb71ef DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ever Supreme Bio Technology Co.\, Ltd. autologous dendritic cells: Trial primary completion DESCRIPTION:As of 19 September 2024\, Ever Supreme Bio Technology Co. estim ated primary completion of a Phase 2 trial in gBM\, on 30 December 2026.\n \nSource: clinicaltrials NCT04115761\nhttps://clinicaltrials.gov/study/NCT 04115761 URL:https://julienwillard.com/calendar/clinical#e-904d5a57-de91-4ee4-abc2-6 c65fdfac634 END:VEVENT BEGIN:VEVENT UID:bbecd0e381e94a5f3b56befa19fbb3c0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Wuhan Createrna Science and Technology Co.\, Ltd MY008211A tablets: Trial primary completion DESCRIPTION:As of 18 April 2025\, Wuhan Createrna Science and Technology Co . estimated primary completion of a Phase 3 trial in Paroxysmal Nocturnal Hemoglobinuria (PNH)\, on 30 December 2026.\n\nSource: clinicaltrials NCT0 6933914\nhttps://clinicaltrials.gov/study/NCT06933914 URL:https://julienwillard.com/calendar/clinical#e-950f60a8-cabe-4199-8d45-c 2c4bd8620b3 END:VEVENT BEGIN:VEVENT UID:c98831c32868e9634007c8b6a6f857e9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ganzhou Hemay Pharmaceutical Co.\, Ltd Hemay005 tablets: Trial prim ary completion DESCRIPTION:As of 3 April 2026\, Ganzhou Hemay Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Moderate to Severe Ulcerative Co litis\, on 30 December 2026.\n\nSource: clinicaltrials NCT05486104\nhttps: //clinicaltrials.gov/study/NCT05486104 URL:https://julienwillard.com/calendar/clinical#e-4b9e6d00-802d-42f7-a00f-0 63d32da7c37 END:VEVENT BEGIN:VEVENT UID:1874efcd87998c68d184f490508c838c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CanariaBio Inc. Oregovomab: Trial primary completion DESCRIPTION:As of 3 April 2026\, CanariaBio estimated primary completion of a Phase 2 trial in Recurrent Ovarian Cancer\, on 30 December 2026.\n\nSou rce: clinicaltrials NCT05335993\nhttps://clinicaltrials.gov/study/NCT05335 993 URL:https://julienwillard.com/calendar/clinical#e-43abbf61-d98a-45ae-a78f-2 b88a82a26f0 END:VEVENT BEGIN:VEVENT UID:c749080b9ec3dab5ccf879fee2349dd7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing Konruns Pharmaceutical Co.\, Ltd. KC1036: Trial primary com pletion DESCRIPTION:As of 7 March 2024\, Beijing Konruns Pharmaceutical Co. estimat ed primary completion of a Phase 3 trial in Esophageal Squamous Cell Carci noma\, on 30 December 2026.\n\nSource: clinicaltrials NCT06194734\nhttps:/ /clinicaltrials.gov/study/NCT06194734 URL:https://julienwillard.com/calendar/clinical#e-268b04d5-b6ed-4738-a7ef-5 ce60f3067f5 END:VEVENT BEGIN:VEVENT UID:6be573a99447182df753aa68aa83d9c4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Abogen Biosciences Co.\, Ltd. ABO2011 Injection: Trial prima ry completion DESCRIPTION:As of 22 August 2025\, Suzhou Abogen Biosciences Co. estimated primary completion of a Phase 2 trial in Solid Tumor\, Adult\, on 30 Decem ber 2026.\n\nSource: clinicaltrials NCT06088004\nhttps://clinicaltrials.go v/study/NCT06088004 URL:https://julienwillard.com/calendar/clinical#e-25043bd6-c1c5-4a95-94e4-2 3dbdc526ef7 END:VEVENT BEGIN:VEVENT UID:f42764f43f8168d67f8c0d3157366b43 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shionogi S-337395: Trial primary completion DESCRIPTION:As of 11 August 2026\, Shionogi estimated primary completion of a Phase 2 trial in Respiratory Syncytial Virus Infections\, on 30 Decembe r 2026.\n\nSource: clinicaltrials NCT07214571\nhttps://clinicaltrials.gov/ study/NCT07214571 URL:https://julienwillard.com/calendar/clinical#e-7be866dd-4194-4bdc-8d87-4 940bba452b9 END:VEVENT BEGIN:VEVENT UID:c5d885bbc78d404d977946c4c84a8ecb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer ARV-471: Trial primary completion DESCRIPTION:As of 9 March 2026\, Pfizer estimated primary completion of a P hase 2 trial in Breast Cancer\, on 30 December 2026.\n\nSource: clinicaltr ials NCT05573555\nhttps://clinicaltrials.gov/study/NCT05573555 URL:https://julienwillard.com/calendar/clinical#e-730fb6b6-8d53-4430-9524-9 16f499d0213 END:VEVENT BEGIN:VEVENT UID:0d0d0f331b19fa6078068129fabcaa4c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd. SKB264: Trial pr imary completion DESCRIPTION:As of 8 May 2026\, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 2 trial in Selected Subjects With Advanced Solid Tumors\, on 30 December 2026.\n\nSource: clinicaltrials NCT 05631262\nhttps://clinicaltrials.gov/study/NCT05631262 URL:https://julienwillard.com/calendar/clinical#e-784ed264-900d-4161-b4eb-c 41ff8fdfa14 END:VEVENT BEGIN:VEVENT UID:40ab9d445f2f07d1669c4883381d4261 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu vcare pharmaceutical technology co.\, LTD Vicagrel: Trial p rimary completion DESCRIPTION:As of 27 July 2026\, Jiangsu vcare pharmaceutical technology co . estimated primary completion of a Phase 3 trial on 30 December 2026.\n\n Source: clinicaltrials NCT06577519\nhttps://clinicaltrials.gov/study/NCT06 577519 URL:https://julienwillard.com/calendar/clinical#e-3f74fac2-6ccc-47dd-af9f-8 7f553ae08aa END:VEVENT BEGIN:VEVENT UID:697ab3a077c4f237bc1f8be375a6298d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Hengrui Pharmaceutical Co.\, Ltd. SHR-1905: Trial primary completion DESCRIPTION:As of 5 June 2026\, Shanghai Hengrui Pharmaceutical Co. estimat ed primary completion of a Phase 2 trial in asthma\, on 30 December 2026.\ n\nSource: clinicaltrials NCT05593250\nhttps://clinicaltrials.gov/study/NC T05593250 URL:https://julienwillard.com/calendar/clinical#e-4e3fe69e-51a3-4305-9df9-3 0115230bbc6 END:VEVENT BEGIN:VEVENT UID:41bb4a09c797bdddabfdab90484a32a7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer Vepdegestrant (ARV-471/PF-07850327): Trial primary completio n DESCRIPTION:As of 10 February 2026\, Pfizer estimated primary completion of a Phase 3 trial in Breast Cancer\, on 30 December 2026.\n\nSource: clinic altrials NCT05909397\nhttps://clinicaltrials.gov/study/NCT05909397 URL:https://julienwillard.com/calendar/clinical#e-85d67bb5-42fb-49c1-82b7-c 6194bd253cd END:VEVENT BEGIN:VEVENT UID:5c1e9e346f55a570d3757a509352f3aa DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bionic Sight LLC BS01: Trial primary completion DESCRIPTION:As of 23 January 2026\, Bionic Sight estimated primary completi on of a Phase 2 trial in Retinitis Pigmentosa\, on 30 December 2026.\n\nSo urce: clinicaltrials NCT04278131\nhttps://clinicaltrials.gov/study/NCT0427 8131 URL:https://julienwillard.com/calendar/clinical#e-5b72e8f0-b04a-49e5-af99-4 e1a797158c5 END:VEVENT BEGIN:VEVENT UID:4533c5ec6ac52b98e67d795fe07c2b27 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:HC Biopharma Inc. HC010: Trial primary completion DESCRIPTION:As of 17 December 2025\, HC Biopharma estimated primary complet ion of a Phase 2 trial in nSCLC\, on 30 December 2026.\n\nSource: clinical trials NCT07169552\nhttps://clinicaltrials.gov/study/NCT07169552 URL:https://julienwillard.com/calendar/clinical#e-c5e6b84a-d933-4729-aadb-7 e24b75abb99 END:VEVENT BEGIN:VEVENT UID:425ca482b808edf28d80595b8c583bb6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Meribank Biotech Co.\, Ltd. UMC119-06-05: Trial primary completion DESCRIPTION:As of 8 July 2024\, Meribank Biotech Co. estimated primary comp letion of a Phase 2 trial in Chronic Obstructive Pulmonary Disease\, on 30 December 2026.\n\nSource: clinicaltrials NCT06491043\nhttps://clinicaltri als.gov/study/NCT06491043 URL:https://julienwillard.com/calendar/clinical#e-474227c4-fa1f-4760-b0a8-0 52222de28b4 END:VEVENT BEGIN:VEVENT UID:a4a517e20486c456955d1cdf17f842f1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:L & L Bio Co.\, Ltd.\, Ningbo\, China LB1410: Trial primary complet ion DESCRIPTION:As of 11 September 2025\, L & L Bio Co.\, Ltd.\, Ningbo\, China estimated primary completion of a Phase 2 trial in Solid Tumor\, on 30 De cember 2026.\n\nSource: clinicaltrials NCT06468358\nhttps://clinicaltrials .gov/study/NCT06468358 URL:https://julienwillard.com/calendar/clinical#e-888d2826-4551-4e1f-a9a4-8 767365b4a49 END:VEVENT BEGIN:VEVENT UID:27339b14494e547e5044d23fb94462b9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Allotera Therapeutics WU-CART-007: Trial primary completion DESCRIPTION:As of 6 August 2026\, Allotera Therapeutics estimated primary c ompletion of a Phase 2 trial in T-cell Acute Lymphoblastic Leukemia\, on 3 0 December 2026.\n\nSource: clinicaltrials NCT06514794\nhttps://clinicaltr ials.gov/study/NCT06514794 URL:https://julienwillard.com/calendar/clinical#e-6fcf5c5b-ea05-493b-bc8c-4 0940ee6c8d8 END:VEVENT BEGIN:VEVENT UID:7b0992225ef49313f3e36457cdeb81c6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Janssen Research & Development\, LLC Seltorexant: Trial primary com pletion DESCRIPTION:As of 31 July 2026\, Janssen Research & Development estimated p rimary completion of a Phase 3 trial in Depressive Disorder\, Major\, on 3 0 December 2026.\n\nSource: clinicaltrials NCT06559306\nhttps://clinicaltr ials.gov/study/NCT06559306 URL:https://julienwillard.com/calendar/clinical#e-8b3c2686-9892-4e54-8eef-1 a864d34ab36 END:VEVENT BEGIN:VEVENT UID:7af44e5d61a4e9e7f751ffd17a52f3fd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Teclison Ltd. Nivolumab Injectable Product: Trial primary completio n DESCRIPTION:As of 16 April 2026\, Teclison estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma\, on 30 December 2026.\n\nSour ce: clinicaltrials NCT03259867\nhttps://clinicaltrials.gov/study/NCT032598 67 URL:https://julienwillard.com/calendar/clinical#e-b06b44ea-ddbe-4ee0-a461-5 93afe065923 END:VEVENT BEGIN:VEVENT UID:4a25f4c23e016fb0fbb354cdd52f513e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Akeso AK112\, Cadonilimab\, nab-paclitaxel\, gemcitabine: Trial pri mary completion DESCRIPTION:As of 9 March 2026\, Akeso estimated primary completion of a Ph ase 2 trial in Metastatic Pancreatic Ductal Adenocarcinoma\, on 30 Decembe r 2026.\n\nSource: clinicaltrials NCT06646055\nhttps://clinicaltrials.gov/ study/NCT06646055 URL:https://julienwillard.com/calendar/clinical#e-823f6831-26b5-408e-8224-f 3bd2aa53a5d END:VEVENT BEGIN:VEVENT UID:38ea1430a2eb437ce38158e136febfb4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NATCO Pharma Ltd. NRC-2694-A: Trial primary completion DESCRIPTION:As of 23 January 2026\, NATCO Pharma estimated primary completi on of a Phase 2 trial in carcinoma\, on 30 December 2026.\n\nSource: clini caltrials NCT05283226\nhttps://clinicaltrials.gov/study/NCT05283226 URL:https://julienwillard.com/calendar/clinical#e-2cc0ab98-d5c0-4f05-bfe5-9 0e742cc6c7c END:VEVENT BEGIN:VEVENT UID:3e01745e329e89f774347d55375bff9c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing Continent Pharmaceutical Co\, Ltd. Pirfenidone Capsules （ 400 mg）: Trial primary completion DESCRIPTION:As of 22 April 2026\, Beijing Continent Pharmaceutical Co estim ated primary completion of a Phase 3 trial in Radiation-induced Lung Injur y\, on 30 December 2026.\n\nSource: clinicaltrials NCT07388680\nhttps://cl inicaltrials.gov/study/NCT07388680 URL:https://julienwillard.com/calendar/clinical#e-bc1f9367-eb73-4ef2-ac9f-0 9e5e0bd8ff5 END:VEVENT BEGIN:VEVENT UID:663b65bad40c54ed808a38d425461e24 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:4TEEN4 Pharmaceuticals GmbH AK1967 (Invobenitug also known as Proci zumab): Trial primary completion DESCRIPTION:As of 9 July 2026\, 4TEEN4 Pharmaceuticals estimated primary co mpletion of a Phase 2 trial in Shock\, Cardiogenic\, on 30 December 2026.\ n\nSource: clinicaltrials NCT06832722\nhttps://clinicaltrials.gov/study/NC T06832722 URL:https://julienwillard.com/calendar/clinical#e-5058f798-a08c-4f5b-b5dd-e 1cf65df911d END:VEVENT BEGIN:VEVENT UID:a61a54a9c3fe6d97f885cdf444f89215 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sellas Life Sciences Group SLS009: Trial primary completion DESCRIPTION:As of 29 July 2026\, Sellas Life Sciences Group estimated prima ry completion of a Phase 2 trial in Hematologic Malignancies\, on 30 Decem ber 2026.\n\nSource: clinicaltrials NCT04588922\nhttps://clinicaltrials.go v/study/NCT04588922 URL:https://julienwillard.com/calendar/clinical#e-ec2bbff0-24c7-4004-8e6d-1 733bdfd3518 END:VEVENT BEGIN:VEVENT UID:a3a242a0f191204f404967e18998ed31 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Neonc Technologies\, Inc. NEO100: Trial primary completion DESCRIPTION:As of 16 July 2026\, Neonc Technologies estimated primary compl etion of a Phase 2 trial on 30 December 2026.\n\nSource: clinicaltrials NC T05023018\nhttps://clinicaltrials.gov/study/NCT05023018 URL:https://julienwillard.com/calendar/clinical#e-60d5585b-42a3-48e4-98a5-d e3a516eb0f9 END:VEVENT BEGIN:VEVENT UID:cdc88f88fbd622b3ee918a3499e5d55a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Henlius Biotech HLX43 Dose 1\;: Trial primary completion DESCRIPTION:As of 17 November 2025\, Shanghai Henlius Biotech estimated pri mary completion of a Phase 2 trial in Colorectal Cancer (CRC)\, on 30 Dece mber 2026.\n\nSource: clinicaltrials NCT07106892\nhttps://clinicaltrials.g ov/study/NCT07106892 URL:https://julienwillard.com/calendar/clinical#e-04be539d-11e9-4d0e-a3f9-7 cf82451132d END:VEVENT BEGIN:VEVENT UID:eca1be1d672a47392cbf808232370fcf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Psyence Australia Pty Ltd Psilocybin therapy: Trial primary complet ion DESCRIPTION:As of 3 March 2026\, Psyence Australia Pty estimated primary co mpletion of a Phase 2 trial in Adjustment Disorder\, on 30 December 2026.\ n\nSource: clinicaltrials NCT07072728\nhttps://clinicaltrials.gov/study/NC T07072728 URL:https://julienwillard.com/calendar/clinical#e-c7a3c9bc-8157-4265-9f72-f 24527cfb1ed END:VEVENT BEGIN:VEVENT UID:c1bde78671f1042db8d40aa682fbbf80 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Akeso AK117: Trial primary completion DESCRIPTION:As of 16 March 2026\, Akeso estimated primary completion of a P hase 2 trial in Metastatic Triple-negative Breast Cancer\, on 30 December 2026.\n\nSource: clinicaltrials NCT05227664\nhttps://clinicaltrials.gov/st udy/NCT05227664 URL:https://julienwillard.com/calendar/clinical#e-619a2118-1d52-460a-86fd-3 f531ba223fa END:VEVENT BEGIN:VEVENT UID:e924f092a37c5aad4cb15503a79ff1e6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:3D Medicines (Sichuan) Co.\, Ltd. KN035: Trial primary completion DESCRIPTION:As of 25 March 2026\, 3D Medicines (Sichuan) Co. estimated prim ary completion of a Phase 2 trial in Solid Tumor\, on 30 December 2026.\n\ nSource: clinicaltrials NCT03667170\nhttps://clinicaltrials.gov/study/NCT0 3667170 URL:https://julienwillard.com/calendar/clinical#e-4f4b3b53-ee6f-453c-b641-b e6a8b82a550 END:VEVENT BEGIN:VEVENT UID:9eb904c66f9a9f460b56fd26a8d7a317 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Janssen Research & Development\, LLC Cetrelimab: Trial primary comp letion DESCRIPTION:As of 31 July 2026\, Janssen Research & Development estimated p rimary completion of a Phase 3 trial in Urinary Bladder Neoplasms\, on 30 December 2026.\n\nSource: clinicaltrials NCT04658862\nhttps://clinicaltria ls.gov/study/NCT04658862 URL:https://julienwillard.com/calendar/clinical#e-ce4b3760-63d0-496a-94d5-0 a7699f1f660 END:VEVENT BEGIN:VEVENT UID:4ecaf663a9793b8b96340b8875f8b2ea DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ThromBio Pty. Ltd. TBO-309: 60 mg: Trial primary completion DESCRIPTION:As of 25 November 2025\, ThromBio Pty. estimated primary comple tion of a Phase 2 trial in Ischemic Stroke\, on 30 December 2026.\n\nSourc e: clinicaltrials NCT06813651\nhttps://clinicaltrials.gov/study/NCT0681365 1 URL:https://julienwillard.com/calendar/clinical#e-38afb856-9278-4555-a005-0 b95490113a7 END:VEVENT BEGIN:VEVENT UID:c61216004e01defa23a4a7bc5c56ce52 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261230 DTEND;VALUE=DATE:20261231 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. SHR-8068: Trial prima ry completion DESCRIPTION:As of 29 May 2026\, Suzhou Suncadia Biopharmaceuticals Co. esti mated primary completion of a Phase 2 trial in Biliary Tract Cancer\, on 3 0 December 2026.\n\nSource: clinicaltrials NCT06465563\nhttps://clinicaltr ials.gov/study/NCT06465563 URL:https://julienwillard.com/calendar/clinical#e-e9742efe-0562-4d07-a1d4-1 4b76e431f9b END:VEVENT BEGIN:VEVENT UID:34f328a3e62828b8242b1670391a36bc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chongqing Precision Biotech Co.\, Ltd BCMA targeted prime CAR-T cel ls: Trial primary completion DESCRIPTION:As of 25 February 2025\, Chongqing Precision Biotech Co. estima ted primary completion of a Phase 2 trial in Multiple Myeloma\, on 31 Dece mber 2026.\n\nSource: clinicaltrials NCT04776330\nhttps://clinicaltrials.g ov/study/NCT04776330 URL:https://julienwillard.com/calendar/clinical#e-d04cdc1a-93d1-4f97-8538-6 a9579c670a6 END:VEVENT BEGIN:VEVENT UID:2bfa0c74df8af2b698ca018bf33bdaa9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ono Pharmaceutical Co.\, Ltd. ONO-2020: Trial primary completion DESCRIPTION:As of 12 May 2026\, Ono Pharmaceutical Co. estimated primary co mpletion of a Phase 2 trial in Agitation Associated With Alzheimer's Disea se Dementia\, on 31 December 2026.\n\nSource: clinicaltrials NCT06803823\n https://clinicaltrials.gov/study/NCT06803823 URL:https://julienwillard.com/calendar/clinical#e-8402b991-79af-4559-b214-0 7022a127d2f END:VEVENT BEGIN:VEVENT UID:ddb8ebfb93828a2f499725b21919eb82 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Impact Therapeutics\, Inc. IMP9064: Trial primary completion DESCRIPTION:As of 1 April 2025\, Impact Therapeutics estimated primary comp letion of a Phase 2 trial in Solid Tumor\, on 31 December 2026.\n\nSource: clinicaltrials NCT05269316\nhttps://clinicaltrials.gov/study/NCT05269316 URL:https://julienwillard.com/calendar/clinical#e-a4201c38-6152-4999-acb5-e 787a1b97ed2 END:VEVENT BEGIN:VEVENT UID:04d5ef44ff6cede5046cda205fd3d85d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Iperboreal Pharma Srl XyloCore Low Strenght\, XyloCore Medium Stren ght\, XyloCore High Strenght: Trial primary completion DESCRIPTION:As of 24 March 2026\, Iperboreal Pharma Srl estimated primary c ompletion of a Phase 3 trial in End Stage Renal Disease\, on 31 December 2 026.\n\nSource: clinicaltrials NCT03994471\nhttps://clinicaltrials.gov/stu dy/NCT03994471 URL:https://julienwillard.com/calendar/clinical#e-3163948f-01c3-4038-a64f-e b174c60b9d2 END:VEVENT BEGIN:VEVENT UID:83e122fc8e72383152242442288ecb91 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Spirovant Sciences\, Inc. SP-101 and doxorubicin Cohort 1: Trial pr imary completion DESCRIPTION:As of 25 November 2024\, Spirovant Sciences estimated primary c ompletion of a Phase 2 trial in Cystic Fibrosis\, on 31 December 2026.\n\n Source: clinicaltrials NCT06526923\nhttps://clinicaltrials.gov/study/NCT06 526923 URL:https://julienwillard.com/calendar/clinical#e-3daac669-93fb-4b08-b9a2-f d1fefb49090 END:VEVENT BEGIN:VEVENT UID:ad7a2a34ad64670323eebc5338cfcecd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TheiaNova Ltd. Low-dose TGF-B3 and Dexamethasone Sodium Phosphate: Trial primary completion DESCRIPTION:As of 4 February 2026\, TheiaNova estimated primary completion of a Phase 2 trial in keratoconus\, on 31 December 2026.\n\nSource: clinic altrials NCT07388069\nhttps://clinicaltrials.gov/study/NCT07388069 URL:https://julienwillard.com/calendar/clinical#e-ba8cf631-d0b2-4ea1-9e47-6 f9c273e7450 END:VEVENT BEGIN:VEVENT UID:786a79212faa88b12a863d326308e54d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Innovent Biologics Technology Limited (Shanghai R&D Center) IBI302: Trial primary completion DESCRIPTION:As of 27 May 2026\, Innovent Biologics Technology estimated pri mary completion of a Phase 2 trial in Diabetic Macular Oedema\, on 31 Dece mber 2026.\n\nSource: clinicaltrials NCT06908876\nhttps://clinicaltrials.g ov/study/NCT06908876 URL:https://julienwillard.com/calendar/clinical#e-15dca72b-0023-43f4-bc85-0 6ed5f027086 END:VEVENT BEGIN:VEVENT UID:7ad119b39238fe8bf032886993109978 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tasly Pharmaceutical Group Co.\, Ltd Lianxiaxiaopi Granules: Trial primary completion DESCRIPTION:As of 20 January 2026\, Tasly Pharmaceutical Group Co. estimate d primary completion of a Phase 3 trial in Postprandial Distress Syndrome\ , on 31 December 2026.\n\nSource: clinicaltrials NCT06696261\nhttps://clin icaltrials.gov/study/NCT06696261 URL:https://julienwillard.com/calendar/clinical#e-959995a2-3a72-40f7-8de1-e ac62e168938 END:VEVENT BEGIN:VEVENT UID:7b5abaf67a2a8484632b81860a86b550 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ascentage Pharma Group Inc. lisaftoclax +BTK inhibitor: Trial prima ry completion DESCRIPTION:As of 18 June 2026\, Ascentage Pharma Group estimated primary c ompletion of a Phase 3 trial in cLL/SLL\, on 31 December 2026.\n\nSource: clinicaltrials NCT06104566\nhttps://clinicaltrials.gov/study/NCT06104566 URL:https://julienwillard.com/calendar/clinical#e-68c98cd9-8780-4075-a6ab-3 471d5435145 END:VEVENT BEGIN:VEVENT UID:f3dc2f843489e51a81e457fde75c252c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tasly Pharmaceutical Group Co.\, Ltd Mesenchymal stem cells(HucMSCs ): Trial primary completion DESCRIPTION:As of 9 January 2026\, Tasly Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Coronary Artery Bypass Grafting (CABG)\, on 31 December 2026.\n\nSource: clinicaltrials NCT07265349\nhttps ://clinicaltrials.gov/study/NCT07265349 URL:https://julienwillard.com/calendar/clinical#e-b564e7d9-5fb4-4147-9dba-f 9349bb751a0 END:VEVENT BEGIN:VEVENT UID:fb760a1274776ca7ce03ec1d7503f700 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer vepdegestrant: Trial primary completion DESCRIPTION:As of 6 May 2026\, Pfizer estimated primary completion of a Pha se 2 trial in Breast Cancer\, on 31 December 2026.\n\nSource: clinicaltria ls NCT06125522\nhttps://clinicaltrials.gov/study/NCT06125522 URL:https://julienwillard.com/calendar/clinical#e-b7e3f026-095d-4697-93fe-9 6b219a23406 END:VEVENT BEGIN:VEVENT UID:5bb75c0d956c096d47dee6eff16184c0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Atezolizumab: Trial primary completion DESCRIPTION:As of 10 July 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 3 trial in cancer\, on 31 December 2026.\n\nSource: clinic altrials NCT03148418\nhttps://clinicaltrials.gov/study/NCT03148418 URL:https://julienwillard.com/calendar/clinical#e-c7ec1d6d-1708-4381-aa7e-3 91fb59178e9 END:VEVENT BEGIN:VEVENT UID:18286abe7d84d546418a248abe002a39 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Beijing Tuohua Weiye Biotechnology Co.\, Ltd. Human Umbilical Cord Mesenchymal Stem Cells Injection: Trial primary completion DESCRIPTION:As of 17 February 2026\, Beijing Tuohua Weiye Biotechnology Co. estimated primary completion of a Phase 2 trial in Decompensated Hepatiti s B Cirrhosis\, on 31 December 2026.\n\nSource: clinicaltrials NCT07413549 \nhttps://clinicaltrials.gov/study/NCT07413549 URL:https://julienwillard.com/calendar/clinical#e-9d06b9c9-2843-4167-8fc4-f 2167f56a131 END:VEVENT BEGIN:VEVENT UID:dc1207803774765039eae8340a3097a1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:E-nitiate Biopharmaceuticals (Hangzhou) Co.\, Ltd. QY201 Tablets(5m g）: Trial primary completion DESCRIPTION:As of 17 July 2026\, E-nitiate Biopharmaceuticals (Hangzhou) Co . estimated primary completion of a Phase 2 trial in Adult Subjects With N on-Segmental Vitiligo\, on 31 December 2026.\n\nSource: clinicaltrials NCT 07712523\nhttps://clinicaltrials.gov/study/NCT07712523 URL:https://julienwillard.com/calendar/clinical#e-6591156b-4994-4f08-a668-b bf60f185699 END:VEVENT BEGIN:VEVENT UID:52f5d2e1b9e0ac7c779702e867608c3f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Henlius Biotech HLX43: Trial primary completion DESCRIPTION:As of 22 April 2026\, Shanghai Henlius Biotech estimated primar y completion of a Phase 2 trial in Cervical Cancer\, on 31 December 2026.\ n\nSource: clinicaltrials NCT06769152\nhttps://clinicaltrials.gov/study/NC T06769152 URL:https://julienwillard.com/calendar/clinical#e-91f0cb71-b0b8-417f-82c7-b 6fc27456964 END:VEVENT BEGIN:VEVENT UID:5855561323902400c349be52acafe1b4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jacobio Pharmaceuticals Co.\, Ltd. JAB-23E73: Trial primary complet ion DESCRIPTION:As of 20 January 2026\, Jacobio Pharmaceuticals Co. estimated p rimary completion of a Phase 2 trial in Advanced Solid Tumor\, on 31 Decem ber 2026.\n\nSource: clinicaltrials NCT06959615\nhttps://clinicaltrials.go v/study/NCT06959615 URL:https://julienwillard.com/calendar/clinical#e-6dea7e64-ec27-441b-8aeb-2 fad67dd9d5a END:VEVENT BEGIN:VEVENT UID:0ccd9d96e360f48ba7a71b9ce9e6b129 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Guangzhou JOYO Pharma Co.\, Ltd SC1011: Trial primary completion DESCRIPTION:As of 19 November 2024\, Guangzhou JOYO Pharma Co. estimated pr imary completion of a Phase 3 trial in Idiopathic Pulmonary Fibrosis\, on 31 December 2026.\n\nSource: clinicaltrials NCT06125327\nhttps://clinicalt rials.gov/study/NCT06125327 URL:https://julienwillard.com/calendar/clinical#e-21e0b680-d2d0-48f3-a076-f 4dcb8516030 END:VEVENT BEGIN:VEVENT UID:c95c7494fd5b40ef70223c2373cca033 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pell Bio-Med Technology Co.\, Ltd. CD19-targeted chimeric antigen r eceptor T-cell: Trial primary completion DESCRIPTION:As of 13 May 2025\, Pell Bio-Med Technology Co. estimated prima ry completion of a Phase 2 trial in Diffuse Large B Cell Lymphoma\, on 31 December 2026.\n\nSource: clinicaltrials NCT05326243\nhttps://clinicaltria ls.gov/study/NCT05326243 URL:https://julienwillard.com/calendar/clinical#e-83312d41-68ed-457c-93cc-3 c516ce5e55c END:VEVENT BEGIN:VEVENT UID:0578f07a38ec9ced999636927f917620 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Skingenix\, Inc. Investigational Drug\, MW-III: Trial primary compl etion DESCRIPTION:As of 16 March 2026\, Skingenix estimated primary completion of a Phase 2 trial in burns\, on 31 December 2026.\n\nSource: clinicaltrials NCT01297400\nhttps://clinicaltrials.gov/study/NCT01297400 URL:https://julienwillard.com/calendar/clinical#e-149fd98d-e021-415b-ad1b-c f162ab9cebb END:VEVENT BEGIN:VEVENT UID:7f49e56b43a39f3310d7132d96b3ec56 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Atezolizumab: Trial primary completion DESCRIPTION:As of 28 July 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 2 trial in Urothelial Cancer\, on 31 December 2026.\n\nSou rce: clinicaltrials NCT05645692\nhttps://clinicaltrials.gov/study/NCT05645 692 URL:https://julienwillard.com/calendar/clinical#e-b4c8fb59-1e13-485c-9fa9-9 b45e2aaaa51 END:VEVENT BEGIN:VEVENT UID:e964779974772d08cd66ae3a29234afb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd. SKB264: Trial pr imary completion DESCRIPTION:As of 8 May 2026\, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Metastatic Breast Cance r\, on 31 December 2026.\n\nSource: clinicaltrials NCT06081959\nhttps://cl inicaltrials.gov/study/NCT06081959 URL:https://julienwillard.com/calendar/clinical#e-9b5df16a-d43b-4691-acf4-7 83749e48fe0 END:VEVENT BEGIN:VEVENT UID:6bad680c20a9ef80a163d0a0649be515 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Lukas Biomedical Inc. ATL administration: Trial primary completion DESCRIPTION:As of 6 March 2025\, Lukas Biomedical estimated primary complet ion of a Phase 2 trial in Hepatocellular Carcinoma\, on 31 December 2026.\ n\nSource: clinicaltrials NCT05304481\nhttps://clinicaltrials.gov/study/NC T05304481 URL:https://julienwillard.com/calendar/clinical#e-6fa20c7a-e6d5-40f7-8170-6 67814f2f470 END:VEVENT BEGIN:VEVENT UID:ce661cfee3b3dfc7b21682309f81162a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Estrella Biopharma\, Inc. EB103: Trial primary completion DESCRIPTION:As of 7 August 2025\, Estrella Biopharma estimated primary comp letion of a Phase 2 trial in B-Cell Non-Hodgkin's Lymphoma (NHL)\, on 31 D ecember 2026.\n\nSource: clinicaltrials NCT06343311\nhttps://clinicaltrial s.gov/study/NCT06343311 URL:https://julienwillard.com/calendar/clinical#e-b4928b95-f570-4544-8203-3 1422c5f6228 END:VEVENT BEGIN:VEVENT UID:20b0e283d0522fceea9fac4811d4cba3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Insmed Incorporated Treprostinil Palmitil: Trial primary completion DESCRIPTION:As of 8 July 2026\, Insmed Incorporated estimated primary compl etion of a Phase 3 trial in Pulmonary Arterial Hypertension\, on 31 Decemb er 2026.\n\nSource: clinicaltrials NCT05649748\nhttps://clinicaltrials.gov /study/NCT05649748 URL:https://julienwillard.com/calendar/clinical#e-a5b4fe84-3e9c-49e2-bb29-d ff9437fb9cb END:VEVENT BEGIN:VEVENT UID:46bb0efd5e6b43d923a7d6f2218707cd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sano Chemicals Inc OCF001 Intravaginal Gel: Trial primary completio n DESCRIPTION:As of 15 June 2026\, Sano Chemicals estimated primary completio n of a Phase 2 trial in Candidiasis\, Vulvovaginal\, on 31 December 2026.\ n\nSource: clinicaltrials NCT07521137\nhttps://clinicaltrials.gov/study/NC T07521137 URL:https://julienwillard.com/calendar/clinical#e-c7feb2eb-e405-45ca-94c2-0 fac821a1eeb END:VEVENT BEGIN:VEVENT UID:70fa672e19c3a85747e75a69bab66216 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. IBI362: Trial primary completi on DESCRIPTION:As of 12 May 2026\, Innovent Biologics (Suzhou) Co. estimated p rimary completion of a Phase 3 trial in overweight\, on 31 December 2026.\ n\nSource: clinicaltrials NCT06884293\nhttps://clinicaltrials.gov/study/NC T06884293 URL:https://julienwillard.com/calendar/clinical#e-48dffd0d-e799-42ce-9a82-8 ee24ad719d9 END:VEVENT BEGIN:VEVENT UID:793045a6fa5750115a0485697533ca6c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Mabwell (Shanghai) Bioscience Co.\, Ltd. 9MW2821: Trial primary com pletion DESCRIPTION:As of 19 September 2024\, Mabwell (Shanghai) Bioscience Co. est imated primary completion of a Phase 2 trial in Advanced Urothelial Carcin oma\, on 31 December 2026.\n\nSource: clinicaltrials NCT06079112\nhttps:// clinicaltrials.gov/study/NCT06079112 URL:https://julienwillard.com/calendar/clinical#e-7e967bd3-f977-4e8d-94ad-e 7389874b97a END:VEVENT BEGIN:VEVENT UID:261d3d85da276142e71f4bf6f261bc6b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:RemeGen Co.\, Ltd. Telitacicept: Trial primary completion DESCRIPTION:As of 9 April 2026\, RemeGen Co. estimated primary completion o f a Phase 3 trial in Myasthenia Gravis\, Ocular\, on 31 December 2026.\n\n Source: clinicaltrials NCT07249632\nhttps://clinicaltrials.gov/study/NCT07 249632 URL:https://julienwillard.com/calendar/clinical#e-9f44b4d9-8366-4d1a-a068-1 806c276f146 END:VEVENT BEGIN:VEVENT UID:e901a6ec2932c633be92b25570cb58b8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Serum Institute of India Pvt. Ltd. Cervavac as three dose regimen: Trial primary completion DESCRIPTION:As of 29 June 2026\, Serum Institute of India Pvt. estimated pr imary completion of a Phase 3 trial in Human Papillomavirus Infection\, on 31 December 2026.\n\nSource: clinicaltrials NCT06281119\nhttps://clinical trials.gov/study/NCT06281119 URL:https://julienwillard.com/calendar/clinical#e-325dc972-3120-4de5-aae9-4 3e1a332906d END:VEVENT BEGIN:VEVENT UID:8526d475a3f9e2f48dfa7ff79eabd71d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Clearmind Medicine Inc. CMND-100: Trial primary completion DESCRIPTION:As of 31 March 2026\, Clearmind Medicine estimated primary comp letion of a Phase 2 trial in Alcohol Use Disorder\, on 31 December 2026.\n \nSource: clinicaltrials NCT05913752\nhttps://clinicaltrials.gov/study/NCT 05913752 URL:https://julienwillard.com/calendar/clinical#e-09bb6e07-f0f6-473e-bef2-5 e57cee601c4 END:VEVENT BEGIN:VEVENT UID:f83984639114d0c249246e7f308624de DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kartos Therapeutics\, Inc. Navtemadlin: Trial primary completion DESCRIPTION:As of 25 September 2025\, Kartos Therapeutics estimated primary completion of a Phase 3 trial in myelofibrosis\, on 31 December 2026.\n\n Source: clinicaltrials NCT06479135\nhttps://clinicaltrials.gov/study/NCT06 479135 URL:https://julienwillard.com/calendar/clinical#e-c9a58cc2-8f29-4a5d-b2ff-6 d8b2a1bd2d5 END:VEVENT BEGIN:VEVENT UID:ddb24378f41ffa2cc4b7201826818017 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Partner Therapeutics\, Inc. zenocutuzumab (MCLA-128): Trial primary completion DESCRIPTION:As of 29 April 2025\, Partner Therapeutics estimated primary co mpletion of a Phase 2 trial in Solid Tumours Harboring NRG1 Fusion\, on 31 December 2026.\n\nSource: clinicaltrials NCT02912949\nhttps://clinicaltri als.gov/study/NCT02912949 URL:https://julienwillard.com/calendar/clinical#e-972b46b2-b509-4c53-9ac5-9 110bc8e4c22 END:VEVENT BEGIN:VEVENT UID:712fffc7a0d9adc8de0783e184e19f97 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Galderma R&D Trifarotene: Trial primary completion DESCRIPTION:As of 21 November 2025\, Galderma R&D estimated primary complet ion of a Phase 3 trial in Acne Vulgaris\, on 31 December 2026.\n\nSource: clinicaltrials NCT07186413\nhttps://clinicaltrials.gov/study/NCT07186413 URL:https://julienwillard.com/calendar/clinical#e-930d107d-0256-4e75-b2ff-3 0e9f542d70c END:VEVENT BEGIN:VEVENT UID:bd55e0f173937b7926c0598d7ef20e2f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Rhizen Pharmaceuticals SA Tenalisib: Trial primary completion DESCRIPTION:As of 2 December 2025\, Rhizen Pharmaceuticals SA estimated pri mary completion of a Phase 2 trial in Triple Negative Breast Cancer (TNBC) \, on 31 December 2026.\n\nSource: clinicaltrials NCT06189209\nhttps://cli nicaltrials.gov/study/NCT06189209 URL:https://julienwillard.com/calendar/clinical#e-2fecb9e6-30b3-4060-8051-9 7de116ebca1 END:VEVENT BEGIN:VEVENT UID:a0afe4c7c98432e341c867ac53f1eb4b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Pharmaceuticals Holding Co.\, Ltd SPH4336 Tablets: Trial p rimary completion DESCRIPTION:As of 5 May 2026\, Shanghai Pharmaceuticals Holding Co. estimat ed primary completion of a Phase 2 trial in Breast Cancer Brain Metastases \, on 31 December 2026.\n\nSource: clinicaltrials NCT05872347\nhttps://cli nicaltrials.gov/study/NCT05872347 URL:https://julienwillard.com/calendar/clinical#e-14bb04f5-aa07-41df-aa95-1 cc486021e0f END:VEVENT BEGIN:VEVENT UID:5f3cf026baa0a75cd9eca9ae389d4d41 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Klus Pharma Inc. SKB264: Trial primary completion DESCRIPTION:As of 11 May 2026\, Klus Pharma estimated primary completion of a Phase 2 trial in Epithelial Ovarian Cancer\, on 31 December 2026.\n\nSo urce: clinicaltrials NCT04152499\nhttps://clinicaltrials.gov/study/NCT0415 2499 URL:https://julienwillard.com/calendar/clinical#e-18c575fb-816a-44de-b107-7 3e5fbccb62e END:VEVENT BEGIN:VEVENT UID:07b47a77b77a14e1010be61909a360bf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Synvida Biotechnology Co.\,Ltd. SV001: Trial primary compl etion DESCRIPTION:As of 11 February 2026\, Shanghai Synvida Biotechnology Co. est imated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibro sis(IPF)\, on 31 December 2026.\n\nSource: clinicaltrials NCT07121413\nhtt ps://clinicaltrials.gov/study/NCT07121413 URL:https://julienwillard.com/calendar/clinical#e-9583e7ce-414e-46ee-9cfb-f 46bc4e25df4 END:VEVENT BEGIN:VEVENT UID:84c6791a6234fe44465bbcead3ea6818 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hangzhou Hanx Biopharmaceuticals\, Ltd. HX301+/Temozolomide: Trial primary completion DESCRIPTION:As of 15 January 2025\, Hangzhou Hanx Biopharmaceuticals estima ted primary completion of a Phase 2 trial in glioma\, on 31 December 2026. \n\nSource: clinicaltrials NCT06703255\nhttps://clinicaltrials.gov/study/N CT06703255 URL:https://julienwillard.com/calendar/clinical#e-855d26eb-da67-48f4-8cee-a 53dba15aba5 END:VEVENT BEGIN:VEVENT UID:487547a9f90164fc27ed0c85504cba7a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Inovio Pharmaceuticals INO-5401: Trial primary completion DESCRIPTION:As of 4 May 2026\, Inovio Pharmaceuticals estimated primary com pletion of a Phase 2 trial in glioblastoma\, on 31 December 2026.\n\nSourc e: clinicaltrials NCT03491683\nhttps://clinicaltrials.gov/study/NCT0349168 3 URL:https://julienwillard.com/calendar/clinical#e-818f01a6-21be-41be-a62c-7 16375bd82db END:VEVENT BEGIN:VEVENT UID:e19fe422c01895fac96404916aed0958 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Valenta Pharm JSC 4-MUST: Trial primary completion DESCRIPTION:As of 11 July 2025\, Valenta Pharm JSC estimated primary comple tion of a Phase 2 trial in Chronic Cholecystitis\, on 31 December 2026.\n\ nSource: clinicaltrials NCT06842966\nhttps://clinicaltrials.gov/study/NCT0 6842966 URL:https://julienwillard.com/calendar/clinical#e-79208b3e-cb2b-40b1-8757-0 c51079dbe5d END:VEVENT BEGIN:VEVENT UID:75e7440e22426d7e295c1fb45600813e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hangzhou Highlightll Pharmaceutical Co.\, Ltd TLL-018: Trial primar y completion DESCRIPTION:As of 20 May 2026\, Hangzhou Highlightll Pharmaceutical Co. est imated primary completion of a Phase 3 trial in Rheumatoid Arthritis\, on 31 December 2026.\n\nSource: clinicaltrials NCT06887127\nhttps://clinicalt rials.gov/study/NCT06887127 URL:https://julienwillard.com/calendar/clinical#e-c0630fe1-01ff-46bf-91de-7 7a8509f0aff END:VEVENT BEGIN:VEVENT UID:044afad066446bad50214879f43e9a2c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:RemeGen Co.\, Ltd. RC48-ADC: Trial primary completion DESCRIPTION:As of 18 December 2023\, RemeGen Co. estimated primary completi on of a Phase 3 trial in Urothelial Carcinoma\, on 31 December 2026.\n\nSo urce: clinicaltrials NCT05302284\nhttps://clinicaltrials.gov/study/NCT0530 2284 URL:https://julienwillard.com/calendar/clinical#e-d6e583be-387f-4dc4-9562-f 7c27e3361e4 END:VEVENT BEGIN:VEVENT UID:15d68f9a5824c7d789b70baa2564e4bf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. Fuzuloparib \, Abiraterone acet ate and Prednisone: Trial primary completion DESCRIPTION:As of 31 December 2024\, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC)\, on 31 December 2026.\n\nSource: clinicaltrials N CT04691804\nhttps://clinicaltrials.gov/study/NCT04691804 URL:https://julienwillard.com/calendar/clinical#e-efea8c38-b891-47e3-a216-4 4bfc47a66ad END:VEVENT BEGIN:VEVENT UID:7534d524071c675cbb529fbe3b3289d3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hillhurst Biopharmaceuticals\, Inc. HBI-002: Trial primary completi on DESCRIPTION:As of 10 August 2026\, Hillhurst Biopharmaceuticals estimated p rimary completion of a Phase 2 trial in Parkinson Disease\, on 31 December 2026.\n\nSource: clinicaltrials NCT07005180\nhttps://clinicaltrials.gov/s tudy/NCT07005180 URL:https://julienwillard.com/calendar/clinical#e-5fbd0498-b621-4a87-a751-6 84c0aead222 END:VEVENT BEGIN:VEVENT UID:fef60f5e18e593588271285cb3cf4b22 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Pertuzumab: Trial primary completion DESCRIPTION:As of 11 August 2026\, Hoffmann-La Roche estimated primary comp letion of a Phase 3 trial in Solid Tumors\, on 31 December 2026.\n\nSource : clinicaltrials NCT02320435\nhttps://clinicaltrials.gov/study/NCT02320435 URL:https://julienwillard.com/calendar/clinical#e-da31f7d8-914f-451c-932f-7 4bd63bac2de END:VEVENT BEGIN:VEVENT UID:7be8f1df99fe07dee9adb7756640f1dd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:BioInvent International AB BI-1808: Trial primary completion DESCRIPTION:As of 18 February 2026\, BioInvent International estimated prim ary completion of a Phase 2 trial in Advanced Malignancies\, on 31 Decembe r 2026.\n\nSource: clinicaltrials NCT04752826\nhttps://clinicaltrials.gov/ study/NCT04752826 URL:https://julienwillard.com/calendar/clinical#e-ae093e94-471c-49fa-919b-2 01ae5936813 END:VEVENT BEGIN:VEVENT UID:b6985d0e24f3a77338172e42e646461c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer Palbociclib: Trial primary completion DESCRIPTION:As of 25 November 2025\, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer\, on 31 December 2026.\n\nSource: clinic altrials NCT05226871\nhttps://clinicaltrials.gov/study/NCT05226871 URL:https://julienwillard.com/calendar/clinical#e-3ffddcb9-f6b1-4f46-8b13-b b5da4a5c60f END:VEVENT BEGIN:VEVENT UID:bbd58b6e81e5f89e1dc04ea658b118cc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AUG Therapeutics AVTX-803: Trial primary completion DESCRIPTION:As of 1 May 2026\, AUG Therapeutics estimated primary completio n of a Phase 3 trial in Leukocyte Adhesion Deficiency\, on 31 December 202 6.\n\nSource: clinicaltrials NCT05754450\nhttps://clinicaltrials.gov/study /NCT05754450 URL:https://julienwillard.com/calendar/clinical#e-19417d38-12dc-4218-90dd-a 718fbf900d0 END:VEVENT BEGIN:VEVENT UID:2c61681cb5a3517e40686b4e60561750 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Valenta Pharm JSC Grammidin with anesthetic: Trial primary completi on DESCRIPTION:As of 10 July 2025\, Valenta Pharm JSC estimated primary comple tion of a Phase 2 trial in Pharyngitis Acute\, on 31 December 2026.\n\nSou rce: clinicaltrials NCT06843018\nhttps://clinicaltrials.gov/study/NCT06843 018 URL:https://julienwillard.com/calendar/clinical#e-e5ec3ef2-5e66-4215-a9f8-5 11df9aab890 END:VEVENT BEGIN:VEVENT UID:ee40fef97588831f691d306be6ae6e15 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Aveta Biomics\, Inc. APG-157: Trial primary completion DESCRIPTION:As of 8 June 2026\, Aveta Biomics estimated primary completion of a Phase 2 trial in glioma\, on 31 December 2026.\n\nSource: clinicaltri als NCT06011109\nhttps://clinicaltrials.gov/study/NCT06011109 URL:https://julienwillard.com/calendar/clinical#e-5db56148-2a3b-4fc1-87e3-2 cde789596c6 END:VEVENT BEGIN:VEVENT UID:b8b8a93521ec3a0672c2d5dab3640352 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Annexon\, Inc. Tanruprubart: Trial primary completion DESCRIPTION:As of 28 May 2026\, Annexon estimated primary completion of a P hase 3 trial in Guillain-Barre Syndrome\, on 31 December 2026.\n\nSource: clinicaltrials NCT07020819\nhttps://clinicaltrials.gov/study/NCT07020819 URL:https://julienwillard.com/calendar/clinical#e-45713dce-5e5b-4657-b153-b cd3097f4407 END:VEVENT BEGIN:VEVENT UID:04192b7bece9da4697669589f06646ff DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TRB Chemedica Artrodar: Trial primary completion DESCRIPTION:As of 22 November 2024\, TRB Chemedica estimated primary comple tion of a Phase 3 trial in Knee Osteoarthritis\, on 31 December 2026.\n\nS ource: clinicaltrials NCT04318041\nhttps://clinicaltrials.gov/study/NCT043 18041 URL:https://julienwillard.com/calendar/clinical#e-429a328c-7329-46b8-bf0e-5 66c4fa3edde END:VEVENT BEGIN:VEVENT UID:b5f7086dda53b32cbf3568974f740064 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Miltenyi Biomedicine GmbH zamtocabtagene autoleucel (MB-CART2019.1) : Trial primary completion DESCRIPTION:As of 13 July 2026\, Miltenyi Biomedicine estimated primary com pletion of a Phase 2 trial in Refractory Diffuse Large B Cell Lymphoma (DL BCL)\, on 31 December 2026.\n\nSource: clinicaltrials NCT04792489\nhttps:/ /clinicaltrials.gov/study/NCT04792489 URL:https://julienwillard.com/calendar/clinical#e-beec55b8-a68f-4d99-b25a-8 560d4284498 END:VEVENT BEGIN:VEVENT UID:ccb8ba9e5f1bbed9ad71d3143a19b10e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AskGene Pharma\, Inc. ASKG915: Trial primary completion DESCRIPTION:As of 27 January 2026\, AskGene Pharma estimated primary comple tion of a Phase 2 trial in Advanced Solid Tumors\, on 31 December 2026.\n\ nSource: clinicaltrials NCT05867420\nhttps://clinicaltrials.gov/study/NCT0 5867420 URL:https://julienwillard.com/calendar/clinical#e-7a60de03-1212-4586-9473-a c7e99b81a69 END:VEVENT BEGIN:VEVENT UID:6b11ecce8372983c45098c21f3892773 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Pharmaceuticals Holding Co.\, Ltd T3011 high dose: Trial p rimary completion DESCRIPTION:As of 5 May 2026\, Shanghai Pharmaceuticals Holding Co. estimat ed primary completion of a Phase 2 trial in Advanced Solid Tumors\, on 31 December 2026.\n\nSource: clinicaltrials NCT06214143\nhttps://clinicaltria ls.gov/study/NCT06214143 URL:https://julienwillard.com/calendar/clinical#e-c126af58-7ed0-4110-9725-b 17c52bf2407 END:VEVENT BEGIN:VEVENT UID:c3fca509a149378d1312e2f997f14ba1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TaiRx\, Inc. Nivolumab Injection [Opdivo]: Trial primary completion DESCRIPTION:As of 13 April 2026\, TaiRx estimated primary completion of a P hase 2 trial in Hepatocellular Carcinoma\, on 31 December 2026.\n\nSource: clinicaltrials NCT05257590\nhttps://clinicaltrials.gov/study/NCT05257590 URL:https://julienwillard.com/calendar/clinical#e-d00d2ef9-814e-45ae-90d5-5 541f013540b END:VEVENT BEGIN:VEVENT UID:7b3466e50d2689b43d2d763ee869bc56 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Elixiron Immunotherapeutics (Hong Kong) Ltd. EI-001: Trial primary completion DESCRIPTION:As of 5 June 2026\, Elixiron Immunotherapeutics (Hong Kong) est imated primary completion of a Phase 2 trial in Non-segmental Vitiligo\, o n 31 December 2026.\n\nSource: clinicaltrials NCT07223229\nhttps://clinica ltrials.gov/study/NCT07223229 URL:https://julienwillard.com/calendar/clinical#e-c442f20a-6bfa-4f6e-827c-3 0f2b2e853f4 END:VEVENT BEGIN:VEVENT UID:7114b3d6d78489a8765ff9e519051f8c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Evopoint Biosciences Inc. XNW28012: Trial primary completion DESCRIPTION:As of 15 April 2026\, Evopoint Biosciences estimated primary co mpletion of a Phase 2 trial in Advanced Solid Tumors\, on 31 December 2026 .\n\nSource: clinicaltrials NCT06799637\nhttps://clinicaltrials.gov/study/ NCT06799637 URL:https://julienwillard.com/calendar/clinical#e-b9d47797-1530-48a7-9767-4 56b0899ebff END:VEVENT BEGIN:VEVENT UID:09f122be08bb1319f9e2f1df6a481253 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Inavolisib: Trial primary completion DESCRIPTION:As of 27 July 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 3 trial in Metastatic Breast Cancer\, on 31 December 2026. \n\nSource: clinicaltrials NCT05894239\nhttps://clinicaltrials.gov/study/N CT05894239 URL:https://julienwillard.com/calendar/clinical#e-4dd40fca-9b40-472f-a038-c cc98ebdece9 END:VEVENT BEGIN:VEVENT UID:bf3b6302b5648ad9d159941d48ad5909 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tarsus Pharmaceuticals\, Inc. lotilaner: Trial primary completion DESCRIPTION:As of 2 March 2026\, Tarsus Pharmaceuticals estimated primary c ompletion of a Phase 2 trial in Ocular Rosacea\, on 31 December 2026.\n\nS ource: clinicaltrials NCT07443202\nhttps://clinicaltrials.gov/study/NCT074 43202 URL:https://julienwillard.com/calendar/clinical#e-fe59441d-9a94-4621-86e4-4 779c70ea72f END:VEVENT BEGIN:VEVENT UID:078b1b3b2c52fa3ff2ecbcd7c08766c9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Janssen Research & Development\, LLC Ibrutinib: Trial primary compl etion DESCRIPTION:As of 31 July 2026\, Janssen Research & Development estimated p rimary completion of a Phase 3 trial in Chronic Lymphocytic Leukemia\, on 31 December 2026.\n\nSource: clinicaltrials NCT01804686\nhttps://clinicalt rials.gov/study/NCT01804686 URL:https://julienwillard.com/calendar/clinical#e-f726bddd-db30-4fed-bda9-5 9f2354d369b END:VEVENT BEGIN:VEVENT UID:cc59ecbe1e11a020deb45790d2e84ef1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Astellas Pharma Global Development\, Inc. zolbetuximab: Trial prima ry completion DESCRIPTION:As of 18 June 2026\, Astellas Pharma Global Development estimat ed primary completion of a Phase 2 trial in Pharmacokinetics of Zolbetuxim ab\, on 31 December 2026.\n\nSource: clinicaltrials NCT03505320\nhttps://c linicaltrials.gov/study/NCT03505320 URL:https://julienwillard.com/calendar/clinical#e-cd78af66-adbc-4981-a7ae-4 8f56d349f72 END:VEVENT BEGIN:VEVENT UID:e897926e103de72c1b883540dd516d2d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vir Biotechnology\, Inc. Tobevibart: Trial primary completion DESCRIPTION:As of 8 April 2026\, Vir Biotechnology estimated primary comple tion of a Phase 3 trial in Viral Hepatitis\, on 31 December 2026.\n\nSourc e: clinicaltrials NCT06903338\nhttps://clinicaltrials.gov/study/NCT0690333 8 URL:https://julienwillard.com/calendar/clinical#e-dc7f453e-7f87-4db0-b34f-e eb419056b5a END:VEVENT BEGIN:VEVENT UID:d371bab5f0c9bbdfd76e97cd90e7a18d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Albireo\, an Ipsen Company Odevixibat: Trial primary completion DESCRIPTION:As of 2 July 2026\, Albireo\, an Ipsen estimated primary comple tion of a Phase 3 trial in Alagille Syndrome\, on 31 December 2026.\n\nSou rce: clinicaltrials NCT05035030\nhttps://clinicaltrials.gov/study/NCT05035 030 URL:https://julienwillard.com/calendar/clinical#e-a2711bfd-8933-4e8e-8d7e-7 394e4b61de8 END:VEVENT BEGIN:VEVENT UID:3259188fe256048907f431deab2cae3c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chongqing Precision Biotech Co.\, Ltd CD19 and CD22 targeted prime CAR-T cells: Trial primary completion DESCRIPTION:As of 25 February 2025\, Chongqing Precision Biotech Co. estima ted primary completion of a Phase 2 trial in b-ALL\, on 31 December 2026.\ n\nSource: clinicaltrials NCT04781634\nhttps://clinicaltrials.gov/study/NC T04781634 URL:https://julienwillard.com/calendar/clinical#e-570b32dc-61a1-4d7c-a7ca-5 8f4a9bf9185 END:VEVENT BEGIN:VEVENT UID:b639cee78d902a1ef886ff05ee767205 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cloudbreak Therapeutics\, LLC CBT-001: Trial primary completion DESCRIPTION:As of 24 September 2025\, Cloudbreak Therapeutics estimated pri mary completion of a Phase 3 trial in pterygium\, on 31 December 2026.\n\n Source: clinicaltrials NCT05456425\nhttps://clinicaltrials.gov/study/NCT05 456425 URL:https://julienwillard.com/calendar/clinical#e-27823096-33ff-478b-b339-7 20906b44dbe END:VEVENT BEGIN:VEVENT UID:69c28f903569f7fb37c7171c5f261954 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Cell Therapy Group Co.\,Ltd Super DC Vaccine: Trial primar y completion DESCRIPTION:As of 28 August 2025\, Shanghai Cell Therapy Group Co. estimate d primary completion of a Phase 2 trial in Solid Tumor Cancer\, on 31 Dece mber 2026.\n\nSource: clinicaltrials NCT07146672\nhttps://clinicaltrials.g ov/study/NCT07146672 URL:https://julienwillard.com/calendar/clinical#e-5d3f61b9-263f-47c5-b06b-b 49b4ff2c132 END:VEVENT BEGIN:VEVENT UID:a65b07d7b2d0172701ee55f8a148e44f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Olatec Therapeutics\, Inc. Dapansutrile: Trial primary completion DESCRIPTION:As of 11 March 2026\, Olatec Therapeutics estimated primary com pletion of a Phase 3 trial in Acute Gout Flare\, on 31 December 2026.\n\nS ource: clinicaltrials NCT05658575\nhttps://clinicaltrials.gov/study/NCT056 58575 URL:https://julienwillard.com/calendar/clinical#e-e00b904d-4622-4bca-8ae4-a 7d391736c21 END:VEVENT BEGIN:VEVENT UID:2b139790cf7ae7b095b0fa1e466d07d7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shenyang Sunshine Pharmaceutical Co.\, LTD. SSGJ-705: Trial primary completion DESCRIPTION:As of 3 August 2025\, Shenyang Sunshine Pharmaceutical Co. esti mated primary completion of a Phase 2 trial in Locally Advanced\, Recurren t or Metastatic Malignancies\, on 31 December 2026.\n\nSource: clinicaltri als NCT07022002\nhttps://clinicaltrials.gov/study/NCT07022002 URL:https://julienwillard.com/calendar/clinical#e-8cc6a108-26b7-43f0-87ab-1 b42a7e5f3f3 END:VEVENT BEGIN:VEVENT UID:1199bfa4f4cb3fff7cd5d69a24998ecd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Innovent Biologics (Suzhou) Co. Ltd. IBI311: Trial primary completi on DESCRIPTION:As of 17 November 2025\, Innovent Biologics (Suzhou) Co. estima ted primary completion of a Phase 3 trial in Thyroid Eye Disease\, on 31 D ecember 2026.\n\nSource: clinicaltrials NCT07113262\nhttps://clinicaltrial s.gov/study/NCT07113262 URL:https://julienwillard.com/calendar/clinical#e-9b3190bf-73f9-4a94-a453-8 9cbaa734e88 END:VEVENT BEGIN:VEVENT UID:a62145d20f640748f58b587be32c8aec DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Akeso AK112: Trial primary completion DESCRIPTION:As of 9 March 2026\, Akeso estimated primary completion of a Ph ase 2 trial in Advanced Malignant Tumors\, on 31 December 2026.\n\nSource: clinicaltrials NCT05229497\nhttps://clinicaltrials.gov/study/NCT05229497 URL:https://julienwillard.com/calendar/clinical#e-892f3408-5830-458d-98e8-9 a1be4b6e8e2 END:VEVENT BEGIN:VEVENT UID:c72446ddf2eddac784f8a4be3faeb91b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Azure Biotech Inc. Lasofoxifene Tartrate: Trial primary completion DESCRIPTION:As of 22 May 2026\, Azure Biotech estimated primary completion of a Phase 2 trial in Vulvo Vaginal Atrophy (VVA)\, on 31 December 2026.\n \nSource: clinicaltrials NCT06197568\nhttps://clinicaltrials.gov/study/NCT 06197568 URL:https://julienwillard.com/calendar/clinical#e-2f3a4ddb-4640-4805-b409-f f63ef5378a6 END:VEVENT BEGIN:VEVENT UID:bfccfc19208386d5e0eee58434f1c4d8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tioga Pharmaceuticals Asimadoline: Trial primary completion DESCRIPTION:As of 9 September 2025\, Tioga Pharmaceuticals estimated primar y completion of a Phase 2 trial in Vasomotor Symptoms\, on 31 December 202 6.\n\nSource: clinicaltrials NCT07042516\nhttps://clinicaltrials.gov/study /NCT07042516 URL:https://julienwillard.com/calendar/clinical#e-9239a498-af88-4b62-b271-c 92386f14077 END:VEVENT BEGIN:VEVENT UID:b54d83ddbdcde76186a0ad04764ea161 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Mapi Pharma Ltd. Cariprazine Depot: Trial primary completion DESCRIPTION:As of 1 May 2026\, Mapi Pharma estimated primary completion of a Phase 2 trial in schizophrenia\, on 31 December 2026.\n\nSource: clinica ltrials NCT07185815\nhttps://clinicaltrials.gov/study/NCT07185815 URL:https://julienwillard.com/calendar/clinical#e-c8efb1ec-5cb4-4bfd-9453-d b0361940b14 END:VEVENT BEGIN:VEVENT UID:802080c51a86140c8a9a32684864b6d5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Remedy MDMA assisted psychotherapy: Trial primary completion DESCRIPTION:As of 26 November 2024\, Remedy estimated primary completion of a Phase 2 trial in Post Traumatic Stress Disorder\, on 31 December 2026.\ n\nSource: clinicaltrials NCT06044675\nhttps://clinicaltrials.gov/study/NC T06044675 URL:https://julienwillard.com/calendar/clinical#e-94d5661c-784a-4b2e-b056-4 e25a4a60047 END:VEVENT BEGIN:VEVENT UID:f214cb33418cfb605d3565ea69752e8f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Lin BioScience\, Inc LBS-007: Trial primary completion DESCRIPTION:As of 27 March 2026\, Lin BioScience estimated primary completi on of a Phase 2 trial in Relapsed or Resistant Acute Leukaemias\, on 31 De cember 2026.\n\nSource: clinicaltrials NCT05756322\nhttps://clinicaltrials .gov/study/NCT05756322 URL:https://julienwillard.com/calendar/clinical#e-5d3965ce-84de-4755-af77-b de74939f5e7 END:VEVENT BEGIN:VEVENT UID:c22741e60c25c99882cd8b46af1a1bc6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kamau Therapeutics nula-cel Drug Product: Trial primary completion DESCRIPTION:As of 2 July 2026\, Kamau Therapeutics estimated primary comple tion of a Phase 2 trial in Sickle Cell Disease\, on 31 December 2026.\n\nS ource: clinicaltrials NCT04819841\nhttps://clinicaltrials.gov/study/NCT048 19841 URL:https://julienwillard.com/calendar/clinical#e-059796ca-58ab-4121-8be3-f e98b56798fd END:VEVENT BEGIN:VEVENT UID:97d695da43db0c1ec184e6aad9a94768 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Laboratorios Silanes S.A. de C.V. Etoricoxib + Betamethasone fixed dose: Trial primary completion DESCRIPTION:As of 3 April 2025\, Laboratorios Silanes S.A. de C.V. estimate d primary completion of a Phase 3 trial in Gout Arthritis\, on 31 December 2026.\n\nSource: clinicaltrials NCT06863701\nhttps://clinicaltrials.gov/s tudy/NCT06863701 URL:https://julienwillard.com/calendar/clinical#e-ba40ce3e-25e3-4bdb-b024-f 025790696dc END:VEVENT BEGIN:VEVENT UID:ff046a57fe9d2f5c3068e9863d90ecd6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Clarity Pharmaceuticals Ltd 64Cu-SAR-bisPSMA: Trial primary complet ion DESCRIPTION:As of 14 May 2026\, Clarity Pharmaceuticals estimated primary c ompletion of a Phase 3 trial in Prostate Cancer\, on 31 December 2026.\n\n Source: clinicaltrials NCT06970847\nhttps://clinicaltrials.gov/study/NCT06 970847 URL:https://julienwillard.com/calendar/clinical#e-4a5f027a-6c22-4aa1-b7db-d b626bad26f1 END:VEVENT BEGIN:VEVENT UID:2cff91cf76c048e784ac65cb3424ebde DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Jiaolian Drug Research and Development Co.\, Ltd B007: Tri al primary completion DESCRIPTION:As of 5 May 2026\, Shanghai Jiaolian Drug Research and Developm ent Co. estimated primary completion of a Phase 3 trial in pemphigus\, on 31 December 2026.\n\nSource: clinicaltrials NCT06454357\nhttps://clinicalt rials.gov/study/NCT06454357 URL:https://julienwillard.com/calendar/clinical#e-a7e01604-e7ff-4a9d-937e-a e86ef718fc6 END:VEVENT BEGIN:VEVENT UID:4c82623e93a0e99159f3867e17551adf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Genfleet Therapeutics (Shanghai) Inc. GFH009: Trial primary complet ion DESCRIPTION:As of 12 August 2025\, Genfleet Therapeutics (Shanghai) estimat ed primary completion of a Phase 2 trial in Large B-cell Lymphoma\, on 31 December 2026.\n\nSource: clinicaltrials NCT06375733\nhttps://clinicaltria ls.gov/study/NCT06375733 URL:https://julienwillard.com/calendar/clinical#e-0c9b7b75-71c9-40cf-a08a-1 45933f1d199 END:VEVENT BEGIN:VEVENT UID:4504f20589c813c0e025275ad9ac9b54 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Takeda Maribavir: Trial primary completion DESCRIPTION:As of 2 March 2026\, Takeda estimated primary completion of a P hase 3 trial in cytomegalovirus (CMV)\, on 31 December 2026.\n\nSource: cl inicaltrials NCT06439342\nhttps://clinicaltrials.gov/study/NCT06439342 URL:https://julienwillard.com/calendar/clinical#e-1e242845-1c1d-454f-a68a-8 c1e512cc80f END:VEVENT BEGIN:VEVENT UID:65c508ae0049d4df6fe2e41ba86b62dc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai RAAS Blood Products Co.\, Ltd. SR604: Trial primary comple tion DESCRIPTION:As of 12 June 2026\, Shanghai RAAS Blood Products Co. estimated primary completion of a Phase 2 trial in Hemophilia A\, on 31 December 20 26.\n\nSource: clinicaltrials NCT07644832\nhttps://clinicaltrials.gov/stud y/NCT07644832 URL:https://julienwillard.com/calendar/clinical#e-ee77b483-3a32-4a21-8cf3-4 e149b186da8 END:VEVENT BEGIN:VEVENT UID:89058f660430e2450714b29cae4f8194 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd. KL590586 Capsule : Trial primary completion DESCRIPTION:As of 8 May 2026\, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor\, on 31 December 2026.\n\nSource: clinicaltrials NCT05265091\nhttps://clinic altrials.gov/study/NCT05265091 URL:https://julienwillard.com/calendar/clinical#e-7bee1bb7-79de-4697-9b16-3 d70a4c529ed END:VEVENT BEGIN:VEVENT UID:21c449bda55693be1df19814a25ea10a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:XyloCor Therapeutics\, Inc. XC001: Trial primary completion DESCRIPTION:As of 3 August 2025\, XyloCor Therapeutics estimated primary co mpletion of a Phase 2 trial in Refractory Angina\, on 31 December 2026.\n\ nSource: clinicaltrials NCT07048808\nhttps://clinicaltrials.gov/study/NCT0 7048808 URL:https://julienwillard.com/calendar/clinical#e-09efa084-c7c5-4572-b1e3-e 4dc24ea604a END:VEVENT BEGIN:VEVENT UID:d5a0fb9f7e761c3f0d9e6c3c8aa95412 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jazz Pharmaceuticals Zanidatamab: Trial primary completion DESCRIPTION:As of 10 July 2026\, Jazz Pharmaceuticals estimated primary com pletion of a Phase 2 trial in Breast Cancer\, on 31 December 2026.\n\nSour ce: clinicaltrials NCT06695845\nhttps://clinicaltrials.gov/study/NCT066958 45 URL:https://julienwillard.com/calendar/clinical#e-bbb987b2-54c0-4100-9401-a 4a1a6c60a3a END:VEVENT BEGIN:VEVENT UID:f83eefc51268d49e85cfd7a8a9ae53ee DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sarepta Therapeutics\, Inc. SRP-1003 IV Infusion: Trial primary com pletion DESCRIPTION:As of 11 August 2026\, Sarepta Therapeutics estimated primary c ompletion of a Phase 2 trial in Myotonic Dystrophy 1\, on 31 December 2026 .\n\nSource: clinicaltrials NCT06138743\nhttps://clinicaltrials.gov/study/ NCT06138743 URL:https://julienwillard.com/calendar/clinical#e-d18a3956-f539-4831-8964-5 d6c265f29b2 END:VEVENT BEGIN:VEVENT UID:e79b549a4e76bccda403d79cbaaf0eee DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Excyte Biopharma Ltd YK012: Trial primary completion DESCRIPTION:As of 6 February 2026\, Excyte Biopharma estimated primary comp letion of a Phase 2 trial in B-cell Acute Lymphoblastic Leukemia\, on 31 D ecember 2026.\n\nSource: clinicaltrials NCT06580301\nhttps://clinicaltrial s.gov/study/NCT06580301 URL:https://julienwillard.com/calendar/clinical#e-145c1165-2b05-4b12-9b71-e 97035e1e9a3 END:VEVENT BEGIN:VEVENT UID:81be4c4b7c752c23283635270d5da08d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GeoVax\, Inc. COVID-19 Vaccine: Trial primary completion DESCRIPTION:As of 11 February 2026\, GeoVax estimated primary completion of a Phase 2 trial in COVID-19 Infection\, on 31 December 2026.\n\nSource: c linicaltrials NCT04977024\nhttps://clinicaltrials.gov/study/NCT04977024 URL:https://julienwillard.com/calendar/clinical#e-89ef54d4-7578-4619-9897-7 ecc7667a72d END:VEVENT BEGIN:VEVENT UID:ee8eca52dce06c639bfbeb51b754fa1e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amicus Therapeutics migalastat HCl 150 mg: Trial primary completion DESCRIPTION:As of 6 July 2026\, Amicus Therapeutics estimated primary compl etion of a Phase 3 trial in Fabry Disease\, on 31 December 2026.\n\nSource : clinicaltrials NCT04020055\nhttps://clinicaltrials.gov/study/NCT04020055 URL:https://julienwillard.com/calendar/clinical#e-c562d7dd-1702-4d73-92a7-7 8c3084fa907 END:VEVENT BEGIN:VEVENT UID:e630720d8f9dbe319b00aaede0110261 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Excelsior EX039: Trial primary completion DESCRIPTION:As of 26 February 2025\, Excelsior estimated primary completion of a Phase 2 trial in Alzheimer Disease\, on 31 December 2026.\n\nSource: clinicaltrials NCT05413655\nhttps://clinicaltrials.gov/study/NCT05413655 URL:https://julienwillard.com/calendar/clinical#e-7d1ec24e-0bc7-4994-9d9d-d 51ab9259dd9 END:VEVENT BEGIN:VEVENT UID:e6864a566818c9a63422049228a42f05 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Newron Pharmaceuticals SPA Evenamide 15 mg bid: Trial primary compl etion DESCRIPTION:As of 30 July 2026\, Newron Pharmaceuticals SPA estimated prima ry completion of a Phase 3 trial in Treatment-resistant Schizophrenia\, on 31 December 2026.\n\nSource: clinicaltrials NCT07184619\nhttps://clinical trials.gov/study/NCT07184619 URL:https://julienwillard.com/calendar/clinical#e-4026e87d-47e4-4338-a930-7 4929ee5aeda END:VEVENT BEGIN:VEVENT UID:759ee8a63cced2b95679b3326e2426c2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NaviFUS Corporation Bevacizumab: Trial primary completion DESCRIPTION:As of 9 April 2026\, NaviFUS estimated primary completion of a Phase 3 trial in Glioblastoma Multiforme\, on 31 December 2026.\n\nSource: clinicaltrials NCT06496971\nhttps://clinicaltrials.gov/study/NCT06496971 URL:https://julienwillard.com/calendar/clinical#e-32e9a027-4e26-47c8-bf39-c b567f413e4c END:VEVENT BEGIN:VEVENT UID:db33b5fd0f7d009473dbcd0e58d518d7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ScinnoHub Pharmaceutical Co.\, Ltd. Low-dose BT-114143: Trial prima ry completion DESCRIPTION:As of 15 December 2025\, ScinnoHub Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Total Knee Arthroplasty\, on 31 December 2026.\n\nSource: clinicaltrials NCT07127042\nhttps://clinicaltria ls.gov/study/NCT07127042 URL:https://julienwillard.com/calendar/clinical#e-a2356f11-a683-40fc-94c1-6 685d627b918 END:VEVENT BEGIN:VEVENT UID:5b81bf849b1827730ff83047f6b34395 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ono Pharmaceutical Co.\, Ltd. ONO-4538: Trial primary completion DESCRIPTION:As of 3 June 2025\, Ono Pharmaceutical Co. estimated primary co mpletion of a Phase 2 trial in pan-tumor\, on 31 December 2026.\n\nSource: clinicaltrials NCT04566380\nhttps://clinicaltrials.gov/study/NCT04566380 URL:https://julienwillard.com/calendar/clinical#e-1eb01fe2-2f7a-41a0-910c-a ad472d62f82 END:VEVENT BEGIN:VEVENT UID:74187a0f4620bbe620d39269f423b390 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Imbioray (Hangzhou) Biomedicine Co.\, Ltd. IBR854: Trial primary co mpletion DESCRIPTION:As of 2 July 2026\, Imbioray (Hangzhou) Biomedicine Co. estimat ed primary completion of a Phase 2 trial in Renal Cell Carcinoma (RCC)\, o n 31 December 2026.\n\nSource: clinicaltrials NCT07087158\nhttps://clinica ltrials.gov/study/NCT07087158 URL:https://julienwillard.com/calendar/clinical#e-fd3aa78e-3f97-4dfc-8069-9 a18a4d2a48c END:VEVENT BEGIN:VEVENT UID:f3120cb0ed51cf4a0e0cdc9256506460 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Corza Medical GmbH TachoSil: Trial primary completion DESCRIPTION:As of 30 June 2026\, Corza Medical estimated primary completion of a Phase 3 trial in hemorrhage\, on 31 December 2026.\n\nSource: clinic altrials NCT06664775\nhttps://clinicaltrials.gov/study/NCT06664775 URL:https://julienwillard.com/calendar/clinical#e-4aa03e93-9cd5-4027-86b1-7 1a01623705f END:VEVENT BEGIN:VEVENT UID:48107cc1241832cf6cf8c43e8c317bfc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biocity Biopharmaceutics Co.\, Ltd. SC0062 strength 10mg: Trial pri mary completion DESCRIPTION:As of 17 February 2025\, Biocity Biopharmaceutics Co. estimated primary completion of a Phase 3 trial in IgA Nephropathy (IgAN)\, on 31 D ecember 2026.\n\nSource: clinicaltrials NCT06819826\nhttps://clinicaltrial s.gov/study/NCT06819826 URL:https://julienwillard.com/calendar/clinical#e-3fad6e01-b3ad-489b-94f9-1 3427110af0e END:VEVENT BEGIN:VEVENT UID:0beb752662f893563569a5d7219aa992 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Avistone Biotechnology Co.\, Ltd. Vebreltinib: Trial primary comple tion DESCRIPTION:As of 21 May 2025\, Avistone Biotechnology Co. estimated primar y completion of a Phase 2 trial in Non-Small-Cell Lung Cancer\, on 31 Dece mber 2026.\n\nSource: clinicaltrials NCT06343064\nhttps://clinicaltrials.g ov/study/NCT06343064 URL:https://julienwillard.com/calendar/clinical#e-957739ba-daf2-410c-bbf3-e 1f629e24420 END:VEVENT BEGIN:VEVENT UID:3d794a1228bbfc1c25ca67972f76a500 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Frantz Viral Therapeutics\, LLC Artesunate ointment: Trial primary completion DESCRIPTION:As of 18 May 2025\, Frantz Viral Therapeutics estimated primary completion of a Phase 2 trial in Anal High-grade Squamous Intraepithelial Lesion\, on 31 December 2026.\n\nSource: clinicaltrials NCT06206564\nhttp s://clinicaltrials.gov/study/NCT06206564 URL:https://julienwillard.com/calendar/clinical#e-89ecbedd-7317-45af-95cb-3 7d2d2c12524 END:VEVENT BEGIN:VEVENT UID:b19b0955bf3bb140a2adacd3027ca16e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Durvalumab: Trial primary completion DESCRIPTION:As of 11 August 2026\, AstraZeneca estimated primary completion of a Phase 3 trial in cancer\, on 31 December 2026.\n\nSource: clinicaltr ials NCT05303532\nhttps://clinicaltrials.gov/study/NCT05303532 URL:https://julienwillard.com/calendar/clinical#e-7953d068-198c-4fd4-b2aa-d 5217100b64e END:VEVENT BEGIN:VEVENT UID:2ca4b7ec1370e29599104f2d3deeaf8e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer Avelumab: Trial primary completion DESCRIPTION:As of 22 June 2026\, Pfizer estimated primary completion of a P hase 3 trial in Advanced Malignancies\, on 31 December 2026.\n\nSource: cl inicaltrials NCT05059522\nhttps://clinicaltrials.gov/study/NCT05059522 URL:https://julienwillard.com/calendar/clinical#e-664d79fc-3c89-4f67-abec-0 b128aca98d5 END:VEVENT BEGIN:VEVENT UID:46e5ed9f0969c82c16c5f2511db4475e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:JCR Pharmaceuticals Co.\, Ltd. JR-141: Trial primary completion DESCRIPTION:As of 24 July 2025\, JCR Pharmaceuticals Co. estimated primary completion of a Phase 2 trial in Mucopolysaccharidosis II\, on 31 December 2026.\n\nSource: clinicaltrials NCT03708965\nhttps://clinicaltrials.gov/s tudy/NCT03708965 URL:https://julienwillard.com/calendar/clinical#e-7767161a-b5ac-47f2-bf84-c bac6e16c841 END:VEVENT BEGIN:VEVENT UID:9dab23fa4bb739e66d8973a8992773e9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Blueprint Medicines Corporation BLU-808: Trial primary completion DESCRIPTION:As of 22 July 2026\, Blueprint Medicines estimated primary comp letion of a Phase 2 trial in Chronic Inducible Urticaria\, on 31 December 2026.\n\nSource: clinicaltrials NCT06931405\nhttps://clinicaltrials.gov/st udy/NCT06931405 URL:https://julienwillard.com/calendar/clinical#e-eb9e7266-9370-42da-bc09-4 81765cb82ee END:VEVENT BEGIN:VEVENT UID:2171438c00477b456e4ba0fb546651ad DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shionogi Sivopixant: Trial primary completion DESCRIPTION:As of 6 May 2026\, Shionogi estimated primary completion of a P hase 2 trial in Sleep Apnea\, on 31 December 2026.\n\nSource: clinicaltria ls NCT06776432\nhttps://clinicaltrials.gov/study/NCT06776432 URL:https://julienwillard.com/calendar/clinical#e-3ebe8e03-7ddf-4c5a-880c-4 454f4acfa47 END:VEVENT BEGIN:VEVENT UID:9e81628f6215fcf11e6b74c6e3f451df DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Supergene\, LLC Recombinant non-immunogenic staphylokinase (Fortely zin®): Trial primary completion DESCRIPTION:As of 1 December 2025\, Supergene estimated primary completion of a Phase 3 trial in Acute Limb Ischemia\, on 31 December 2026.\n\nSource : clinicaltrials NCT05372718\nhttps://clinicaltrials.gov/study/NCT05372718 URL:https://julienwillard.com/calendar/clinical#e-38783e0a-abc4-4d55-a5cd-d c218b6665bb END:VEVENT BEGIN:VEVENT UID:c4c3e6a02273799eae4d96dbfaba2008 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. SHR-A1811: Trial primary comple tion DESCRIPTION:As of 22 August 2025\, Jiangsu HengRui Medicine Co. estimated p rimary completion of a Phase 3 trial on 31 December 2026.\n\nSource: clini caltrials NCT05424835\nhttps://clinicaltrials.gov/study/NCT05424835 URL:https://julienwillard.com/calendar/clinical#e-665a3338-8d14-4a7e-85e7-5 75ba623a032 END:VEVENT BEGIN:VEVENT UID:7fe66c03ef826fa5eaa1a15e5a09d809 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Afimkibart: Trial primary completion DESCRIPTION:As of 23 June 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 2 trial in Crohns Disease\, on 31 December 2026.\n\nSource : clinicaltrials NCT05910528\nhttps://clinicaltrials.gov/study/NCT05910528 URL:https://julienwillard.com/calendar/clinical#e-e920edb4-bc5c-4c42-a630-4 4bfcd88a867 END:VEVENT BEGIN:VEVENT UID:8c6060a530bc0514b903266ecb1666e5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Pharmaceuticals Holding Co.\, Ltd SPH4336: Trial primary c ompletion DESCRIPTION:As of 6 August 2026\, Shanghai Pharmaceuticals Holding Co. esti mated primary completion of a Phase 2 trial in Advanced Solid Tumors\, on 31 December 2026.\n\nSource: clinicaltrials NCT05944224\nhttps://clinicalt rials.gov/study/NCT05944224 URL:https://julienwillard.com/calendar/clinical#e-f48ed01b-8880-4823-bc48-e b195f43a0e2 END:VEVENT BEGIN:VEVENT UID:64f4c24950af04e00dac4b01afc38447 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer PF-07104091 monotherapy dose escalation: Trial primary compl etion DESCRIPTION:As of 6 May 2026\, Pfizer estimated primary completion of a Pha se 2 trial in Small Cell Lung Cancer\, on 31 December 2026.\n\nSource: cli nicaltrials NCT04553133\nhttps://clinicaltrials.gov/study/NCT04553133 URL:https://julienwillard.com/calendar/clinical#e-503d2225-2195-4467-8d0a-3 5fac3f40ab0 END:VEVENT BEGIN:VEVENT UID:b1fbf96e7c30cb92f303a8d2a103f733 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jiangsu HengRui Medicine Co.\, Ltd. SHR-A1811: Trial primary comple tion DESCRIPTION:As of 17 July 2026\, Jiangsu HengRui Medicine Co. estimated pri mary completion of a Phase 2 trial on 31 December 2026.\n\nSource: clinica ltrials NCT06413745\nhttps://clinicaltrials.gov/study/NCT06413745 URL:https://julienwillard.com/calendar/clinical#e-90f5f9f9-6c26-4dcd-aa8e-1 72e663d792e END:VEVENT BEGIN:VEVENT UID:839c27caaaffccd6ba1658274f03761b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GeneCradle Inc GC101 adeno-associated virus injection: Trial primar y completion DESCRIPTION:As of 5 June 2025\, GeneCradle estimated primary completion of a Phase 3 trial in SMA - Spinal Muscular Atrophy\, on 31 December 2026.\n\ nSource: clinicaltrials NCT06971094\nhttps://clinicaltrials.gov/study/NCT0 6971094 URL:https://julienwillard.com/calendar/clinical#e-06703282-6525-45bb-aaa7-d 3de410142d3 END:VEVENT BEGIN:VEVENT UID:0881d37a575c759cf4c0ed1c851dec37 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AMO Pharma Limited Tideglusib: Trial primary completion DESCRIPTION:As of 28 May 2025\, AMO Pharma estimated primary completion of a Phase 3 trial in Congenital Myotonic Dystrophy\, on 31 December 2026.\n\ nSource: clinicaltrials NCT05004129\nhttps://clinicaltrials.gov/study/NCT0 5004129 URL:https://julienwillard.com/calendar/clinical#e-d45ab580-d6e7-464a-abee-d 329696a85b9 END:VEVENT BEGIN:VEVENT UID:20a1caf5af021d3ea24408768b2d79a7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Allist Pharmaceuticals\, Inc. JAB-21822: Trial primary completion DESCRIPTION:As of 13 March 2026\, Allist Pharmaceuticals estimated primary completion of a Phase 2 trial in KRAS P.G12C\, on 31 December 2026.\n\nSou rce: clinicaltrials NCT06008288\nhttps://clinicaltrials.gov/study/NCT06008 288 URL:https://julienwillard.com/calendar/clinical#e-9318804d-8f37-4d5c-b9cb-2 c266381be92 END:VEVENT BEGIN:VEVENT UID:967251ee4039b2a0e1fb2f6a101b6060 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Zhejiang ACEA Pharmaceutical Co. Ltd. STI-6129: Trial primary compl etion DESCRIPTION:As of 15 August 2025\, Zhejiang ACEA Pharmaceutical Co. estimat ed primary completion of a Phase 2 trial in Relapsed or Refractory Multipl e Myeloma\, on 31 December 2026.\n\nSource: clinicaltrials NCT05565807\nht tps://clinicaltrials.gov/study/NCT05565807 URL:https://julienwillard.com/calendar/clinical#e-2fa53ae1-a57e-4ebe-83f3-2 90073c05c01 END:VEVENT BEGIN:VEVENT UID:38dfebb8c2c3e71437883cc8e4bdd348 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MediciNova MN-001: Trial primary completion DESCRIPTION:As of 5 February 2026\, MediciNova estimated primary completion of a Phase 2 trial in Diabetes Mellitus\, Type 2\, on 31 December 2026.\n \nSource: clinicaltrials NCT05464784\nhttps://clinicaltrials.gov/study/NCT 05464784 URL:https://julienwillard.com/calendar/clinical#e-156070e3-d1f5-4d63-8b07-f 5c08284419a END:VEVENT BEGIN:VEVENT UID:77fd564744f2e640550165870f4b74b7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Jiaolian Drug Research and Development Co.\, Ltd B007: Tri al primary completion DESCRIPTION:As of 5 May 2026\, Shanghai Jiaolian Drug Research and Developm ent Co. estimated primary completion of a Phase 3 trial in Primary Membran ous Nephropathy\, on 31 December 2026.\n\nSource: clinicaltrials NCT064701 91\nhttps://clinicaltrials.gov/study/NCT06470191 URL:https://julienwillard.com/calendar/clinical#e-8e5ef4be-8837-45d7-bad5-6 e6d72e32597 END:VEVENT BEGIN:VEVENT UID:498c116167b4d4bde041d2232d9e03ba DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Materia Medica Holding Raphamin: Trial primary completion DESCRIPTION:As of 13 February 2026\, Materia Medica Holding estimated prima ry completion of a Phase 3 trial in Cystitis Chronic\, on 31 December 2026 .\n\nSource: clinicaltrials NCT06284265\nhttps://clinicaltrials.gov/study/ NCT06284265 URL:https://julienwillard.com/calendar/clinical#e-13f36aa9-cf00-4170-b348-e 327ca7e3d9e END:VEVENT BEGIN:VEVENT UID:31ead40441cad1d2798e2105b5c83efa DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Supernus Pharmaceuticals\, Inc. SPN-821 2400 mg: Trial primary comp letion DESCRIPTION:As of 24 March 2026\, Supernus Pharmaceuticals estimated primar y completion of a Phase 2 trial in Major Depressive Disorder (MDD)\, on 31 December 2026.\n\nSource: clinicaltrials NCT07226661\nhttps://clinicaltri als.gov/study/NCT07226661 URL:https://julienwillard.com/calendar/clinical#e-fbb24760-7065-48f7-b674-4 175b1541056 END:VEVENT BEGIN:VEVENT UID:48ed0266428776bdf3163f46649f5e55 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Guangzhou Gloria Biosciences Co.\, Ltd. Motixafortide+G-CSF: Trial primary completion DESCRIPTION:As of 16 December 2025\, Guangzhou Gloria Biosciences Co. estim ated primary completion of a Phase 3 trial in Multiple Myeloma\, on 31 Dec ember 2026.\n\nSource: clinicaltrials NCT06514508\nhttps://clinicaltrials. gov/study/NCT06514508 URL:https://julienwillard.com/calendar/clinical#e-0dc8799e-a7a8-414b-a595-8 cd22c5645fe END:VEVENT BEGIN:VEVENT UID:47a5d3f31c4a786caca380ba938b98dc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NaviFUS Corporation NaviFUS System: Trial primary completion DESCRIPTION:As of 9 April 2026\, NaviFUS estimated primary completion of a Phase 2 trial in Drug Resistant Epilepsy\, on 31 December 2026.\n\nSource: clinicaltrials NCT06388707\nhttps://clinicaltrials.gov/study/NCT06388707 URL:https://julienwillard.com/calendar/clinical#e-1e62fbdc-9756-4db5-abee-d f54ef4dc45f END:VEVENT BEGIN:VEVENT UID:659d6752ad259a1ab63800cca7be9aa4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ENCell EN001: Trial primary completion DESCRIPTION:As of 26 May 2026\, ENCell estimated primary completion of a Ph ase 2 trial in Charcot-Marie-Tooth Disease Type 1A\, on 31 December 2026.\ n\nSource: clinicaltrials NCT06328712\nhttps://clinicaltrials.gov/study/NC T06328712 URL:https://julienwillard.com/calendar/clinical#e-a310cdf7-1561-4c86-98a9-2 1a42bf9e808 END:VEVENT BEGIN:VEVENT UID:1b7acec32b6dfa428d1cb1af879c105e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20261231 DTEND;VALUE=DATE:20270101 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chongqing Precision Biotech Co.\, Ltd BCMA CAR-T cells: Trial prima ry completion DESCRIPTION:As of 25 February 2025\, Chongqing Precision Biotech Co. estima ted primary completion of a Phase 2 trial in Multiple Myeloma\, on 31 Dece mber 2026.\n\nSource: clinicaltrials NCT04271644\nhttps://clinicaltrials.g ov/study/NCT04271644 URL:https://julienwillard.com/calendar/clinical#e-94f2351a-f629-41b5-a46f-b 4655100c902 END:VEVENT BEGIN:VEVENT UID:55e37e49370073b25f31aafebef5060e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270102 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biotheus Inc. PM8002: Trial primary completion DESCRIPTION:As of 9 July 2026\, Biotheus estimated primary completion of a Phase 2 trial in Neuroendocrine Neoplasm\, on 1 January 2027.\n\nSource: c linicaltrials NCT05879055\nhttps://clinicaltrials.gov/study/NCT05879055 URL:https://julienwillard.com/calendar/clinical#e-827e5bbb-eb3e-49b9-8f07-6 a75bf55e9b3 END:VEVENT BEGIN:VEVENT UID:6f7d311d168176dbfa33094b8730fe05 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:OncoVerity\, Inc. Cusatuzumab: Trial primary completion DESCRIPTION:As of 11 May 2026\, OncoVerity estimated primary completion of a Phase 2 trial in Leukemia\, Myeloid\, Acute\, in January 2027.\n\nSource : clinicaltrials NCT06384261\nhttps://clinicaltrials.gov/study/NCT06384261 URL:https://julienwillard.com/calendar/clinical#e-a4009c72-3a47-4449-a639-d 236b2e8d9dc END:VEVENT BEGIN:VEVENT UID:cf665ab898372993a0f27070b483eb58 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:CStone Pharmaceuticals CS2009: Trial primary completion DESCRIPTION:As of 9 July 2026\, CStone Pharmaceuticals estimated primary co mpletion of a Phase 2 trial in Advanced Solid Tumors\, in January 2027.\n\ nSource: clinicaltrials NCT06741644\nhttps://clinicaltrials.gov/study/NCT0 6741644 URL:https://julienwillard.com/calendar/clinical#e-b67fe943-6200-4ae7-b961-2 281fe60b4ec END:VEVENT BEGIN:VEVENT UID:315a51bbb886d607b78fac69a3bfb3f9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. SHR-4375 Injection: T rial primary completion DESCRIPTION:As of 1 May 2026\, Suzhou Suncadia Biopharmaceuticals Co. estim ated primary completion of a Phase 2 trial in Advanced Solid Tumor\, in Ja nuary 2027.\n\nSource: clinicaltrials NCT07298772\nhttps://clinicaltrials. gov/study/NCT07298772 URL:https://julienwillard.com/calendar/clinical#e-b11f8740-718b-42d4-b5b6-c 810ffbe3af6 END:VEVENT BEGIN:VEVENT UID:5c676c4c4abe85ebc05d35f9ae0bc9c9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gilead Sciences Tilpisertib Fosmecarbil: Trial primary completion DESCRIPTION:As of 11 February 2026\, Gilead Sciences estimated primary comp letion of a Phase 2 trial in Ulcerative Colitis\, in January 2027.\n\nSour ce: clinicaltrials NCT06029972\nhttps://clinicaltrials.gov/study/NCT060299 72 URL:https://julienwillard.com/calendar/clinical#e-3442c9fd-adb7-4b76-9b1d-9 2fcd2fb8b44 END:VEVENT BEGIN:VEVENT UID:2311f138ee2b825d8a9e62145d9ed88a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Rempex (a wholly owned subsidiary of Melinta Therapeutics\, LLC) Me ropenem-Vaborbactam: Trial primary completion DESCRIPTION:As of 3 June 2026\, Rempex estimated primary completion of a Ph ase 2 trial in Acute Pyelonephritis\, in January 2027.\n\nSource: clinical trials NCT06672978\nhttps://clinicaltrials.gov/study/NCT06672978 URL:https://julienwillard.com/calendar/clinical#e-d1fdcce6-94d6-4710-b90c-2 98987005da1 END:VEVENT BEGIN:VEVENT UID:8271fbcb036a86fc1742d32182976202 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Prolium Bioscience\, Inc PRO-203: Trial primary completion DESCRIPTION:As of 18 June 2026\, Prolium Bioscience estimated primary compl etion of a Phase 2 trial in Healthy Volunteers\, in January 2027.\n\nSourc e: clinicaltrials NCT07641634\nhttps://clinicaltrials.gov/study/NCT0764163 4 URL:https://julienwillard.com/calendar/clinical#e-e32d3321-1cc6-4870-ac5b-0 ee815672011 END:VEVENT BEGIN:VEVENT UID:411beea03f37744c85a7b2f164be274c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Newleos Therapeutics\, Inc. NTX-1472: Trial primary completion DESCRIPTION:As of 9 July 2026\, Newleos Therapeutics estimated primary comp letion of a Phase 2 trial in Social Anxiety Disorder (SAD)\, in January 20 27.\n\nSource: clinicaltrials NCT07323784\nhttps://clinicaltrials.gov/stud y/NCT07323784 URL:https://julienwillard.com/calendar/clinical#e-d67b30c3-4083-4650-8a6b-c a96fb676857 END:VEVENT BEGIN:VEVENT UID:033fcfa0be360786c73fc0ae0dfff750 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Qilu Pharmaceutical Co.\, Ltd. QL1206: Trial primary completion DESCRIPTION:As of 14 July 2025\, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in January 2027.\n\nSource: clinicaltrials N CT07062978\nhttps://clinicaltrials.gov/study/NCT07062978 URL:https://julienwillard.com/calendar/clinical#e-32eddd7c-d9e2-411d-8792-6 5df72ef7c6f END:VEVENT BEGIN:VEVENT UID:0dd84805f347c041a2d912174c3df05d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Caravel Oculus Pty Ltd Ophthalmic solution (matching formulation wi thout ascorbic acid): Trial primary completion DESCRIPTION:As of 6 August 2026\, Caravel Oculus Pty estimated primary comp letion of a Phase 2 trial in Corneal Endothelial Cell Loss\, in January 20 27.\n\nSource: clinicaltrials NCT07694375\nhttps://clinicaltrials.gov/stud y/NCT07694375 URL:https://julienwillard.com/calendar/clinical#e-75c4bdd5-e421-4dc1-905c-f dfc451f1e61 END:VEVENT BEGIN:VEVENT UID:7aa9ff7423cc3479cb32b77e4714ddfd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hanmi Pharmaceutical Company Limited HM15275: Trial primary complet ion DESCRIPTION:As of 8 April 2026\, Hanmi Pharmaceutical Company estimated pri mary completion of a Phase 2 trial in obese\, in January 2027.\n\nSource: clinicaltrials NCT07205900\nhttps://clinicaltrials.gov/study/NCT07205900 URL:https://julienwillard.com/calendar/clinical#e-98a6ff34-7169-4eff-8a82-1 8b74b706a15 END:VEVENT BEGIN:VEVENT UID:e63d956ce188d6a993bba0aaf4aca4cd DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Coya Therapeutics COYA 302: Trial primary completion DESCRIPTION:As of 6 August 2026\, Coya Therapeutics estimated primary compl etion of a Phase 3 trial in Amyotrophic Lateral Sclerosis (ALS)\, in Janua ry 2027.\n\nSource: clinicaltrials NCT07161999\nhttps://clinicaltrials.gov /study/NCT07161999 URL:https://julienwillard.com/calendar/clinical#e-4d9ed5d7-7c9f-47e9-ae66-b 4e7df58f62b END:VEVENT BEGIN:VEVENT UID:060973087278c21d103a85e5c22c0326 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:QED Therapeutics\, a BridgeBio company infigratinib 0.128 mg/kg/day : Trial primary completion DESCRIPTION:As of 16 July 2026\, QED Therapeutics\, a BridgeBio estimated p rimary completion of a Phase 3 trial in hypochondroplasia\, in January 202 7.\n\nSource: clinicaltrials NCT06873035\nhttps://clinicaltrials.gov/study /NCT06873035 URL:https://julienwillard.com/calendar/clinical#e-9388050a-c4e3-46fd-baa1-a 2e7f77091ad END:VEVENT BEGIN:VEVENT UID:9e4abd589bba8e1c92ae9451b7a441a6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Loxo Oncology\, Inc. Pirtobrutinib: Trial primary completion DESCRIPTION:As of 15 May 2026\, Loxo Oncology estimated primary completion of a Phase 3 trial in Lymphoma\, Mantle-Cell\, in January 2027.\n\nSource: clinicaltrials NCT04662255\nhttps://clinicaltrials.gov/study/NCT04662255 URL:https://julienwillard.com/calendar/clinical#e-828df6dd-1711-4a8c-a3cc-5 d109a66c4b5 END:VEVENT BEGIN:VEVENT UID:8e14c4fd54fe13f7828dcca9a9f8c169 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Alesta Therapeutics ALE1: Trial primary completion DESCRIPTION:As of 3 August 2026\, Alesta Therapeutics estimated primary com pletion of a Phase 2 trial in hypophosphatasia (HPP)\, in January 2027.\n\ nSource: clinicaltrials NCT07179640\nhttps://clinicaltrials.gov/study/NCT0 7179640 URL:https://julienwillard.com/calendar/clinical#e-22ae085c-fb6d-4b36-bcba-d 363571f8e7e END:VEVENT BEGIN:VEVENT UID:ddcf719c3e219ab2cf852852af5ae4cb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cumberland Pharmaceuticals Ifetroban Sodium: Trial primary completi on DESCRIPTION:As of 5 March 2026\, Cumberland Pharmaceuticals estimated prima ry completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis\, in Jan uary 2027.\n\nSource: clinicaltrials NCT05571059\nhttps://clinicaltrials.g ov/study/NCT05571059 URL:https://julienwillard.com/calendar/clinical#e-39a6d045-2697-47ee-b930-f 42130cf5964 END:VEVENT BEGIN:VEVENT UID:d154f7f3923131e3d046d4de5c225662 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:iOnctura roginolisib: Trial primary completion DESCRIPTION:As of 16 January 2026\, iOnctura estimated primary completion o f a Phase 2 trial in Non-Squamous Non-Small Cell Lung Cancer (NSCLC)\, in January 2027.\n\nSource: clinicaltrials NCT06879717\nhttps://clinicaltrial s.gov/study/NCT06879717 URL:https://julienwillard.com/calendar/clinical#e-99bda922-fb1c-440a-ad85-2 f8d49bd6f48 END:VEVENT BEGIN:VEVENT UID:a18c17477bc631f4847ee2e166c106e3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Xenon Pharmaceuticals Inc. Azetukalner: Trial primary completion DESCRIPTION:As of 3 August 2026\, Xenon Pharmaceuticals estimated primary c ompletion of a Phase 3 trial in Major Depressive Disorder\, in January 202 7.\n\nSource: clinicaltrials NCT06922110\nhttps://clinicaltrials.gov/study /NCT06922110 URL:https://julienwillard.com/calendar/clinical#e-0e8206fa-d3ae-4aa3-bbbf-c 4e1b58c627e END:VEVENT BEGIN:VEVENT UID:bba34ee6186953dfd316dc73d570b7bb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AION Healthspan\, Inc. AION-301: Trial primary completion DESCRIPTION:As of 1 April 2026\, AION Healthspan estimated primary completi on of a Phase 2 trial in Chronic Kidney Disease Stage 3\, in January 2027. \n\nSource: clinicaltrials NCT06721143\nhttps://clinicaltrials.gov/study/N CT06721143 URL:https://julienwillard.com/calendar/clinical#e-5911cfa0-a2e8-41da-ae39-b 35aeeb56ec2 END:VEVENT BEGIN:VEVENT UID:7e8f8a4ed86419784a21d5b43ac0f363 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biocad BCD-217: Trial primary completion DESCRIPTION:As of 8 July 2025\, Biocad estimated primary completion of a Ph ase 3 trial in Melanoma Stage III\, in January 2027.\n\nSource: clinicaltr ials NCT05751928\nhttps://clinicaltrials.gov/study/NCT05751928 URL:https://julienwillard.com/calendar/clinical#e-a8f1e042-902d-4a03-bd5a-a df7951066f0 END:VEVENT BEGIN:VEVENT UID:1758e4508203a43e184959f036501576 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vaxcyte\, Inc. 31 valent pneumococcal conjugate vaccine: Trial prim ary completion DESCRIPTION:As of 15 May 2026\, Vaxcyte estimated primary completion of a P hase 3 trial in Pneumococcal Vaccines\, in January 2027.\n\nSource: clinic altrials NCT07284654\nhttps://clinicaltrials.gov/study/NCT07284654 URL:https://julienwillard.com/calendar/clinical#e-a0bae348-d913-4483-bd9c-6 328b136077a END:VEVENT BEGIN:VEVENT UID:37c5d2add3e84aef470edc9e0913b5c8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sun Pharmaceutical Industries\, Inc. Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl)\, 20%: Trial prima ry completion DESCRIPTION:As of 22 April 2026\, Sun Pharmaceutical Industries estimated p rimary completion of a Phase 3 trial in Actinic Keratosis\, in January 202 7.\n\nSource: clinicaltrials NCT07144852\nhttps://clinicaltrials.gov/study /NCT07144852 URL:https://julienwillard.com/calendar/clinical#e-a9c8d7eb-01f3-40de-8835-7 16c979c2517 END:VEVENT BEGIN:VEVENT UID:4d94d1ee920d49efd51151cb5e38060d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270102 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Second Life Therapeutics SL-28: Trial primary completion DESCRIPTION:As of 10 July 2026\, Second Life Therapeutics estimated primary completion of a Phase 2 trial in Head & Neck Cancer\, on 1 January 2027.\ n\nSource: clinicaltrials NCT07341737\nhttps://clinicaltrials.gov/study/NC T07341737 URL:https://julienwillard.com/calendar/clinical#e-3d271f4f-cc28-47b6-94f6-e 4cb5c0251e6 END:VEVENT BEGIN:VEVENT UID:dad6c647b51a9fb53754b7585fded807 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Edgewise Therapeutics\, Inc. Sevasemten Dose 1: Trial primary compl etion DESCRIPTION:As of 12 November 2025\, Edgewise Therapeutics estimated primar y completion of a Phase 2 trial in Duchenne Muscular Dystrophy\, in Januar y 2027.\n\nSource: clinicaltrials NCT05540860\nhttps://clinicaltrials.gov/ study/NCT05540860 URL:https://julienwillard.com/calendar/clinical#e-6c977cc2-989a-4937-bf79-c 65ae02ebc5e END:VEVENT BEGIN:VEVENT UID:383bd1f6003b0982d274dfc288127334 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ultragenyx Pharmaceutical Inc setrusumab: Trial primary completion DESCRIPTION:As of 15 June 2026\, Ultragenyx Pharmaceutical estimated primar y completion of a Phase 3 trial in Osteogenesis Imperfecta\, in January 20 27.\n\nSource: clinicaltrials NCT06636071\nhttps://clinicaltrials.gov/stud y/NCT06636071 URL:https://julienwillard.com/calendar/clinical#e-25bbe1c6-ca4b-4d2a-9562-5 927b4d67156 END:VEVENT BEGIN:VEVENT UID:d189c99ce76781ef8dfbfc83fb9f0a1d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sun Pharmaceutical Industries\, Inc. Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl)\, 20%: Trial prima ry completion DESCRIPTION:As of 22 April 2026\, Sun Pharmaceutical Industries estimated p rimary completion of a Phase 3 trial in Actinic Keratosis\, in January 202 7.\n\nSource: clinicaltrials NCT07144345\nhttps://clinicaltrials.gov/study /NCT07144345 URL:https://julienwillard.com/calendar/clinical#e-7e6a2f12-30af-4bfd-bd89-f 693da3a30fb END:VEVENT BEGIN:VEVENT UID:6afb3222256180baf492113878c3957f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merz Aesthetics GmbH NT 201: Trial primary completion DESCRIPTION:As of 23 July 2026\, Merz Aesthetics estimated primary completi on of a Phase 3 trial in Neuromuscular Agents\, in January 2027.\n\nSource : clinicaltrials NCT07210463\nhttps://clinicaltrials.gov/study/NCT07210463 URL:https://julienwillard.com/calendar/clinical#e-ac088a30-a296-4b03-92f5-a ca72bf10a3e END:VEVENT BEGIN:VEVENT UID:375227099a221437136fb2add64a99db DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Henlius Biotech HLX79 10mg/kg/Placebo+HLX01: Trial primary completion DESCRIPTION:As of 18 November 2025\, Shanghai Henlius Biotech estimated pri mary completion of a Phase 2 trial in Membranous Nephropathy\, in January 2027.\n\nSource: clinicaltrials NCT07038382\nhttps://clinicaltrials.gov/st udy/NCT07038382 URL:https://julienwillard.com/calendar/clinical#e-ccd20027-97c8-4d6a-8956-4 94eb9abe0b9 END:VEVENT BEGIN:VEVENT UID:135746c095e8e14767d3bd4c4a1cf464 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:LigaChem Biosciences\, Inc. LCB84: Trial primary completion DESCRIPTION:As of 24 September 2025\, LigaChem Biosciences estimated primar y completion of a Phase 2 trial in Advanced Solid Tumors\, in January 2027 .\n\nSource: clinicaltrials NCT05941507\nhttps://clinicaltrials.gov/study/ NCT05941507 URL:https://julienwillard.com/calendar/clinical#e-8824c6b7-3c9c-4ee1-b1f1-7 e28cd3b3020 END:VEVENT BEGIN:VEVENT UID:fafba4cb9a933b177280f989788b91c1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vaderis Therapeutics AG VAD044 Part I: Trial primary completion DESCRIPTION:As of 17 March 2026\, Vaderis Therapeutics estimated primary co mpletion of a Phase 2 trial in Hereditary Hemorrhagic Telangiectasia (HHT) \, in January 2027.\n\nSource: clinicaltrials NCT05406362\nhttps://clinica ltrials.gov/study/NCT05406362 URL:https://julienwillard.com/calendar/clinical#e-d26cdae9-84c6-4fd0-a314-5 6ef9e356bd2 END:VEVENT BEGIN:VEVENT UID:16dd9ff3f04cff088f4aa5dc00b0e5c4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Synendos Therapeutics AG SYT-510: Trial primary completion DESCRIPTION:As of 18 June 2026\, Synendos Therapeutics estimated primary co mpletion of a Phase 2 trial in Generalized Anxiety Disorder\, in January 2 027.\n\nSource: clinicaltrials NCT07478744\nhttps://clinicaltrials.gov/stu dy/NCT07478744 URL:https://julienwillard.com/calendar/clinical#e-9d695873-7342-441c-840a-6 fa4f1ef02c8 END:VEVENT BEGIN:VEVENT UID:8e1722670ea00e1937cf68131c82aa77 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Akeso AK117 in combination with AK112: Trial primary completion DESCRIPTION:As of 14 November 2024\, Akeso estimated primary completion of a Phase 3 trial in Head and Neck Squamous Cell Carcinoma\, in January 2027 .\n\nSource: clinicaltrials NCT06601335\nhttps://clinicaltrials.gov/study/ NCT06601335 URL:https://julienwillard.com/calendar/clinical#e-ca55ca63-edb2-45dc-b9f5-7 5bd2dca4ca1 END:VEVENT BEGIN:VEVENT UID:1e8a3920fc511b37ab63756e15cfc6b5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:QBiotics Group Limited Tigilanol Tiglate: Trial primary completion DESCRIPTION:As of 12 March 2026\, QBiotics Group estimated primary completi on of a Phase 2 trial in Soft Tissue Sarcoma\, in January 2027.\n\nSource: clinicaltrials NCT05755113\nhttps://clinicaltrials.gov/study/NCT05755113 URL:https://julienwillard.com/calendar/clinical#e-be43e2ed-26fc-4357-b48b-8 cebac5f50f7 END:VEVENT BEGIN:VEVENT UID:426e663af6152ea26f74e1e7f0c0a42e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Marengo Therapeutics\, Inc. STAR0602: Trial primary completion DESCRIPTION:As of 24 September 2025\, Marengo Therapeutics estimated primar y completion of a Phase 2 trial in Triple Negative Locally Advanced Non-re sectable Breast Cancer\, in January 2027.\n\nSource: clinicaltrials NCT068 27613\nhttps://clinicaltrials.gov/study/NCT06827613 URL:https://julienwillard.com/calendar/clinical#e-e0194794-9b37-4768-bd6b-e 46b5b566fc3 END:VEVENT BEGIN:VEVENT UID:8a7b54907ee6960ef2ae34c86d3ede0a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Dr. F. Köhler Chemie GmbH Custodiol-N: Trial primary completion DESCRIPTION:As of 30 January 2026\, Dr. F. Köhler Chemie estimated primary completion of a Phase 2 trial in Heart Transplantation\, in January 2027. \n\nSource: clinicaltrials NCT06032195\nhttps://clinicaltrials.gov/study/N CT06032195 URL:https://julienwillard.com/calendar/clinical#e-1c77e52f-7804-4557-8140-7 5dddb633f02 END:VEVENT BEGIN:VEVENT UID:ecb4a566aaa3f596a64da9538727ac35 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Actio Biosciences\, Inc. ABS-1230: Trial primary completion DESCRIPTION:As of 7 August 2026\, Actio Biosciences estimated primary compl etion of a Phase 2 trial in KCNT1-Related Epilepsy\, in January 2027.\n\nS ource: clinicaltrials NCT07600736\nhttps://clinicaltrials.gov/study/NCT076 00736 URL:https://julienwillard.com/calendar/clinical#e-9b3e1c1d-b805-4458-8c92-f 205f548014c END:VEVENT BEGIN:VEVENT UID:bfc3202c2ac27d3b942c9dbf081f8794 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Imvax IGV-001 Cell Immunotherapy: Trial primary completion DESCRIPTION:As of 9 July 2026\, Imvax estimated primary completion of a Pha se 2 trial in glioblastoma\, in January 2027.\n\nSource: clinicaltrials NC T04485949\nhttps://clinicaltrials.gov/study/NCT04485949 URL:https://julienwillard.com/calendar/clinical#e-5032f105-75b6-4615-bbcf-7 e7a2cade3ac END:VEVENT BEGIN:VEVENT UID:1114cda726585176c03c8d7d034da318 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Larimar Therapeutics\, Inc. CTI-1601: Trial primary completion DESCRIPTION:As of 13 May 2026\, Larimar Therapeutics estimated primary comp letion of a Phase 2 trial in Friedreich Ataxia\, in January 2027.\n\nSourc e: clinicaltrials NCT06447025\nhttps://clinicaltrials.gov/study/NCT0644702 5 URL:https://julienwillard.com/calendar/clinical#e-bc5c5cc8-9332-405b-98c6-f 1d6a3c59dc6 END:VEVENT BEGIN:VEVENT UID:ff73dc9feb27f639285252867ab1cc8b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie Upadacitinib: Trial primary completion DESCRIPTION:As of 23 February 2026\, AbbVie estimated primary completion of a Phase 3 trial in Atopic Dermatitis\, in January 2027.\n\nSource: clinic altrials NCT06701331\nhttps://clinicaltrials.gov/study/NCT06701331 URL:https://julienwillard.com/calendar/clinical#e-e599cacd-3963-4bde-b5e2-6 e387b6e5029 END:VEVENT BEGIN:VEVENT UID:711ddf9dc7db46713fed55d857190282 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Praxis Precision Medicines 40 mg/day vormatrogine for 12 weeks: Tri al primary completion DESCRIPTION:As of 3 August 2026\, Praxis Precision Medicines estimated prim ary completion of a Phase 3 trial in Focal Epilepsy\, in January 2027.\n\n Source: clinicaltrials NCT07505004\nhttps://clinicaltrials.gov/study/NCT07 505004 URL:https://julienwillard.com/calendar/clinical#e-92f78f57-478a-4e4d-8b2a-d 325e4c08fe9 END:VEVENT BEGIN:VEVENT UID:c194efa650dc23d57a4412dc164ba822 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eledon Pharmaceuticals AT-1501: Trial primary completion DESCRIPTION:As of 29 June 2025\, Eledon Pharmaceuticals estimated primary c ompletion of a Phase 2 trial in Prevention of Rejection in Kidney Transpla nt\, in January 2027.\n\nSource: clinicaltrials NCT05027906\nhttps://clini caltrials.gov/study/NCT05027906 URL:https://julienwillard.com/calendar/clinical#e-76c23d9c-7b80-4dee-9896-5 54f2f21840e END:VEVENT BEGIN:VEVENT UID:af19a127e9da542dfd27320f2fbbe149 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Telix Pharmaceuticals (Innovations) Pty Limited 68Ga-PSMA-11: Trial primary completion DESCRIPTION:As of 23 July 2026\, Telix Pharmaceuticals (Innovations) Pty es timated primary completion of a Phase 3 trial in pCA\, in January 2027.\n\ nSource: clinicaltrials NCT07052214\nhttps://clinicaltrials.gov/study/NCT0 7052214 URL:https://julienwillard.com/calendar/clinical#e-8e4920d6-7632-4943-acc6-c a90127544ad END:VEVENT BEGIN:VEVENT UID:a31747391418892e44ff728ef7d2337e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MediLink Therapeutics (Suzhou) Co.\, Ltd. YL201: Trial primary comp letion DESCRIPTION:As of 18 June 2026\, MediLink Therapeutics (Suzhou) Co. estimat ed primary completion of a Phase 2 trial in Advanced Solid Tumors\, in Jan uary 2027.\n\nSource: clinicaltrials NCT07208773\nhttps://clinicaltrials.g ov/study/NCT07208773 URL:https://julienwillard.com/calendar/clinical#e-47052d07-eb87-4c24-96c4-5 f634082f63a END:VEVENT BEGIN:VEVENT UID:1910d726a406291e7bc987906fd2a845 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biocad anti-TL1A monoclonal antibody\, low dose: Trial primary comp letion DESCRIPTION:As of 19 September 2025\, Biocad estimated primary completion o f a Phase 2 trial in Ulcerative Colitis (UC)\, in January 2027.\n\nSource: clinicaltrials NCT07080034\nhttps://clinicaltrials.gov/study/NCT07080034 URL:https://julienwillard.com/calendar/clinical#e-9a7fcc73-efc9-4109-b417-9 c1b5821bd30 END:VEVENT BEGIN:VEVENT UID:f66892820390e5119382bd9016036694 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270102 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:SIGA Technologies Tecovirimat: Trial primary completion DESCRIPTION:As of 2 April 2026\, SIGA Technologies estimated primary comple tion of a Phase 2 trial in smallpox\, on 1 January 2027.\n\nSource: clinic altrials NCT04957485\nhttps://clinicaltrials.gov/study/NCT04957485 URL:https://julienwillard.com/calendar/clinical#e-e240b14c-7c84-4449-a427-8 c731e7e843d END:VEVENT BEGIN:VEVENT UID:3d60e2d7a7afb028d8a74dc09d6e7f5b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Arcus Biosciences\, Inc. Domvanalimab: Trial primary completion DESCRIPTION:As of 29 July 2026\, Arcus Biosciences estimated primary comple tion of a Phase 2 trial in Gastrointestinal Tract Malignancies\, in Januar y 2027.\n\nSource: clinicaltrials NCT05329766\nhttps://clinicaltrials.gov/ study/NCT05329766 URL:https://julienwillard.com/calendar/clinical#e-ed80f883-362b-43ae-a823-2 38c1d6fd6b4 END:VEVENT BEGIN:VEVENT UID:d669954a26874cc01d4fb4a289e67774 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hyundai Bioscience Co.\, Ltd. CP-COV03: Trial primary completion DESCRIPTION:As of 10 July 2026\, Hyundai Bioscience Co. estimated primary c ompletion of a Phase 3 trial in dengue\, in January 2027.\n\nSource: clini caltrials NCT07576868\nhttps://clinicaltrials.gov/study/NCT07576868 URL:https://julienwillard.com/calendar/clinical#e-f9e1515b-1e27-44c0-b279-8 df25510a7f7 END:VEVENT BEGIN:VEVENT UID:b4e3a3c1acc804aa1515627294ca4ca7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.\, Ltd. Hemopfin+Gr een Light: Trial primary completion DESCRIPTION:As of 3 March 2026\, Shanghai Fudan-Zhangjiang Bio-Pharmaceutic al Co. estimated primary completion of a Phase 2 trial in Port-wine Birthm arks\, in January 2027.\n\nSource: clinicaltrials NCT05171894\nhttps://cli nicaltrials.gov/study/NCT05171894 URL:https://julienwillard.com/calendar/clinical#e-f0ba70c1-ecbe-47dd-b563-8 60e16cf1d48 END:VEVENT BEGIN:VEVENT UID:3fcfd3c16fe48cc4932152dcd97680b4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sinovac Biotech Co.\, Ltd experimental vaccine: Trial primary compl etion DESCRIPTION:As of 10 August 2026\, Sinovac Biotech Co. estimated primary co mpletion of a Phase 3 trial in Epidemic Meningitis\, in January 2027.\n\nS ource: clinicaltrials NCT07505836\nhttps://clinicaltrials.gov/study/NCT075 05836 URL:https://julienwillard.com/calendar/clinical#e-6084477d-d010-491e-b9cd-9 8ab5619dac6 END:VEVENT BEGIN:VEVENT UID:f9a4eed54756ec9ace6dbd130fa8f19f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. AL2846 Capsules: Trial primary completion DESCRIPTION:As of 31 December 2025\, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Thyroid Cancer\, i n January 2027.\n\nSource: clinicaltrials NCT06860971\nhttps://clinicaltri als.gov/study/NCT06860971 URL:https://julienwillard.com/calendar/clinical#e-09e1c15e-03ac-4dc8-a090-9 28d89e5cb83 END:VEVENT BEGIN:VEVENT UID:b19f49c123893b25f48f575f3eca6ab7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hope Biosciences Research Foundation Autologous HB-adMSCs: Trial pr imary completion DESCRIPTION:As of 20 November 2025\, Hope Biosciences Research Foundation e stimated primary completion of a Phase 2 trial in Relapsing Remitting Mult iple Sclerosis (RRMS)\, in January 2027.\n\nSource: clinicaltrials NCT0680 0404\nhttps://clinicaltrials.gov/study/NCT06800404 URL:https://julienwillard.com/calendar/clinical#e-c7af94fb-94d8-485e-bd49-b d5b05e1213b END:VEVENT BEGIN:VEVENT UID:896536a35f7172e74c05bf1da904c240 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Resilience Resilience PRO: Trial primary completion DESCRIPTION:As of 3 April 2026\, Resilience estimated primary completion of a Phase 3 trial in cancer\, in January 2027.\n\nSource: clinicaltrials NC T06867705\nhttps://clinicaltrials.gov/study/NCT06867705 URL:https://julienwillard.com/calendar/clinical#e-cda2eda6-daa0-46e3-b8a9-e 2e37ade66b0 END:VEVENT BEGIN:VEVENT UID:3b44dc462feca174d04109358733b052 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:EyeD Pharma TimoD implant: Trial primary completion DESCRIPTION:As of 30 July 2026\, EyeD Pharma estimated primary completion o f a Phase 2 trial in glaucoma\, in January 2027.\n\nSource: clinicaltrials NCT07036510\nhttps://clinicaltrials.gov/study/NCT07036510 URL:https://julienwillard.com/calendar/clinical#e-688fca2d-ed44-4bce-858a-8 6eec237b8b5 END:VEVENT BEGIN:VEVENT UID:9c16b7768bf26da9396b2a1ef1124d6b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Jacobio Pharmaceuticals Co.\, Ltd. JAB-30355: Trial primary complet ion DESCRIPTION:As of 22 May 2026\, Jacobio Pharmaceuticals Co. estimated prima ry completion of a Phase 2 trial in Solid Tumors\, in January 2027.\n\nSou rce: clinicaltrials NCT06386146\nhttps://clinicaltrials.gov/study/NCT06386 146 URL:https://julienwillard.com/calendar/clinical#e-0b5fd01e-4415-4ae4-99a0-5 d0d8ceababa END:VEVENT BEGIN:VEVENT UID:e48064e7a56efaaaa14f2bd9c5778935 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270101 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:A. Menarini International Licensing S.A. Obicetrapib 10 mg/Bempedoi c Acid Placebo: Trial primary completion DESCRIPTION:As of 9 June 2026\, A. Menarini International Licensing estimat ed primary completion of a Phase 3 trial in Mixed Dyslipidemia\, in Januar y 2027.\n\nSource: clinicaltrials NCT07614958\nhttps://clinicaltrials.gov/ study/NCT07614958 URL:https://julienwillard.com/calendar/clinical#e-b04f40b0-f05b-448c-98c0-e 1138bdeede2 END:VEVENT BEGIN:VEVENT UID:ccaa66ce81164e357d7fe437f2a68fa0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270103 DTEND;VALUE=DATE:20270104 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Shenzhen Kangzhe Biotechnology Co.\, Ltd. CMS-D002 Capsules 10 mg: Trial primary completion DESCRIPTION:As of 11 March 2026\, Shenzhen Kangzhe Biotechnology Co. estima ted primary completion of a Phase 2 trial in Uterine Fibroids With Menorrh agia\, on 3 January 2027.\n\nSource: clinicaltrials NCT07402369\nhttps://c linicaltrials.gov/study/NCT07402369 URL:https://julienwillard.com/calendar/clinical#e-3331dd0a-cca9-4b08-a81c-f 7fbf289551e END:VEVENT BEGIN:VEVENT UID:914722b1470b7be4159b3b1ac6d3b6b7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270104 DTEND;VALUE=DATE:20270105 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Sacituzumab tirumotecan: Trial primary comp letion DESCRIPTION:As of 27 February 2026\, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Gastroesophageal Cancer\, on 4 January 20 27.\n\nSource: clinicaltrials NCT06356311\nhttps://clinicaltrials.gov/stud y/NCT06356311 URL:https://julienwillard.com/calendar/clinical#e-cc2f183f-f6da-40bc-b936-b eeb0b6865cd END:VEVENT BEGIN:VEVENT UID:8a5a0a0e329efb7760f7d2998ed7c4c4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270104 DTEND;VALUE=DATE:20270105 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD0780: Trial primary completion DESCRIPTION:As of 16 July 2026\, AstraZeneca estimated primary completion o f a Phase 3 trial in Heterozygous Familial Hypercholesterolaemia\, on 4 Ja nuary 2027.\n\nSource: clinicaltrials NCT07000136\nhttps://clinicaltrials. gov/study/NCT07000136 URL:https://julienwillard.com/calendar/clinical#e-7ef3bf82-0eca-4acc-a875-8 f4d566bbaa8 END:VEVENT BEGIN:VEVENT UID:b5078e1f1f2b2807902344f411f3ad27 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270106 DTEND;VALUE=DATE:20270107 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Anifrolumab (blinded): Trial primary completion DESCRIPTION:As of 23 July 2026\, AstraZeneca estimated primary completion o f a Phase 3 trial in Systemic Sclerosis\, on 6 January 2027.\n\nSource: cl inicaltrials NCT05925803\nhttps://clinicaltrials.gov/study/NCT05925803 URL:https://julienwillard.com/calendar/clinical#e-d846597d-710c-4eb4-b489-e 0edc26db95c END:VEVENT BEGIN:VEVENT UID:5bb2915529306cde266af48f32ce09c2 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270106 DTEND;VALUE=DATE:20270107 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Norgine PLENVU®: Trial primary completion DESCRIPTION:As of 27 May 2026\, Norgine estimated primary completion of a P hase 3 trial in Bowel Cleansing Prior to Clinical Procedures\, on 6 Januar y 2027.\n\nSource: clinicaltrials NCT07218523\nhttps://clinicaltrials.gov/ study/NCT07218523 URL:https://julienwillard.com/calendar/clinical#e-f56d83c3-aac2-4611-812a-6 f0a37705bed END:VEVENT BEGIN:VEVENT UID:b75f1ff36ffcd67d73284faa73a4333d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270106 DTEND;VALUE=DATE:20270107 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amgen AMG 732: Trial primary completion DESCRIPTION:As of 10 August 2026\, Amgen estimated primary completion of a Phase 2 trial in Thyroid Eye Disease\, on 6 January 2027.\n\nSource: clini caltrials NCT06401044\nhttps://clinicaltrials.gov/study/NCT06401044 URL:https://julienwillard.com/calendar/clinical#e-caeeeefd-aeac-46ac-acf3-e bd69e2c72e8 END:VEVENT BEGIN:VEVENT UID:3faed3d1f1504f37779f7a5f111e5a4c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270106 DTEND;VALUE=DATE:20270107 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Incyte Corporation INCA034176: Trial primary completion DESCRIPTION:As of 10 August 2026\, Incyte estimated primary completion of a Phase 2 trial in Chronic Graft-versus-host-disease\, on 6 January 2027.\n \nSource: clinicaltrials NCT06843408\nhttps://clinicaltrials.gov/study/NCT 06843408 URL:https://julienwillard.com/calendar/clinical#e-84acdb99-58ea-480b-bd1c-f 994e3cd00c6 END:VEVENT BEGIN:VEVENT UID:bc88604fc5d96a7cf6e3261d8f3c58ec DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270107 DTEND;VALUE=DATE:20270108 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi PCV21: Trial primary completion DESCRIPTION:As of 15 April 2026\, Sanofi estimated primary completion of a Phase 3 trial in Sickle Cell Disease\, on 7 January 2027.\n\nSource: clini caltrials NCT07247188\nhttps://clinicaltrials.gov/study/NCT07247188 URL:https://julienwillard.com/calendar/clinical#e-1ab5297a-a8f9-4d9f-8798-9 2cb20b82b84 END:VEVENT BEGIN:VEVENT UID:815c54db6cace6523bc2b45fa23f797d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270108 DTEND;VALUE=DATE:20270109 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ocular Therapeutix\, Inc. OTX-TKI: Trial primary completion DESCRIPTION:As of 17 June 2025\, Ocular Therapeutix estimated primary compl etion of a Phase 3 trial in Neovascular Age-related Macular Degeneration\, on 8 January 2027.\n\nSource: clinicaltrials NCT06495918\nhttps://clinica ltrials.gov/study/NCT06495918 URL:https://julienwillard.com/calendar/clinical#e-176a88a5-3d86-497c-846d-b ac48851b0a0 END:VEVENT BEGIN:VEVENT UID:25df680fc03c7256f696520ec4e81690 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270108 DTEND;VALUE=DATE:20270109 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi Isatuximab SC-OBDS: Trial primary completion DESCRIPTION:As of 23 February 2026\, Sanofi estimated primary completion of a Phase 2 trial in Plasma Cell Myeloma Refractory\, on 8 January 2027.\n\ nSource: clinicaltrials NCT06356571\nhttps://clinicaltrials.gov/study/NCT0 6356571 URL:https://julienwillard.com/calendar/clinical#e-08c9bf16-6474-4997-b9f5-2 bee88af5090 END:VEVENT BEGIN:VEVENT UID:9c3d4c77492afacfeecfc71d993e0d49 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270109 DTEND;VALUE=DATE:20270110 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GeneQuantum Healthcare (Suzhou) Co.\, Ltd. GQ1005: Trial primary co mpletion DESCRIPTION:As of 29 June 2026\, GeneQuantum Healthcare (Suzhou) Co. estima ted primary completion of a Phase 3 trial in HER2-positive Breast Cancer\, on 9 January 2027.\n\nSource: clinicaltrials NCT07673029\nhttps://clinica ltrials.gov/study/NCT07673029 URL:https://julienwillard.com/calendar/clinical#e-c5593776-1e35-4c8d-af6f-a 15ecb7930cf END:VEVENT BEGIN:VEVENT UID:978b843ac1fd78c4b4983e66e22bf041 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270110 DTEND;VALUE=DATE:20270111 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Celgene mezigdomide: Trial primary completion DESCRIPTION:As of 29 July 2026\, Celgene estimated primary completion of a Phase 3 trial in Relapsed or Refractory Multiple Myeloma\, on 10 January 2 027.\n\nSource: clinicaltrials NCT05519085\nhttps://clinicaltrials.gov/stu dy/NCT05519085 URL:https://julienwillard.com/calendar/clinical#e-b4c92ae4-90f8-4770-bdcc-b 8d98f39a5c8 END:VEVENT BEGIN:VEVENT UID:042a229adbc98d017836955927f92462 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270111 DTEND;VALUE=DATE:20270112 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:LaNova Medicines Limited LM101: Trial primary completion DESCRIPTION:As of 19 December 2024\, LaNova Medicines estimated primary com pletion of a Phase 2 trial in Malignant Tumors\, on 11 January 2027.\n\nSo urce: clinicaltrials NCT05615974\nhttps://clinicaltrials.gov/study/NCT0561 5974 URL:https://julienwillard.com/calendar/clinical#e-07bc667d-e313-4716-bbda-d cf8b248d9e8 END:VEVENT BEGIN:VEVENT UID:27ee71d672871fdecb6a5626630cb462 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270111 DTEND;VALUE=DATE:20270112 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD0780: Trial primary completion DESCRIPTION:As of 11 August 2026\, AstraZeneca estimated primary completion of a Phase 3 trial in Cardiovascular Disease\, on 11 January 2027.\n\nSou rce: clinicaltrials NCT07000123\nhttps://clinicaltrials.gov/study/NCT07000 123 URL:https://julienwillard.com/calendar/clinical#e-c5c6927c-ce13-47ae-84b2-b b0f3f3b1bfd END:VEVENT BEGIN:VEVENT UID:9c4140c2082ed4685b44166cd2e3cac0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270112 DTEND;VALUE=DATE:20270113 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Sacituzumab Govitecan: Trial primary comple tion DESCRIPTION:As of 24 December 2025\, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Carcinoma\, Non-Small-Cell Lung\, on 12 J anuary 2027.\n\nSource: clinicaltrials NCT05609968\nhttps://clinicaltrials .gov/study/NCT05609968 URL:https://julienwillard.com/calendar/clinical#e-80bb46ac-332a-42e7-a7a4-6 ca995f8646d END:VEVENT BEGIN:VEVENT UID:6b79d2dcde6f04b0858ac70c14b52f10 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270112 DTEND;VALUE=DATE:20270113 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline Adjuvanted RSVPreF3 vaccine: Trial primary completi on DESCRIPTION:As of 30 July 2026\, GlaxoSmithKline estimated primary completi on of a Phase 2 trial in Respiratory Syncytial Virus Infections\, on 12 Ja nuary 2027.\n\nSource: clinicaltrials NCT07092865\nhttps://clinicaltrials. gov/study/NCT07092865 URL:https://julienwillard.com/calendar/clinical#e-645b0a0e-6750-4d29-92e9-8 66f6a4b181d END:VEVENT BEGIN:VEVENT UID:69e75d050b3b0ec23811b55dc3a18565 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270113 DTEND;VALUE=DATE:20270114 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Avirmax Biopharma Inc ABI-110 Low Dose: Trial primary completion DESCRIPTION:As of 12 February 2026\, Avirmax Biopharma estimated primary co mpletion of a Phase 2 trial in Neovascular (Wet) AMD\, on 13 January 2027. \n\nSource: clinicaltrials NCT06550011\nhttps://clinicaltrials.gov/study/N CT06550011 URL:https://julienwillard.com/calendar/clinical#e-9b268ed8-e577-4ae9-94ad-2 b138f2e5dd7 END:VEVENT BEGIN:VEVENT UID:fa9a4a05534d8733582d1568fd189ede DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270113 DTEND;VALUE=DATE:20270114 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:iVascular S.L.U. Angiolite: Sirolimus-eluting stent: Trial primary completion DESCRIPTION:As of 15 May 2026\, iVascular S.L.U. estimated primary completi on of a Phase 3 trial in Coronary Artery Disease\, on 13 January 2027.\n\n Source: clinicaltrials NCT05952206\nhttps://clinicaltrials.gov/study/NCT05 952206 URL:https://julienwillard.com/calendar/clinical#e-ceb67cf8-d373-44d0-ae9a-0 1dde4df0c63 END:VEVENT BEGIN:VEVENT UID:4ca2bd156c96a7b667706e4ee09ca643 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270113 DTEND;VALUE=DATE:20270114 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Akeso AK112: Trial primary completion DESCRIPTION:As of 4 March 2026\, Akeso estimated primary completion of a Ph ase 3 trial in Colorectal Adenocarcinoma\, on 13 January 2027.\n\nSource: clinicaltrials NCT06951503\nhttps://clinicaltrials.gov/study/NCT06951503 URL:https://julienwillard.com/calendar/clinical#e-75a9c049-cd94-471c-87e1-e ef5f5ed68d6 END:VEVENT BEGIN:VEVENT UID:f27b554fea857fdfb7325fe826f52858 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270113 DTEND;VALUE=DATE:20270114 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Tezepelumab: Trial primary completion DESCRIPTION:As of 5 August 2026\, AstraZeneca estimated primary completion of a Phase 3 trial in Chronic Rhinosinusitis With Nasal Polyps\, on 13 Jan uary 2027.\n\nSource: clinicaltrials NCT06706817\nhttps://clinicaltrials.g ov/study/NCT06706817 URL:https://julienwillard.com/calendar/clinical#e-e85f2ab9-f38a-4cbf-aaf6-d f31d6aa8fb2 END:VEVENT BEGIN:VEVENT UID:682772707ed9935b1054c73015712f85 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270114 DTEND;VALUE=DATE:20270115 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novo Nordisk A/S UBT251: Trial primary completion DESCRIPTION:As of 21 April 2026\, Novo Nordisk estimated primary completion of a Phase 2 trial in overweight\, on 14 January 2027.\n\nSource: clinica ltrials NCT07395687\nhttps://clinicaltrials.gov/study/NCT07395687 URL:https://julienwillard.com/calendar/clinical#e-e718e183-9da0-45f2-93f8-3 cfffd467ec3 END:VEVENT BEGIN:VEVENT UID:df7192f3ead5b728d6c708d4f07b07b0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270114 DTEND;VALUE=DATE:20270115 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sunshine Guojian Pharmaceutical (Shanghai) Co.\, Ltd. 608 dose: Tri al primary completion DESCRIPTION:As of 10 December 2025\, Sunshine Guojian Pharmaceutical (Shang hai) Co. estimated primary completion of a Phase 3 trial in Ankylosing Spo ndylitis\, on 14 January 2027.\n\nSource: clinicaltrials NCT07261644\nhttp s://clinicaltrials.gov/study/NCT07261644 URL:https://julienwillard.com/calendar/clinical#e-27485e38-5fa1-4b4d-962f-e 83dfb578a6a END:VEVENT BEGIN:VEVENT UID:f3bc0733de8eb908d9a57b673b5c1bfb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270115 DTEND;VALUE=DATE:20270116 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bioverativ\, a Sanofi company efanesoctocog alfa (BIVV001): Trial p rimary completion DESCRIPTION:As of 28 July 2026\, Bioverativ\, a Sanofi estimated primary co mpletion of a Phase 3 trial in Hemophilia A\, on 15 January 2027.\n\nSourc e: clinicaltrials NCT04644575\nhttps://clinicaltrials.gov/study/NCT0464457 5 URL:https://julienwillard.com/calendar/clinical#e-fc6743a9-aa82-4df8-9958-3 32e49ef1671 END:VEVENT BEGIN:VEVENT UID:9b734603abe72503a6486c025a5f6aba DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270115 DTEND;VALUE=DATE:20270116 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Azitra Inc. ATR04-484: Trial primary completion DESCRIPTION:As of 11 February 2026\, Azitra estimated primary completion of a Phase 2 trial in EGFR Inhibitor-associated Rash\, on 15 January 2027.\n \nSource: clinicaltrials NCT06830863\nhttps://clinicaltrials.gov/study/NCT 06830863 URL:https://julienwillard.com/calendar/clinical#e-4e89e67d-696e-48df-9aa7-e 2a64d2e39f7 END:VEVENT BEGIN:VEVENT UID:b6704b723585651b26f5bb9991872a46 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270115 DTEND;VALUE=DATE:20270116 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MoonLake Immunotherapeutics AG Sonelokimab: Trial primary completio n DESCRIPTION:As of 13 July 2026\, MoonLake Immunotherapeutics estimated prim ary completion of a Phase 3 trial in Arthritis\, Psoriatic\, on 15 January 2027.\n\nSource: clinicaltrials NCT06641089\nhttps://clinicaltrials.gov/s tudy/NCT06641089 URL:https://julienwillard.com/calendar/clinical#e-e473cf43-205f-4914-aca1-0 d11cff3cb52 END:VEVENT BEGIN:VEVENT UID:69908bf742c95cbe0306dd5d33279210 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270115 DTEND;VALUE=DATE:20270116 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Huabo Biopharm Co.\, Ltd. HB0025 20 mg/kg plus nab-paclitaxel: Tria l primary completion DESCRIPTION:As of 29 January 2026\, Huabo Biopharm Co. estimated primary co mpletion of a Phase 2 trial in tNBC\, on 15 January 2027.\n\nSource: clini caltrials NCT07376629\nhttps://clinicaltrials.gov/study/NCT07376629 URL:https://julienwillard.com/calendar/clinical#e-adffa175-1f58-4018-bfa6-5 ebb53caede7 END:VEVENT BEGIN:VEVENT UID:ca3d36b34690acfc9fba4e56ff934249 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270115 DTEND;VALUE=DATE:20270116 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:IDEAYA Biosciences IDE196: Trial primary completion DESCRIPTION:As of 17 February 2026\, IDEAYA Biosciences estimated primary c ompletion of a Phase 3 trial in Metastatic Uveal Melanoma\, on 15 January 2027.\n\nSource: clinicaltrials NCT05987332\nhttps://clinicaltrials.gov/st udy/NCT05987332 URL:https://julienwillard.com/calendar/clinical#e-a2b2e739-96ac-4e8c-9efd-4 be8153c1493 END:VEVENT BEGIN:VEVENT UID:ed0f625ec395c279d1ecdf8fa0a84935 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270115 DTEND;VALUE=DATE:20270116 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biostar Pharma\, Inc. Utidelone: Trial primary completion DESCRIPTION:As of 28 November 2025\, Biostar Pharma estimated primary compl etion of a Phase 2 trial in HER2-negative Breast Cancer Patients With Brai n Metastases\, on 15 January 2027.\n\nSource: clinicaltrials NCT06764940\n https://clinicaltrials.gov/study/NCT06764940 URL:https://julienwillard.com/calendar/clinical#e-0d9b2485-8480-4320-a56a-3 8a1e1a0caf4 END:VEVENT BEGIN:VEVENT UID:65c0431a553243761457c47e27992312 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270116 DTEND;VALUE=DATE:20270117 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Corbus Pharmaceuticals Inc. CRB-701: Trial primary completion DESCRIPTION:As of 8 January 2026\, Corbus Pharmaceuticals estimated primary completion of a Phase 2 trial in Solid Tumor\, Adult\, on 16 January 2027 .\n\nSource: clinicaltrials NCT06265727\nhttps://clinicaltrials.gov/study/ NCT06265727 URL:https://julienwillard.com/calendar/clinical#e-35b78f23-2b8a-49c2-bf46-2 57090ffd465 END:VEVENT BEGIN:VEVENT UID:998027c146276caaa916a47fbe3fd2fa DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270118 DTEND;VALUE=DATE:20270119 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Centre for Neuro Skills Aerobic Exercise (AER): Trial primary compl etion DESCRIPTION:As of 28 March 2023\, Centre for Neuro Skills estimated primary completion of a Phase 2 trial in Traumatic Brain Injury\, on 18 January 2 027.\n\nSource: clinicaltrials NCT05786729\nhttps://clinicaltrials.gov/stu dy/NCT05786729 URL:https://julienwillard.com/calendar/clinical#e-8ca14279-83a6-4039-85c3-0 bcd52f083fa END:VEVENT BEGIN:VEVENT UID:e6ce0574757ae73e216a1c93f11ea311 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270118 DTEND;VALUE=DATE:20270119 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer RSVpreF: Trial primary completion DESCRIPTION:As of 28 January 2026\, Pfizer estimated primary completion of a Phase 3 trial in Lower Respiratory Tract Illness\, on 18 January 2027.\n \nSource: clinicaltrials NCT05035212\nhttps://clinicaltrials.gov/study/NCT 05035212 URL:https://julienwillard.com/calendar/clinical#e-ba37658c-10cb-4a94-b36e-1 5efaeaaca9f END:VEVENT BEGIN:VEVENT UID:aba9cbbf8aa9cf408a9a5576cafde8bf DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270118 DTEND;VALUE=DATE:20270119 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi Pasteur\, a Sanofi Company Investigational hMPV/RSV vaccine: Trial primary completion DESCRIPTION:As of 11 December 2025\, Sanofi Pasteur\, a Sanofi estimated pr imary completion of a Phase 2 trial in Human Metapneumovirus Immunization\ , on 18 January 2027.\n\nSource: clinicaltrials NCT06686654\nhttps://clini caltrials.gov/study/NCT06686654 URL:https://julienwillard.com/calendar/clinical#e-4d966392-c8da-4311-bb4a-f 67c727f12f6 END:VEVENT BEGIN:VEVENT UID:a506216cf72ff10c8a8c58aae84eb526 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270118 DTEND;VALUE=DATE:20270119 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca Savolitinib: Trial primary completion DESCRIPTION:As of 14 May 2026\, AstraZeneca estimated primary completion of a Phase 2 trial in Lung Cancer\, on 18 January 2027.\n\nSource: clinicalt rials NCT05374603\nhttps://clinicaltrials.gov/study/NCT05374603 URL:https://julienwillard.com/calendar/clinical#e-a7d2b3b0-5ec3-42ed-9657-f 37f327459a7 END:VEVENT BEGIN:VEVENT UID:e8b5843709038cc3364c10603be846e5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270118 DTEND;VALUE=DATE:20270119 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Takeda Maribavir: Trial primary completion DESCRIPTION:As of 22 May 2026\, Takeda estimated primary completion of a Ph ase 3 trial in cytomegalovirus (CMV)\, on 18 January 2027.\n\nSource: clin icaltrials NCT05319353\nhttps://clinicaltrials.gov/study/NCT05319353 URL:https://julienwillard.com/calendar/clinical#e-62d66cc6-d72c-4f3c-8d7b-e 915096ea231 END:VEVENT BEGIN:VEVENT UID:d813ead9ea1789c99ff637afc98a07ce DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270119 DTEND;VALUE=DATE:20270120 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanofi SAR445877: Trial primary completion DESCRIPTION:As of 23 June 2026\, Sanofi estimated primary completion of a P hase 2 trial in Solid Tumor\, on 19 January 2027.\n\nSource: clinicaltrial s NCT05584670\nhttps://clinicaltrials.gov/study/NCT05584670 URL:https://julienwillard.com/calendar/clinical#e-f763fd02-61fb-454d-b07d-a 4d78e8df567 END:VEVENT BEGIN:VEVENT UID:1d90f4dca6b45b2d17c542a77ee13836 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270120 DTEND;VALUE=DATE:20270121 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Acepodia Biotech\, Inc. ACE1831: Trial primary completion DESCRIPTION:As of 13 February 2026\, Acepodia Biotech estimated primary com pletion of a Phase 2 trial in IgG4 Related Disease\, on 20 January 2027.\n \nSource: clinicaltrials NCT07061938\nhttps://clinicaltrials.gov/study/NCT 07061938 URL:https://julienwillard.com/calendar/clinical#e-db1c52df-ff4a-4c97-9562-4 6c05b5b6817 END:VEVENT BEGIN:VEVENT UID:8e82c952ae96619bbf321bcdaecd0369 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270121 DTEND;VALUE=DATE:20270122 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amgen Maridebart cafraglutide: Trial primary completion DESCRIPTION:As of 31 December 2025\, Amgen estimated primary completion of a Phase 3 trial in Type 2 Diabetes Mellitus (T2DM)\, Obesity\, Overweight\ , on 21 January 2027.\n\nSource: clinicaltrials NCT06858878\nhttps://clini caltrials.gov/study/NCT06858878 URL:https://julienwillard.com/calendar/clinical#e-6f32f672-103d-44a4-b0b2-5 38a7d384c86 END:VEVENT BEGIN:VEVENT UID:6e3be39413a34d7776ae9a4d54b31b02 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270121 DTEND;VALUE=DATE:20270122 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Laboratoires Thea Slit Lamp Examination: Trial primary completion DESCRIPTION:As of 22 April 2026\, Laboratoires Thea estimated primary compl etion of a Phase 2 trial in Moderate to Severe Vernal Keratoconjunctivitis \, on 21 January 2027.\n\nSource: clinicaltrials NCT07169695\nhttps://clin icaltrials.gov/study/NCT07169695 URL:https://julienwillard.com/calendar/clinical#e-4d4b6d3a-a1ca-45eb-b9b7-3 11eb2cdecda END:VEVENT BEGIN:VEVENT UID:e40377303b24472e456408f87b2b2e3a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270121 DTEND;VALUE=DATE:20270122 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amgen Maridebart Cafraglutide: Trial primary completion DESCRIPTION:As of 20 October 2025\, Amgen estimated primary completion of a Phase 3 trial in obesity\, on 21 January 2027.\n\nSource: clinicaltrials NCT06858839\nhttps://clinicaltrials.gov/study/NCT06858839 URL:https://julienwillard.com/calendar/clinical#e-d5e64ce9-8207-434b-945c-7 7d90c0db66a END:VEVENT BEGIN:VEVENT UID:297825c5fa3a2626f8626543e7dafebb DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270122 DTEND;VALUE=DATE:20270123 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Lupin Ltd. Granular powder in unit dose foil-lined sachet Mexiletin e (PR): Trial primary completion DESCRIPTION:As of 22 December 2025\, Lupin estimated primary completion of a Phase 3 trial in myotonia\, on 22 January 2027.\n\nSource: clinicaltrial s NCT07097701\nhttps://clinicaltrials.gov/study/NCT07097701 URL:https://julienwillard.com/calendar/clinical#e-27661a29-cd5e-4866-9ad6-f 21e83474c99 END:VEVENT BEGIN:VEVENT UID:642a668f0f4d182e19c6377aed6545fe DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270122 DTEND;VALUE=DATE:20270123 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GlaxoSmithKline FF/UMEC/VI: Trial primary completion DESCRIPTION:As of 16 July 2026\, GlaxoSmithKline estimated primary completi on of a Phase 3 trial in asthma\, on 22 January 2027.\n\nSource: clinicalt rials NCT05757102\nhttps://clinicaltrials.gov/study/NCT05757102 URL:https://julienwillard.com/calendar/clinical#e-fdb5937c-40c3-472e-abcd-1 e84b07f91c3 END:VEVENT BEGIN:VEVENT UID:0922b6c3c5e549d89630de53610629d6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270123 DTEND;VALUE=DATE:20270124 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Egle Therapeutics EGL-001: Trial primary completion DESCRIPTION:As of 7 November 2024\, Egle Therapeutics estimated primary com pletion of a Phase 2 trial in Solid Tumor\, Adult\, on 23 January 2027.\n\ nSource: clinicaltrials NCT06622486\nhttps://clinicaltrials.gov/study/NCT0 6622486 URL:https://julienwillard.com/calendar/clinical#e-cbf9952e-c7d2-44d9-8dac-8 968b46fda84 END:VEVENT BEGIN:VEVENT UID:edd7393f20fd6246e0651694e0868029 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270124 DTEND;VALUE=DATE:20270125 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Dompé Farmaceutici S.p.A DFL24498: Trial primary completion DESCRIPTION:As of 26 June 2026\, Dompé Farmaceutici S.p.A estimated primar y completion of a Phase 2 trial in Dry Eye Disease (DED)\, on 24 January 2 027.\n\nSource: clinicaltrials NCT07503886\nhttps://clinicaltrials.gov/stu dy/NCT07503886 URL:https://julienwillard.com/calendar/clinical#e-4b3f6efc-8146-4e96-a3d0-f 0c3b6fe780b END:VEVENT BEGIN:VEVENT UID:681049e8d93fcf4736aec2e7acd044f3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270125 DTEND;VALUE=DATE:20270126 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Biotheus Inc. PM8002: Trial primary completion DESCRIPTION:As of 22 May 2026\, Biotheus estimated primary completion of a Phase 3 trial in sCLC\, on 25 January 2027.\n\nSource: clinicaltrials NCT0 6616532\nhttps://clinicaltrials.gov/study/NCT06616532 URL:https://julienwillard.com/calendar/clinical#e-115c2da6-1fea-4951-91ef-2 d53e08236ef END:VEVENT BEGIN:VEVENT UID:841e42f5ce944a6093ffb4c2daf87606 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270125 DTEND;VALUE=DATE:20270126 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novo Nordisk A/S Insulin icodec: Trial primary completion DESCRIPTION:As of 29 June 2026\, Novo Nordisk estimated primary completion of a Phase 3 trial in Diabetes Mellitus\, Type 1\, on 25 January 2027.\n\n Source: clinicaltrials NCT07076199\nhttps://clinicaltrials.gov/study/NCT07 076199 URL:https://julienwillard.com/calendar/clinical#e-0eb1acfc-74cb-404e-b395-4 f92ea1aaec6 END:VEVENT BEGIN:VEVENT UID:61f3862d1082ccd9a3fb9f9f5f80bb55 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270125 DTEND;VALUE=DATE:20270126 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Pfizer RSVpreF: Trial primary completion DESCRIPTION:As of 29 July 2026\, Pfizer estimated primary completion of a P hase 3 trial in Respiratory Syncytial Virus (RSV)\, on 25 January 2027.\n\ nSource: clinicaltrials NCT07653100\nhttps://clinicaltrials.gov/study/NCT0 7653100 URL:https://julienwillard.com/calendar/clinical#e-fc0c8abc-7bdd-40c8-87f2-2 bca490d760a END:VEVENT BEGIN:VEVENT UID:ebbe0695bf03c202daa64601c38d5f67 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270125 DTEND;VALUE=DATE:20270126 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals JDQ443: Trial primary completion DESCRIPTION:As of 18 March 2026\, Novartis Pharmaceuticals estimated primar y completion of a Phase 2 trial in KRAS G12C Mutant Solid Tumors\, on 25 J anuary 2027.\n\nSource: clinicaltrials NCT04699188\nhttps://clinicaltrials .gov/study/NCT04699188 URL:https://julienwillard.com/calendar/clinical#e-a71eb952-99f7-4308-84bc-d 9f57914f961 END:VEVENT BEGIN:VEVENT UID:721ea5e61a74a6875878f878ae521702 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270125 DTEND;VALUE=DATE:20270126 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vertex Pharmaceuticals Incorporated Suzetrigine: Trial primary comp letion DESCRIPTION:As of 18 May 2026\, Vertex Pharmaceuticals Incorporated estimat ed primary completion of a Phase 3 trial in Diabetic Peripheral Neuropathi c Pain\, on 25 January 2027.\n\nSource: clinicaltrials NCT06696443\nhttps: //clinicaltrials.gov/study/NCT06696443 URL:https://julienwillard.com/calendar/clinical#e-5ba16311-afd8-4d48-ba2e-f 8da6b4091e8 END:VEVENT BEGIN:VEVENT UID:6371dba490bc2c49b26986fa84536b84 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270128 DTEND;VALUE=DATE:20270129 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals Alpelisib: Trial primary completion DESCRIPTION:As of 14 July 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Breast Cancer\, on 28 January 2027.\n\nS ource: clinicaltrials NCT05038735\nhttps://clinicaltrials.gov/study/NCT050 38735 URL:https://julienwillard.com/calendar/clinical#e-1d808dab-4dd9-4e8a-8040-2 df071c5268c END:VEVENT BEGIN:VEVENT UID:9cbec0ad3ba0d8befd37a7fb797b8bd6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270128 DTEND;VALUE=DATE:20270129 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:ModernaTX\, Inc. mRNA-1018-H5: Trial primary completion DESCRIPTION:As of 11 August 2026\, ModernaTX estimated primary completion o f a Phase 3 trial in influenza\, on 28 January 2027.\n\nSource: clinicaltr ials NCT07496450\nhttps://clinicaltrials.gov/study/NCT07496450 URL:https://julienwillard.com/calendar/clinical#e-e0b3c00b-9897-4e59-b950-7 a8097301646 END:VEVENT BEGIN:VEVENT UID:5f221c11d37b75f79ae11085f092427b DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270128 DTEND;VALUE=DATE:20270129 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD0901: Trial primary completion DESCRIPTION:As of 10 July 2026\, AstraZeneca estimated primary completion o f a Phase 2 trial in Gastroesophageal Adenocarcinoma\, on 28 January 2027. \n\nSource: clinicaltrials NCT07069712\nhttps://clinicaltrials.gov/study/N CT07069712 URL:https://julienwillard.com/calendar/clinical#e-25ebd658-9b8e-407b-a9c5-9 edef67c899d END:VEVENT BEGIN:VEVENT UID:aa8e9df9d31a68c36ce7d7722f66d88c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270129 DTEND;VALUE=DATE:20270130 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals iptacopan: Trial primary completion DESCRIPTION:As of 13 July 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in c3G\, on 29 January 2027.\n\nSource: cli nicaltrials NCT04817618\nhttps://clinicaltrials.gov/study/NCT04817618 URL:https://julienwillard.com/calendar/clinical#e-06b4b055-46d2-43a2-ad10-5 cb48f4336fc END:VEVENT BEGIN:VEVENT UID:75cdfa52a09efd80e90750e346fbb601 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270129 DTEND;VALUE=DATE:20270130 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals QCZ484: Trial primary completion DESCRIPTION:As of 6 July 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in hypertension\, on 29 January 2027.\n\nSou rce: clinicaltrials NCT06857955\nhttps://clinicaltrials.gov/study/NCT06857 955 URL:https://julienwillard.com/calendar/clinical#e-00d9c630-5fd4-46d1-94d6-4 3f1abdf65fc END:VEVENT BEGIN:VEVENT UID:aa531456a6535108a861ef9bfc4bbb4c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270129 DTEND;VALUE=DATE:20270130 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Seagen\, a wholly owned subsidiary of Pfizer disitamab vedotin: Tri al primary completion DESCRIPTION:As of 22 July 2026\, Seagen estimated primary completion of a P hase 3 trial in Urothelial Carcinoma\, on 29 January 2027.\n\nSource: clin icaltrials NCT05911295\nhttps://clinicaltrials.gov/study/NCT05911295 URL:https://julienwillard.com/calendar/clinical#e-dc64869d-55a7-4d49-b97a-8 282e490396f END:VEVENT BEGIN:VEVENT UID:cd62b66079e9824b1dbe83f363daa489 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270129 DTEND;VALUE=DATE:20270130 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AstraZeneca AZD9550: Trial primary completion DESCRIPTION:As of 23 June 2026\, AstraZeneca estimated primary completion o f a Phase 2 trial in Overweight and Obesity\, on 29 January 2027.\n\nSourc e: clinicaltrials NCT06151964\nhttps://clinicaltrials.gov/study/NCT0615196 4 URL:https://julienwillard.com/calendar/clinical#e-b100c473-3de8-45ae-89d0-b f56a751040b END:VEVENT BEGIN:VEVENT UID:27b25b202a688b403ad73a43c1517117 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270129 DTEND;VALUE=DATE:20270130 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals Alpelisib: Trial primary completion DESCRIPTION:As of 11 June 2026\, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Breast Neoplasms\, on 29 January 2027.\n \nSource: clinicaltrials NCT04544189\nhttps://clinicaltrials.gov/study/NCT 04544189 URL:https://julienwillard.com/calendar/clinical#e-251914e5-1abc-4f9b-9054-7 7d2119a41db END:VEVENT BEGIN:VEVENT UID:d00df347800a4a87de753b420dad06bc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270129 DTEND;VALUE=DATE:20270130 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:IDEAYA Biosciences IDE196: Trial primary completion DESCRIPTION:As of 8 June 2026\, IDEAYA Biosciences estimated primary comple tion of a Phase 2 trial in Metastatic Uveal Melanoma\, on 29 January 2027. \n\nSource: clinicaltrials NCT03947385\nhttps://clinicaltrials.gov/study/N CT03947385 URL:https://julienwillard.com/calendar/clinical#e-ac9c804a-49a5-400c-8d4e-5 81f87871a27 END:VEVENT BEGIN:VEVENT UID:5c3bad3b126ca6ce5dede47f3f6efb69 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270129 DTEND;VALUE=DATE:20270130 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Dynavax Technologies Corporation rF1V-1018: Trial primary completio n DESCRIPTION:As of 18 June 2026\, Dynavax Technologies estimated primary com pletion of a Phase 2 trial on 29 January 2027.\n\nSource: clinicaltrials N CT07207408\nhttps://clinicaltrials.gov/study/NCT07207408 URL:https://julienwillard.com/calendar/clinical#e-ec77d23f-93b5-443c-973e-d da833eb78d8 END:VEVENT BEGIN:VEVENT UID:90433cbb3d554b9e346a77e5e46259be DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270130 DTEND;VALUE=DATE:20270131 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Curasight 64Cu-DOTA-AE105: Trial primary completion DESCRIPTION:As of 1 June 2026\, Curasight estimated primary completion of a Phase 2 trial in Prostate Cancer\, on 30 January 2027.\n\nSource: clinica ltrials NCT06474806\nhttps://clinicaltrials.gov/study/NCT06474806 URL:https://julienwillard.com/calendar/clinical#e-ea274b5d-59ee-4cd4-986f-d 131e348654f END:VEVENT BEGIN:VEVENT UID:bb7435ca57a7a8c35f90fd42310b570a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270130 DTEND;VALUE=DATE:20270131 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bristol-Myers Squibb BMS-986369: Trial primary completion DESCRIPTION:As of 1 May 2026\, Bristol-Myers Squibb estimated primary compl etion of a Phase 2 trial in Relapsed or Refractory T-cell Lymphomas\, on 3 0 January 2027.\n\nSource: clinicaltrials NCT06035497\nhttps://clinicaltri als.gov/study/NCT06035497 URL:https://julienwillard.com/calendar/clinical#e-19dcc2a2-4a88-4d47-aeeb-d 6dbd97bdcf0 END:VEVENT BEGIN:VEVENT UID:6a38aa10bd2ac7e9bab5e93f26938e84 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270130 DTEND;VALUE=DATE:20270131 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Afimkibart: Trial primary completion DESCRIPTION:As of 18 June 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 3 trial in Moderately to Severely Active Ulcerative Coliti s\, on 30 January 2027.\n\nSource: clinicaltrials NCT06589986\nhttps://cli nicaltrials.gov/study/NCT06589986 URL:https://julienwillard.com/calendar/clinical#e-05afcfd6-9c32-439a-bbaa-d bd23eba8e23 END:VEVENT BEGIN:VEVENT UID:4b19dc43dcc7b85553d1357f7a85a30f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270130 DTEND;VALUE=DATE:20270131 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Afimkibart: Trial primary completion DESCRIPTION:As of 5 August 2026\, Hoffmann-La Roche estimated primary compl etion of a Phase 3 trial in Moderately to Severely Active Ulcerative Colit is\, on 30 January 2027.\n\nSource: clinicaltrials NCT06588855\nhttps://cl inicaltrials.gov/study/NCT06588855 URL:https://julienwillard.com/calendar/clinical#e-6e4ffaa7-58bf-44b7-92b0-9 f879fb50bc1 END:VEVENT BEGIN:VEVENT UID:e2d1ba6c4b7263d17207782341c5ce59 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270130 DTEND;VALUE=DATE:20270131 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Psivac Ltd Ixovex-1: Trial primary completion DESCRIPTION:As of 30 January 2025\, Psivac estimated primary completion of a Phase 2 trial in Solid Tumor\, on 30 January 2027.\n\nSource: clinicaltr ials NCT06549946\nhttps://clinicaltrials.gov/study/NCT06549946 URL:https://julienwillard.com/calendar/clinical#e-b49bdc58-f721-41ac-908b-1 a631e0c2e60 END:VEVENT BEGIN:VEVENT UID:0a1af91cb284efbb0d4210c8900c85aa DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Janssen Research & Development\, LLC Cetrelimab: Trial primary comp letion DESCRIPTION:As of 6 July 2026\, Janssen Research & Development estimated pr imary completion of a Phase 2 trial in Carcinoma\, Non-Small-Cell Lung\, o n 31 January 2027.\n\nSource: clinicaltrials NCT05908734\nhttps://clinical trials.gov/study/NCT05908734 URL:https://julienwillard.com/calendar/clinical#e-317090d7-91d3-4c92-82ab-c 501924bd755 END:VEVENT BEGIN:VEVENT UID:0503e87e1bca1e7f558653bbcfeeae7f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Daiichi Sankyo Co.\, Ltd. DS-5141b: Trial primary completion DESCRIPTION:As of 19 September 2025\, Daiichi Sankyo Co. estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy\, on 31 Janua ry 2027.\n\nSource: clinicaltrials NCT04433234\nhttps://clinicaltrials.gov /study/NCT04433234 URL:https://julienwillard.com/calendar/clinical#e-38fa05fe-d44f-4632-99dd-3 09247d1e3e9 END:VEVENT BEGIN:VEVENT UID:14b9dc3b66bd821380b6cdab6f8223b0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ono Pharmaceutical Co.\, Ltd. Cenobamate: Trial primary completion DESCRIPTION:As of 17 June 2025\, Ono Pharmaceutical Co. estimated primary c ompletion of a Phase 3 trial in Epilepsy\, Generalized\, on 31 January 202 7.\n\nSource: clinicaltrials NCT06579573\nhttps://clinicaltrials.gov/study /NCT06579573 URL:https://julienwillard.com/calendar/clinical#e-6d75406c-372c-41e7-aaa6-f 3bae0750098 END:VEVENT BEGIN:VEVENT UID:048a7e4813de7875c9566f8c843f44f9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Miltenyi Biomedicine GmbH MB-CART2019.1: Trial primary completion DESCRIPTION:As of 8 January 2026\, Miltenyi Biomedicine estimated primary c ompletion of a Phase 2 trial in DLBCL - Diffuse Large B Cell Lymphoma\, on 31 January 2027.\n\nSource: clinicaltrials NCT07288879\nhttps://clinicalt rials.gov/study/NCT07288879 URL:https://julienwillard.com/calendar/clinical#e-edf49938-596e-4300-96a2-f ad510454b0e END:VEVENT BEGIN:VEVENT UID:b83c69f312c040e906b4223d9db3e54c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Scancell Ltd SCIB1 or iSCIB1+ DNA vaccine: Trial primary completion DESCRIPTION:As of 19 December 2025\, Scancell estimated primary completion of a Phase 2 trial in Malignant Melanoma\, on 31 January 2027.\n\nSource: clinicaltrials NCT04079166\nhttps://clinicaltrials.gov/study/NCT04079166 URL:https://julienwillard.com/calendar/clinical#e-e2440e5b-a902-48a3-be96-1 5e767d9b5ac END:VEVENT BEGIN:VEVENT UID:a600b8a5b4967200f864dd6674afdbab DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Quoin Pharmaceuticals QRX003: Trial primary completion DESCRIPTION:As of 21 April 2026\, Quoin Pharmaceuticals estimated primary c ompletion of a Phase 3 trial in Netherton Syndrome\, on 31 January 2027.\n \nSource: clinicaltrials NCT07538583\nhttps://clinicaltrials.gov/study/NCT 07538583 URL:https://julienwillard.com/calendar/clinical#e-93f31f93-d66c-41e4-a926-c a3da1c6f98e END:VEVENT BEGIN:VEVENT UID:ca1fb9f4c185cd2ad22578ccffc08ba4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Creative Medical Technology Holdings Inc CELZ-201 Administration: T rial primary completion DESCRIPTION:As of 19 February 2026\, Creative Medical Technology Holdings e stimated primary completion of a Phase 2 trial in Type 1 Diabetes\, on 31 January 2027.\n\nSource: clinicaltrials NCT05626712\nhttps://clinicaltrial s.gov/study/NCT05626712 URL:https://julienwillard.com/calendar/clinical#e-876e9b81-d617-4355-815e-6 c6a998e1c38 END:VEVENT BEGIN:VEVENT UID:4a28a3fb83ee227392f8927e48dacb4f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:EXO Biologics S.A. Endotracheopulmonary Instillation\, Suspension: Trial primary completion DESCRIPTION:As of 19 September 2024\, EXO Biologics estimated primary compl etion of a Phase 2 trial in Bronchopulmonary Dysplasia\, on 31 January 202 7.\n\nSource: clinicaltrials NCT06279741\nhttps://clinicaltrials.gov/study /NCT06279741 URL:https://julienwillard.com/calendar/clinical#e-2cd353b1-3dc5-4890-86ff-2 42ef32b12d1 END:VEVENT BEGIN:VEVENT UID:dfe0a8f47ce3bd1edd341e0f409c4184 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Acerta Pharma BV Acalabrutinib: Trial primary completion DESCRIPTION:As of 27 December 2024\, Acerta Pharma BV estimated primary com pletion of a Phase 3 trial in Chronic Lymphocytic Leukemia\, on 31 January 2027.\n\nSource: clinicaltrials NCT03836261\nhttps://clinicaltrials.gov/s tudy/NCT03836261 URL:https://julienwillard.com/calendar/clinical#e-146364ea-9e80-41a1-859b-c 948471845c0 END:VEVENT BEGIN:VEVENT UID:809ec89448dea3b7adb76c16d7f80101 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Merck Sharp & Dohme LLC Pembrolizumab: Trial primary completion DESCRIPTION:As of 1 May 2026\, Merck Sharp & Dohme estimated primary comple tion of a Phase 3 trial in Urinary Bladder Neoplasms\, on 31 January 2027. \n\nSource: clinicaltrials NCT04241185\nhttps://clinicaltrials.gov/study/N CT04241185 URL:https://julienwillard.com/calendar/clinical#e-9d339f10-30f8-4c90-b8dc-c 3a023fc8d7e END:VEVENT BEGIN:VEVENT UID:11a945741bef87fc3c3d25985f9d25ee DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ono Pharmaceutical Co.\, Ltd. Cenobamate: Trial primary completion DESCRIPTION:As of 3 June 2025\, Ono Pharmaceutical Co. estimated primary co mpletion of a Phase 2 trial in Epilepsies\, Partial\, on 31 January 2027.\ n\nSource: clinicaltrials NCT06590896\nhttps://clinicaltrials.gov/study/NC T06590896 URL:https://julienwillard.com/calendar/clinical#e-bbfe4cca-4195-491d-9bb6-7 213206d1f8c END:VEVENT BEGIN:VEVENT UID:60f1c14a5a64ac3231cc293ea4c688ee DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tiohundra AB Vasopressin\; Methylprednisolone\; Hydrocortisone: Tri al primary completion DESCRIPTION:As of 20 January 2022\, Tiohundra estimated primary completion of a Phase 3 trial in Cardiac Arrest\;In-hospital Cardiac Arrest\; Methylp rednisolone\; Vasopressin\; Adrenaline\, on 31 January 2027.\n\nSource: cl inicaltrials NCT05139849\nhttps://clinicaltrials.gov/study/NCT05139849 URL:https://julienwillard.com/calendar/clinical#e-bec53899-3ce9-4009-b367-d 2fcd3a801d2 END:VEVENT BEGIN:VEVENT UID:a665a9139c5b11d7bb48238d91e86f24 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Obinutuzumab: Trial primary completion DESCRIPTION:As of 20 July 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 2 trial in B-Cell Non-Hodgkins Lymphoma\, on 31 January 20 27.\n\nSource: clinicaltrials NCT06806033\nhttps://clinicaltrials.gov/stud y/NCT06806033 URL:https://julienwillard.com/calendar/clinical#e-9a8fa614-3957-44c2-8091-5 0cf0e0ec84c END:VEVENT BEGIN:VEVENT UID:01b03cf4d1f9c975a7c9a4f6b7159894 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Actelion Macitentan: Trial primary completion DESCRIPTION:As of 31 July 2026\, Actelion estimated primary completion of a Phase 3 trial in Hypertension\, Pulmonary\, on 31 January 2027.\n\nSource : clinicaltrials NCT05179876\nhttps://clinicaltrials.gov/study/NCT05179876 URL:https://julienwillard.com/calendar/clinical#e-8431e67d-4b09-433a-99da-5 629e35aed97 END:VEVENT BEGIN:VEVENT UID:fa07726a6c0e61436f1dcc8b41b04236 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:NeuroBiogen Co.\, Ltd KDS2010: Trial primary completion DESCRIPTION:As of 24 June 2026\, NeuroBiogen Co. estimated primary completi on of a Phase 2 trial in overweight\, on 31 January 2027.\n\nSource: clini caltrials NCT07009171\nhttps://clinicaltrials.gov/study/NCT07009171 URL:https://julienwillard.com/calendar/clinical#e-23d70801-52ee-4152-ab1b-4 eff8a407325 END:VEVENT BEGIN:VEVENT UID:f96916d931be5d7ff6b91c8b06e0712d DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270131 DTEND;VALUE=DATE:20270201 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Grit Biotechnology GT101 injection: Trial primary completion DESCRIPTION:As of 15 April 2026\, Grit Biotechnology estimated primary comp letion of a Phase 2 trial in adult\, on 31 January 2027.\n\nSource: clinic altrials NCT06241781\nhttps://clinicaltrials.gov/study/NCT06241781 URL:https://julienwillard.com/calendar/clinical#e-0195aa8d-8354-4959-853f-9 4e81fccfd39 END:VEVENT BEGIN:VEVENT UID:74fb8fb89fae828d6ee17b01f3401982 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sunshine Guojian Pharmaceutical (Shanghai) Co.\, Ltd. 610: Trial pr imary completion DESCRIPTION:As of 7 January 2026\, Sunshine Guojian Pharmaceutical (Shangha i) Co. estimated primary completion of a Phase 3 trial in asthma\, in Febr uary 2027.\n\nSource: clinicaltrials NCT06323213\nhttps://clinicaltrials.g ov/study/NCT06323213 URL:https://julienwillard.com/calendar/clinical#e-6634bb40-8f3a-4bc3-8980-9 ef7cc97b859 END:VEVENT BEGIN:VEVENT UID:77068f4484cb42d9b0769d7f7fb429fa DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:argenx Efgartigimod PH20 SC: Trial primary completion DESCRIPTION:As of 21 July 2026\, argenx estimated primary completion of a P hase 2 trial in Systemic Sclerosis (SSc)\, in February 2027.\n\nSource: cl inicaltrials NCT06655155\nhttps://clinicaltrials.gov/study/NCT06655155 URL:https://julienwillard.com/calendar/clinical#e-ecdba3f7-693a-49cc-bf78-3 4a99e0bed7b END:VEVENT BEGIN:VEVENT UID:bf922a689329ef84a82f2f22186ce11f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Genmab Rina-S: Trial primary completion DESCRIPTION:As of 7 July 2026\, Genm estimated primary completion of a Phas e 3 trial in Platinum-resistant Ovarian Cancer\, in February 2027.\n\nSour ce: clinicaltrials NCT06619236\nhttps://clinicaltrials.gov/study/NCT066192 36 URL:https://julienwillard.com/calendar/clinical#e-60d1a1ce-7e18-435a-89bd-5 f4f98e198fa END:VEVENT BEGIN:VEVENT UID:101f3f004081f49aee32957ef7825335 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie Azacitidine: Trial primary completion DESCRIPTION:As of 14 August 2025\, AbbVie estimated primary completion of a Phase 2 trial in Acute Myeloid Leukemia\, in February 2027.\n\nSource: cl inicaltrials NCT04086264\nhttps://clinicaltrials.gov/study/NCT04086264 URL:https://julienwillard.com/calendar/clinical#e-c47f70cf-8469-4049-b3e7-1 6b6d6e71d01 END:VEVENT BEGIN:VEVENT UID:37f01853122d3b1c95d4cc1457b042c7 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbCellera Biologics Inc. ABCL635: Trial primary completion DESCRIPTION:As of 15 June 2026\, AbCellera Biologics estimated primary comp letion of a Phase 2 trial in Vasomotor Symptoms Associated With Menopause\ , in February 2027.\n\nSource: clinicaltrials NCT07118891\nhttps://clinica ltrials.gov/study/NCT07118891 URL:https://julienwillard.com/calendar/clinical#e-df7e4730-e48f-4062-8ceb-3 ce32226b2ea END:VEVENT BEGIN:VEVENT UID:bd6e07fb27bafb5cc7d985f33705970a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Rivus Pharmaceuticals\, Inc. HU6: Trial primary completion DESCRIPTION:As of 18 May 2026\, Rivus Pharmaceuticals estimated primary com pletion of a Phase 2 trial in MASH - Metabolic Dysfunction-Associated Stea tohepatitis\, in February 2027.\n\nSource: clinicaltrials NCT07491458\nhtt ps://clinicaltrials.gov/study/NCT07491458 URL:https://julienwillard.com/calendar/clinical#e-84ab574d-e2b3-48ee-8c26-f 69b5ecd95dd END:VEVENT BEGIN:VEVENT UID:c2cdbfbe3538a38e0138b9dee04b0655 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bond Biosciences BBI-001: Trial primary completion DESCRIPTION:As of 13 May 2026\, Bond Biosciences estimated primary completi on of a Phase 2 trial in Hereditary Hemochromatosis\, in February 2027.\n\ nSource: clinicaltrials NCT07371793\nhttps://clinicaltrials.gov/study/NCT0 7371793 URL:https://julienwillard.com/calendar/clinical#e-5f7559b9-b105-4cdf-901c-4 2fb85efa4ae END:VEVENT BEGIN:VEVENT UID:068e7f0b263ae2978b4a70063d766127 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Antag Therapeutics AT673 low dose: Trial primary completion DESCRIPTION:As of 24 July 2026\, Antag Therapeutics estimated primary compl etion of a Phase 2 trial in Adults With Overweight/Obesity and Type 2 Diab etes\, in February 2027.\n\nSource: clinicaltrials NCT07724340\nhttps://cl inicaltrials.gov/study/NCT07724340 URL:https://julienwillard.com/calendar/clinical#e-ef41aa66-a5f2-4ffd-97fc-d 5beff87928e END:VEVENT BEGIN:VEVENT UID:ed18f3031767f7ae107e08b5984a46e3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Disc Medicine\, Inc DISC-3405: Trial primary completion DESCRIPTION:As of 31 July 2026\, Disc Medicine estimated primary completion of a Phase 2 trial in Polycythemia Vera (PV)\, in February 2027.\n\nSourc e: clinicaltrials NCT06985147\nhttps://clinicaltrials.gov/study/NCT0698514 7 URL:https://julienwillard.com/calendar/clinical#e-b10e0950-565b-462f-8b3a-0 aca59f53a08 END:VEVENT BEGIN:VEVENT UID:2d8fc78098926243bf071c46d35e6cd4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Arrowhead Pharmaceuticals ARO-ALK7: Trial primary completion DESCRIPTION:As of 8 July 2026\, Arrowhead Pharmaceuticals estimated primary completion of a Phase 2 trial in obesity\, in February 2027.\n\nSource: c linicaltrials NCT06937203\nhttps://clinicaltrials.gov/study/NCT06937203 URL:https://julienwillard.com/calendar/clinical#e-243f0985-592c-4b55-ac0f-b bffdcc63448 END:VEVENT BEGIN:VEVENT UID:f6734bb4a5d60c0d91d803d462231fe0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kallyope Inc. Elismetrep: Trial primary completion DESCRIPTION:As of 5 August 2026\, Kallyope estimated primary completion of a Phase 3 trial in migraine\, in February 2027.\n\nSource: clinicaltrials NCT07645924\nhttps://clinicaltrials.gov/study/NCT07645924 URL:https://julienwillard.com/calendar/clinical#e-5d64aa3f-9132-4af3-94a0-a e651522f788 END:VEVENT BEGIN:VEVENT UID:b45a2848f4cb16000e54fa849a32b907 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Celltrion CT-P53: Trial primary completion DESCRIPTION:As of 22 May 2024\, Celltrion estimated primary completion of a Phase 3 trial in Relapsing-remitting Multiple Sclerosis\, in February 202 7.\n\nSource: clinicaltrials NCT05906992\nhttps://clinicaltrials.gov/study /NCT05906992 URL:https://julienwillard.com/calendar/clinical#e-86d7a0fc-ee7a-41f8-8d9c-7 b4659b33530 END:VEVENT BEGIN:VEVENT UID:799fc485c66cb7c15a823442bbe4feba DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Genelux Corporation Olvimulogene nanivacirepvec: Trial primary comp letion DESCRIPTION:As of 4 June 2026\, Genelux estimated primary completion of a P hase 2 trial in Advanced Non-squamous Non-small-cell Lung Cancer\, in Febr uary 2027.\n\nSource: clinicaltrials NCT06463665\nhttps://clinicaltrials.g ov/study/NCT06463665 URL:https://julienwillard.com/calendar/clinical#e-6a932414-e103-4d34-bb90-b 1103fde7909 END:VEVENT BEGIN:VEVENT UID:df5e5f5d8137130a0a1591e5396d4cb6 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Kodiak Sciences Inc KSI-101: Trial primary completion DESCRIPTION:As of 18 May 2026\, Kodiak Sciences estimated primary completio n of a Phase 3 trial in Macular Edema Secondary to Inflammation\, in Febru ary 2027.\n\nSource: clinicaltrials NCT06996080\nhttps://clinicaltrials.go v/study/NCT06996080 URL:https://julienwillard.com/calendar/clinical#e-646bb6ea-5124-4842-82e4-0 7363740994e END:VEVENT BEGIN:VEVENT UID:7b9484fdfefff76a45c5f0b711fe5295 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sunshine Guojian Pharmaceutical (Shanghai) Co.\, Ltd. 610: Trial pr imary completion DESCRIPTION:As of 29 January 2026\, Sunshine Guojian Pharmaceutical (Shangh ai) Co. estimated primary completion of a Phase 2 trial in asthma\, in Feb ruary 2027.\n\nSource: clinicaltrials NCT06680947\nhttps://clinicaltrials. gov/study/NCT06680947 URL:https://julienwillard.com/calendar/clinical#e-277972bd-e6f3-4d3d-8db4-1 3edd9b8d761 END:VEVENT BEGIN:VEVENT UID:8b96e014c86314f1cd247aac39ba0dca DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Neurocrine Biosciences NBI-1065890: Trial primary completion DESCRIPTION:As of 23 June 2026\, Neurocrine Biosciences estimated primary c ompletion of a Phase 2 trial in Tardive Dyskinesia\, in February 2027.\n\n Source: clinicaltrials NCT07365462\nhttps://clinicaltrials.gov/study/NCT07 365462 URL:https://julienwillard.com/calendar/clinical#e-187bc054-5348-4045-957a-e f40d5abf063 END:VEVENT BEGIN:VEVENT UID:e7816faa416c6a60af2bcfa4393a8a1e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sanaria Inc. Genetically attenuated PfSPZ Vaccine: Trial primary co mpletion DESCRIPTION:As of 1 June 2026\, Sanaria estimated primary completion of a P hase 2 trial in Malaria (Plasmodium Falciparum)\, in February 2027.\n\nSou rce: clinicaltrials NCT07385287\nhttps://clinicaltrials.gov/study/NCT07385 287 URL:https://julienwillard.com/calendar/clinical#e-22218c72-dae8-4e26-94b9-6 301003707b6 END:VEVENT BEGIN:VEVENT UID:cb1865920f45425cb33c1d13aefc9666 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:RDC Clinical Pty Ltd Lavender Oil: Trial primary completion DESCRIPTION:As of 23 April 2026\, RDC Clinical Pty estimated primary comple tion of a Phase 2 trial in Sleep Disorder (Disorder)\, in February 2027.\n \nSource: clinicaltrials NCT07315516\nhttps://clinicaltrials.gov/study/NCT 07315516 URL:https://julienwillard.com/calendar/clinical#e-1eea268f-0cd8-4caa-87b9-7 1a153e95dfd END:VEVENT BEGIN:VEVENT UID:3ccafe66beda28a2ed03ed3bd90165b0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Reunion Neuroscience Inc RE104 for Injection: Trial primary complet ion DESCRIPTION:As of 26 June 2026\, Reunion Neuroscience estimated primary com pletion of a Phase 2 trial in Generalized Anxiety Disorder\, in February 2 027.\n\nSource: clinicaltrials NCT07489651\nhttps://clinicaltrials.gov/stu dy/NCT07489651 URL:https://julienwillard.com/calendar/clinical#e-ef6d2f7c-cf9a-49e6-95d1-1 1dbfe28252f END:VEVENT BEGIN:VEVENT UID:462581740e5edcd89c758c76e4372f3e DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ionis Pharmaceuticals\, Inc. ION717: Trial primary completion DESCRIPTION:As of 5 August 2026\, Ionis Pharmaceuticals estimated primary c ompletion of a Phase 2 trial in Prion Disease\, in February 2027.\n\nSourc e: clinicaltrials NCT06153966\nhttps://clinicaltrials.gov/study/NCT0615396 6 URL:https://julienwillard.com/calendar/clinical#e-152041ff-0bfd-42b2-a309-9 7dbde3a74e8 END:VEVENT BEGIN:VEVENT UID:568c5fa1308a4728d833dbf16b665e68 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:DualityBio Inc. DB-1419: Trial primary completion DESCRIPTION:As of 5 June 2026\, DualityBio estimated primary completion of a Phase 2 trial in Solid Tumor\, Adult\, in February 2027.\n\nSource: clin icaltrials NCT06554795\nhttps://clinicaltrials.gov/study/NCT06554795 URL:https://julienwillard.com/calendar/clinical#e-84d82b43-a0a0-476f-be8b-b a6fe385fe71 END:VEVENT BEGIN:VEVENT UID:e399570224fb4edcbeddcd6783862dd5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals LEE011: Trial primary completion DESCRIPTION:As of 16 April 2026\, Novartis Pharmaceuticals estimated primar y completion of a Phase 2 trial on 1 February 2027.\n\nSource: clinicaltri als NCT02934568\nhttps://clinicaltrials.gov/study/NCT02934568 URL:https://julienwillard.com/calendar/clinical#e-71ba417d-bc02-4b8b-bee0-7 fd7fe241e6a END:VEVENT BEGIN:VEVENT UID:123488be68fb97e562721a87793bf902 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:GI Innovation\, Inc. GI-108: Trial primary completion DESCRIPTION:As of 15 September 2025\, GI Innovation estimated primary compl etion of a Phase 2 trial in Advanced Solid Tumor\, in February 2027.\n\nSo urce: clinicaltrials NCT07172802\nhttps://clinicaltrials.gov/study/NCT0717 2802 URL:https://julienwillard.com/calendar/clinical#e-1bc4f8c8-17c1-457f-b1b5-1 fc710860de2 END:VEVENT BEGIN:VEVENT UID:df3509b9c14a66982839d065f74323fc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AB Biotics\, SA Lactiplantibacillus plantarum Probiotic Mixture: Tr ial primary completion DESCRIPTION:As of 30 April 2026\, AB Biotics\, SA estimated primary complet ion of a Phase 2 trial in MASLD - Metabolic Dysfunction-Associated Steatot ic Liver Disease\, on 1 February 2027.\n\nSource: clinicaltrials NCT071939 27\nhttps://clinicaltrials.gov/study/NCT07193927 URL:https://julienwillard.com/calendar/clinical#e-1f70a6d7-a774-436d-bb65-1 30fcbc7cd54 END:VEVENT BEGIN:VEVENT UID:aec7e59da302c3f07ac177898a0a86fc DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Fujian Shengdi Pharmaceutical Co.\, Ltd. HRS9531: Trial primary com pletion DESCRIPTION:As of 2 January 2026\, Fujian Shengdi Pharmaceutical Co. estima ted primary completion of a Phase 3 trial in Type 2 Diabetes\, in February 2027.\n\nSource: clinicaltrials NCT07060456\nhttps://clinicaltrials.gov/s tudy/NCT07060456 URL:https://julienwillard.com/calendar/clinical#e-61be79db-bb47-4673-8d88-7 457aeb7239b END:VEVENT BEGIN:VEVENT UID:3d13a2981940c5665e80f95cd946e236 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:SK Life Science\, Inc. Carisbamate: Trial primary completion DESCRIPTION:As of 24 July 2025\, SK Life Science estimated primary completi on of a Phase 3 trial in seizures\, in February 2027.\n\nSource: clinicalt rials NCT05219617\nhttps://clinicaltrials.gov/study/NCT05219617 URL:https://julienwillard.com/calendar/clinical#e-44b51d97-0cb1-4c05-be81-8 b313a5b6f8e END:VEVENT BEGIN:VEVENT UID:adead55d367c7c59788f61d3adbd1121 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:SparingVision SPVN06: Trial primary completion DESCRIPTION:As of 15 May 2026\, SparingVision estimated primary completion of a Phase 2 trial in Retinitis Pigmentosa\, in February 2027.\n\nSource: clinicaltrials NCT05748873\nhttps://clinicaltrials.gov/study/NCT05748873 URL:https://julienwillard.com/calendar/clinical#e-b4189e09-2dc3-402d-ad3c-9 76eed9129c1 END:VEVENT BEGIN:VEVENT UID:1dd614974bf2d92e693ac94d6fb56132 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Trust Bio-sonics\, Inc. NH002 (Perflutren Lipid Microspheres) Injec table Suspension: Trial primary completion DESCRIPTION:As of 9 July 2026\, Trust Bio-sonics estimated primary completi on of a Phase 3 trial in Cardiac Diseases\, in February 2027.\n\nSource: c linicaltrials NCT06815627\nhttps://clinicaltrials.gov/study/NCT06815627 URL:https://julienwillard.com/calendar/clinical#e-3ced22ee-e6d1-42c7-b24f-f c7d77681d98 END:VEVENT BEGIN:VEVENT UID:a1a9c54ccf2dfdaae34e3dae81bb54fe DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hangzhou Gensciences Biopharmaceutical Co.\, Ltd. FRSW107: Trial pr imary completion DESCRIPTION:As of 23 June 2026\, Hangzhou Gensciences Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Severe Hemophilia A\, in February 2027.\n\nSource: clinicaltrials NCT07663903\nhttps://clinicalt rials.gov/study/NCT07663903 URL:https://julienwillard.com/calendar/clinical#e-6a5810e7-7f2f-47d4-93fe-4 0a4aca0e9d4 END:VEVENT BEGIN:VEVENT UID:b64730b88403c46e1a0e184d790b5480 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gracell Biotechnologies (Shanghai) Co.\, Ltd. GC012F Injection: Tri al primary completion DESCRIPTION:As of 9 June 2026\, Gracell Biotechnologies (Shanghai) Co. esti mated primary completion of a Phase 2 trial in Refractory Systemic Lupus E rythematosus\, on 1 February 2027.\n\nSource: clinicaltrials NCT06530849\n https://clinicaltrials.gov/study/NCT06530849 URL:https://julienwillard.com/calendar/clinical#e-8fc9761d-3476-4d6c-97d5-a 24440b40a42 END:VEVENT BEGIN:VEVENT UID:e47946f81af66f050b0c2eb30e5faab8 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:RIGImmune Inc. RIG-101: Trial primary completion DESCRIPTION:As of 23 March 2026\, RIGImmune estimated primary completion of a Phase 2 trial in Healthy Adult Participants\, in February 2027.\n\nSour ce: clinicaltrials NCT07488897\nhttps://clinicaltrials.gov/study/NCT074888 97 URL:https://julienwillard.com/calendar/clinical#e-d01a00e1-5696-4a50-a988-4 1ed018a1727 END:VEVENT BEGIN:VEVENT UID:8bf559c8a12e6737126bc8c91b006e6f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Amplia Therapeutics Limited AMP945 ascending doses: Trial primary c ompletion DESCRIPTION:As of 10 July 2026\, Amplia Therapeutics estimated primary comp letion of a Phase 2 trial in Pancreatic Cancer\, on 1 February 2027.\n\nSo urce: clinicaltrials NCT05355298\nhttps://clinicaltrials.gov/study/NCT0535 5298 URL:https://julienwillard.com/calendar/clinical#e-d194e05e-0692-4912-bb38-4 ac113350375 END:VEVENT BEGIN:VEVENT UID:aff059d468c83a66ce0ca0645cb71f11 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MediLink Therapeutics (Suzhou) Co.\, Ltd. YL201 for Injection: Tria l primary completion DESCRIPTION:As of 27 August 2025\, MediLink Therapeutics (Suzhou) Co. estim ated primary completion of a Phase 2 trial in Metastatic Castration-resist ant Prostate Cancer (mCRPC)\, in February 2027.\n\nSource: clinicaltrials NCT06241846\nhttps://clinicaltrials.gov/study/NCT06241846 URL:https://julienwillard.com/calendar/clinical#e-8b41bb76-3e4b-49e9-b240-f e6d282b46a9 END:VEVENT BEGIN:VEVENT UID:b02fa2e72d80fd56f12a0d3337f9f130 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co.\, Ltd. 0.4% ZOC201 7217: Trial primary completion DESCRIPTION:As of 11 August 2026\, Ocusun Ophthalmic Pharmaceutical (Guangz hou) Co. estimated primary completion of a Phase 2 trial in Age Related Ca taracts\, in February 2027.\n\nSource: clinicaltrials NCT07395986\nhttps:/ /clinicaltrials.gov/study/NCT07395986 URL:https://julienwillard.com/calendar/clinical#e-95b5c93d-5e3f-4e89-8926-b 2ce5f32fe6d END:VEVENT BEGIN:VEVENT UID:010e229e6edccae1ab4c438197e2f259 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company Abemaciclib: Trial primary completion DESCRIPTION:As of 17 July 2026\, Eli Lilly and estimated primary completion of a Phase 2 trial in glioma\, in February 2027.\n\nSource: clinicaltrial s NCT06413706\nhttps://clinicaltrials.gov/study/NCT06413706 URL:https://julienwillard.com/calendar/clinical#e-dff225cf-2834-4669-b169-7 ab653958940 END:VEVENT BEGIN:VEVENT UID:1625482490ee9fa15c5a2c99f3a71c50 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie Lutikizumab: Trial primary completion DESCRIPTION:As of 10 July 2026\, AbbVie estimated primary completion of a P hase 2 trial in Rheumatoid Arthritis\, in February 2027.\n\nSource: clinic altrials NCT06972446\nhttps://clinicaltrials.gov/study/NCT06972446 URL:https://julienwillard.com/calendar/clinical#e-339df390-1686-47a8-bc1c-5 7a5e47db3d3 END:VEVENT BEGIN:VEVENT UID:dc12e8e72449f805bc1dc864ebeed0d0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270202 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Tvardi Therapeutics\, Incorporated TTI-101: Trial primary completio n DESCRIPTION:As of 27 April 2026\, Tvardi Therapeutics\, Incorporated estima ted primary completion of a Phase 2 trial in Hepatocellular Carcinoma\, on 1 February 2027.\n\nSource: clinicaltrials NCT05440708\nhttps://clinicalt rials.gov/study/NCT05440708 URL:https://julienwillard.com/calendar/clinical#e-50b52e06-fdb1-413d-85b1-b c264e93898d END:VEVENT BEGIN:VEVENT UID:6709656660eaa5957c70d0f9792dae0f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company Orforglipron: Trial primary completion DESCRIPTION:As of 20 July 2026\, Eli Lilly and estimated primary completion of a Phase 3 trial in obesity\, in February 2027.\n\nSource: clinicaltria ls NCT06672549\nhttps://clinicaltrials.gov/study/NCT06672549 URL:https://julienwillard.com/calendar/clinical#e-d2ad8115-a33c-4a19-9e82-d 73d9f2bdbe2 END:VEVENT BEGIN:VEVENT UID:f4c08ea770fb13befa0c04cc5c56b831 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Theravia Hydroxycarbamid: Trial primary completion DESCRIPTION:As of 17 September 2025\, Theravia estimated primary completion of a Phase 2 trial in Sickle Cell Disease\, in February 2027.\n\nSource: clinicaltrials NCT06578507\nhttps://clinicaltrials.gov/study/NCT06578507 URL:https://julienwillard.com/calendar/clinical#e-b970e2b4-0425-48c5-a684-f a94f533bdd9 END:VEVENT BEGIN:VEVENT UID:4ee2732bccceb1516002cdf3243936ba DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Celltrion CT-P51: Trial primary completion DESCRIPTION:As of 8 July 2026\, Celltrion estimated primary completion of a Phase 3 trial in Non Squamous Non Small Cell Lung Cancer\, in February 20 27.\n\nSource: clinicaltrials NCT06939595\nhttps://clinicaltrials.gov/stud y/NCT06939595 URL:https://julienwillard.com/calendar/clinical#e-93ff931e-3ca4-4c3e-9d62-2 230e3e15ef0 END:VEVENT BEGIN:VEVENT UID:049f13b39103ebf0444ed0e1a7da56b9 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Day One Biopharmaceuticals\, Inc. Emi-Le: Trial primary completion DESCRIPTION:As of 29 June 2026\, Day One Biopharmaceuticals estimated prima ry completion of a Phase 2 trial in Triple Negative Breast Cancer\, in Feb ruary 2027.\n\nSource: clinicaltrials NCT05377996\nhttps://clinicaltrials. gov/study/NCT05377996 URL:https://julienwillard.com/calendar/clinical#e-f7a9707c-f13a-410a-a51b-c 4a7fd6ef40a END:VEVENT BEGIN:VEVENT UID:30868613c8ccedff531889fbdaf4ab6a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:60 Degrees Pharmaceuticals LLC Tafenoquine 100mg: Trial primary com pletion DESCRIPTION:As of 21 November 2025\, 60 Degrees Pharmaceuticals estimated p rimary completion of a Phase 2 trial in Chronic Babesiosis\, in February 2 027.\n\nSource: clinicaltrials NCT06656351\nhttps://clinicaltrials.gov/stu dy/NCT06656351 URL:https://julienwillard.com/calendar/clinical#e-9bde3726-3de5-4d8a-b690-9 63980b1fdcd END:VEVENT BEGIN:VEVENT UID:1b13e5fa780818fd0dcdae3f9f2ba5b5 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Suzhou HepaThera Biotech Co.\, Ltd. HT-101: Trial primary completio n DESCRIPTION:As of 24 November 2025\, Suzhou HepaThera Biotech Co. estimated primary completion of a Phase 2 trial in Chronic Hepatitis B\, in Februar y 2027.\n\nSource: clinicaltrials NCT07245953\nhttps://clinicaltrials.gov/ study/NCT07245953 URL:https://julienwillard.com/calendar/clinical#e-74ba6fae-5dc1-46f6-b8a5-7 425c760f9e3 END:VEVENT BEGIN:VEVENT UID:13234fd9b5b68747802a19b37aad5fff DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Enlivex Therapeutics Ltd. Allocetra: Trial primary completion DESCRIPTION:As of 17 June 2026\, Enlivex Therapeutics estimated primary com pletion of a Phase 2 trial in Primary Knee Osteoarthritis\, in February 20 27.\n\nSource: clinicaltrials NCT07580716\nhttps://clinicaltrials.gov/stud y/NCT07580716 URL:https://julienwillard.com/calendar/clinical#e-bc4e30b5-25d9-494c-ac96-d d4605f49232 END:VEVENT BEGIN:VEVENT UID:c82ffd7590d33a0b7c638dcb69edf881 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bavarian Nordic MVA-BN-WEV: Trial primary completion DESCRIPTION:As of 1 October 2025\, Bavarian Nordic estimated primary comple tion of a Phase 2 trial in encephalitis\, in February 2027.\n\nSource: cli nicaltrials NCT06899802\nhttps://clinicaltrials.gov/study/NCT06899802 URL:https://julienwillard.com/calendar/clinical#e-ae6fd4ba-5360-4f7f-8379-8 4975012f69f END:VEVENT BEGIN:VEVENT UID:4ac0cbf24de2622df29d4e94a0312190 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Eli Lilly and Company Brenipatide: Trial primary completion DESCRIPTION:As of 6 August 2026\, Eli Lilly and estimated primary completio n of a Phase 2 trial in smoking\, in February 2027.\n\nSource: clinicaltri als NCT07223840\nhttps://clinicaltrials.gov/study/NCT07223840 URL:https://julienwillard.com/calendar/clinical#e-457ea95c-d16f-460d-b169-e 109e3b6bbe0 END:VEVENT BEGIN:VEVENT UID:f73660e29f4b7a5d3c47be9fc0018b34 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:TearSolutions\, Inc. Lacripep: Trial primary completion DESCRIPTION:As of 11 May 2026\, TearSolutions estimated primary completion of a Phase 2 trial in Neurotrophic Keratitis\, in February 2027.\n\nSource : clinicaltrials NCT07568730\nhttps://clinicaltrials.gov/study/NCT07568730 URL:https://julienwillard.com/calendar/clinical#e-c07b8aec-3471-4327-a128-e fd2773d7bc4 END:VEVENT BEGIN:VEVENT UID:28fa3bb657efd82f50d092c22134a0df DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Sovargen SVG103: Trial primary completion DESCRIPTION:As of 10 August 2026\, Sovargen estimated primary completion of a Phase 2 trial in Focal Cortical Dysplasia\, in February 2027.\n\nSource : clinicaltrials NCT07287202\nhttps://clinicaltrials.gov/study/NCT07287202 URL:https://julienwillard.com/calendar/clinical#e-b33acdce-4855-40a8-8887-d ecaa344a012 END:VEVENT BEGIN:VEVENT UID:790493044e446e6ab3037cf845e17148 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Krystal Biotech\, Inc. KB707: Trial primary completion DESCRIPTION:As of 24 October 2025\, Krystal Biotech estimated primary compl etion of a Phase 2 trial in Lung Cancer\, Non-small Cell\, in February 202 7.\n\nSource: clinicaltrials NCT06228326\nhttps://clinicaltrials.gov/study /NCT06228326 URL:https://julienwillard.com/calendar/clinical#e-dd86a01c-dd4c-41eb-9d8f-e 6dcbf627d06 END:VEVENT BEGIN:VEVENT UID:4b3cd8e41f297a90a89c50abf1bd7ba4 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:AbbVie Lutikizumab: Trial primary completion DESCRIPTION:As of 24 January 2025\, AbbVie estimated primary completion of a Phase 2 trial in Hidradenitis Suppurativa\, in February 2027.\n\nSource: clinicaltrials NCT06524635\nhttps://clinicaltrials.gov/study/NCT06524635 URL:https://julienwillard.com/calendar/clinical#e-dd97b12a-cb80-4f5d-9093-b e981c3ba0b4 END:VEVENT BEGIN:VEVENT UID:05e6abad1750d2c7f23f47a0b9f47099 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270201 DTEND;VALUE=DATE:20270301 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Gilead Sciences Sacituzumab Govitecan-hziy: Trial primary completio n DESCRIPTION:As of 18 September 2025\, Gilead Sciences estimated primary com pletion of a Phase 3 trial in Triple Negative Breast Cancer\, in February 2027.\n\nSource: clinicaltrials NCT05382286\nhttps://clinicaltrials.gov/st udy/NCT05382286 URL:https://julienwillard.com/calendar/clinical#e-a19cde8d-6415-4132-aada-f ce59bb8b872 END:VEVENT BEGIN:VEVENT UID:efa0c8b10bccf48e92e5e6293e2f4af0 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270202 DTEND;VALUE=DATE:20270203 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Noema Pharma AG Basimglurant: Trial primary completion DESCRIPTION:As of 23 January 2026\, Noema Pharma estimated primary completi on of a Phase 3 trial in Trigeminal Neuralgia\, on 2 February 2027.\n\nSou rce: clinicaltrials NCT05217628\nhttps://clinicaltrials.gov/study/NCT05217 628 URL:https://julienwillard.com/calendar/clinical#e-37581582-0fe4-44b9-ab4f-c f79c9eb052a END:VEVENT BEGIN:VEVENT UID:e72474999a93c610aec9d7f32cfb4b7a DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270202 DTEND;VALUE=DATE:20270203 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Cellvax Therapeutics Inc FK-PC101: Trial primary completion DESCRIPTION:As of 21 October 2024\, Cellvax Therapeutics estimated primary completion of a Phase 2 trial in Prostate Cancer (Adenocarcinoma)\, on 2 F ebruary 2027.\n\nSource: clinicaltrials NCT06636682\nhttps://clinicaltrial s.gov/study/NCT06636682 URL:https://julienwillard.com/calendar/clinical#e-0c598125-b3a8-4cfa-a416-7 ffd4c7ef559 END:VEVENT BEGIN:VEVENT UID:2de973a3ff2362a571c5c07fba48829f DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270202 DTEND;VALUE=DATE:20270203 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Vertex Pharmaceuticals Incorporated VX-670: Trial primary completio n DESCRIPTION:As of 8 June 2026\, Vertex Pharmaceuticals Incorporated estimat ed primary completion of a Phase 2 trial in Myotonic Dystrophy Type 1 (DM1 )\, on 2 February 2027.\n\nSource: clinicaltrials NCT06185764\nhttps://cli nicaltrials.gov/study/NCT06185764 URL:https://julienwillard.com/calendar/clinical#e-c0576d08-b4cb-4587-81c7-b 083e0471575 END:VEVENT BEGIN:VEVENT UID:4eca16b314772128c4367b6bb3e10a8c DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270202 DTEND;VALUE=DATE:20270203 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Novartis Pharmaceuticals LXH254: Trial primary completion DESCRIPTION:As of 12 March 2026\, Novartis Pharmaceuticals estimated primar y completion of a Phase 2 trial in melanoma\, on 2 February 2027.\n\nSourc e: clinicaltrials NCT04417621\nhttps://clinicaltrials.gov/study/NCT0441762 1 URL:https://julienwillard.com/calendar/clinical#e-3b13ed3c-a5fd-43ff-bce3-7 8ef3bf2103c END:VEVENT BEGIN:VEVENT UID:7e40d8a26629080605868908616e35e3 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270203 DTEND;VALUE=DATE:20270204 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bayer BAY2927088: Trial primary completion DESCRIPTION:As of 7 July 2026\, Bayer estimated primary completion of a Pha se 2 trial in Advanced Solid Tumors\, on 3 February 2027.\n\nSource: clini caltrials NCT06760819\nhttps://clinicaltrials.gov/study/NCT06760819 URL:https://julienwillard.com/calendar/clinical#e-aee47b5f-f775-4688-8d3f-7 4adbf1d83b9 END:VEVENT BEGIN:VEVENT UID:b9c7def5b6fb95826bbba82e21c968b1 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270203 DTEND;VALUE=DATE:20270204 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:InventVacc Biologicals Inc. Haemophilus influenzae serotype a vacci ne candidate: Trial primary completion DESCRIPTION:As of 3 August 2026\, InventVacc Biologicals estimated primary completion of a Phase 2 trial in Haemophilus Influenzae\, on 3 February 20 27.\n\nSource: clinicaltrials NCT07743008\nhttps://clinicaltrials.gov/stud y/NCT07743008 URL:https://julienwillard.com/calendar/clinical#e-34137257-e241-4e26-862e-4 030373f0da5 END:VEVENT BEGIN:VEVENT UID:0a3881a532f59a2979818c09d08514de DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270204 DTEND;VALUE=DATE:20270205 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hoffmann-La Roche Ranibizumab: Trial primary completion DESCRIPTION:As of 31 July 2026\, Hoffmann-La Roche estimated primary comple tion of a Phase 3 trial in Neovascular Age-related Macular Degeneration (n AMD)\, on 4 February 2027.\n\nSource: clinicaltrials NCT04657289\nhttps:// clinicaltrials.gov/study/NCT04657289 URL:https://julienwillard.com/calendar/clinical#e-60218990-181a-4ba9-a688-a 582a00d04f5 END:VEVENT BEGIN:VEVENT UID:61a4593890c6cc7e76b8895e0dd56515 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270204 DTEND;VALUE=DATE:20270205 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:MoonLake Immunotherapeutics AG Sonelokimab: Trial primary completio n DESCRIPTION:As of 13 July 2026\, MoonLake Immunotherapeutics estimated prim ary completion of a Phase 3 trial in Arthritis\, Psoriatic\, on 4 February 2027.\n\nSource: clinicaltrials NCT06641076\nhttps://clinicaltrials.gov/s tudy/NCT06641076 URL:https://julienwillard.com/calendar/clinical#e-aed67b3e-d9f1-4964-93ed-8 6daeacb8a2f END:VEVENT BEGIN:VEVENT UID:f634a08c5fd3439f3f7ea76acfe27588 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270204 DTEND;VALUE=DATE:20270205 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Hangzhou Zhongmei Huadong Pharmaceutical Co.\, Ltd. HDM1005 dose le vel 1: Trial primary completion DESCRIPTION:As of 13 April 2026\, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 2 trial in obesity\, on 4 Febr uary 2027.\n\nSource: clinicaltrials NCT07521631\nhttps://clinicaltrials.g ov/study/NCT07521631 URL:https://julienwillard.com/calendar/clinical#e-b75077e8-07bf-4607-843b-8 1c828529251 END:VEVENT BEGIN:VEVENT UID:4d87e889cab5d00a419721afa49866be DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270205 DTEND;VALUE=DATE:20270206 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Bristol-Myers Squibb Nivolumab: Trial primary completion DESCRIPTION:As of 14 May 2026\, Bristol-Myers Squibb estimated primary comp letion of a Phase 2 trial in Non-Small Cell Lung Cancer\, on 5 February 20 27.\n\nSource: clinicaltrials NCT06946797\nhttps://clinicaltrials.gov/stud y/NCT06946797 URL:https://julienwillard.com/calendar/clinical#e-b38c9157-2674-48a2-9a92-a 7cd5621cdda END:VEVENT BEGIN:VEVENT UID:4188090f8054ab0b1a3e8c9a364925ec DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270207 DTEND;VALUE=DATE:20270208 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Intra-IMMUSG Pte Ltd PRL3-ZUMAB: Trial primary completion DESCRIPTION:As of 29 April 2026\, Intra-IMMUSG Pte estimated primary comple tion of a Phase 2 trial in Neovascular Age Related Macular Degeneration\, on 7 February 2027.\n\nSource: clinicaltrials NCT07547228\nhttps://clinica ltrials.gov/study/NCT07547228 URL:https://julienwillard.com/calendar/clinical#e-d75a83ef-35ed-4917-9f44-4 c9330a87e88 END:VEVENT BEGIN:VEVENT UID:02881539440af085ee81716cb51b0445 DTSTAMP:20260812T042022Z DTSTART;VALUE=DATE:20270208 DTEND;VALUE=DATE:20270209 SEQUENCE:0 STATUS:TENTATIVE TRANSP:TRANSPARENT SUMMARY:Abcentra Orticumab: Trial primary completion DESCRIPTION:As of 27 January 2026\, Abcentra estimated primary completion o f a Phase 2 trial in Acute Coronary Syndromes\, on 8 February 2027.\n\nSou rce: clinicaltrials NCT06927739\nhttps://clinicaltrials.gov/study/NCT06927 739 URL:https://julienwillard.com/calendar/clinical#e-b2a1ec5d-3aeb-4ef9-8353-a 5f53994e59c END:VEVENT END:VCALENDAR